US20130345208A1 - Ion channel modulators and methods of use - Google Patents

Ion channel modulators and methods of use Download PDF

Info

Publication number
US20130345208A1
US20130345208A1 US13/974,986 US201313974986A US2013345208A1 US 20130345208 A1 US20130345208 A1 US 20130345208A1 US 201313974986 A US201313974986 A US 201313974986A US 2013345208 A1 US2013345208 A1 US 2013345208A1
Authority
US
United States
Prior art keywords
optionally substituted
aliphatic
compound
heterocycloaliphatic
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/974,986
Inventor
Esther Martinborough
Nicole Zimmerman
Robert B. Perni
Michael Arnost
Upul K. Bandarage
Francois Maltais
Guy Bemis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Priority to US13/974,986 priority Critical patent/US20130345208A1/en
Publication of US20130345208A1 publication Critical patent/US20130345208A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • the present invention relates to compounds useful as inhibitors of ion channels.
  • the invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
  • Na channels are central to the generation of action potentials in all excitable cells such as neurons and myocytes. They play key roles in excitable tissue including brain, smooth muscles of the gastrointestinal tract, skeletal muscle, the peripheral nervous system, spinal cord and airway. As such, they play key roles in a variety of disease states such as epilepsy (See, Moulard, B. and D. Bertrand (2002) “Epilepsy and sodium channel blockers” Expert Opin. Ther. Patents 12(1): 85-91)), pain (See, Waxman, S. G., S. Dib-Hajj, et al. (1999) “Sodium channels and pain” Proc Natl Aced Sci USA 96(14): 7635-9 and Waxman, S. G., T. R.
  • Voltage gated Na channels comprise a gene family consisting of 9 different subtypes (NaV1.1-NaV1.9). As shown in Table A, these subtypes show tissue specific localization and functional differences (See, Goldin, A. L. (2001) “Resurgence of sodium channel research” Annu Rev Physiol 63: 871-94). Three members of the gene family (NaV1.8, 1.9, 1.5) are resistant to block by the well-known Na channel blocker TTX, demonstrating subtype specificity within this gene family. Mutational analysis has identified glutamate 387 as a critical residue for TTX binding (See, Nada, M., H. Suzuki, et al. (1989) “A single point mutation confers tetrodotoxin and saxitoxin insensitivity on the sodium channel II” FEBS Lett 259(1): 213-6).
  • CNS central nervous system
  • PNS peripheral nervous sytem
  • DRG dorsal root ganglion
  • TG Trigeminal ganglion
  • NaV1.1 CNS PNS 10 nM Pain, Epilepsy, soma of neurodegeneration neurons NaV1.2 CNS, high in 10 nM Neurodegeneration axons
  • NaVs voltage-gated sodium channels
  • Antagonists of NaV channels can attenuate these pain signals and are useful for treating a variety of pain conditions, including but not limited to acute, chronic, inflammatory, and neuropathic pain.
  • Known NaV antagonists such as TTX, lidocaine (See, Mao, J. and L. L. Chen (2000) “Systemic lidocaine for neuropathic pain relief” Pain 87(1): 7-17.), bupivacaine, phenyloin (See, Jensen, T. S.
  • Hyperalgesia extreme sensitivity to something painful
  • Voltage sensitive sodium channels activation is critical for the generation and propagation of neuronal action potentials.
  • modulation of NaV currents is an endogenous mechanism used to control neuronal excitability (See, Goldin, A. L. (2001) “Resurgence of sodium channel research” Annu Rev Physiol 63: 871-94.).
  • DRG dorsal root ganglion
  • TTX-resistant current is insensitive to micromolar concentrations of tetrodotoxin, and displays slow activation and inactivation kinetics and a more depolarized activation threshold when compared to other voltage-gated sodium channels.
  • TTX-resistant sodium currents are primarily restricted to a subpopulation of sensory neurons likely to be involved in nociception. Specifically, TTX-resistant sodium currents are expressed almost exclusively in neurons that have a small cell-body diameter and give rise to small-diameter slow-conducting axons and that are responsive to capsaicin.
  • a large body of experimental evidence demonstrates that TTX-resistant sodium channels are expressed on C-fibers and are important in the transmission of nociceptive information to the spinal cord.
  • Intrathecal administration of antisense oligo-deoxynucleotides targeting a unique region of the TTX-resistant sodium channel (NaV1.8) resulted in a significant reduction in PGE 2 induced hyperalgesia (See, Khasar, S. G., M. S. Gold, et al. (1998) “A tetrodotoxin-resistant sodium current mediates inflammatory pain in the rat” Neurosci Lett 256(1): 17-20). More recently, a knockout mouse line was generated by Wood and colleagues, which lacks functional NaV1.8. The mutation has an analgesic effect in tests assessing the animal's response to the inflammatory agent carrageenan (See, Akopian, A. N., V.
  • NaV1.8 protein is upregulated along uninjured C-fibers adjacent to the nerve injury.
  • Antisense treatment prevents the redistribution of NaV1.8 along the nerve and reverses neuropathic pain.
  • neuropathic pain states there is a remodeling of Na channel distribution and subtype.
  • expression of NaV1.8 and NaV1.9 are greatly reduced whereas expression of the TTX sensitive subunit NaV1.3 is 5-10 fold upregulated (See, Dib-Hajj, S. D., J. Fjell, et al. (1999) “Plasticity of sodium channel expression in DRG neurons in the chronic constriction injury model of neuropathic pain.” Pain 83(3): 591-600.)
  • the timecourse of the increase in NaV1.3 parallels the appearance of allodynia in animal models subsequent to nerve injury.
  • the biophysics of the NaV1.3 channel is distinctive in that it shows very fast repriming after inactivation following an action potential.
  • NaV1.3 is expressed in the central and peripheral systems of man.
  • NaV1.9 is similar to NaV1.8 as it is selectively localized to small sensory neurons of the dorsal root ganglion and trigeminal ganglion (See. Fang, X., L. Djouhri, et al. (2002).
  • the resting membrane potential of NaV1.9 expressing cells is in the ⁇ 55 to ⁇ 50 mV range compared to ⁇ 65 mV for most other peripheral and central neurons.
  • This persistent depolarization is in large part due to the sustained low-level activation of NaV1.9 channels. This depolarization allows the neurons to more easily reach the threshold for firing action potentials in response to nociceptive stimuli.
  • Compounds that block the NaV1.9 channel may play an important role in establishing the set point for detection of painful stimuli. In chronic pain states, nerve and nerve ending can become swollen and hypersensitive exhibiting high frequency action potential firing with mild or even no stimulation. These pathologic nerve swellings are termed neuromas and the primary.
  • Na channels expressed in them are NaV 1.8 and NaV 1.7 (See, Kretschmer, T., L. T. Happel, et al. (2002) “Accumulation of PN1 and PN3 sodium channels in painful human neuroma-evidence from immunocytochemistry” Acta Neurochir ( Wien ) 144(8): 803-10; discussion 810.).
  • NaV1.6 and NaV1.7 are also expressed in dorsal root ganglion neurons and contribute to the small TTX sensitive component seen in these cells. NaV1.7 in particular may therefore be a potential pain target in addition to its role in neuroendocrine excitability (See, Klugbauer, N., L. Lacinova, et al. (1995) “Structure and functional expression of a new member of the tetrodotoxin-sensitive voltage-activated sodium channel family from human neuroendocrine cells” Embo J 14(6): 1084-90).
  • NaV1.1 See, Sugawara, T., E. Mazaki-Miyazaki, et al. (2001) “Nav1.1 mutations cause febrile seizures associated with afebrile partial seizures.” Neurology 57(4): 703-5.
  • NaV 1.2 See, Sugawara, T., Y. Tsurubuchi, et al. (2001) “A missense mutation of the Na+ channel alpha II subunit gene Na(v)1.2 in a patient with febrile and afebrile seizures causes channel dysfunction” Proc Natl Acad Sci USA 98(11): 6384-9) have been linked to epilepsy conditions including febrile seizures.
  • Antagonists for NaV1.5 have been developed and used to treat cardiac arrhythmias.
  • a gene defect in NaV1.5 that produces a larger noninactivating component to the current has been linked to long QT in man and the orally available local anesthetic mexilitine has been used to treat this condition (See, Wang, D. W., K. Yazawa, et al. (1997) “Pharmacological targeting of long QT mutant sodium channels.” J Clin Invest 99(7): 1714-20).
  • Na channel blockers are currently used or being tested in the clinic to treat epilepsy (See, Moulard, B. and D. Bertrand (2002) “Epilepsy and sodium channel blockers” Expert Opin. Ther. Patents 12(1): 85-91.); acute (See, Wiffen, P., S. Collins, et al. (2000) “Anticonvulsant drugs for acute and chronic pain” Cochrane Database Syst Rev 3), chronic (See, Wiffen, P., S. Collins, et al. (2000) “Anticonvulsant drugs for acute and chronic pain” Cochrane Database Syst Rev 3, and Guay, D. R.
  • Narasimhan (1997) “Sodium channels and therapy of central nervous system diseases” Adv Pharmacol 39: 47-98) and as anesthetics (See, Strichartz, G. R., Z. Zhou, et al. (2002) “Therapeutic concentrations of local anaesthetics unveil the potential role of sodium channels in neuropathic pain.” Novartis Found Symp 241: 189-201).
  • pancreatic see, Vera-Portocarrero, L. B., et al., Anesthesiology. 2003; 98(2):474-84
  • IBS pain see, Verne, G. N., et al., Pain. 2003; 105(1-2):223-30; La J H et al., World Gastroenterol. 2003; 9(12):2791-5
  • chronic headache pain see, Willimas & Stark, Cephalalgia. 2003; 23(10):963-71
  • migraine see, Yamamura, H., et al., J. Neurophysiol.
  • tension headache including cluster headaches (see, Costa, A., et al., Cephalalgia. 2000; 20(2):85-91); chronic neuropathic pain, including post-herpetic neuralgia (see, Attal, N., et al., Neurology. 2004; 62(2):218-25; Kim & Chung 1992, Pain 50:355); diabetic neuropathy (see, Beidoun A et al., Clin J. Pain. 2004; 20(3):174-8; Courteix, C., et al., Pain. 1993; 53(1):81-8); HIV-associated neuropathy (see, Portegies & Rosenberg, Ned Tijdschr Geneeskd.
  • post-mastectomy pain see, Devers & Galer, Clin J Pain. 2000; 16(3):205-8
  • central pain Cahana, A., et al., Anesth Analg. 2004; 98(6):1581-4
  • spinal cord injury pain see, Hains, B. C., et al., Exp Neurol. 2000; 164(2):426-37
  • post-stroke pain thalamic pain
  • thalamic pain see, LaBuda, C. J., et al., Neurosci Lett. 2000; 290(1):79-83
  • complex regional pain syndrome see, Wallace, M. S., et al., Anesthesiology.
  • Bladder and urogenital disease including urinary incontinence (see, Berggren, T., et al., J Urol. 1993; 150(5 Pt 1):1540-3); hyperactivity bladder (see, Chuang, Y. C., et al., Urology. 2003; 61(3):664-70); painful bladder syndrome (see, Yoshimura, N., et al., J Neurosci. 2001; 21(21):8690-6); interstitial cyctitis (IC) (see, Giannakopoulos & Campilomatos, Arch Ital Urol Nefrol Androl.
  • urinary incontinence see, Berggren, T., et al., J Urol. 1993; 150(5 Pt 1):1540-3
  • hyperactivity bladder see, Chuang, Y. C., et al., Urology. 2003; 61(3):664-70
  • painful bladder syndrome see, Yoshimura, N., et al., J Neuro
  • Voltage-gated calcium channels are membrane-spanning, multi-subunit proteins that open in response to membrane depolarization, allowing Ca entry from the extracellular milieu.
  • Calcium channels were initially classified based on the time and voltage-dependence of channel opening and on the sensitivity to pharmacological block. The categories were low-voltage activated (primarily T-type) and high-voltage activated (L,N,P,Q or R-type). This classification scheme was replaced by a nomenclature based upon the molecular subunit composition, as summarized in Table B (Hockerman G H, Peterson B Z, Johnson B D, Catterall W A. 1997 . Annu Rev Pharmacol Toxicol 37: 361-96; Striessnig J. 1999 . Cell Physiol Biochem 9: 242-69).
  • the ⁇ 1 subunit is the primary determinant of the pharmacological properties and contains the channel pore and voltage sensor (Hockerman et al., 1997; Striessnig, 1999). Ten isoforms of the ⁇ 1 subunit are known, as indicated in Table I below.
  • the ⁇ 2 ⁇ subunit consists of two disulfide linked subunits, ⁇ 2 , which is primarily extracellular, and a transmembrane ⁇ subunit.
  • ⁇ 2 ⁇ disulfide linked subunits
  • Four isoforms of ⁇ 2 ⁇ are known, ⁇ 2 ⁇ -1, ⁇ 2 ⁇ -2, ⁇ 2 ⁇ -3 and ⁇ 2 ⁇ -4.
  • the ⁇ subunit is a non-glycosylated cytoplasmic protein that binds to the ⁇ 1 subunit.
  • Four isoforms are known, termed ⁇ 1 to ⁇ 4 .
  • the ⁇ subunit is a transmembrane protein that has been biochemically isolated as a component of C v 1 and Ca v 2 channels.
  • At least 8 isoforms are known ( ⁇ 1 to ⁇ 8 ) [Kang M G, Campbell K P. 2003 . J Biol Chem 278: 21315-8].
  • the nomenclature for voltage-gated calcium channels is based upon the content of the ⁇ 1 subunit, as indicated in Table B.
  • Each type of ⁇ 1 subunit can associate with a variety of ⁇ , ⁇ 2 ⁇ or ⁇ subunits, so that each Ca v type corresponds to many different combinations of subunits.
  • Ca v 2 currents are found almost exclusively in the central and peripheral nervous system and in neuroendocrine cells and constitute the predominant forms of presynaptic voltage-gated calcium current. Presynaptic action potentials cause channel opening, and neurotransmitter release is steeply dependent upon the subsequent calcium entry. Thus, Ca v 2 channels play a central role in mediating neurotransmitter release.
  • Ca v 2.1 and Ca v 2.2 contain high affinity binding sites for the peptide toxins ⁇ -conotoxin-MVIIC and ⁇ -conotoxin-GVIA, respectively, and these peptides have been used to determine the distribution and function of each channel type.
  • Ca v 2.2 is highly expressed at the presynaptic nerve terminals of neurons from the dorsal root ganglion and neurons of lamina I and II of the dorsal horn (Westenbroek R E, Hoskins L, Catterall W A. 1998. J Neurosci 18: 6319-30; Cizkova D, Marsala J, Lukacova N, Marsala M, Jergova S, et al. 2002 . Exp Brain Res 147: 456-63). Ca v 2.2 channels are also found in presynaptic terminals between second and third order interneurons in the spinal cord. Both sites of neurotransmission are very important in relaying pain information to the brain.
  • Acute pain serves an important protective function in keeping the organism safe from stimuli that may produce tissue damage. Severe thermal, mechanical, or chemical inputs have the potential to cause severe damage to the organism if unheeded.
  • Acute pain serves to quickly remove the individual from the damaging environment. Acute pain by its very nature generally is short lasting and intense. Inflammatory pain, on the other hand, may last for much longer periods of time and its intensity is more graded. Inflammation may occur for many reasons including tissue damage, autoimmune response, and pathogen invasion.
  • Inflammatory pain is mediated by an “inflammatory soup” that consists of substance P, histamines, acid, prostaglandin, bradykinin, CGRP, cytokines, ATP, and neurotransmitter release.
  • the third class of pain is neuropathic and involves nerve damage that results in reorganization of neuronal proteins and circuits yielding a pathologic “sensitized” state that can produce chronic pain lasting for years. This type of pain provides no adaptive benefit and is particularly difficult to treat with existing therapies.
  • Pain, particularly neuropathic and intractable pain is a large unmet medical need. Millions of individuals suffer from severe pain that is not well controlled by current therapeutics.
  • the current drugs used to treat pain include NSAIDS, COX2 inhibitors, opioids, tricyclic antidepressants, and anticonvulsants.
  • Neuropathic pain has been particularly difficult to treat as it does not respond well to opioids until high doses are reached.
  • Gabapentin is currently the favored therapeutic for the treatment of neuropathic pain although it works in only 60% of patients where it shows modest efficacy. The drug is however very safe and side effects are generally tolerable although sedation is an issue at higher doses.
  • Cav2.2 as a target for the treatment of neuropathic pain is provided by studies with ziconotide (also known as ⁇ -conotoxin-MVIIA), a selective peptide blocker of this channel (Bowersox S S, Gadbois T, Singh T, Pettus M, Wang Y X, Luther R R. 1996. J Pharmacol Exp Ther 279: 1243-9; Jain K K. 2000 . Exp. Opin. Invest. Drugs 9: 2403-10; Vanegas H, Schaible H. 2000 . Pain 85: 9-18).
  • intrathecal infusion of Ziconotide is effective for the treatment of intractable pain, cancer pain, opioid resistant pain, and neuropathic pain.
  • the toxin has an 85% success rate for the treatment of pain in humans with a greater potency than morphine.
  • An orally available antagonist of Ca v 2.2 should have similar efficacy without the need for intrathecal infusion.
  • Ca v 2.1 and Ca v 2.3 are also in neurons of nociceptive pathways and antagonists of these channels could be used to treat pain.
  • Antagonists of Ca v 2.1, Ca v 2.2 or Ca v 2.3 should also be useful for treating other pathologies of the central nervous system that apparently involve excessive calcium entry. Cerebral ischaemia and stroke are associated with excessive calcium entry due to depolarization of neurons.
  • the Ca v 2.2 antagonist ziconotide is effective in reducing infarct size in a focal ischemia model using laboratory animals, suggesting that Ca v 2.2 antagonists could be used for the treatment of stroke.
  • reducing excessive calcium influx into neurons may be useful for the treatment of epilepsy, traumatic brain injury, Alzheimer's disease, multi-infarct dementia and other classes of dementia, amyotrophic lateral sclerosis, amnesia, or neuronal damage caused by poison or other toxic substances.
  • Ca v 2.2 also mediates release of neurotransmitters from neurons of the sympathetic nervous system and antagonists could be used to treat cardiovascular diseases such as hypertension, cardiac arrhythmia, angina pectoris, myocardial infarction, and congestive heart failure.
  • the invention relates to compounds useful as ion channel modulators. It has now been found that compounds of this invention, and pharmaceutically acceptable compositions thereof, are useful as inhibitors of voltage-gated sodium channels. These compounds have the general formula I:
  • R 1 , R 2 , R 3 , R 4 , X, Y and n are described generally below.
  • compounds of this invention are useful as inhibitors of voltage-gated sodium channels and/or calcium channels.
  • These compounds have the general formula Ia:
  • R 1 , R 2 , R 3 , R 4 , X, and n are described generally below.
  • the present invention also includes methods for treating or lessening the severity of a disease, condition, or disorder where activation or hyperactivity of calcium and/or sodium ion channels is implicated in the disease state. Methods for treating or lessening the severity of a pain condition are also disclosed.
  • the method comprises the step of administering to the patient an effective amount of a pharmaceutical composition comprising at least one compound of the present invention.
  • the compounds of the present invention are useful for treating or lessening the severity of diseases, disorders, or conditions, including, but not limited to, acute, chronic, neuropathic, or inflammatory pain, arthritis, migraine, cluster headaches, trigeminal neuralgia, herpetic neuralgia, general neuralgias, epilepsy or epilepsy conditions, neurodegenerative disorders, psychiatric disorders such as anxiety and depression, myotonia, arrhythmia, movement disorders, neuroendocrine disorders, ataxia, multiple sclerosis, irritable bowel syndrome, incontinence, visceral pain, osteoarthritis pain, postherpetic neuralgia, diabetic neuropathy, radicular pain, sciatica, back pain, head or neck pain, severe or intractable pain, nociceptive pain, breakthrough pain, postsurgical pain, or cancer pain.
  • diseases, disorders, or conditions including, but not limited to, acute, chronic, neuropathic, or inflammatory pain, arthritis, migraine, cluster headaches, trigeminal neuralgia
  • modulating means increasing or decreasing, e.g. activity, by a measurable amount.
  • Compounds that modulate ion channel activity such as calcium ion channel activity and/or sodium ion channel activity, by increasing the activity of the ion channel, e.g., a calcium ion channel and/or a sodium ion channel, are called agonists.
  • Compounds that modulate ion channel activity, such as calcium ion channel activity and/or sodium ion channel activity, by decreasing the activity of the ion channel, e.g., calcium ion channel and/or sodium ion channel are called antagonists.
  • An agonist interacts with an ion channel, such as calcium ion channel, to increase the ability of the receptor to transduce an intracellular signal in response to endogenous ligand binding.
  • An antagonist interacts with an ion channel and competes with the endogenous ligand(s) or substrate(s) for binding site(s) on the receptor to decrease the ability of the receptor to transduce an intracellular signal in response to endogenous ligand binding.
  • the phrase “treating or reducing the severity of an ion channel mediated disease” refers both to treatments for diseases that are directly caused by ion channel activities and alleviation of symptoms of diseases not directly caused by ion channel activities.
  • diseases whose symptoms may be affected by ion channel activities include, but are not limited to, acute, chronic, neuropathic, or inflammatory pain, arthritis, migraine, cluster headaches, trigeminal neuralgia, herpetic neuralgia, general neuralgias, epilepsy or epilepsy conditions, neurodegenerative disorders, psychiatric disorders such as anxiety and depression, myotonia, arrhythmia, movement disorders, neuroendocrine disorders, ataxia, multiple sclerosis, irritable bowel syndrome, incontinence, visceral pain, osteoarthritis pain, postherpetic neuralgia, diabetic neuropathy, radicular pain, sciatica, back pain, head or neck pain, severe or intractable pain, nociceptive pain, breakthrough pain, postsurgical pain, or cancer
  • compounds of the invention may optionally be substituted with one or more substituents, such as are illustrated generally above, or as exemplified by particular classes, subclasses, and species of the invention.
  • aliphatic encompasses the terms alkyl, alkenyl, alkynyl.
  • an “alkyl” group refers to a saturated aliphatic hydrocarbon group containing 1-8 (e.g., 1-6 or 1-4) carbon atoms.
  • An alkyl group can be straight or branched. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-heptyl, or 2-ethylhexyl.
  • An alkyl group can be optionally substituted with one or more substituents such as halo, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aroyl, heteroaroyl, alkoxycarbonyl, alkoxycarbonylamino, alkylcarbonyloxy, nitro, cyano, amino, acyl, sulfonyl, sulfinyl, sulfanyl, sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, carbamoyl, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroarylalkoxy, or hydroxyl.
  • substituents such as halo, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aroyl, heteroaroyl,
  • an “alkenyl” group refers to an aliphatic carbon group that contains 2-10 (e.g., 2, 3, 4, 5, 6, 7, 8, 9 or 10) carbon atoms and at least one double bond. Like an alkyl group, an alkenyl group can be straight or branched. Examples of an alkenyl group include, but are not limited to, allyl, isoprenyl, 2-butenyl, and 2-hexenyl.
  • An alkenyl group may be optionally substituted with one or more substituents such as halo, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aroyl, heteroaroyl, alkoxycarbonyl, alkylcarbonyloxy, nitro, cyano, amino, acyl, sulfonyl, sulfinyl, sulfanyl, sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, carbamoyl, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroarylalkoxy, or hydroxyl.
  • substituents such as halo, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aroyl, heteroaroyl, alkoxycarbonyl, al
  • an “alkynyl” group refers to an aliphatic carbon group that contains 2-8 (e.g., 2-6 or 2-4) carbon atoms and at least one triple bond. Like an alkyl group, an alkynyl group can be straight or branched.
  • An alkynyl group may be optionally substituted with one or more substituents such as halo, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aroyl, heteroaroyl, alkoxycarbonyl, alkylcarbonyloxy, nitro, cyano, amino, acyl, sulfonyl, sulfinyl, sulfanyl, sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, carbamoyl, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroarylalkoxy, or hydroxyl.
  • substituents such as halo, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aroyl, heteroaroyl, alkoxycarbonyl,
  • an “amino” group refers to —NR X R Y wherein each of R X and R Y is independently hydrogen, alkyl, cycloalkyl, sulfonyl, (cycloalkyl)alkyl, aryl, aralkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, heteroaryl, or heteroaralkyl each of which are defined herein and are optionally substituted.
  • the term “amino” is not the terminal group (e.g., alkylcarbonylamino), it is represented by —NR X —.
  • R X has the same meaning as defined above.
  • an “aryl” group used alone or as part of a larger moiety as in “aralkyl”, “aralkoxy”, or “aryloxyalkyl” refers to monocyclic (e.g., phenyl); bicyclic (e.g., indenyl, naphthalenyl, tetrahydronaphthyl, tetrahydroindenyl); tricyclic (e.g., fluorenyl, tetrahydrofluorenyl, anthracenyl, or tetrahydroanthracenyl); or a benzofused group having 3 rings.
  • a benzofused group includes phenyl fused with two or more C 4-8 carbocyclic moieties.
  • An aryl is optionally substituted with one or more substituents including aliphatic (e.g., alkyl, alkenyl, or alkynyl); cycloalkyl; (cycloalkyl)alkyl; heterocycloalkyl; (heterocycloalkyl)alkyl; aryl; heteroaryl; alkoxy; cycloalkyloxy; heterocycloalkyloxy; aryloxy; heteroaryloxy; aralkyloxy; heteroaralkyloxy; aroyl; heteroaroyl; amino; aminoalkyl; nitro; —C(O)OH; carbonyl (e.g., alkoxycarbonyl, alkylcarbonyl, aminocarbonyl, (alkylamino)alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl
  • substituted aryls include haloaryl, alkoxycarbonylaryl, alkylaminoalkylaminocarbonylaryl, p,m-dihaloaryl, p-amino-p-alkoxycarbonylaryl, m-amino-m-cyanoaryl, aminoaryl, alkylcarbonylaminoaryl, cyanoalkylaryl, alkoxyaryl, aminosulfonylaryl, alkylsulfonylaryl, aminoaryl, p-halo-m-aminoaryl, cyanoaryl, hydroxyalkylaryl, alkoxyalkylaryl, hydroxyaryl, carboxyalkylaryl, dialkylaminoalkylaryl, m-heterocycloaliphatic-o-alkylaryl, heteroarylaminocarbonylaryl, nitroalkylaryl, alkylsulfonylaminoalkylaryl, heterocycloaliphaticcarbonylaryl, alky
  • an “araliphatic” group refers to an aliphatic group (e.g., a C 1-4 alkyl group, a C 1-4 alkenyl group, or a C 1-4 alkynyl group) that is substituted with an aryl group. Both “aliphatic” and “aryl” have been defined above.
  • an “aralkyl” group refers to an alkyl group (e.g., a C 1-4 alkyl group) that is substituted with an aryl group. Both “alkyl” and “aryl” are defined herein. An example of an aralkyl group is benzyl.
  • a “bicyclic ring system” includes 7-12 (e.g., 9, 10, or 11) membered structures that form two rings, wherein the two rings have at least one atom in common (e.g., 2 atoms in common).
  • Bicyclic ring structures include bicycloaliphatics (e.g., bicycloalkyl or bicycloalkenyl), bicycloheteroaliphatics (e.g., bicycloheteroalkyl or bicycloheteroalkenyl), bicyclic aryls, and bicyclic heteroaryls.
  • cycloaliphatic means a saturated or partially unsaturated monocyclic, bicyclic, or tricyclic hydrocarbon ring that has a single point of attachment to the rest of the molecule. Cycloaliphatic rings are 3-8 membered monocyclic rings (e.g., 3-6 membered rings). Cycloaliphatic rings also include 8-12 membered bicyclic hydrocarbon rings, (e.g., 10 membered bicyclic hydrocarbon rings).
  • a cycloaliphatic group encompasses a “cycloalkyl” group and a “cycloalkenyl” group.
  • a “cycloalkyl” group refers to a saturated carbocyclic mono-, bi-, or tri-, or multicyclic (fused or bridged) ring of 3-10 (e.g., 5-10) carbon atoms.
  • monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or the like.
  • bicyclic cycloalkyl groups include octahydro-indenyl, decahydro-naphthyl, bicyclo[3.2.1]octyl, bicyclo[2.2.2]octyl, bicyclo[3.3.1]nonyl, bicyclo[3.3.2.]decyl, bicyclo[2.2.2]octyl, bicyclo[2.2.1]heptanyl, bicyclo[3.1.1]heptanyl, or the like.
  • multicyclic groups include adamantyl, cubyl, norbornyl, or the like. Cycloalkyl rings can be optionally substituted at any chemically viable ring position.
  • a “cycloalkenyl” group refers to a non-aromatic carbocyclic ring of 3-10 (e.g., 4-8) carbon atoms having one or more double bonds.
  • Examples of cycloalkenyl groups include cyclopentenyl, 1,4-cyclohexa-di-enyl, cycloheptenyl, cyclooctenyl, hexahydro-indenyl, octahydro-naphthyl, cyclohexenyl, cyclopentenyl, bicyclo[2.2.2]octenyl, and bicyclo[3.3.1]nonenyl. Cycloalkenyl ring structures can be optionally substituted at any chemically viable position on the ring or rings.
  • a cycloalkyl or cycloalkenyl group can be optionally substituted with one or more substituents such as aliphatic (e.g., alkyl, alkenyl, or alkynyl), cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, aryl, heteroaryl, alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, aroyl, heteroaroyl, amino, nitro, carboxy, alkoxycarbonyl, alkylcarbonyloxy, aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, (cycloalkyl)alkylcarbonylamino, arylcarbonylamino, aralkylcarbonylamino, (heterocycloalkyl)carbon
  • substituted cycloaliphatics include alkylcycloalkyl (e.g., propylcyclohexyl), alkylbicyclo[3.1.1]heptyl, alkylcycloalkenyl, or the like.
  • heterocycloaliphatic and “heterocyclic” encompasses a heterocycloalkyl group and a heterocycloalkenyl group.
  • heterocycloalkyl refers to a 3-10 membered mono or bicyclic (fused or bridged) (e.g., 5 to 10 membered mono or bicyclic) saturated ring structure, in which one or more of the ring atoms is a heteroatom (e.g., N, O, S, or combinations thereof).
  • heterocycloalkyl group examples include optionally substituted piperidinyl, piperazinyl, tetrahydropyranyl, tetrahydrofuranyl, 1,4-dioxolanyl, 1,4-dithianyl; 1,3-dioxolanyl, oxazolidyl, isoxazolidyl, morpholinyl, thiomorpholinyl, octahydro-benzofuranyl, octahydro-chromenyl, octahydro-thiochromenyl, octahydro-indolyl, octahydro-pyrindinyl, decahydro-quinolinyl, octahydro-benzo[b]thiophenyl, 2-oxa-bicyclo[2.2.2]octyl, 1-aza-bicyclo[2.2.2]octyl, 3-aza-bicyclo[3.2.1]
  • a monocyclic heterocycloalkyl group may be fused with a phenyl moiety such as tetrahydroisoquinoline.
  • Heterocycloalkyl ring structures can be optionally substituted at any chemically viable position on the ring or rings.
  • heterocycloalkenyl refers to a mono- or bicyclic (e.g., 5- to 10-membered mono- or bicyclic) non-aromatic ring structure having one or more double bonds, and wherein one or more of the ring atoms is a heteroatom (e.g., N, O, or S).
  • heterocycloalkenyls include 2-pyrrolyl, 3-pyrrolyl, 2-imidazolyl, or 2-pyrazolyl.
  • Monocyclic heterocycloaliphatics are numbered according to standard chemical nomenclature. For instance:
  • Heterocycloalkenyl ring structures can be optionally substituted at any chemically viable position on the ring or rings.
  • a heterocycloalkyl or heterocycloalkenyl group can be optionally substituted with one or more substituents such as alkyl (including carboxyalkyl, hydroxyalkyl, and haloalkyl such as trifluoromethyl), alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl (such as a benzimidazolidinyl), (heterocycloalkyl)alkyl, aryl, heteroaryl, alkoxy (two alkoxy groups on the same atom or adjacent atoms may form a ring together with the atom(s) to which they are bound), cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, aroyl, heteroaroyl, amino, nitro, carboxy, alkoxycarbonyl, alkylcarbonyloxy, aminocarbonyl, alky
  • substituted heterocycloaliphatics include alkoxycarbonylheterocycloalkyl (e.g., ethoxycarbonyltropane), alkoxycarbonylheterocycloalkyl (e.g., ethoxycarbonylpiperidyl), or the like.
  • heteroaryl group refers to a monocyclic, bicyclic, or tricyclic ring structure having 4 to 15 ring atoms wherein one or more of the ring atoms is a heteroatom (e.g., N, O, S, or combinations thereof) and wherein one or more rings of the bicyclic or tricyclic ring structure is aromatic.
  • a heteroaryl group includes a benzofused ring system having 2 to 3 rings.
  • a benzofused group includes benzo fused with one or two C 4-8 heterocyclic moieties (e.g., indolizyl, indolyl, isoindolyl, 3H-indolyl, indolinyl, benzo[b]furyl, benzo[b]thiophenyl, quinolinyl, or isoquinolinyl).
  • C 4-8 heterocyclic moieties e.g., indolizyl, indolyl, isoindolyl, 3H-indolyl, indolinyl, benzo[b]furyl, benzo[b]thiophenyl, quinolinyl, or isoquinolinyl.
  • heteroaryl examples include azetidinyl, pyridinyl, 1H-indazolyl, furyl, pyrrolyl, thienyl, thiazolyl, oxazolyl, imidazolyl, tetrazolyl, benzofuryl, isoquinolinyl, benzthiazolyl, xanthene, thioxanthene, phenothiazine, dihydroindole, benzo[1,3]dioxole, benzo[b]furyl, benzo[b]thiophenyl, indazolyl, benzimidazolyl, benzthiazolyl, puryl, cinnolyl, quinolyl, quinazolyl, cinnolyl, phthalazyl, quinazolyl, quinoxalyl, isoquinolyl, 4H-quinolizyl, benzo-1,2,5-thiadiazolyl, or
  • monocyclic heteroaryls include furyl, thiophenyl, 2H-pyrrolyl, pyrrolyl, oxazolyl, thazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, 1,3,4-thiadiazolyl, 2H-pyranyl, 4-H-pyranyl, pyridinyl, pyridazinyl, pyrimidyl, pyrazolyl, pyrazyl, or 1,3,5-triazyl.
  • Monocyclic heteroaryls are numbered according to standard chemical nomenclature. For instance:
  • bicyclic heteroaryls include indolizyl, indolyl, isoindolyl, 3H-indolyl, indolinyl, benzo[b]furyl, benzo[b]thiophenyl, quinolinyl, isoquinolinyl, indolizyl, isoindolyl, indazolyl, benzimidazyl, benzthiazolyl, purinyl, 4H-quinolizyl, quinolyl, isoquinolyl, cinnolyl, phthalazyl, quinazolyl, quinoxalyl, 1,8-naphthyridyl, or pteridyl.
  • Bicyclic heteroaryls are numbered according to standard chemical nomenclature. For instance:
  • a heteroaryl is optionally substituted with one or more substituents such as aliphatic including alkyls (e.g., alkoxyalkyl, carboxyalkyl, hydroxyallyl, oxoalkyl, aralkyl, (alkylsulfonylamino)alkyl, (sulfonylamino)alkyl, cyanoalkyl, aminoallyl, oxoalkyl, alkoxycarbonylalkyl, (cycloalkyl)alkyl heterocycloalkyl, (heterocycloalkyl)alkyl aralkyl, and haloalkyl such as trifluoromethyl), alkenyl, alkynyl; cycloaliphatic including cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl); heterocycloaliphatic including heterocycloalkyl (e.g.
  • heteroaryl group refers to an aliphatic group (e.g., C 1-4 alkyl group, C 1-4 alkenyl group, or C 1-4 alkynyl group) that is substituted with a heteroaryl group. Both “aliphatic” and “heteroaryl” have been defined above.
  • heteroaryl group refers to an alkyl group (e.g., a C 1-4 alkyl group) that is substituted with a heteroaryl group. Both “alkyl” and “heteroaryl” have been defined above.
  • cyclic moiety includes cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, aryl, or heteroaryl, each of which has been defined previously.
  • cyclic group includes mono-, bi-, and tri-cyclic structures including cycloaliphatic, heterocycloaliphatic, aryl, or heteroaryl, each of which has been previously defined.
  • an “acyl” group refers to a formyl group or alkyl-C( ⁇ O)— (also referred to as “alkylcarbonyl”) where “alkyl” has been defined previously. Acetyl and pivaloyl are examples of acyl groups.
  • a “carbonyl” group when used alone or as part of another structure refers to the structure —C(O)—.
  • a “carbamoyl” group refers to a group having the structure —O—CO—NR X R Y or —NR X —CO—O—R Z wherein R X and R Y have been defined above and R Z can be alkyl, aryl, aralkyl, heterocycloalkyl, heteroaryl, or heteroaralkyl.
  • a “carboxy” and a “sulfo” group refer to —C(O)OH or —C(O)OR X and —SO 3 H or —SO 3 R X , respectively.
  • an “alkoxy” group refers to an alkyl-O— group where “alkyl” has been defined previously. Moreover an alkoxy group includes structures comprising two alkoxy groups on the same atom or adjacent atoms that form a ring together with the atom(s) to which they are bound.
  • a “sulfoxy” group refers to —O—SO—R X or —SO—O—R X , where R X has been defined above.
  • mercapto refers to —SH.
  • sulfonyl refers to —S(O) 2 —.
  • sulfinyl refers to —S(O)—.
  • sulfanyl refers to —S—.
  • halogen or “halo” group refers to fluorine, chlorine, bromine or iodine.
  • haloaliphatic refers to an aliphatic group substituted with 1-3 halogen.
  • haloalkyl includes the group —CF 3 .
  • a “sulfamoyl” group refers to the structure —S(O) 2 —NR X R Y or —NR X —S(O) 2 —R Z wherein R X , R Y , and R Z have been defined above.
  • sulfamide refers to the structure —NR X —S(O) 2 —NR Y R Z wherein R X , R Y , and R Z have been defined above.
  • a “carbonylamino” group used alone or in connection with another group refers to an amido group such as R X —C(O)—NR X —.
  • an alkylcarbonylamino includes alkyl-C(O)—NR X —, wherein R X has been defined above.
  • aminocarbonyl used alone or in connection with another group refers to an amido group such as N(R X ) 2 —C(O)—.
  • an “alkoxycarbonyl” used alone or in connection with another group refers to a carbonyl group such as alkyl-O—C(O)—.
  • alkoxyalkyl refers to an alkyl group such as alkyl-O-alkyl-, wherein alkyl has been defined above.
  • aminocarbonyl refers to an amido group such as —NR X —C(O)—, wherein R X has been defined above.
  • an “aminosulfonyl” refers to the structure —N(R X ) 2 —S(O) 2 —, wherein R X has been defined above.
  • an “oxo” refers to ⁇ O.
  • aminoalkyl refers to the structure N(R X ) 2 -alkyl-.
  • cyanoalkyl refers to the structure (CN)-alkyl-.
  • alkylsulfonyl refers to the structure alkyl-S(O) 2 —.
  • a “sulfonylamino” group refers to the structure R X —S(O) 2 —N(R X ) 2 —, wherein R X has been defined above.
  • guanidinyl refers to the structure NH 2 C(NH)NH—.
  • an “aliphatic chain” refers to a branched or straight aliphatic group.
  • a straight aliphatic chain has the structure —[CH 2 ] p —, where p is 1-6.
  • a branched aliphatic chain is a straight aliphatic chain that is substituted with one or more aliphatic groups.
  • a branched aliphatic chain has the structure —[CHW] p — where W is hydrogen or an aliphatic group; however, W shall be an aliphatic group in at least one instance.
  • urea refers to the structure —NR X —CO—NR Y R Z and a “thiourea” group refers to the structure —NR X —CS—NR Y R Z .
  • R X , R Y , and R Z have been defined above.
  • substituted refers to the replacement of hydrogen radicals in a given structure with the radical of a specified substituent.
  • Specific substituents are described above in the definitions and below in the description of compounds and examples thereof.
  • an optionally substituted group may have a substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position.
  • a ring substituent such as a heterocycloalkyl
  • substituents envisioned by this invention are those combinations that result in the formation of stable or chemically feasible compounds.
  • stable or chemically feasible refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and preferably their recovery, purification, and use for one or more of the purposes disclosed herein.
  • a stable compound or chemically feasible compound is one that is not substantially altered when kept at a temperature of 40° C. or less, in the absence of moisture or other chemically reactive conditions, for at least a week.
  • an effective amount is defined as the amount required to confer a therapeutic effect on the treated patient, and is typically determined based on age, surface area, weight, and condition of the patient.
  • the interrelationship of dosages for animals and humans (based on milligrams per meter squared of body surface) is described by Freireich et al., Cancer Chemother. Rep., 50: 219 (1966).
  • Body surface area may be approximately determined from height and weight of the patient. See, e.g., Scientific Tables, Geigy Pharmaceuticals, Ardsley, N.Y., 537 (1970).
  • patient refers to a mammal, including a human.
  • patient refers to a mammal, including a human.
  • structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, all tautomeric forms of the compounds of the invention are within the scope of the invention.
  • structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms.
  • compounds having the present structures except for the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 13 C- or 14 C-enriched carbon are within the scope of this invention.
  • Such compounds are useful, for example, as analytical tools or probes in biological assays.
  • the present invention provides a method of modulating a sodium ion channel comprising the step of contacting said ion channel with a compound of formula I:
  • Each X is defined by —Z A R 6 , wherein each Z A is independently a bond or an optionally substituted branched or straight C 1-6 aliphatic chain wherein up to two carbon units of Z A are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONR A —, —CONR A NR A —, —CO 2 —, —OCO—, —NR A CO 2 —, —O—, —NR A CONR A —, —OCONR A —, —NR A NR A , NR A NR A CO—, —NR A CO—, —S—, —SO—, —SO 2 —, —NR A —, —SO 2 NR A —, —NR A SO 2 —, or —NR A SO 2 NR A —.
  • Each R 4 is independently R A , halo, —OH, —NH 2 , —NO 2 , —CN, —CF 3 , or —OCF 3 .
  • Each R A is independently hydrogen, an optionally substituted C 1-8 aliphatic group; a 3-8 membered optionally substituted fully saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; an 8-12 membered optionally substituted fully saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two occurrences of R A are taken together with the atom(s) to which they are attached to form an optionally substituted 3-12 membered fully saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • n 1-4.
  • Each R 1 and R 2 is defined by —Z B R 7 , wherein each Z B is independently a bond or an optionally substituted straight or branched C 1-6 aliphatic chain wherein up to two carbon units of Z B are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONR B —, —CONR B NR B —, —CO 2 —, —OCO—, —NR B CO 2 —, —O—, —NR B CONR B —, —OCONR B —, —NR B NR B , —NR B NR B CO—, —NR B CO—, —S—, —SO—, —SO 2 —, —NR B —, —SO 2 NR B —, —NR B SO 2 —, or —NR B SO 2 NR B —.
  • Each R 7 is independently R B , halo, —OH, —NHC(NH)NH 2 , —NH 2 , —NO 2 , —CN, —CF 3 , or —OCF 3 .
  • Each R B is independently hydrogen, an optionally substituted C 14 aliphatic group, an optionally substituted 3-8 membered fully saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; an optionally substituted 8-12 membered fully saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two occurrences of R B are taken together with the atom(s) to which they are attached to form an optionally substituted 3-12 membered fully saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • Each R 3 and R 4 is defined by —Z C R 8 , wherein each Z C is independently a bond or an optionally substituted straight or branched C 1-6 aliphatic chain wherein up to two carbon units of Z C are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONR C —, —CONR C NR C —, —CO 2 —, —OCO—, —NR C CO 2 —, —O—, —NR C CONR C —, —OCONR C —, —NR C NR C , —NR C NR C CO—, —NR C CO—, —S—, —SO—, —SO 2 —, —NR C —, —SO 2 NR C —, —NR C SO 2 —, or —NR C SO 2 NR C —.
  • Each R 8 is independently R C , halo, —OH, —NH 2 , —NO 2 , —CN, —CF 3 , or —OCF 3 .
  • Each R C is independently hydrogen, or an optionally substituted C 1-3 aliphatic group, an optionally substituted 3-8 membered fully saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; an optionally substituted 8-12 membered fully saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two occurrences of R C are taken together with the atom(s) to which they are attached to form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • Each Y is hydrogen or unsubstituted C 1-3 alkyl.
  • Each R 1 and R 2 are defined by —Z B R 7 , wherein each Z B is independently a bond, or an optionally substituted straight or branched C 1 aliphatic chain wherein up to two carbon units of Z B are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONR B —, —CONR B NR B —, —CO 2 —, —OCO—, —NR B CO 2 —, —O—, —NR B CONR B —, —OCONR B —, —NR B NR B , —NR B NR B CO—, —NR B CO—, —S—, —SO—, —SO 2 —, —NR B —, —SO 2 NR B —, —NR B SO 2 —, or —NR B SO 2 NR B —.
  • Each R 7 is independently R B , halo, —OH, —NHC(NH)NH 2 , —NH 2 , —NO 2 , —CN, —CF 3 , or —OCF 3 .
  • Each R B is independently hydrogen, an optionally substituted C 1-8 aliphatic group, an optionally substituted 3-8 membered fully saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; an optionally substituted 8-12 membered fully saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or two occurrences of R B are taken together with the atom(s) to which they are attached to form an optionally substituted 3-12 membered fully saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, each of which is optionally substituted with 1 to 3 substituents.
  • R 1 and R 2 are independently hydrogen; or C 1-8 aliphatic, araliphatic, heteroaralkyl, alkoxyalkyl, heterocycloaliphatic, guanidinylalkyl, aryloxyalkyl, C 1-6 cycloaliphatic; or R 1 and R 2 together with the nitrogen atom to which they are attached form an optionally substituted 5-8 membered fully saturated, partially unsaturated, or fully unsaturated heterocyclic ring.
  • one of R 1 and R 2 is an optionally substituted araliphatic or arylcycloaliphatic.
  • R 1 or R 2 include —C 1-3 aliphatic-aryl that is optionally substituted.
  • R 1 or R 2 is optionally substituted arylcycloalkyl (e.g., -cyclopropyl-aryl, -cyclobutyl-aryl, -cyclopentyl-aryl, or the like).
  • R 1 or R 2 is optionally substituted monocyclic or bicyclic aralkyl.
  • R 1 or R 2 include optionally substituted —C 1-3 aliphatic-phenyl (e.g., phenylmethyl, phenylethyl, phenylpropyl).
  • R 1 or R 2 is optionally substituted bicyclic —C 1-3 aliphatic-aryl (e.g., —C 1-3 aliphatic-naphthyl or —C 1-3 aliphatic-indenyl).
  • R 1 or R 2 is a naphthylmethyl, naphthylethyl, naphthylpropyl, indenylmethyl, indenylethyl, or indenylpropyl, each of which is optionally substituted.
  • R 1 or R 2 is an unsubstituted naphthylmethyl, naphthylethyl, naphthylpropyl, indenylmethyl, indenylethyl, or indenylpropyl.
  • R 1 or R 2 is a substituted aralkyl or arylcycloalkyl.
  • R 1 or R 2 is an aralkyl that is substituted at any chemically feasible position along the aliphatic chain, or on the aryl group.
  • R 1 or R 2 is substituted with 1-3 of halo, hydroxy, cyano, nitro, aliphatic, haloaliphatic, alkylamino, cycloaliphatic, heterocycloaliphatic, (heterocycloaliphatic)alkyl, aminocarbonyl, aryl, heteroaryl, or combinations thereof, each of which is optionally substituted.
  • R 1 or R 2 is an unsubstituted aralkyl.
  • R 1 or R 2 is an unsubstituted phenylmethyl, unsubstituted phenylethyl, or an unsubstituted phenylpropyl.
  • R 1 or R 2 is a C 1-8 aliphatic that is optionally substituted with 1-3 substituents.
  • R 1 or R 2 are optionally substituted straight (e.g., ethyl, propyl, sec-butyl, or the like) or branched (e.g., isopropyl, isobutyl, sec-propyl, sec-butyl, or the like) aliphatic.
  • R 1 or R 2 is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, or octyl, each substituted with 1-3 substituents (e.g., 1-2 substituents).
  • R 1 or R 2 is an isopropyl that is optionally substituted with 1-2 substituents, or R 1 or R 2 is an unsubstituted isopropyl.
  • R 1 or R 2 is a sec-propyl that is substituted with 1-2 substituents.
  • R 1 or R 2 is substituted with 1-3 halo, cyano, hydroxy, or optionally substituted aryl, aryloxy, alkylamino, heteroaryl, cycloaliphatic, heterocycloaliphatic, or combinations thereof.
  • R 1 or R 2 is substituted with alkoxyalkyl.
  • R 1 or R 2 is unsubstituted methyl or sec-propyl.
  • R 1 or R 2 is an optionally substituted monocyclic or bicyclic cycloaliphatic.
  • R 1 or R 2 is an optionally substituted monocyclic C 3-4 cycloaliphatic.
  • R 1 or R 2 is fully saturated or partially unsaturated.
  • R 1 or R 2 is a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl, each of which is optionally substituted with 1-2 substituents.
  • R 1 or R 2 is unsubstituted cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
  • R 1 or R 2 is substituted cyclopropyl.
  • R 1 or R 2 is substituted with 1-3 of halo, hydroxy, aliphatic, aryl, heteroaryl, or combinations thereof.
  • R 1 or R 2 is an optionally substituted bicyclic cycloaliphatic.
  • R 1 or R 2 is an optionally substituted bridged bicyclic cycloaliphatic.
  • R 1 or R 2 is optionally substituted bicyclo[2.1.1]hexyl, bicyclo[3.1.1]heptyl, or bicyclo[2.2.1]heptyl.
  • R 1 or R 2 is unsubstituted bicyclo[2.1.1]hexyl, or bicyclo[2.2.1]heptyl substituted with 1-3 methyl groups.
  • R 1 or R 2 is 2,6,6-trimethylbicyclo[3.1.1]heptyl.
  • R 1 or R 2 is an optionally substituted aryl.
  • R 1 or R 2 is an optionally substituted 6-10 membered monocyclic or bicyclic aryl.
  • R 1 or R 2 is an optionally substituted phenyl, indenyl, dihydroindenyl or naphthyl.
  • R 1 or R 2 is substituted with 1-2 halo, hydroxy, cyano, or optionally substituted aliphatic, alkoxy, aryl, or heteroaryl; or combinations thereof.
  • R 1 or R 2 is unsubstituted phenyl, indenyl, dihydroindenyl or naphthyl.
  • R 1 or R 2 is an optionally substituted monocyclic or bicyclic heterocycloaliphatic including 1-3 heteroatoms selected from N, O, and S.
  • R 1 or R 2 is fully saturated or partially unsaturated.
  • R 1 or R 2 is an optionally substituted fully saturated monocyclic heterocycloaliphatic.
  • R 1 or R 2 is morpholinyl, pyrroldinyl, thiomorpholinyl, tetrahydro-2H-pyranyl, or tetrahydrothiophenyl, each of which is optionally substituted.
  • R 1 or R 2 is morpholinyl, pyrroldinyl, thiomorpholinyl, tetrahydro-2H-pyranyl, or tetrahydrothiophenyl, each of which is optionally substituted with 1-3 substituents selected from halo, hydroxyl, aliphatic, or aryl.
  • R 1 or R 2 is unsubstituted morpholinyl, thiomorpholinyl, tetrahydro-2H-pyranyl, or tetrahydrothiophenyl.
  • R 1 or R 2 is an unsubstituted tropane.
  • R 1 or R 2 is an optionally substituted heteroaraliphatic.
  • R 1 or R 2 includes a straight or branched aliphatic chain.
  • R 1 or R 2 includes a straight C 1-4 aliphatic chain.
  • R 1 or R 2 is optionally substituted —C 1-3 aliphatic-heteroaryl.
  • R 1 or R 2 can be substituted at any chemically feasible position on the aliphatic chain or on the heteroaryl group.
  • R 1 or R 2 includes a 6-10 membered monocyclic or bicyclic heteroaryl group attached to the core structure with a C 1-3 aliphatic chain.
  • R 1 or R 2 is an optionally substituted 2,3-dihydrobenzofurylalkyl, indolinylalkyl, 2,3-dihydrobenzo[b][1,4]dioxinylalkyl, benzo[d][1,3]dioxolylalkyl, pyridinylalkyl, isoindolinylalkyl, or quinolinylalkyl.
  • R 1 or R 2 is an unsubstituted heteroaralkyl.
  • R 1 or R 2 is an optionally substituted heteroaryl.
  • R 1 or R 2 is 2,3-dihydrobenzo[b][1,4]dioxinyl, or benzo[d][1,3]dioxolyl, each of which is optionally substituted.
  • R 1 or R 2 is unsubstituted 2,3-dihydrobenzo[b][1,4]dioxinyl, or benzo[d][1,3]dioxolyl.
  • R 1 , R 2 , and the nitrogen atom to which they are attached form an optionally substituted 4-12 membered monocyclic or bicyclic fully saturated or partially unsaturated ring having 1-3 heteroatoms.
  • R 1 and R 2 form a morpholinyl, piperadinyl, piperazinyl, pyrrolyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolidinyl, imidazolidinyl, pyrazolyl, pyrazolidinyl, thiomorpholinyl, or 3,4-dihydro-benzo[b][1,4]oxazine, each of which is optionally substituted with 1-3 substituents independently selected from halo, alkylcarbonyl, C 1-4 alkyl, ethyl, alkoxy, and heterocycloalkyl.
  • R 1 , R 2 , and the nitrogen atom to which they are attached form a partially saturated heterocyclic ring that is optionally substituted with 1-2 substituents.
  • R 1 , R 2 , and the nitrogen atom to which they are attached form a substituted 1,2,3,6-tetrahydropyridinyl.
  • R 1 , R 2 , and the nitrogen atom to which they are attached form a piperidinyl, or tetrahydropyridinyl substituted with 1-2 substituents selected from alkyl, alkylcarbonyl, alkoxy, haloaryl, alkoxyaryl, or aryl.
  • R 1 , R 2 , and the nitrogen atom to which they are attached form an unsubstituted fully saturated or partially unsaturated heterocycloaliphatic.
  • R 1 and R 2 together with the nitrogen atom to which they are attached form an optionally substituted 5-10 membered monocyclic or bicyclic ring that is partially unsaturated, or fully unsaturated, and has 1-3 heteroatoms selected from N, O, and S.
  • R 1 and R 2 together with the nitrogen atom to which they are attached form an optionally substituted monocyclic or bicyclic heteroaryl.
  • the heteroaryl formed from R 1 , R 2 , and the nitrogen atom to which they are attached is substituted with 1-3 of halo, cyano, hydroxyl, alkoxy, aliphatic, aryl, or cycloaliphatic.
  • R 1 , R 2 , and the nitrogen atom to which they are attached are optionally substituted indolinyl, 1,2,3,4-tetrahydroquinolinyl, or 3,4-dihydro-2H-benzo[b][1,4]oxazinyl.
  • the heteroaryl formed from R 1 , R 2 , and the nitrogen atom to which they are attached is substituted with 1-2 aliphatic groups.
  • the heteroaryl formed from R 1 , R 2 , and the nitrogen atom to which they are attached is substituted with 1-2 methyl groups.
  • R 1 or R 2 is hydrogen
  • R 1 or R 2 is an optionally substituted guanidinylalkyl having 1-2 substituents. In other embodiments, R 1 or R 2 is an unsubstituted guanidinylalkyl.
  • R 1 and R 2 are each independently selected from: hydrogen, methyl, ethyl,
  • R 1 , R 2 and the nitrogen atom to which they are attached form a heterocycloaliphatic or a heterocycloaliphatic fused with phenyl selected from:
  • Each R 3 and R 4 are defined by —Z C R 8 , wherein each Z C is independently a bond or an optionally substituted straight or branched C 1-6 aliphatic chain wherein up to two carbon units of Z C are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONR C —, —CONR C NR C —, —CO 2 —, —OCO—, —NR C CO 2 —, —O—, —NR C CONR C —, —OCONR C —, —NR C NR C , —NR C NR C CO—, —NR C CO—, —S—, —SO—, —SO 2 —, —NR C —, —SO 2 NR C —, —NR C SO 2 —, or —NR C SO 2 NR C —.
  • Each R g is independently R C , halo, —OH, —NH 2 , —NO 2 , —CN, —CF 3 , or —OCF 3 .
  • Each R C is independently hydrogen, an optionally substituted C 1-8 aliphatic group; an optionally substituted 3-8 membered fully saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; an optionally substituted 8-12 membered fully saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two occurrences of R C are taken together with the atom(s) to which they are attached to form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, each of which is optionally substituted with 1 to 3 substituents.
  • R 3 , R 4 and the nitrogen atom to which they are attached form an optionally substituted 4-8 membered saturated or partially unsaturated monocyclic or bicyclic heterocycloaliphatic.
  • the heterocycloaliphatic formed from the R 3 , R 4 and the nitrogen atom to which they are attached is substituted with 1-3 substituents.
  • R 3 , R 4 and the nitrogen atom to which they are attached form an optionally substituted monocyclic heterocycloaliphatic with 1-3 heteroatoms selected from N, O, and S.
  • R 3 , R 4 and the nitrogen atom to which they are attached form a fully saturated optionally substituted heterocycloaliphatic (e.g., heterocycloalkyl).
  • R 3 , R 4 , and the nitrogen atom to which they are attached form an optionally substituted morpholinyl, thiomorpholinyl, piperadinyl, piperazinyl, pyrrolidinyl, tetrahydrofuranyl, or imidazolinyl.
  • the fully saturated heterocycloaliphatic formed by R 3 , R 4 , and the nitrogen atom to which they are attached is substituted with 1-3 substituents selected from halo, cyano, hydroxy, or optionally substituted C 1-5 aliphatic, heterocycloaliphatic, alkoxy, alkoxycarbonyl, alkylaminocarbonyl, or aralkyl.
  • the heterocycloaliphatic formed from R 3 , R 4 , and the nitrogen atom to which they are attached is a piperadinyl that is substituted with aliphatic, cycloaliphatic, alkoxy, alkoxycarbonyl, heterocycloaliphatic, cycloaliphatic, heteroaralkyl or aralkyl; or it is an unsubstituted piperadinyl.
  • the piperadinyl formed from R 3 , R 4 and the nitrogen atom to which they are attached is substituted with methyl, pyrrolidinyl, cyclopentyl, phenylmethyl, or pryridinylmethyl.
  • R 3 , R 4 , and the nitrogen atom to which they are attached form unsubstituted morpholinyl, thiomorpholinyl, piperadinyl, piperazinyl, pyrrolidinyl, or tetrahydrofuranyl.
  • R 3 , R 4 , and the nitrogen atom to which they are attached form an alkyl substituted piperazinyl or morpholinyl.
  • R 3 , R 4 , and the nitrogen atom to which they are attached form a piperazinyl or morpholinyl that is optionally substituted with 1-2 alkyl groups.
  • R 3 , R 4 , and the nitrogen atom to which they are attached form a piperazinyl or a morpholinyl, each of which is substituted with 1-2 alkyl groups.
  • R 3 , R 4 , and the nitrogen atom to which they are attached form an optionally substituted fully saturated or partially unsaturated bicyclic heterocycloaliphatic.
  • the bicyclic heterocycloaliphatic formed from R 3 , R 4 , and the nitrogen atom to which they are attached has 1-3 heteroatoms selected from N, O, and S.
  • the heterocycloaliphatic formed by R 3 , R 4 , and the nitrogen atom to which they are attached is substituted with 1-3 substituents.
  • R 3 , R 4 , and the nitrogen atom to which they are attached form an optionally substituted decahydroquinaolinyl, tropane, or octahydroindolyl. In several embodiments, R 3 , R 4 , and the nitrogen atom to which they are attached form an unsubstituted decahydroquinaolinyl. In several other embodiments, R 3 , R 4 , and the nitrogen atom to which they are attached form a decahydroquinolinyl that is optionally substituted with 1-2 methyl groups.
  • R 3 , R 4 , and the nitrogen atom to which they are attached form an optionally substituted 6-10 membered heteroaryl.
  • the heteroaryl formed by R 3 , R 4 , and the nitrogen atom to which they are attached is substituted with 1-3 substituents.
  • the optionally substituted heteroaryl formed by R 3 , R 4 , and the nitrogen atom to which they are attached is a monocyclic or bicyclic ring system.
  • R 3 , R 4 , and the nitrogen atom to which they are attached form optionally substituted 1,2,3,4-tetrahydroquinolinyl, or octahydroisoindolyl.
  • R 3 , R 4 , and the nitrogen atom to which they are attached form unsubstituted 1,2,3,4-tetrahydroquinolinyl, or octahydroisoindolyl.
  • R 3 or R 4 is an optionally substituted 6-10 membered monocyclic or bicyclic aryl.
  • R 3 or R 4 is substituted with 1-3 substituents.
  • R 3 or R 4 is an optionally substituted monocyclic aryl.
  • R 3 or R 4 is a monocyclic aryl substituted with 1-3 of halo, cyano, hydroxy, methyl, alkoxy, alkoxycarbonyl, C 1-6 aliphatic, aminocarbonyl, or combinations thereof.
  • R 3 or R 4 is a phenyl.
  • R 3 or R 4 is an optionally substituted bicyclic aryl.
  • R 3 or R 4 is an optionally substituted naphthyl or indenyl.
  • R 3 or R 4 is substituted with 1-3 substituents.
  • R 3 or R 4 is substituted with 1-3 substituents selected from halo, cyano, hydroxy, alkoxy, alkoxycarbonyl, alkylaminocarbonyl, C 1-4 aliphatic, aryl or heteroaryl.
  • R 3 or R 4 is an unsubstituted naphthyl or indenyl.
  • R 3 or R 4 is an optionally substituted straight or branched C 1-8 aliphatic.
  • R 3 or R 4 is optionally substituted straight (e.g., methyl, ethyl, propyl, butyl, or the like) or branched (e.g., isopropyl, isobutyl, sec-propyl, sec-butyl or the like) aliphatic.
  • R 3 or R 4 is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, or octyl, each substituted with 1-3 substituents (e.g., 1-2 substituents).
  • R 3 or R 4 is an isopropyl or sec-propyl that is optionally substituted with 1-3 substituents (e.g., 1-2 substituents), or R 3 or R 4 is an unsubstituted sec-propyl or isopropyl. In several embodiments, R 3 or R 4 is unsubstituted methyl, ethyl, propyl, butyl, pentyl, or hexyl. In other embodiments, R 3 or R 4 is a —C(O)OH substituted aliphatic (e.g., alkyl-C(O)OH).
  • R 3 or R 4 is a methyl, ethyl, or propyl, each of which is substituted with —C(O)OH.
  • R 3 or R 4 is substituted with 1-2 substituents including halo, cyano, hydroxy, or optionally substituted cycloaliphatic, heterocycloaliphatic, aryl, alkoxy, haloalkylaryl, bicycloaliphatic, aryloxy, haloaryl, alkylamino, heteroaryl, cycloaliphatic, heterocycloaliphaticpropyl, isopropyl, or combinations thereof.
  • R 3 or R 4 is methyl, ethyl, or propyl that is substituted with a monocyclic optionally substituted aryl.
  • R 3 or R 4 is methyl, ethyl, or propyl that is substituted with alkoxyphenyl, cycloaliphaticphenyl, haloalkylphenyl, cyanophenyl, halophenyl, or hydroxyphenyl.
  • R 3 or R 4 is methyl, ethyl, or propyl that is substituted with a bicyclic aryl.
  • R 3 or R 4 is methyl, ethyl, or propyl that is substituted with unsubstituted naphthyl or indenyl.
  • R 3 or R 4 is substituted with two substituents independently selected from halo, cyano, hydroxyl, aliphatic, aryl, heteroaryl, cycloaliphatic, heterocycloaliphatic, or alkoxy.
  • R 3 or R 4 is methyl substituted with aliphatic and aryl.
  • R 3 or R 4 includes an optionally substituted partially unsaturated aliphatic (e.g., alkenyl or alkynyl).
  • R 3 or R 4 includes optionally substituted ethenyl, propenyl, or butenyl.
  • R 3 or R 4 includes unsubstituted propenyl.
  • R 3 or R 4 is an optionally substituted heteroaryl.
  • R 3 or R 4 is an optionally substituted 6-10 membered monocyclic or bicyclic heteroaryl.
  • R 3 or R 4 is a monocyclic heteroaryl optionally substituted with 1-3 substituents.
  • R 3 or R 4 is a substituted pyridinyl, pyrimidinyl, pyridazinyl, or pyrazinyl.
  • R 3 or R 4 is an unsubstituted pyridinyl, pyrimidinyl, pyridazinyl, or pyrazinyl.
  • R 3 or R 4 is an optionally substituted bicyclic heteroaryl.
  • R 3 or R 4 is a bicyclic heteroaryl substituted with 1-3 substituents.
  • R 3 or R 4 is an optionally substituted isoindolinyl.
  • R 3 or R 4 is unsubstituted isoindolinyl.
  • R 3 or R 4 is an optionally substituted monocyclic or bicyclic cycloaliphatic.
  • R 3 or R 4 is a monocyclic cycloaliphatic optionally substituted with 1-3 substituents including hydroxy, alkoxy, alkylamino, alkyl carbonyl, aliphatic, halo, or combinations thereof.
  • R 3 or R 4 is optionally substituted cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl.
  • R 3 or R 4 is unsubstituted cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl.
  • R 3 or R 4 is optionally substituted bicycloaliphatic.
  • R 3 or R 4 is bicycloaliphatic or bridged bicycloaliphatic optionally substituted with 1-3 substituents selected from hydroxy, alkoxy, alkylamino, alkyl carbonyl, aliphatic, and halo.
  • R 3 or R 4 is optionally substituted bicyclo[2.1.1]hexyl, bicyclo[3.1.1]heptyl, or bicyclo[2.2.1]heptyl. In other examples R 3 or R 4 is unsubstituted bicyclo[2.1.1]hexyl, or bicyclo[2.2.1]heptyl.
  • R 3 or R 4 is hydrogen
  • each R 3 , R 4 is independently selected from: hydrogen, methyl, ethyl,
  • R 3 , R 4 , and the nitrogen atom to which they are attached is one selected from:
  • Each X is defined by —Z A R 6 , wherein Z A is independently a bond or an optionally substituted branched or straight C 1-6 aliphatic chain wherein up to two carbon units of Z A are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONR A —, —CONR A NR A —, —CO 2 —, —OCO—, —NR A CO 2 —, —O—, —NR A CONR A —, —OCONR A —, —NR A NR A , —NR A NR A CO—, —NR A CO—, —S—, —SO—, —SO 2 —, —NR A —, —SO 2 NR A —, —NR A SO 2 —, or —NR A SO 2 NR A —.
  • Each R 6 is independently R A , halo, —OH, —NH 2 , —NO 2 , —CN, —CF 3 , or —OCF 3 .
  • Each R A is independently hydrogen, an optionally substituted C 1-3 aliphatic group; a 3-8-membered optionally substituted fully saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; an 8-12 membered optionally substituted fully saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two occurrences of R A are taken together with the atom(s) to which they are attached to form an optionally substituted 3-12 membered fully saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • X is a C 1-6 aliphatic that is optionally substituted and branched or straight.
  • X is an optionally substituted branched or straight C 1-6 aliphatic that is fully saturated or partially unsaturated.
  • X is fully saturated (e.g., alkyl).
  • X is methyl, ethyl, propyl, butyl, pentyl, or hexyl, each of which is optionally substituted with 1-3 substituents.
  • X is an optionally substituted branched aliphatic.
  • X is an isopropyl, isobutyl, isopentane, sec-butyl, or sec-propyl, each of which is optionally substituted with 1-2 substituents.
  • X is an unsubstituted C 1-6 aliphatic.
  • X is unsubstituted methyl, ethyl, propyl, butyl, pentyl, or hexyl.
  • X is substituted with 1-3 substituents independently selected from alkylcarbonyl, alkoxy, —C(O)OH, aryl, heteroaryl, cycloaliphatic, heterocycloaliphatic, and alkylamino.
  • X is optionally substituted C 1-6 aliphatic that is partially unsaturated.
  • X is an optionally substituted C 1-6 aliphatic that has at least 1 C—C double bond, or at least 1 C—C triple bond.
  • X is optionally substituted ethenyl, propenyl, but-1-enyl, or but-2-enyl.
  • X is substituted with 1-3 substituents independently selected from alkylcarbonyl, alkoxy, —C(O)OH, aryl, heteroaryl, cycloaliphatic, heterocycloaliphatic, and alkylamino.
  • X is ethenyl substituted with —C(O)OH (e.g., acrylic acid).
  • X is an optionally substituted C 1-6 alkoxy.
  • the alkyl group of the alkoxy can be optionally substituted with 1-3 substituents.
  • X is methoxy, ethoxy, propoxy, butoxy, pentoxy, or hexoxy, each of which is optionally substituted.
  • X is prop-2-oxy, but-2-oxy, pent-2-oxy, or pent-3-oxy, each of which is optionally substituted.
  • X is unsubstituted prop-2-oxy, but-2-oxy, pent-2-oxy, or pent-3-oxy.
  • X is substituted with a C 1-3 aliphatic group.
  • X is ethoxy, propoxy, butoxy, pentoxy, or hexoxy, each of which is substituted with methyl or ethyl.
  • X is an optionally substituted ring system that that is fully saturated, partially unsaturated, or fully unsaturated and attaches to the core phenyl with an oxy (—O—) group.
  • X is selected from optionally substituted aryloxy, heteroaryloxy, cycloaliphaticoxy, or heterocycloaliphaticoxy.
  • X is an unsubstituted aryloxy, heteroaryloxy, cycloaliphaticoxy, or heterocycloaliphaticoxy.
  • X is an unsubstituted phenoxy.
  • X is a phenoxy that is substituted with 1-3 substituents selected from halo, —CF 3 , alkoxy, alkylcarbonyl, and cyano.
  • X is an optionally substituted amino.
  • X is substituted with 1-3 substituents selected from aliphatic, alkoxy, alkylsulfonyl, alkylcarbonyl, aryl, heteroaryl, cycloaliphatic, and heterocycloaliphatic.
  • X is alkylcarbonylamino.
  • X is a halo (e.g., F, Cl, Br, or I).
  • each X is independently selected from: halo,
  • Each Y is hydrogen, or optionally substituted methyl.
  • n 1-4.
  • Y is methyl
  • n 1 or 2.
  • Another aspect of the present invention includes compounds of formula Ia:
  • R 1 , R 2 , R 3 , R 4 , X and n are defined above.
  • R 1 when R 1 is alkyl, R 2 is not 3,5-bis-trifluoromethyl-phenyl-alkyl; when R 1 and R 2 together form pyrrolidinyl, morpholinyl, or piperidinyl, each optionally substituted with —CH 3 or —CH 2 CH 3 , then X is not m-methyl, o-halo, p-aryl, or p-cyano; when R 1 or R 2 are aliphatic or alkoxyalkyl, then X is not m-methyl, o-halo, p-aryl, or p-cyano; and when R 1 is phenylmethyl optionally substituted with 1-2 —CH 3 groups or cycloaliphatic, and R 2 is one selected from substituted methyl, ethyl, and isopropyl, then
  • R 3 or R 4 is heterocycloaliphatic, bicycloaryl, bicycloheteroaliphatic, bicycloheteroaryl, heterocycloalkenyl, cycloaliphatic, alkenyl, 5-membered heterocycloaliphatic, heteroaralkyl, or bicycloaralkyl, each of which is optionally substituted; or one of R 3 and R 4 is hydrogen, R 3 or R 4 is alkyl substituted with cycloaliphatic, heteroaryl, heterocycloaliphatic, cyano, alkoxycarbonyl, —C(O)OH, guanidinylalkyl, bicycloaryl, halo, or alkoxy, or R 3 together with R 4 form a ring system selected from thiomorpholinyl, bicycloheteroaryl, bicyclic heterocycloaliphatic, 5-membered heterocycloaliphatic, and 6-membered heterocycloalkenyl, provided that when
  • Another aspect of the present invention includes compounds of formula II:
  • R 1 , R 2 , X, n, and Y are defined above.
  • Each V is one selected from —CH—, —CH 2 —, —N—, —O—, and —S—.
  • Each m is 1 or 2.
  • Each R 9 and R 10 are defined by —Z D R 14 , wherein each Z D is independently a bond or an optionally substituted straight or branched C 1-6 aliphatic chain wherein up to two carbon units of Z D are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONR D —, —CONR D NR D —, —CO 2 —, —OCO—, —NR D CO 2 —, —O—, —NR D CONR D —, —OCONR D —, —NR D NR D , —NR D NR D CO—, —NR D CO—, —S—, —SO—, —SO 2 —, —NR D —, —SO 2 NR D —, —NR D SO 2 —, or —NR D SO 2 NR D —.
  • Each R 14 is independently R D , halo, —OH, —NH 2 , —NO 2 , —CN, —CF 3 , or —OCF 3 .
  • Each R D is independently hydrogen, or an optionally substituted C 1-8 aliphatic group, an optionally substituted 3-8 membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two occurrences of R D are taken together with the atom(s) to which they are attached form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, each of which is optionally substituted with 1 to 3 substituents.
  • R 1 or R 2 when R 1 or R 2 is 3,5-bis-trifluoromethylphenylmethyl, ring A together with R 9 and R 10 is not piperazinyl, optionally substituted piperidinyl, morpholinyl, or imidazolyl; when R 1 and R 2 together form pyrrolidinyl, morpholinyl, piperidinyl, each optionally substituted with —CH 3 or —CH 2 CH 3 , then X is not m-methyl, o-halo, p-aryl, and p-cyano; when R 1 and R 2 are aliphatic or alkoxyalkyl, then X is not from m-methyl, o-halo, p-aryl, and p-cyano; and when R 1 is phenylmethyl optionally substituted with 1-2 —CH 3 groups or cycloaliphatic, and R 2 is one selected from unsubstituted methyl, ethyl, and isopropyl, then
  • Each R 9 and R 10 is hydrogen, halo, hydroxy, cyano, or C 1-6 aliphatic, alkoxy, alkoxycarbonyl, alkoxycarbonylamino, aryl, heteroaryl, aralkyl, heteroaralkyl, cycloaliphatic, or heterocycloaliphatic, each of which is optionally substituted with 1-3 substituents; or R 9 and R 10 together with the atom(s) to which they are attached form a 5-6 membered ring that is optionally substituted with 1-3 substituents.
  • R 9 or R 10 is an optionally substituted C 1-6 aliphatic.
  • R 9 or R 10 is an optionally substituted straight or branched C 1-6 aliphatic.
  • R 9 or R 10 is optionally substituted straight (e.g., methyl, ethyl, propyl, butyl, or the like) or branched (e.g., isopropyl, isobutyl, sec-propyl, sec-butyl or the like) aliphatic.
  • R 9 or R 10 is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, or octyl, each substituted with 1-3 substituents.
  • R 9 or R 10 is an isopropyl or sec-propyl that is optionally substituted with 1-2 substituents, or R 9 or R 10 is an unsubstituted sec-propyl or isopropyl.
  • R 9 or R 10 is unsubstituted methyl, ethyl, propyl, butyl, pentyl, or hexyl.
  • R 9 or R 10 is a —C(O)OH substituted aliphatic (e.g., hydroxycarbonylalkyl).
  • R 9 or R 10 is a methyl, ethyl, or propyl, each of which is substituted with —C(O)OH.
  • R 9 or R 10 is substituted with halo, cyano, hydroxy, or optionally substituted cycloaliphatic, heterocycloaliphatic, aryl, alkoxy, haloalkylaryl, bicycloaliphatic, aryloxy, haloaryl, alkylamino, heteroaryl, cycloaliphatic, or heterocycloaliphatic.
  • R 9 or R 10 is methyl, ethyl, or propyl that is substituted with a monocyclic optionally substituted aryl.
  • R 9 or R 10 is methyl, ethyl, or propyl that is substituted with alkoxyphenyl, cycloaliphaticphenyl, haloalkylphenyl, cyanophenyl, halophenyl, or hydroxyphenyl.
  • R 9 or R 10 is methyl, ethyl, or propyl that is substituted with a bicyclic aryl.
  • R 9 or R 10 is methyl, ethyl, or propyl that is substituted with unsubstituted naphthyl or indenyl.
  • R 9 or R 10 is di-substituted with two substituents independently selected from halo, cyano, hydroxyl, aliphatic, aryl, heteroaryl, cycloaliphatic, heterocycloaliphatic, or alkoxy.
  • R 9 or R 10 is methyl substituted with aliphatic and aryl.
  • R 9 or R 10 includes an optionally substituted partially unsaturated aliphatic (e.g., alkenyl or alkynyl).
  • R 9 or R 10 includes optionally substituted ethenyl, propenyl, or butenyl.
  • R 9 or R 10 includes unsubstituted methyl or propenyl.
  • R 9 , R 10 , and the atom(s) to which they are attached form a 5-6 membered ring that is optionally substituted with 1-3 substituents.
  • R 9 and R 10 are attached to different carbon atoms and together with the carbon atoms form an optionally substituted 5-6 membered ring that is fused to ring A of formula II.
  • R 9 , R 10 , and the carbon atoms to which they are attached form an optionally substituted fully saturated, partially unsaturated, or fully unsaturated ring that is optionally substituted.
  • R 9 , R 10 , and the carbon atoms to which they are attached form a fully saturated 5-6 membered ring that is optionally substituted.
  • R 9 , R 10 , and the carbon atoms to which they are attached form a 5-6 membered cycloalkyl or heterocycloalkyl that is optionally substituted.
  • R 9 , R 10 , and the carbon atoms to which they are attached form an optionally substituted cyclohexyl or cyclopentyl ring that is fused to ring A.
  • R 9 , R 10 , and the carbon atoms to which they are attached form an unsubstituted cyclohexyl that is fused to ring A to create an unsubstituted decahydroquinolinyl or octahydroindolyl.
  • R 9 , R 10 , and the carbon atoms to which they are attached form an unsubstituted cyclopentyl that is fused to ring A to create an unsubstituted octahydrocyclopenta[b]pyridinyl or octahydrocyclopenta[b]pyrrolyl.
  • R 9 , R 10 , and the carbon atoms to which they are attached form a cycloalkyl ring that is fused to ring A and substituted with halo, aliphatic, alkoxy, cycloaliphatic, heterocycloaliphatic, aryl or heteroaryl.
  • R 9 , R 10 , and the carbon atoms to which they are attached form an optionally substituted aryl ring that is fused to ring A.
  • R 9 , R 10 , and the carbon atoms to which they are attached form an optionally substituted phenyl that is fused to ring A to form a substituted or unsubstituted 1,2,3,4-tetrahydroquinolinyl or indolinyl.
  • R 9 or R 10 is an optionally substituted alkoxy.
  • the aliphatic chain of the alkoxy can be straight or branched and substituted at any chemically feasible position.
  • R 9 or R 10 is an optionally substituted methoxy, ethoxy, propoxy, butoxy, pentoxy, or hexoxy. In other embodiments, R 9 or R 10 is unsubstituted.
  • R 9 or R 10 is an optionally substituted alkoxy carbonyl.
  • the aliphatic chain of the alkoxy can be straight or branched and substituted at any chemically feasible position.
  • R 9 or R 10 is an optionally substituted methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, pentoxycarbonyl, or hexoxycarbonyl.
  • R 9 or R 10 is an optionally substituted monocyclic or bicyclic cycloaliphatic.
  • R 9 or R 10 is a monocyclic cycloaliphatic optionally substituted with 1-3 substituents selected from hydroxy, alkoxy, alkylamino, alkyl carbonyl, aliphatic, and halo.
  • R 9 or R 10 is optionally substituted cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl.
  • R 9 or R 10 is unsubstituted cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl.
  • R 9 or R 10 is optionally substituted bicycloaliphatic.
  • R 9 or R 10 is bicycloaliphatic optionally substituted with 1-3 substituents selected from hydroxy, alkoxy, alkylamino, alkyl carbonyl, aliphatic, and halo.
  • R 9 or R 10 is optionally substituted bicyclo[1.1.1]pentane, bicyclo[2.1.1]hexane, or bicyclo[2.2.1]heptane.
  • R 9 or R 10 is unsubstituted bicyclo[2.1.1]hexyl, or bicyclo[2.2.1]heptyl.
  • R 9 or R 10 is an optionally substituted monocyclic or bicyclic heterocycloaliphatic including 1-3 heteroatoms selected from N, O, and S.
  • R 9 or R 10 is fully saturated or partially unsaturated.
  • R 9 or R 10 is an optionally substituted fully saturated monocyclic heterocycloaliphatic.
  • R 9 or R 10 is morpholinyl, pyrroldinyl, thiomorpholinyl, tetrahydro-2H-pyranyl, or tetrahydrothiophenyl, each optionally substituted with 1-3 substituents.
  • R 9 or R 10 is unsubstituted morpholinyl, pyrrolidinyl, thiomorpholinyl, tetrahydro-2H-pyranyl, or tetrahydrothiophenyl. In another group of examples, R 9 or R 10 is an unsubstituted tropane.
  • R 9 and R 10 are hydrogen, neither R 1 nor R 2 are H, —CH 3 , or —CH 3 C 6 H 5 .
  • Another aspect of the present invention includes compounds of formula III:
  • Each U is one selected from —CH—, —CH 2 —, —N—, —O—, and —S—.
  • Each p is 1 or 2.
  • Each R 12 and R 13 are defined by —Z E R 15 , wherein each Z E is independently a bond or an optionally substituted straight or branched C 1-6 aliphatic chain wherein up to two carbon units of Z C are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONR E —, —CONR E NR E —CO 2 —, —OCO—, —NR E CO 2 —, —O—, —NR E CONR E —, —OCONR E —, —NR E NR E , —NR E NR E CO—, —NR E CO—, —S—, —SO—, —SO 2 —, —NR E —, —SO 2 NR E —, —NR E SO 2 —, or —NR E SO 2 NR E —.
  • Each R 15 is independently R E , halo, —OH, —NH 2 , —NO 2 , —CN, —CF 3 , or —OCF 3 .
  • Each R E is independently hydrogen, an optionally substituted C 1-8 aliphatic group, an optionally substituted 3-8 membered fully saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; an optionally substituted 8-12 membered fully saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two occurrences of R E are taken together with the atom(s) to which they are attached to form an optionally substituted 3-12 membered fully saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, each of which is optionally substituted with 1 to 3 substituents.
  • X is not m-methyl, o-halo, p-aryl, or p-cyano.
  • Each R 12 and R 13 is hydrogen, halo, hydroxy, cyano, or C 1-4 aliphatic, alkoxy, alkoxycarbonyl, alkoxycarbonylamino, aryl, heteroaryl, aralkyl, heteroaralkyl, cycloaliphatic, or heterocycloaliphatic, each of which is optionally substituted with 1-3 substituents; or R 12 and R 13 together with the atom(s) to which they are attached form a 5-6 membered ring that is optionally substituted with 1-3 substituents.
  • R 12 , R 13 , and the atom(s) to which they are attached form a 5-6 membered ring that is optionally substituted with 1-3 substituents.
  • R 12 and R 13 are attached to different carbon atoms and together with the carbon atoms form an optionally substituted 5-6 membered ring that is fused to ring B of formula III.
  • R 12 , R 13 , and the carbon atoms to which they are attached form an optionally substituted fully saturated, partially unsaturated, or fully unsaturated ring that is optionally substituted.
  • R 12 , R 13 , and the carbon atoms to which they are attached form a fully saturated 5-6 membered ring that is optionally substituted.
  • R 12 , R 13 , and the carbon atoms to which they are attached form a 5-6 membered cycloalkyl or heterocycloalkyl that is optionally substituted.
  • R 12 , R 13 , and the carbon atoms to which they are attached form an optionally substituted cyclohexyl or cyclopentyl ring that is fused to ring B.
  • R 12 , R 13 , and the carbon atoms to which they are attached form an unsubstituted cyclohexyl that is fused to ring B to create an unsubstituted decahydroquinolinyl or octahydroindolyl.
  • R 12 , R 13 , and the carbon atoms to which they are attached form an unsubstituted cyclopentyl that is fused to ring B to create an unsubstituted octahydrocyclopenta[b]pyridinyl or octahydrocyclopenta[b]pyrrolyl.
  • R 12 , R 13 , and the carbon atoms to which they are attached form a cycloalkyl ring that is fused to ring B and is substituted with halo, aliphatic, alkoxy, cycloaliphatic, heterocycloaliphatic, aryl or heteroaryl.
  • R 12 , R 13 , and the carbon atoms to which they are attached form an optionally substituted aryl ring that is fused to ring B.
  • R 12 , R 13 , and the carbon atoms to which they are attached form an optionally substituted phenyl that is fused to ring B to form a substituted or unsubstituted 1,2,3,4-tetrahydroquinolinyl or indolinyl.
  • R 12 , R 13 , and the carbon atoms to which they are attached form a mono- or di-substituted phenyl.
  • R 12 , R 13 , and the carbon atoms to which they are attached form a phenyl that is substituted with alkoxy (e.g., methoxy), aliphatic, alkylcarbonyl, or alkoxycarbonyl.
  • alkoxy e.g., methoxy
  • R 12 , R 13 , and the carbon atoms to which they are attached form a phenyl substituted with 1-2 methoxy groups that is fused to ring B.
  • R 12 or R 13 is optionally substituted aryl.
  • R 12 or R 13 is aryl substituted with 1-2 substituents.
  • R 12 or R 13 is aryl substituted with aliphatic, halo, hydroxy, cyano, aryl, alkoxy, alkylcarbonyl, or alkoxycarbonyl.
  • R 12 or R 13 is unsubstituted.
  • R 12 or R 13 is an optionally substituted alkoxy.
  • R 12 or R 13 is optionally substituted C 1-6 -alkoxy.
  • R 12 or R 13 is optionally substituted methoxy, ethoxy, propoxy, butoxy, pentoxy, or hexoxy.
  • R 12 or R 13 is substituted with aliphatic, aryl, heteroaryl, cycloaliphatic, or heterocycloaliphatic.
  • R 12 or R 13 is unsubstituted methoxy, ethoxy, propoxy, butoxy, pentoxy, or hexoxy.
  • R 12 or R 13 is optionally substituted alkylcarbonyl.
  • R 12 or R 13 is optionally substituted C 1-6 -alkyl-carbonyl.
  • Other examples include methylcarbonyl, ethylcarbonyl, propylcarbonyl, butylcarbonyl, pentylcarbonyl, or hexylcarbonyl, each of which is optionally substituted with 1-2 substituents.
  • R 12 or R 13 is substituted with aliphatic, amino, hydroxyl, aryl, or heteroaryl.
  • R 12 or R 13 is unsubstituted methylcarbonyl, ethylcarbonyl, propylcarbonyl, butylcarbonyl, pentylcarbonyl, or hexylcarbonyl.
  • R 12 or R 13 is an optionally substituted C 1-6 aliphatic.
  • R 12 or R 13 is an optionally substituted straight or branched C 1-6 aliphatic.
  • R 12 or R 13 is optionally substituted straight (e.g., methyl, ethyl, propyl, butyl, or the like) or branched (e.g., isopropyl, isobutyl, sec-propyl, sec-butyl or the like) aliphatic.
  • R 12 or R 13 is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, or octyl, each substituted with 1-3 substituents.
  • R 12 or R 13 is an isopropyl or sec-propyl that is optionally substituted with 1-2 substituents, or R 12 or R 13 is an unsubstituted sec-propyl or isopropyl.
  • R 12 or R 13 is unsubstituted methyl, ethyl, propyl, butyl, pentyl, or hexyl.
  • R 12 or R 13 is a —C(O)OH substituted aliphatic (e.g., alkyl-C(O)OH).
  • R 12 or R 13 is a methyl, ethyl, or propyl, each of which is substituted with —C(O)OH.
  • R 12 or R 13 is substituted with halo, cyano, hydroxy, or optionally substituted cycloaliphatic, heterocycloaliphatic, aryl, alkoxy, haloalkylaryl, bicycloaliphatic, aryloxy, haloaryl, alkylamino, heteroaryl, cycloaliphatic, or heterocycloaliphatic.
  • R 12 or R 13 is methyl, ethyl, or propyl that is substituted with a monocyclic optionally substituted aryl.
  • R 12 or R 13 is methyl, ethyl, or propyl that is substituted with alkoxyphenyl, cycloaliphaticphenyl, haloalkylphenyl, cyanophenyl, halophenyl, or hydroxyphenyl.
  • R 12 or R 13 is methyl, ethyl, or propyl that is substituted with a bicyclic aryl.
  • R 12 or R 13 is methyl, ethyl, or propyl that is substituted with unsubstituted naphthyl or indenyl.
  • R 12 or R 13 is di-substituted with two substituents independently selected from halo, cyano, hydroxyl, aliphatic, aryl, heteroaryl, cycloaliphatic, heterocycloaliphatic, or alkoxy.
  • R 12 or R 13 is methyl substituted with aliphatic and aryl.
  • R 12 or R 13 includes an optionally substituted partially unsaturated aliphatic (e.g., alkenyl or alkynyl).
  • R 12 or R 13 includes optionally substituted ethenyl, propenyl, or butenyl.
  • R 12 or R 13 includes unsubstituted methyl or propenyl.
  • R 1 is alkyl
  • R 2 is not 3,5-bis-trifluoromethyl-phenyl-alkyl
  • R 1 and R 2 together form pyrrolidinyl, morpholinyl, or piperidinyl, each optionally substituted with —CH 3 or —CH 2 CH 3 , then X is not m-methyl, o-halo, p-aryl, or p-cyano.
  • R 1 or R 2 is aliphatic or alkoxyalkyl
  • X is not m-methyl, o-halo, p-aryl, and p-cyano.
  • R 1 is phenylmethyl optionally substituted with 1-2 —CH 3 groups or cycloaliphatic
  • R 2 is unsubstituted methyl, ethyl, or isopropyl
  • R 3 together with R 4 must form pyrrolidinyl, morpholinyl, piperidinyl optionally substituted with aliphatic, aminocarbonyl, or alkylcarbonyl
  • each R 3 or R 4 is phenylmethyl, methylfuranyl, or methoxypropyl
  • X is not m-methyl, p-aryl, o-halo or p-cyano.
  • Exemplary compounds of the present invention include, but are not limited to, those illustrated in Table 1 below.
  • R 5 is a C 1-5 alkyl.
  • Reaction of the keto-ester b with a formamide dialkylacetal such as, for example, dimethylformamide dimethylacetal provides the aminomethylene compound c.
  • Reaction of d with 2-methylisothiourea sulfate in the presence of sodium acetate provides the thiopyrimidine e.
  • Oxidation off with a suitable oxidizing reagent provides the sulfoxo-pyrimidine f.
  • Suitable oxidizing reagents include, for example, m-chloroperbenzoic acid.
  • Reaction off with the amine R 3 R 4 NH provides the 2-aminopyrimidine g.
  • Hydrolysis of g with, for example, an alkaline earth hydroxide such as potassium hydroxide or sodium hydroxide provides the acid g.
  • Conversion of g to the amide a, compounds of the invention can be achieved by converting the acid g first to an active acid derivative such as, for example, an acid chloride followed by reaction of the active derivative with the amine R 1 R 2 NH.
  • the amide formation may be achieved by reaction of g with the amine R 1 R 2 NH in the presence of a suitable coupling reagent such as, for example, EDC or HATU.
  • Acid addition salts such as, for example, a hydrochloride, may be prepared by reaction of the basic compound 1 with an acid in a solvent from which the salt will precipitate such as, for example, diethylether.
  • condensation of an aryl aldehyde with an acetoacetate ester and urea in the presence of a catalyst such as, for example, cuprous chloride and a Lewis acid such as, for example, borontrifluoride ethereate provides the dihydropyrimidinone j.
  • Oxidation of h with, for example, 60% nitric acid gives the pyrimidinone k.
  • Condensation of with an amine HNR 3 R 4 in the presence of a condensation reagent such as, for example, PyBrop (Bromo-tris-pyrrolidino phosphoniumhexafluorophosphate) provides the aminopyridine f. Conversion off to the compounds of the invention can be achieved as described above in Scheme 1.
  • the amine intermediates HNR 1 R 2 are commercially available, known in the art, or may be prepared by known reductive amination methods or condensation of the amine with an aryl halide using known methodology and as illustrated in the Examples herein.
  • the pyrimidinedione a′ is converted to the dichloropyrimidine b′ by reaction with phosphorous oxychloride in the presence of dimethylformamide.
  • Coupling of b′ with an arylboronic acid in the presence of a palladium catalyst such as, for example, Pd 2 (dba) 3 and a trialkylphosphine such as, for example, tri-t-butyl phosphine provides the aryl substituted pyrimidine c′.
  • Displacement of the chloro group in c′ with the amine HNR 3 R 4 provides the aminopyrimidine d′.
  • Hydrolysis of the ester in d′ with, for example, sodium hydroxide in ethanol provides the corresponding acid which is converted to the compounds of the invention a using known amide forming conditions.
  • compositions A. Pharmaceutically Acceptable Compositions
  • the present invention provides compounds that are inhibitors of voltage-gated sodium ion channels and/or calcium channels, and thus the present compounds are useful for the treatment of diseases, disorders, and conditions including, but not limited to acute, chronic, neuropathic, or inflammatory pain, arthritis, migraine, cluster headaches, trigeminal neuralgia, herpetic neuralgia, general neuralgias, epilepsy or epilepsy conditions, neurodegenerative disorders, psychiatric disorders such as anxiety and depression, myotonia, arrhythmia, movement disorders, neuroendocrine disorders, ataxia, multiple sclerosis, irritable bowel syndrome, and incontinence.
  • diseases, disorders, and conditions including, but not limited to acute, chronic, neuropathic, or inflammatory pain, arthritis, migraine, cluster headaches, trigeminal neuralgia, herpetic neuralgia, general neuralgias, epilepsy or epilepsy conditions, neurodegenerative disorders, psychiatric disorders such as anxiety and depression, myotonia, arrhythm
  • compositions comprising any of the compounds as described herein, and optionally comprise a pharmaceutically acceptable carrier, adjuvant or vehicle.
  • these compositions optionally further comprise one or more additional therapeutic agents.
  • a pharmaceutically acceptable derivative includes, but is not limited to, pharmaceutically acceptable salts, esters, salts of such esters, or any other adduct or derivative which upon administration to a patient in need is capable of providing, directly or indirectly, a compound as otherwise described herein, or a metabolite or residue thereof.
  • the term “pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
  • a “pharmaceutically acceptable salt” means any non-toxic salt or salt of an ester of a compound of this invention that, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or an inhibitorily active metabolite or residue thereof.
  • the term “inhibitorily active metabolite or residue thereof” means that a metabolite or residue thereof is also an inhibitor of a voltage-gated sodium ion channel or calcium channel.
  • Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge, et al. describes pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference.
  • Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases.
  • Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
  • salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate,
  • Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N + (C 1-4 alkyl) 4 salts.
  • This invention also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersible products may be obtained by such quaternization.
  • Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
  • Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.
  • the pharmaceutically acceptable compositions of the present invention additionally comprise a pharmaceutically acceptable carrier, adjuvant, or vehicle, which, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
  • a pharmaceutically acceptable carrier, adjuvant, or vehicle which, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
  • Remington's Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980) discloses various carriers used in formulating pharmaceutically acceptable compositions
  • any conventional carrier medium is incompatible with the compounds of the invention, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutically acceptable composition, its use is contemplated to be within the scope of this invention.
  • materials which can serve as pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, or potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, wool fat, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc
  • a method for the treatment or lessening the severity of acute, chronic, neuropathic, or inflammatory pain, arthritis, migraine, cluster headaches, trigeminal neuralgia, herpetic neuralgia, general neuralgias, epilepsy or epilepsy conditions, neurodegenerative disorders, psychiatric disorders such as anxiety and depression, myotonia, arrhythmia, movement disorders, neuroendocrine disorders, ataxia, multiple sclerosis, irritable bowel syndrome, incontinence, visceral pain, osteoarthritis pain, postherpetic neuralgia, diabetic neuropathy, radicular pain, sciatica, back pain, head or neck pain, severe or intractable pain, nociceptive pain, breakthrough pain, postsurgical pain, or cancer pain comprising administering an effective amount of a compound, or a pharmaceutically acceptable composition comprising a compound to a subject in need thereof.
  • a method for the treatment or lessening the severity of acute, chronic, neuropathic, or inflammatory pain comprising administering an effective amount of a compound or a pharmaceutically acceptable composition to a subject in need thereof.
  • a method for the treatment or lessening the severity of radicular pain, sciatica, back pain, head pain, or neck pain is provided comprising administering an effective amount of a compound or a pharmaceutically acceptable composition to a subject in need thereof.
  • a method for the treatment or lessening the severity of severe or intractable pain, acute pain, postsurgical pain, back pain, tinnitis or cancer pain comprising administering an effective amount of a compound or a pharmaceutically acceptable composition to a subject in need thereof.
  • an “effective amount” of the compound or pharmaceutically acceptable composition is that amount effective for treating or lessening the severity of one or more of acute, chronic, neuropathic, or inflammatory pain, arthritis, migraine, cluster headaches, trigeminal neuralgia, herpetic neuralgia, general neuralgias, epilepsy or epilepsy conditions, neurodegenerative disorders, psychiatric disorders such as anxiety and depression, myotonia, arrhythmia, movement disorders, neuroendocrine disorders, ataxia, multiple sclerosis, irritable bowel syndrome, incontinence, visceral pain, osteoarthritis pain, postherpetic neuralgia, diabetic neuropathy, radicular pain, sciatica, back pain, head or neck pain, severe or intractable pain, nociceptive pain, breakthrough pain, postsurgical pain, tinnitis or cancer pain.
  • the compounds and compositions, according to the method of the present invention may be administered using any amount and any route of administration effective for treating or lessening the severity of one or more of acute, chronic, neuropathic, or inflammatory pain, arthritis, migraine, cluster headaches, trigeminal neuralgia, herpetic neuralgia, general neuralgias, epilepsy or epilepsy conditions, neurodegenerative disorders, psychiatric disorders such as anxiety and depression, myotonia, arrhythmia, movement disorders, neuroendocrine disorders, ataxia, multiple sclerosis, irritable bowel syndrome, incontinence, visceral pain, osteoarthritis pain, postherpetic neuralgia, diabetic neuropathy, radicular pain, sciatica, back pain, head or neck pain, severe or intractable pain, nociceptive pain, breakthrough pain, postsurgical pain, tinnitis or cancer pain.
  • trigeminal neuralgia such as anxiety and depression, myotonia, arrhythmia, movement disorders, neuroen
  • the exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular agent, its mode of administration, and the like.
  • the compounds of the invention are preferably formulated in dosage unit form for ease of administration and uniformity of dosage.
  • dosage unit form refers to a physically discrete unit of agent appropriate for the patient to be treated. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment.
  • the specific effective dose level for any particular patient or organism will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed, and like factors well known in the medical arts.
  • patient means an animal, preferably a mammal, and most preferably a human.
  • compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), bucally, as an oral or nasal spray, or the like, depending on the severity of the infection being treated.
  • the compounds of the invention may be administered orally or parenterally at dosage levels of about 0.01 mg/kg to about 50 mg/kg and preferably from about 1 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.
  • Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • the oral compositions can also include adjuvants such as, for example, water or other solvents, solubil
  • sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil can be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid are used in the preparation of injectables.
  • the injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
  • the rate of compound release can be controlled.
  • biodegradable polymers include poly(orthoesters) and poly(anhydrides).
  • Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.
  • compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
  • the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and gly
  • Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • the active compounds can also be in microencapsulated form with one or more excipients as noted above.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art.
  • the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch.
  • Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose.
  • the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner.
  • buffering agents include polymeric substances and waxes.
  • Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches.
  • the active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required.
  • Ophthalmic formulation, eardrops, and eye drops are also contemplated as being within the scope of this invention.
  • the present invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of a compound to the body.
  • Such dosage forms are prepared by dissolving or dispensing the compound in the proper medium.
  • Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
  • the compounds of the invention are useful as inhibitors of voltage-gated sodium ion channels or calcium channels, preferably N-type calcium channels.
  • the compounds and compositions of the invention are inhibitors of one or more of NaV1.1, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8, NaV1.9, or CaV2.2, and thus, without wishing to be bound by any particular theory, the compounds and compositions are particularly useful for treating or lessening the severity of a disease, condition, or disorder where activation or hyperactivity of one or more of NaV1.1, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8, NaV1.9, or CaV2.2 is implicated in the disease, condition, or disorder.
  • NaV1.1, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8, NaV1.9, or CaV2.2 When activation or hyperactivity of NaV1.1, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8, NaV1.9, or CaV2.2, is implicated in a particular disease, condition, or disorder, the disease, condition, or disorder may also be referred to as a “NaV1.1, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8 or NaV1.9-mediated disease, condition or disorder” or a “CaV2.2-mediated condition or disorder”.
  • the present invention provides a method for treating or lessening the severity of a disease, condition, or disorder where activation or hyperactivity of one or more of NaV1.1, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8, NaV1.9, or CaV2.2 is implicated in the disease state.
  • the activity of a compound utilized in this invention as an inhibitor of NaV1.1, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8, NaV1.9, or CaV2.2 may be assayed according to methods described generally in the Examples herein, or according to methods available to one of ordinary skill in the art.
  • compounds of the invention are useful as inhibitors of NaV1.3. In other embodiments, compounds of the invention are useful as inhibitors of NaV1.3 and CaV2.2. In still other embodiments, compounds of the invention are useful as inhibitors of CaV2.2.
  • the compounds and pharmaceutically acceptable compositions of the present invention can be employed in combination therapies, that is, the compounds and pharmaceutically acceptable compositions can be administered concurrently with, prior to, or subsequent to, one or more other desired therapeutics or medical procedures.
  • the particular combination of therapies (therapeutics or procedures) to employ in a combination regimen will take into account compatibility of the desired therapeutics and/or procedures and the desired therapeutic effect to be achieved.
  • the therapies employed may achieve a desired effect for the same disorder (for example, an inventive compound may be administered concurrently with another agent used to treat the same disorder), or they may achieve different effects (e.g., control of any adverse effects).
  • additional therapeutic agents that are normally administered to treat or prevent a particular disease, or condition, are known as “appropriate for the disease, or condition, being treated”.
  • exemplary additional therapeutic agents include, but are not limited to: nonopioid analgesics (indoles such as Etodolac, Indomethacin, Sulindac, Tolmetin; naphthylalkanones such as Nabumetone; oxicams such as Piroxicam; para-aminophenol derivatives, such as Acetaminophen; propionic acids such as Fenoprofen, Flurbiprofen, Ibuprofen, Ketoprofen, Naproxen, Naproxen sodium, Oxaprozin; salicylates such as Asprin, Choline magnesium trisalicylate, Diflunisal; fenamates such as meclofenamic acid, Mefenamic acid; and pyrazoles such as Phenylbutazone); or opioid (narcotic)
  • nondrug analgesic approaches may be utilized in conjunction with administration of one or more compounds of the invention.
  • anesthesiologic intraspinal infusion, neural blocade
  • neurosurgical neurolysis of CNS pathways
  • neurostimulatory transcutaneous electrical nerve stimulation, dorsal column stimulation
  • physiatric physical therapy, orthotic devices, diathermy
  • psychologic psychologic
  • the amount of additional therapeutic agent present in the compositions of this invention will be no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent.
  • the amount of additional therapeutic agent in the presently disclosed compositions will range from about 50% to 100% of the amount normally present in a composition comprising that agent as the only therapeutically active agent.
  • the present invention in another aspect, includes a composition for coating an implantable device comprising a compound of the present invention as described generally above, and in classes and subclasses herein, and a carrier suitable for coating said implantable device.
  • the present invention includes an implantable device coated with a composition comprising a compound of the present invention as described generally above, and in classes and subclasses herein, and a carrier suitable for coating said implantable device. Suitable coatings and the general preparation of coated implantable devices are described in U.S. Pat. Nos.
  • the coatings are typically biocompatible polymeric materials such as a hydrogel polymer, polymethyldisiloxane, polycaprolactone, polyethylene glycol, polylactic acid, ethylene vinyl acetate, and mixtures thereof.
  • the coatings may optionally be further covered by a suitable topcoat of fluorosilicone, polysaccarides, polyethylene glycol, phospholipids or combinations thereof to impart controlled release characteristics in the composition.
  • Another aspect of the invention relates to inhibiting one or more of NaV1.1, NaV1.2, NaV1.3,NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8, NaV1.9, or CaV2.2 activity in a biological sample or a patient, which method comprises administering to the patient, or contacting said biological sample with a compound of formula I or a composition comprising said compound.
  • biological sample includes, without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof, and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.
  • Inhibition of one or more of NaV1.1, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8, NaV1.9, or CaV2.2 activity in a biological sample is useful for a variety of purposes that are known to one of skill in the art. Examples of such purposes include, but are not limited to, the study of sodium ion channels in biological and pathological phenomena; and the comparative evaluation of new sodium ion channel inhibitors.
  • a sodium cyanoborohydride (0.88 g, 14 mmol) was added slowly to a stirred solution of benzaldehyde (0.71 g, 7.00 mmol) in methanol (9 mL) and glacial acetic acid (1 mL) at room temperature and the mixture was heated at 60° C. for 3 hr and cooled to room temperature. The solvent was evaporated under reduced pressure, and the crude material was dissolved in water and basified with a 2N NaOH solution (10 mL). The aqueous layer was extracted with EtOAc (3 ⁇ 50 mL), dried and concentrated.
  • Step ii 4-(2-Fluoro-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid ethyl ester
  • 3-Dimethylamino-2-(2-fluoro-benzoyl)-acrylic acid ethyl ester was dissolved in DMF (100 mL). To the solution was added isothiourea sulfate (18.92 g, 68.0 mmol) and NaOAc (23.24 g, 0.28 mol). The reaction mixture was heated at 80-90° C. overnight. Water was added to the cooled solution. The product was extracted with EtOAc (3 ⁇ 100 mL). The combined organic layers were washed with a saturated aqueous NaHCO 3 solution and water, dried over Na 2 SO 4 , and concentrated.
  • Step iii 4-(2-Fluoro-phenyl)-2-methanesulfinyl-pyrimidine-5-carboxylic acid ethyl ester
  • Morpholine (7.0 mL, 6.9 g, 80 mmol) was added to a solution of 4-(2-fluoro-phenyl)-2-methanesulfinyl-pyrimidine-5-carboxylic acid ethyl ester in THF (80 mL). The resulting mixture was heated at reflux for 3 hours. Concentration of the solution afforded the product as a yellow oil. Traces of morpholine were removed at oil pump vacuum in a Kugelrohr apparatus to yield 4-(2-fluoro-phenyl)-2-morpholin-4-yl-pyrimidine-5-carboxylic acid ethyl ester (16.00 g, >100%).
  • Step v 4-(2-Fluoro-phenyl)-2-morpholin-4-yl-pyrimidine-5-carboxylic acid
  • 4-(2-Fluoro-phenyl)-2-morpholin-4-yl-pyrimidine-5-carboxylic acid ethyl ester was dissolved in a mixture of methanol (150 mL) and a 33% aqueous NaOH solution (150 mL). The mixture was heated at reflux for 3 hours, and allowed to cool to room temperature overnight. The solution was concentrated to ca. half the volume under reduced pressure. The resulting suspension was adjusted to pH 7 with a 1-5N aqueous HCl solution. The formed precipitate was filtered off, washed with water (3 ⁇ ), and air-dried at 45° C. overnight to give 4-(2-fluoro-phenyl)-2-morpholin-4-yl-pyrimidine-5-carboxylic acid as a tan solid (9.051 g, 29.8 mmol, 74% over 3 steps).
  • Step vi 4-(2-Fluoro-phenyl)-2-morpholin-4-yl-pyrimidine-5-carboxylic acid benzyl-isopropyl-amide
  • the crude acid chloride was taken up in toluene (50 mL, distilled, dried over Na 2 SO 4 ) and cooled in ice. N-Isopropylbenzylamine (9.5 mL, 8.5 g, 56.8 mmol) was added. The resulting suspension was stirred at room temperature for 90 minutes, washed with water and a saturated aqueous NaCl solution, dried over Na 2 SO 4 , and concentrated. The crude product was purified by column chromatography (400 mL silica, EtOAc/heptanes 1:1). All fractions containing the product were combined and concentrated. Some of the excess amine eluted with the product.
  • Step vii 4-(2-Fluoro-phenyl)-2-morpholin-4-yl-pyrimidine-5-carboxylic acid benzyl-isopropyl-amide HCl salt
  • Step iii N-(3-Methoxybenzyl)-4-(2-fluorophenyl)-N-isopropyl-2-(methylsulphonyl)pyrimidine-5-carboxamide
  • Piperidine (0.0054 g, 0.064 mmol) was added to a stirred solution of N-(3-methoxybenzyl)-4-(2-fluorophenyl)-N-isopropyl-2-(methylsulfonyl)pyrimidine-5-carboxamide (0.015 g, 0.032 mmol) in THF (1 mL) and the mixture was heated at 80° C. for 1 h.
  • Step i Ethyl 4-(2-fluorophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxopyrimidine-5-carboxylate
  • Step ii Ethyl 4-(2-fluorophenyl)-1,2-dihydro-6-methyl-2-oxopyrimidine-5-carboxylate
  • Step iii 4-(2-Fluorophenyl)-6-methyl-2-morpholin-4-yl-pyrimidine-5-carboxylic acid ethyl ester
  • Morpholine (0.5 mL) was added to a stirred solution of ethyl 4-(2-fluorophenyl)-1,2-dihydro-6-methyl-2-oxopyrimidine-5-carboxylate (0.75 g, 2.72 mmol), PyBroP (1.4 g, 3 mmol), and triethylamine (1 mL) in 1,4-dioxane (20 mL) at room temperature. The solution was stirred at room temperature for 3 h and diluted with EtOAc. The solution was washed with saturated NH 4 Cl and saturated aqueous NaCl solution, and dried.
  • Step v 4-(2-Fluorophenyl)-6-methyl-2-morpholin-4-yl-pyrimidine-5-carboxylic acid benzyl-isopropyl-amide (Compound No. 338)
  • CD3OD 8.41 (s, 1H), 7.65 (t, 1H), 7.56 (m, 1H), 7.34 (m., 4H), 7.25 (t, 1H), 7.15 (d, 2H), 4.44 (s, 2H), 3.88 (m, 4H), 3.73 (m, 4H), 3.65 (m, 2H), 3.07 (m, 2H), 2.83 (s, 6H) 29 459.1 3.7 CD3OD: 8.38 (s, 1H), 7.51 (m, 2H), 7.18-7.30 (m, 5H), 7.04 (m, 2H),, 4.15 (s, 2H), 3.97 (m, 1H), 3.79 (m, 1H), 2.29 (m, 2H), 1.80 (m, 1H), 1.15-1.60 (8H), 1.01 (brm, 6H).
  • CD3OD 8.48 (s, 1H), 7.57 (d, 1H), 7.50 (t, 1H), 7.49 (m, 1H), 7.39 (m, 1H), 7.00-7.30 (m, 7H), 7.35 (m, 2H), 7.11 (m, 2H), 6.72 (m, 2H), 3.95 (m, 1H), 3.78 (m, 6H), 1.91 (m, 1H), 1.63 (m, 2H), 1.53 (m, 4H), 1.24 (s, 9H), 0.83 (m, 4H) 120 531.5 4.2 CD3OD: 8.36 (s, 1H), 7.49 (m, 2H), 7.24 (m, 1H), 7.15 (m, 1H), 6.56-6.70 (m, 3H), 5.90 (s, 2H), 4.4 (m, 4H), 3.95 (m, 1H), 3.40 (m, 2H), 1.35-1.95 (m, 12H), 1.02 (m, 6H) 121 497.1 3.4 NMR 1H
  • Compounds of the embodiments are useful as antagonists of voltage-gated calcium ion channels.
  • Antagonist properties of test compounds were assessed as follows. Cells expressing the CaV of interest were placed into microtiter plates. After an incubation period, the cells were stained with fluorescent dyes sensitive to the transmembrane potential. The test compounds were added to the microtiter plate. The cells were stimulated with electrical means to evoke a CaV dependent membrane potential change from unblocked channels, which was detected and measured with trans-membrane potential-sensitive dyes. Antagonists were detected as a decreased membrane potential response to the stimulus.
  • the optical membrane potential assay utilized voltage-sensitive FRET sensors described by Gonzalez and Tsien (See, Gonzalez, J. E. and R. Y.
  • HEK293 cells stably expressing CaV2.2 are plated into 96-well microtiter plates. After an appropriate incubation period, the cells are stained with the voltage sensitive dyes CC2-DMPE/DiSBAC2(3) as follows.
  • 10 mM CC2-DMPE is vortexed with an equivalent volume of 10% Pluronic, followed by vortexing in required amount of HBSS containing 10 mM HEPES.
  • Each cell plate will require 5 mL of 2 ⁇ CC2-DMPE.
  • 50 ⁇ L of 2 ⁇ CC2-DMPE is added to wells containing washed cells, resulting in a 10 ⁇ M final staining concentration. The cells are stained for 30 minutes in the dark at RT.
  • the electrical stimulation instrument and methods of use are described in ION Channel Assay Methods PCT/US01/21652, herein incorporated by reference.
  • the instrument comprises a microtiter plate handler, an optical system for exciting the coumarin dye while simultaneously recording the coumarin and oxonol emissions, a waveform generator, a current- or voltage-controlled amplifier, and a device for inserting electrodes in well. Under integrated computer control, this instrument passes user-programmed electrical stimulus protocols to cells within the wells of the microtiter plate.
  • R ⁇ ( t ) ( intensity 460 ⁇ ⁇ nm - background ⁇ 460 ⁇ ⁇ nm ) ( intensity 580 ⁇ ⁇ nm - background ⁇ 580 ⁇ ⁇ nm )
  • the data is further reduced by calculating the initial (R i ) and final (R f ) ratios. These are the average ratio values during part or all of the pre-stimulation period, and during sample points during the stimulation period.
  • Control responses are obtained by performing assays in the presence of a compound with the desired properties (positive control), such as mibefradil, and in the absence of pharmacological agents (negative control). Responses to the negative (N) and positive (P) controls are calculated as above.
  • the compound antagonist activity A is defined as:
  • R is the ratio response of the test compound.
  • HEK293 cells expressing CaV2.2 have been visually identified and probed with fine tip glass electrodes connected to an amplifier (Axon Instruments).
  • the “voltage clamp” mode has been used to assess the compound's IC50 holding the cells at ⁇ 100 mV. The results of these experiments have contributed to the definition of the efficacy profile of the compounds.
  • CaV2.2 calcium currents were recorded from HEK293 cells using the whole-cell variation of the patch clamp technique. Recordings were made at room temperature ( ⁇ 22° C.) with thick walled borosilicate glass electrodes (WPI; resistance 3-4 M ⁇ using an Axopatch 200B amplifier (Axon Instruments). After establishing the whole-cell configuration, approximately 15 minutes were allowed for the pipette solution to equilibrate within the cell before beginning recording. Currents were lowpass filtered between 2-5 kHz and digitally sampled at 10 kHz. Series resistance was compensated 60-70% and was monitored continuously throughout the experiment. The liquid junction potential ( ⁇ 7 mV) between the intracellular pipette solution and the external recording solution was not accounted for in the data analysis. Test solutions were applied to the cells with a gravity driven fast perfusion system (SF-77; Warner Instruments).
  • SF-77 gravity driven fast perfusion system
  • Dose-response relationships were determined in voltage clamp mode by repeatedly depolarizing the cell from the experiment specific holding potential to a test potential of +20 mV for 50 ms at frequencies of 0.1, 1, 5, 10, 15, and 20 Hz. Blocking effects were allowed to plateau before proceeding to the next test concentration.
  • Extracellular solution (in mM): NaCl (138), BaCl 2 (10), KCl (5.33), KH 2 PO 4 (0.44), MgCl 2 (0.5), MgSO 4 (0.41), NaHCO 3 (4), Na 2 HPO 4 (0.3), glucose (5.6), HEPES (10).
  • Compounds of the invention are useful as antagonists of voltage-gated sodium ion channels. Antagonist properties of test compounds were assessed as follows. Cells expressing the NaV of interest were placed into microtiter plates. After an incubation period, the cells were stained with fluorescent dyes sensitive to the transmembrane potential. The test compounds were added to the microtiter plate. The cells were stimulated with either chemical or electrical means to evoke a NaV dependent membrane potential change from unblocked channels, which was detected and measured with trans-membrane potential-sensitive dyes. Antagonists were detected as a decreased membrane potential response to the stimulus.
  • the optical membrane potential assay utilized voltage-sensitive FRET sensors described by Gonzalez and Tsien (See, Gonzalez, J. E. and R. Y.
  • CHO cells endogenously expressing a NaV 1.2 type voltage-gated NaV are seeded in 96-well poly-lysine coated plates at 60,000 cells per well.
  • Other subtypes are performed in an analogous mode in a cell line expressing the NaV of interest.
  • R ⁇ ( t ) ( intensity 460 ⁇ ⁇ nm - background ⁇ 460 ⁇ ⁇ nm ) ( intensity 580 ⁇ ⁇ nm - background ⁇ 580 ⁇ ⁇ nm )
  • the data is further reduced by calculating the initial (R i ) and final (R f ) ratios. These are the average ratio values during part or all of the pre-stimulation period, and during sample points during the stimulation period.
  • the response to the stimulus R r R f /R i is then calculated.
  • baseline 2-7 sec and final response is sampled at 15-24 sec.
  • Control responses are obtained by performing assays in the presence of a compound with the desired properties (positive control), such as tetracaine, and in the absence of pharmacological agents (negative control). Responses to the negative (N) and positive (P) controls are calculated as above.
  • the compound antagonist activity A is defined as:
  • CHO cells are grown in DMEM (Dulbecco's Modified Eagle Medium; GibcoBRL #10569-010) supplemented with 10% FBS (Fetal Bovine Serum, qualified; GibcoBRL #16140-071) and 1% Pen-Strep (Penicillin-Streptomycin; GibcoBRL #15140-122).
  • Cells are grown in vented cap flasks, in 90% humidity and 10% CO 2 , to 100% confluence. They are usually split by trypsinization 1:10 or 1:20, depending on scheduling needs, and grown for 2-3 days before the next split.
  • HEK293 cells stably expressing NaV 1.3 are plated into 96-well microtiter plates. After an appropriate incubation period, the cells are stained with the voltage sensitive dyes CC2-DMPE/DiSBAC2(3) as follows.
  • 10 mM CC2-DMPE is vortexed with an equivalent volume of 10% pluronic, followed by vortexing in required amount of HBSS containing 10 mM HEPES.
  • Each cell plate will require 5 mL of 2 ⁇ CC2-DMPE.
  • 50 ⁇ L of 2 ⁇ CC2-DMPE is added to wells containing washed cells, resulting in a 10 ⁇ M final staining concentration. The cells are stained for 30 minutes in the dark at RT.
  • ABSC1 6 ⁇ M DISBAC 2 (3) and 1 mM ABSC1:
  • the 2 ⁇ DiSBAC 2 (3) solution can be used to solvate compound plates. Note that compound plates are made at 2 ⁇ drug concentration. Wash stained plate again, leaving residual volume of 50 ⁇ L. Add 50 ⁇ L/well of the 2 ⁇ DiSBAC 2 (3) w/ABSC1. Stain for 30 minutes in the dark at RT.
  • the electrical stimulation instrument and methods of use are described in ION Channel Assay Methods PCT/US01/21652, herein incorporated by reference.
  • the instrument comprises a microtiter plate handler, an optical system for exciting the coumarin dye while simultaneously recording the coumarin and oxonol emissions, a waveform generator, a current- or voltage-controlled amplifier, and a device for inserting electrodes in well. Under integrated computer control, this instrument passes user-programmed electrical stimulus protocols to cells within the wells of the microtiter plate.
  • R ⁇ ( t ) ( intensity 460 ⁇ ⁇ nm - background ⁇ 460 ⁇ ⁇ nm ) ( intensity 580 ⁇ ⁇ nm - background ⁇ 580 ⁇ ⁇ nm )
  • the data is further reduced by calculating the initial (R i ) and final (R f ) ratios. These are the average ratio values during part or all of the pre-stimulation period, and during sample points during the stimulation period.
  • the response to the stimulus R r R f /R i is then calculated.
  • Control responses are obtained by performing assays in the presence of a compound with the desired properties (positive control), such as tetracaine, and in the absence of pharmacological agents (negative control). Responses to the negative (N) and positive (P) controls are calculated as above.
  • the compound antagonist activity A is defined as:
  • R is the ratio response of the test compound.
  • Patch clamp electrophysiology was used to assess the efficacy and selectivity of sodium channel blockers in dorsal root ganglion neurons.
  • Rat neurons were isolated from the dorsal root ganglions and maintained in culture for 2 to 10 days in the presence of NGF (50 ng/ml) (culture media consisted of NeurobasalA supplemented with B27, glutamine and antibiotics). Small diameter neurons (nociceptors, 8-12 ⁇ m in diameter) have been visually identified and probed with fine tip glass electrodes connected to an amplifier (Axon Instruments).
  • the “voltage clamp” mode has been used to assess the compound's IC50 holding the cells at ⁇ 60 mV.
  • the “current clamp” mode has been employed to test the efficacy of the compounds in blocking action potential generation in response to current injections. The results of these experiments have contributed to the definition of the efficacy profile of the compounds.
  • TTX-resistant sodium currents were recorded from DRG somata using the whole-cell variation of the patch clamp technique. Recordings were made at room temperature ( ⁇ 22° C.) with thick walled borosilicate glass electrodes (WPI; resistance 3-4 M ⁇ ) using an Axopatch 200B amplifier (Axon Instruments). After establishing the whole-cell configuration, approximately 15 minutes were allowed for the pipette solution to equilibrate within the cell before beginning recording. Currents were lowpass filtered between 2-5 kHz and digitally sampled at 10 kHz. Series resistance was compensated 60-70% and was monitored continuously throughout the experiment. The liquid junction potential ( ⁇ 7 mV) between the intracellular pipette solution and the external recording solution was not accounted for in the data analysis. Test solutions were applied to the cells with a gravity driven fast perfusion system (SF-77; Warner Instruments).
  • SF-77 gravity driven fast perfusion system
  • Dose-response relationships were determined in voltage clamp mode by repeatedly depolarizing the cell from the experiment specific holding potential to a test potential of +10 mV once every 60 seconds. Blocking effects were allowed to plateau before proceeding to the next test concentration.
  • Extracellular solution (in mM): NaCl (138), CaCl 2 (1.26), KCl (5.33), KH 2 PO 4 (0.44), MgCl 2 (0.5), MgSO 4 (0.41), NaHCO 3 (4), Na 2 HPO 4 (0.3), glucose (5.6), HEPES (10), CdCl 2 (0.4 NiCl 2 (0.1), TTX (0.25 ⁇ 10 ⁇ 3 ).
  • Examples of activities of the ion channel modulators of formulae (I and Ia) on modulating CaV 2.2, NaV 1.3, and NaV 1.8 receptors are shown below in Table 9.
  • the compound activity for the CaV 2.2, NaV 1.3, and NaV 1.8 receptors is illustrated with “+++” if activity was measured to be less than 2.0 ⁇ M, “++” if activity was measured to be 2.0 ⁇ M to 10.0 ⁇ M, “+” if activity was measured to be greater than 10.0 ⁇ M, and “ ⁇ ” if no data was available.

Abstract

In general, the invention relates to novel 4-phenylpyrimidine compounds useful as ion channel modulators. It has now been found that compounds of this invention, and pharmaceutically acceptable compositions thereof, are useful as inhibitors of voltage-gated sodium channels and/or calcium channels for the treatment of pain.

Description

    CLAIM OF PRIORITY
  • This application claims priority to U.S. Provisional Patent Application Nos. 60/624,718; 60/624,716; and 60/624,800, all of which were filed on Nov. 3, 2004. The entire contents of the aforementioned applications are incorporated in their entirety.
    • TECHNICAL FIELD OF THE INVENTION
  • The present invention relates to compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
    • BACKGROUND OF THE INVENTION
  • Na channels are central to the generation of action potentials in all excitable cells such as neurons and myocytes. They play key roles in excitable tissue including brain, smooth muscles of the gastrointestinal tract, skeletal muscle, the peripheral nervous system, spinal cord and airway. As such, they play key roles in a variety of disease states such as epilepsy (See, Moulard, B. and D. Bertrand (2002) “Epilepsy and sodium channel blockers” Expert Opin. Ther. Patents 12(1): 85-91)), pain (See, Waxman, S. G., S. Dib-Hajj, et al. (1999) “Sodium channels and pain” Proc Natl Aced Sci USA 96(14): 7635-9 and Waxman, S. G., T. R. Cummins, et al. (2000) “Voltage-gated sodium channels and the molecular pathogenesis of pain: a review” J Rehabil Res Dev 37(5): 517-28), myotonia (See, Meola, G. and V. Sansone (2000) “Therapy in myotonic disorders and in muscle channelopathies” Neurol Sci 21(5): S953-61 and Mankodi, A. and C. A. Thornton (2002) “Myotonic syndromes” Curr Opin Neurol 15(5): 545-52), ataxia (See, Meister, M. H., J. A. Kearney, et al. (2002) “Mutations of voltage-gated sodium channels in movement disorders and epilepsy” Novartis Found Symp 241: 72-81), multiple sclerosis (See, Black, J. A., S. Dib-Hajj, et al. (2000) “Sensory neuron-specific sodium channel SNS is abnormally expressed in the brains of mice with experimental allergic encephalomyelitis and humans with multiple sclerosis” Proc Natl Acad Sci USA 97(21): 11598-602, and Renganathan, M., M. Gelderblom, et al. (2003) “Expression of Na(v)1.8 sodium channels perturbs the firing patterns of cerebellar purkinje cells” Brain Res 959(2): 235-42), irritable bowel (See, Su, X., R. E. Wachtel, et al. (1999) “Capsaicin sensitivity and voltage-gated sodium currents in colon sensory neurons from rat dorsal root ganglia” Am J Physiol 277(6 Pt 1): 01180-8, and Laird, J. M., V. Souslova, et al. (2002) “Deficits in visceral pain and referred hyperalgesia in Nav1.8 (SNS/PN3)-null mice” J Neurosci 22(19): 8352-6), urinary incontinence and visceral pain (See, Yoshimura, N., S. Seki, et al. (2001) “The involvement of the tetrodotoxin-resistant sodium channel Na(v)1.8 (PN3/SNS) in a rat model of visceral pain” J Neurosci 21(21): 8690-6), as well as an array of psychiatry dysfunctions such as anxiety and depression (See, Hurley, S. C. (2002) “Lamotrigine update and its use in mood disorders” Ann Pharmacother 36(5): 860-73).
  • Voltage gated Na channels comprise a gene family consisting of 9 different subtypes (NaV1.1-NaV1.9). As shown in Table A, these subtypes show tissue specific localization and functional differences (See, Goldin, A. L. (2001) “Resurgence of sodium channel research” Annu Rev Physiol 63: 871-94). Three members of the gene family (NaV1.8, 1.9, 1.5) are resistant to block by the well-known Na channel blocker TTX, demonstrating subtype specificity within this gene family. Mutational analysis has identified glutamate 387 as a critical residue for TTX binding (See, Nada, M., H. Suzuki, et al. (1989) “A single point mutation confers tetrodotoxin and saxitoxin insensitivity on the sodium channel II” FEBS Lett 259(1): 213-6).
  • TABLE A
    (Abbreviations: CNS = central nervous system,
    PNS = peripheral nervous sytem, DRG =
    dorsal root ganglion, TG = Trigeminal ganglion):
    Na
    isoform Tissue TTX IC50 Indications
    NaV1.1 CNS, PNS 10 nM Pain, Epilepsy,
    soma of neurodegeneration
    neurons
    NaV1.2 CNS, high in 10 nM Neurodegeneration
    axons Epilepsy
    NaV1.3 CNS, 15 nM Pain
    embryonic,
    injured nerves
    NaV1.4 Skeletal 25 nM Myotonia
    muscle
    NaV1.5 Heart 2 μM Arrythmia,
    long QT
    NaV1.6 CNS 6 nM Pain, movement disorders
    widespread,
    most abuntant
    NaV1.7 PNS, DRG, 25 nM Pain, Neuroendocrine
    terminals disorders
    neuroendocrine
    NaV1.8 PNS, small >50 μM Pain
    neurons in
    DRG & TG
    NaV1.9 PNS, small 1 μM Pain
    neurons in
    DRG & TG
  • In general, voltage-gated sodium channels (NaVs) are responsible for initiating the rapid upstroke of action potentials in excitable tissue in nervous system, which transmit the electrical signals that compose and encode normal and aberrant pain sensations. Antagonists of NaV channels can attenuate these pain signals and are useful for treating a variety of pain conditions, including but not limited to acute, chronic, inflammatory, and neuropathic pain. Known NaV antagonists, such as TTX, lidocaine (See, Mao, J. and L. L. Chen (2000) “Systemic lidocaine for neuropathic pain relief” Pain 87(1): 7-17.), bupivacaine, phenyloin (See, Jensen, T. S. (2002) “Anticonvulsants in neuropathic pain: rationale and clinical evidence” Eur J Pain 6 (Suppl A): 61-8), lamotrigine (See, Rozen, T. D. (2001) “Antiepileptic drugs in the management of cluster headache and trigeminal neuralgia” Headache 41 Suppl 1: S25-32 and Jensen, T. S. (2002) “Anticonvulsants in neuropathic pain: rationale and clinical evidence” Eur J Pain 6 (Suppl A): 61-8.), and carbamazepine (See, Backonja, M. M. (2002) “Use of anticonvulsants for treatment of neuropathic pain” Neurology 59(5 Suppl 2): S14-7), have been shown to be useful attenuating pain in humans and animal models.
  • Hyperalgesia (extreme sensitivity to something painful) that develops in the presence of tissue injury or inflammation reflects, at least in part, an increase in the excitability of high-threshold primary afferent neurons innervating the site of injury. Voltage sensitive sodium channels activation is critical for the generation and propagation of neuronal action potentials. There is a growing body of evidence indicating that modulation of NaV currents is an endogenous mechanism used to control neuronal excitability (See, Goldin, A. L. (2001) “Resurgence of sodium channel research” Annu Rev Physiol 63: 871-94.). Several kinetically and pharmacologically distinct voltage-gated sodium channels are found in dorsal root ganglion (DRG) neurons. The TTX-resistant current is insensitive to micromolar concentrations of tetrodotoxin, and displays slow activation and inactivation kinetics and a more depolarized activation threshold when compared to other voltage-gated sodium channels. TTX-resistant sodium currents are primarily restricted to a subpopulation of sensory neurons likely to be involved in nociception. Specifically, TTX-resistant sodium currents are expressed almost exclusively in neurons that have a small cell-body diameter and give rise to small-diameter slow-conducting axons and that are responsive to capsaicin. A large body of experimental evidence demonstrates that TTX-resistant sodium channels are expressed on C-fibers and are important in the transmission of nociceptive information to the spinal cord.
  • Intrathecal administration of antisense oligo-deoxynucleotides targeting a unique region of the TTX-resistant sodium channel (NaV1.8) resulted in a significant reduction in PGE2induced hyperalgesia (See, Khasar, S. G., M. S. Gold, et al. (1998) “A tetrodotoxin-resistant sodium current mediates inflammatory pain in the rat” Neurosci Lett 256(1): 17-20). More recently, a knockout mouse line was generated by Wood and colleagues, which lacks functional NaV1.8. The mutation has an analgesic effect in tests assessing the animal's response to the inflammatory agent carrageenan (See, Akopian, A. N., V. Souslova, et al. (1999) “The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways” Nat Neurosci 2(6): 541-8.). In addition, deficit in both mechano- and thermoreception were observed in these animals. The analgesia shown by the Nav1.8 knockout mutants is consistent with observations about the role of TTX-resistant currents in nociception.
  • Immunohistochemical, in-situ hybridization and in-vitro electrophysiology experiments have all shown that the sodium channel NaV1.8 is selectively localized to the small sensory neurons of the dorsal root ganglion and trigeminal ganglion (See, Akopian, A. N., L. Sivilotti, et al. (1996) “A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons” Nature 379(6562): 257-62.). The primary role of these neurons is the detection and transmission of nociceptive stimuli. Antisense and immunohistochemical evidence also supports a role for NaV1.8 in neuropathic pain (See, Lai, J., M. S. Gold, et al. (2002) “Inhibition of neuropathic pain by decreased expression of the tetrodotoxin-resistant sodium channel, NaV1.8” Pain 95(1-2): 143-52, and Lai, J., J. C. Hunter, et al. (2000) “Blockade of neuropathic pain by antisense targeting of tetrodotoxin-resistant sodium channels in sensory neurons” Methods Enzymol 314: 201-13.). NaV1.8 protein is upregulated along uninjured C-fibers adjacent to the nerve injury. Antisense treatment prevents the redistribution of NaV1.8 along the nerve and reverses neuropathic pain. Taken together the gene-knockout and antisense data support a role for NaV1.8 in the detection and transmission of inflammatory and neuropathic pain.
  • In neuropathic pain states, there is a remodeling of Na channel distribution and subtype. In the injured nerve, expression of NaV1.8 and NaV1.9 are greatly reduced whereas expression of the TTX sensitive subunit NaV1.3 is 5-10 fold upregulated (See, Dib-Hajj, S. D., J. Fjell, et al. (1999) “Plasticity of sodium channel expression in DRG neurons in the chronic constriction injury model of neuropathic pain.” Pain 83(3): 591-600.) The timecourse of the increase in NaV1.3 parallels the appearance of allodynia in animal models subsequent to nerve injury. The biophysics of the NaV1.3 channel is distinctive in that it shows very fast repriming after inactivation following an action potential. This allows for sustained rates of high firing as is often seen in the injured nerve (See, Cummins, T. R., F. Aglieco, et al. (2001) “Nav1.3 sodium channels: rapid repriming and slow closed-state inactivation display quantitative differences after expression in a mammalian cell line and in spinal sensory neurons” J Neurosci 21(16): 5952-61.). NaV1.3 is expressed in the central and peripheral systems of man. NaV1.9 is similar to NaV1.8 as it is selectively localized to small sensory neurons of the dorsal root ganglion and trigeminal ganglion (See. Fang, X., L. Djouhri, et al. (2002). “The presence and role of the tetrodotoxin-resistant sodium channel Na(v)1.9 (NaN) in nociceptive primary afferent neurons.” J Neurosci 22(17): 7425-33.). It has a slow rate of inactivation and left-shifted voltage dependence for activation (See, Dib-Hajj, S., J. A. Black, et al. (2002) “NaN/Nav1.9: a sodium channel with unique properties” Trends Neurosci 25(5): 253-9.). These two biophysical properties allow NaV1.9 to play a role in establishing the resting membrane potential of nociceptive neurons. The resting membrane potential of NaV1.9 expressing cells is in the −55 to −50 mV range compared to −65 mV for most other peripheral and central neurons. This persistent depolarization is in large part due to the sustained low-level activation of NaV1.9 channels. This depolarization allows the neurons to more easily reach the threshold for firing action potentials in response to nociceptive stimuli. Compounds that block the NaV1.9 channel may play an important role in establishing the set point for detection of painful stimuli. In chronic pain states, nerve and nerve ending can become swollen and hypersensitive exhibiting high frequency action potential firing with mild or even no stimulation. These pathologic nerve swellings are termed neuromas and the primary. Na channels expressed in them are NaV 1.8 and NaV 1.7 (See, Kretschmer, T., L. T. Happel, et al. (2002) “Accumulation of PN1 and PN3 sodium channels in painful human neuroma-evidence from immunocytochemistry” Acta Neurochir (Wien) 144(8): 803-10; discussion 810.). NaV1.6 and NaV1.7 are also expressed in dorsal root ganglion neurons and contribute to the small TTX sensitive component seen in these cells. NaV1.7 in particular may therefore be a potential pain target in addition to its role in neuroendocrine excitability (See, Klugbauer, N., L. Lacinova, et al. (1995) “Structure and functional expression of a new member of the tetrodotoxin-sensitive voltage-activated sodium channel family from human neuroendocrine cells” Embo J 14(6): 1084-90).
  • NaV1.1 (See, Sugawara, T., E. Mazaki-Miyazaki, et al. (2001) “Nav1.1 mutations cause febrile seizures associated with afebrile partial seizures.” Neurology 57(4): 703-5.) and NaV 1.2 (See, Sugawara, T., Y. Tsurubuchi, et al. (2001) “A missense mutation of the Na+ channel alpha II subunit gene Na(v)1.2 in a patient with febrile and afebrile seizures causes channel dysfunction” Proc Natl Acad Sci USA 98(11): 6384-9) have been linked to epilepsy conditions including febrile seizures. There are over 9 genetic mutations in NaV1.1 associated with febrile seizures (See, Meisler, M. H., J. A. Kearney, et al. (2002) “Mutations of voltage-gated sodium channels in movement disorders and epilepsy” Novartis Found Symp 241: 72-81)
  • Antagonists for NaV1.5 have been developed and used to treat cardiac arrhythmias. A gene defect in NaV1.5 that produces a larger noninactivating component to the current has been linked to long QT in man and the orally available local anesthetic mexilitine has been used to treat this condition (See, Wang, D. W., K. Yazawa, et al. (1997) “Pharmacological targeting of long QT mutant sodium channels.” J Clin Invest 99(7): 1714-20).
  • Several Na channel blockers are currently used or being tested in the clinic to treat epilepsy (See, Moulard, B. and D. Bertrand (2002) “Epilepsy and sodium channel blockers” Expert Opin. Ther. Patents 12(1): 85-91.); acute (See, Wiffen, P., S. Collins, et al. (2000) “Anticonvulsant drugs for acute and chronic pain” Cochrane Database Syst Rev 3), chronic (See, Wiffen, P., S. Collins, et al. (2000) “Anticonvulsant drugs for acute and chronic pain” Cochrane Database Syst Rev 3, and Guay, D. R. (2001) “Adjunctive agents in the management of chronic pain” Pharmacotherapy 21(9): 1070-81), inflammatory (See, Gold, M. S. (1999) “Tetrodotoxin-resistant Na+ currents and inflammatory hyperalgesia.” Proc Natl Acad Sci USA 96(14): 7645-9), and neuropathic pain (See, Strichartz, G. R., Z. Zhou, et al. (2002) “Therapeutic concentrations of local anaesthetics unveil the potential role of sodium channels in neuropathic pain” Novartis Found Symp 241: 189-201, and Sandner-Kiesling, A., G. Rumpold Seitlinger, et al. (2002) “Lamotrigine monotherapy for control of neuralgia after nerve section” Acta Anaesthesiol Scand 46(10): 1261-4); cardiac arrhythmias (See, An, R. H., R. Bangalore, et al. (1996) “Lidocaine block of LQT-3 mutant human Na+ channels” Circ Res 79(1): 103-8, and Wang, D. W., K. Yazawa, et al. (1997) “Pharmacological targeting of long QT mutant sodium channels” J Clin Invest 99(7): 1714-20); for neuroprotection (See, Taylor, C. P. and L. S. Narasimhan (1997) “Sodium channels and therapy of central nervous system diseases” Adv Pharmacol 39: 47-98) and as anesthetics (See, Strichartz, G. R., Z. Zhou, et al. (2002) “Therapeutic concentrations of local anaesthetics unveil the potential role of sodium channels in neuropathic pain.” Novartis Found Symp 241: 189-201).
  • Various animal models with clinical significance have been developed for the study of sodium channel modulators for numerous different pain indications. E.g., malignant chronic pain, see, Kohase, H., et al., Acta Anaesthesiol Scand. 2004; 48(3):382-3; femur cancer pain (see, Kohase, H., et al., Acta Anaesthesiol Scand. 2004; 48(3):382-3); non-malignant chronic bone pain (see, Ciocon, J. O. et al, J Am Geriatr Soc. 1994; 42(6):593-6); rheumatoid arthritis (see, Calvino, B. et al., Behav Brain Res. 1987; 24(1):11-29); osteoarthritis (see, Guzman, R. E., et al., Toxicol Pathol. 2003; 31(6):619-24); spinal stenosis (see, Takenobu, Y. et al., J Neurosci Methods. 2001; 104(2):191-8); neuropathic low back pain (see, Hines, R., et al., Pain Med. 2002; 3(4):361-5; Massie, J. B., et al., J Neurosci Methods. 2004; 137(2):283-9); myofascial pain syndrome (see, Dalpiaz & Dodds, J Pain Palliat Care Pharmacother. 2002; 16(1):99-104; Sluka K A et al., Muscle Nerve. 2001; 24(1):37-46); fibromyalgia (see, Bennet & Tai, Int J Clin Pharmacol Res. 1995; 15(3):115-9); temporomandibular joint pain (see, Ime H, Ren K, Brain Res Mol Brain Res. 1999; 67(1):87-97); chronic visceral pain, including abdominal (see, Al-Chaer, E. D., et al., Gastroenterology. 2000; 119(5):1276-85); pelvic/perineal pain, (see, Wesselmann et al., Neurosci Lett. 1998; 246(2):73-6); pancreatic (see, Vera-Portocarrero, L. B., et al., Anesthesiology. 2003; 98(2):474-84); IBS pain (see, Verne, G. N., et al., Pain. 2003; 105(1-2):223-30; La J H et al., World Gastroenterol. 2003; 9(12):2791-5); chronic headache pain (see, Willimas & Stark, Cephalalgia. 2003; 23(10):963-71); migraine (see, Yamamura, H., et al., J. Neurophysiol. 1999; 81(2):479-93); tension headache, including cluster headaches (see, Costa, A., et al., Cephalalgia. 2000; 20(2):85-91); chronic neuropathic pain, including post-herpetic neuralgia (see, Attal, N., et al., Neurology. 2004; 62(2):218-25; Kim & Chung 1992, Pain 50:355); diabetic neuropathy (see, Beidoun A et al., Clin J. Pain. 2004; 20(3):174-8; Courteix, C., et al., Pain. 1993; 53(1):81-8); HIV-associated neuropathy (see, Portegies & Rosenberg, Ned Tijdschr Geneeskd. 2001; 145(15):731-5; Joseph E K et al., Pain. 2004; 107(1-2):147-58; Oh, S. B., et al., J Neurosci. 2001; 21(14):5027-35); trigeminal neuralgia (see, Sato, J., et al., Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004; 97(1):18-22; Imamura Y et al., Exp Brain Res. 1997; 116(1):97-103); Charcot-Marie Tooth neuropathy (see, Sereda, M., et al., Neuron. 1996; 16(5):1049-60); hereditary sensory neuropathies (see, Lee, M. J., et al., Hum Mol Genet. 2003; 12(15):1917-25); peripheral nerve injury (see, Attal, N., et al., Neurology. 2004; 62(2):218-25; Kim & Chung 1992, Pain 50:355; Bennett & Xie, 1988, Pain 33:87; Decostered, I. & Woolf, C. J., 2000, Pain 87:149; Shir, Y. & Seltzer, Z. 1990; Neurosci Lett 115:62); painful neuromas (see, Nahabedian & Johnson, Ann Plast Surg. 2001; 46(1):15-22; Devor & Raber, Behav Neural Biol. 1983; 37(2):276-83); ectopic proximal and distal discharges (see, Liu, X. et al., Brain Res. 2001; 900(1):119-27); radiculopathy (see, Devers & Galer, (see, Clin J. Pain. 2000; 16(3):205-8; Hayashi N et al., Spine. 1998; 23(8):877-85); chemotherapy induced neuropathic pain (see, Aley, K. O., et al., Neuroscience. 1996; 73(1):259-65); radiotherapy-induced neuropathic pain;
  • post-mastectomy pain (see, Devers & Galer, Clin J Pain. 2000; 16(3):205-8); central pain (Cahana, A., et al., Anesth Analg. 2004; 98(6):1581-4), spinal cord injury pain (see, Hains, B. C., et al., Exp Neurol. 2000; 164(2):426-37); post-stroke pain; thalamic pain (see, LaBuda, C. J., et al., Neurosci Lett. 2000; 290(1):79-83); complex regional pain syndrome (see, Wallace, M. S., et al., Anesthesiology. 2000; 92(1):75-83; Xantos D et al., J. Pain. 2004; 5(3 Suppl 2):S1); phanton pain (see, Weber, W. E., Ned Tijdschr Geneeskd. 2001; 145(17):813-7; Levitt & Heyback, Pain. 1981; 10(1):67-73); intractable pain (see, Yokoyama, M., et al., Can J Anaesth. 2002; 49(8):810-3); acute pain, acute post-operative pain (see, Koppert, W., et al., Anesth Analg. 2004; 98(4):1050-5; Brennan, T. J., et al., Pain. 1996; 64(3):493-501); acute musculoskeletal pain; joint pain (see, Gotoh, S., et al., Ann Rheum Dis. 1993; 52(11):817-22); mechanical low back pain (see, Kehl, L. J., et al., Pain. 2000; 85(3):333-43); neck pain; tendonitis; injury/exercise pain (see, Sesay, M., et al., Can J Anaesth. 2002; 49(2):137-43); acute visceral pain, including abdominal pain; pyelonephritis; appendicitis; cholecystitis; intestinal obstruction; hernias; etc (see, Giambernardino, M. A., et al., Pain. 1995; 61(3):459-69); chest pain, including cardiac Pain (see, Vergona, R. A., et al., Life Sci. 1984; 35(18):1877-84); pelvic pain, renal colic pain, acute obstetric pain, including labor pain (see, Segal, S., et al., Anesth Analg. 1998; 87(4):864-9); cesarean section pain; acute inflammatory, burn and trauma pain; acute intermittent pain, including endometriosis (see, Cason, A. M., et al., Horm Behav. 2003; 44(2):123-31);
    acute herpes zoster pain; sickle cell anemia; acute pancreatitis (see, Toma, H; Gastroenterology. 2000; 119(5):1373-81); breakthrough pain; orofacial pain, including sinusitis pain, dental pain (see, Nusstein, J., et al., J Endod. 1998; 24(7):487-91; Chidiac, J. J., et al., Eur J Pain. 2002; 6(1):55-67); multiple sclerosis (MS) pain (see, Sakurai & Kanazawa, J Neurol Sci. 1999; 162(2):162-8); pain in depression (see, Greene B, Curr Med Res Opin. 2003; 19(4):272-7); leprosy pain; behcet's disease pain; adiposis dolorosa (see, Devillers & Oranje, Clin Exp Dermatol. 1999; 24(3):240-1); phlebitic pain; Guillain-Barre pain; painful legs and moving toes; Haglund syndrome; erythromelalgia pain (see, Legroux-Crespel, E., et al., Ann Dermatol Venereol. 2003; 130(4):429-33); Fabry's disease pain (see, Germain, D. P., J Soc Biol. 2002; 196(2):183-90); Bladder and urogenital disease, including urinary incontinence (see, Berggren, T., et al., J Urol. 1993; 150(5 Pt 1):1540-3); hyperactivity bladder (see, Chuang, Y. C., et al., Urology. 2003; 61(3):664-70); painful bladder syndrome (see, Yoshimura, N., et al., J Neurosci. 2001; 21(21):8690-6); interstitial cyctitis (IC) (see, Giannakopoulos & Campilomatos, Arch Ital Urol Nefrol Androl. 1992; 64(4):337-9; Boucher, M., et al., J Urol. 2000; 164(1):203-8); and prostatitis (see, Mayersak, J. S., hit Surg. 1998; 83(4):347-9; Keith, I. M., et al., J Urol. 2001; 166(1):323-8).
  • Voltage-gated calcium channels are membrane-spanning, multi-subunit proteins that open in response to membrane depolarization, allowing Ca entry from the extracellular milieu. Calcium channels were initially classified based on the time and voltage-dependence of channel opening and on the sensitivity to pharmacological block. The categories were low-voltage activated (primarily T-type) and high-voltage activated (L,N,P,Q or R-type). This classification scheme was replaced by a nomenclature based upon the molecular subunit composition, as summarized in Table B (Hockerman G H, Peterson B Z, Johnson B D, Catterall W A. 1997. Annu Rev Pharmacol Toxicol 37: 361-96; Striessnig J. 1999. Cell Physiol Biochem 9: 242-69). There are four primary subunit types that make up calcium channels—α1, α2δ, β and
    Figure US20130345208A1-20131226-P00001
    See, e.g., De Waard et al. Structural and functional diversity of voltage-activated calcium channels. In Ion Channels, (ed. T. Narahashi) 41-87, (Plenum Press, New York, 1996)). The α1 subunit is the primary determinant of the pharmacological properties and contains the channel pore and voltage sensor (Hockerman et al., 1997; Striessnig, 1999). Ten isoforms of the α1 subunit are known, as indicated in Table I below. The α2δ subunit consists of two disulfide linked subunits, α2, which is primarily extracellular, and a transmembrane δ subunit. Four isoforms of α2δ are known, α2δ-1, α2δ-2, α2δ-3 and α2δ-4. The β subunit is a non-glycosylated cytoplasmic protein that binds to the α1 subunit. Four isoforms are known, termed β1 to β4. The γsubunit is a transmembrane protein that has been biochemically isolated as a component of Cv1 and Cav2 channels. At least 8 isoforms are known (γ1 to γ8) [Kang M G, Campbell K P. 2003. J Biol Chem 278: 21315-8]. The nomenclature for voltage-gated calcium channels is based upon the content of the α1 subunit, as indicated in Table B. Each type of α1 subunit can associate with a variety of β, α2δ or γ subunits, so that each Cav type corresponds to many different combinations of subunits.
  • TABLE B
    Cav Nomenclature α1 subunit Pharmacological name
    Cav1.1 α1S L-type
    Cav1.2 α1C L-type
    Cav1.3 α1D L-type
    Cav1.4 α1F
    Cav2.1 α1A P- or Q-type
    Cav2.2 α1B N-type
    Cav2.3 α1E R-type
    Cav3.1 α1G T-type
    Cav3.2 α1H T-type
    Cav3.3 α1I T-type
  • Cav2 currents are found almost exclusively in the central and peripheral nervous system and in neuroendocrine cells and constitute the predominant forms of presynaptic voltage-gated calcium current. Presynaptic action potentials cause channel opening, and neurotransmitter release is steeply dependent upon the subsequent calcium entry. Thus, Cav2 channels play a central role in mediating neurotransmitter release.
  • Cav2.1 and Cav2.2 contain high affinity binding sites for the peptide toxins ω-conotoxin-MVIIC and ω-conotoxin-GVIA, respectively, and these peptides have been used to determine the distribution and function of each channel type. Cav2.2 is highly expressed at the presynaptic nerve terminals of neurons from the dorsal root ganglion and neurons of lamina I and II of the dorsal horn (Westenbroek R E, Hoskins L, Catterall W A. 1998. J Neurosci 18: 6319-30; Cizkova D, Marsala J, Lukacova N, Marsala M, Jergova S, et al. 2002. Exp Brain Res 147: 456-63). Cav2.2 channels are also found in presynaptic terminals between second and third order interneurons in the spinal cord. Both sites of neurotransmission are very important in relaying pain information to the brain.
  • Pain can be roughly divided into three different types: acute, inflammatory, and neuropathic. Acute pain serves an important protective function in keeping the organism safe from stimuli that may produce tissue damage. Severe thermal, mechanical, or chemical inputs have the potential to cause severe damage to the organism if unheeded. Acute pain serves to quickly remove the individual from the damaging environment. Acute pain by its very nature generally is short lasting and intense. Inflammatory pain, on the other hand, may last for much longer periods of time and its intensity is more graded. Inflammation may occur for many reasons including tissue damage, autoimmune response, and pathogen invasion. Inflammatory pain is mediated by an “inflammatory soup” that consists of substance P, histamines, acid, prostaglandin, bradykinin, CGRP, cytokines, ATP, and neurotransmitter release. The third class of pain is neuropathic and involves nerve damage that results in reorganization of neuronal proteins and circuits yielding a pathologic “sensitized” state that can produce chronic pain lasting for years. This type of pain provides no adaptive benefit and is particularly difficult to treat with existing therapies.
  • Pain, particularly neuropathic and intractable pain is a large unmet medical need. Millions of individuals suffer from severe pain that is not well controlled by current therapeutics. The current drugs used to treat pain include NSAIDS, COX2 inhibitors, opioids, tricyclic antidepressants, and anticonvulsants. Neuropathic pain has been particularly difficult to treat as it does not respond well to opioids until high doses are reached. Gabapentin is currently the favored therapeutic for the treatment of neuropathic pain although it works in only 60% of patients where it shows modest efficacy. The drug is however very safe and side effects are generally tolerable although sedation is an issue at higher doses.
  • Validation of Cav2.2 as a target for the treatment of neuropathic pain is provided by studies with ziconotide (also known as ω-conotoxin-MVIIA), a selective peptide blocker of this channel (Bowersox S S, Gadbois T, Singh T, Pettus M, Wang Y X, Luther R R. 1996. J Pharmacol Exp Ther 279: 1243-9; Jain K K. 2000. Exp. Opin. Invest. Drugs 9: 2403-10; Vanegas H, Schaible H. 2000. Pain 85: 9-18). In man, intrathecal infusion of Ziconotide is effective for the treatment of intractable pain, cancer pain, opioid resistant pain, and neuropathic pain. The toxin has an 85% success rate for the treatment of pain in humans with a greater potency than morphine. An orally available antagonist of Cav2.2 should have similar efficacy without the need for intrathecal infusion. Cav2.1 and Cav2.3 are also in neurons of nociceptive pathways and antagonists of these channels could be used to treat pain.
  • Antagonists of Cav2.1, Cav2.2 or Cav2.3 should also be useful for treating other pathologies of the central nervous system that apparently involve excessive calcium entry. Cerebral ischaemia and stroke are associated with excessive calcium entry due to depolarization of neurons. The Cav2.2 antagonist ziconotide is effective in reducing infarct size in a focal ischemia model using laboratory animals, suggesting that Cav2.2 antagonists could be used for the treatment of stroke. Likewise, reducing excessive calcium influx into neurons may be useful for the treatment of epilepsy, traumatic brain injury, Alzheimer's disease, multi-infarct dementia and other classes of dementia, amyotrophic lateral sclerosis, amnesia, or neuronal damage caused by poison or other toxic substances.
  • Cav2.2 also mediates release of neurotransmitters from neurons of the sympathetic nervous system and antagonists could be used to treat cardiovascular diseases such as hypertension, cardiac arrhythmia, angina pectoris, myocardial infarction, and congestive heart failure.
  • Unfortunately, as described above, the efficacy of currently used sodium channel blockers and calcium channel blockers for the disease states described above has been to a large extent limited by a number of side effects. These side effects include various CNS disturbances such as blurred vision, dizziness, nausea, and sedation as well more potentially life threatening cardiac arrhythmias and cardiac failure. Accordingly, there remains a need to develop additional Na channel and Ca channel antagonists, preferably those with higher potency and fewer side effects. Unfortunately, as described above, the efficacy of currently used sodium channel blockers and calcium channel blockers for the disease states described above has been to a large extent limited by a number of side effects. These side effects include various CNS disturbances such as blurred vision, dizziness, nausea, and sedation as well more potentially life threatening cardiac arrhythmias and cardiac failure. Accordingly, there remains a need to develop additional Na channel and Ca channel antagonists, preferably those with higher potency and fewer side effects.
    • SUMMARY OF THE INVENTION
  • In general, the invention relates to compounds useful as ion channel modulators. It has now been found that compounds of this invention, and pharmaceutically acceptable compositions thereof, are useful as inhibitors of voltage-gated sodium channels. These compounds have the general formula I:
  • Figure US20130345208A1-20131226-C00001
  • or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, X, Y and n are described generally below.
  • In another aspect, compounds of this invention, and pharmaceutically acceptable compositions thereof, are useful as inhibitors of voltage-gated sodium channels and/or calcium channels. These compounds have the general formula Ia:
  • Figure US20130345208A1-20131226-C00002
  • or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, X, and n are described generally below.
  • The present invention also includes methods for treating or lessening the severity of a disease, condition, or disorder where activation or hyperactivity of calcium and/or sodium ion channels is implicated in the disease state. Methods for treating or lessening the severity of a pain condition are also disclosed. In one aspect, the method comprises the step of administering to the patient an effective amount of a pharmaceutical composition comprising at least one compound of the present invention.
  • The compounds of the present invention are useful for treating or lessening the severity of diseases, disorders, or conditions, including, but not limited to, acute, chronic, neuropathic, or inflammatory pain, arthritis, migraine, cluster headaches, trigeminal neuralgia, herpetic neuralgia, general neuralgias, epilepsy or epilepsy conditions, neurodegenerative disorders, psychiatric disorders such as anxiety and depression, myotonia, arrhythmia, movement disorders, neuroendocrine disorders, ataxia, multiple sclerosis, irritable bowel syndrome, incontinence, visceral pain, osteoarthritis pain, postherpetic neuralgia, diabetic neuropathy, radicular pain, sciatica, back pain, head or neck pain, severe or intractable pain, nociceptive pain, breakthrough pain, postsurgical pain, or cancer pain.
    • DETAILED DESCRIPTION OF THE INVENTION I. Definitions
  • For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Ed. Additionally, general principles of organic chemistry are described in “Organic Chemistry”, Thomas Sorrell, University Science Books, Sausalito: 1999, and “March's Advanced Organic Chemistry”, 5th Ed., Ed.: Smith, M. B. and March, J., John Wiley & Sons, New York: 2001, the entire contents of which are hereby incorporated by reference.
  • The term “modulating” as used herein means increasing or decreasing, e.g. activity, by a measurable amount. Compounds that modulate ion channel activity, such as calcium ion channel activity and/or sodium ion channel activity, by increasing the activity of the ion channel, e.g., a calcium ion channel and/or a sodium ion channel, are called agonists. Compounds that modulate ion channel activity, such as calcium ion channel activity and/or sodium ion channel activity, by decreasing the activity of the ion channel, e.g., calcium ion channel and/or sodium ion channel, are called antagonists. An agonist interacts with an ion channel, such as calcium ion channel, to increase the ability of the receptor to transduce an intracellular signal in response to endogenous ligand binding. An antagonist interacts with an ion channel and competes with the endogenous ligand(s) or substrate(s) for binding site(s) on the receptor to decrease the ability of the receptor to transduce an intracellular signal in response to endogenous ligand binding.
  • The phrase “treating or reducing the severity of an ion channel mediated disease” refers both to treatments for diseases that are directly caused by ion channel activities and alleviation of symptoms of diseases not directly caused by ion channel activities. Examples of diseases whose symptoms may be affected by ion channel activities include, but are not limited to, acute, chronic, neuropathic, or inflammatory pain, arthritis, migraine, cluster headaches, trigeminal neuralgia, herpetic neuralgia, general neuralgias, epilepsy or epilepsy conditions, neurodegenerative disorders, psychiatric disorders such as anxiety and depression, myotonia, arrhythmia, movement disorders, neuroendocrine disorders, ataxia, multiple sclerosis, irritable bowel syndrome, incontinence, visceral pain, osteoarthritis pain, postherpetic neuralgia, diabetic neuropathy, radicular pain, sciatica, back pain, head or neck pain, severe or intractable pain, nociceptive pain, breakthrough pain, postsurgical pain, or cancer pain.
  • As described herein, compounds of the invention may optionally be substituted with one or more substituents, such as are illustrated generally above, or as exemplified by particular classes, subclasses, and species of the invention.
  • As used herein the term “aliphatic’ encompasses the terms alkyl, alkenyl, alkynyl.
  • As used herein, an “alkyl” group refers to a saturated aliphatic hydrocarbon group containing 1-8 (e.g., 1-6 or 1-4) carbon atoms. An alkyl group can be straight or branched. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-heptyl, or 2-ethylhexyl. An alkyl group can be optionally substituted with one or more substituents such as halo, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aroyl, heteroaroyl, alkoxycarbonyl, alkoxycarbonylamino, alkylcarbonyloxy, nitro, cyano, amino, acyl, sulfonyl, sulfinyl, sulfanyl, sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, carbamoyl, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroarylalkoxy, or hydroxyl.
  • As used herein, an “alkenyl” group refers to an aliphatic carbon group that contains 2-10 (e.g., 2, 3, 4, 5, 6, 7, 8, 9 or 10) carbon atoms and at least one double bond. Like an alkyl group, an alkenyl group can be straight or branched. Examples of an alkenyl group include, but are not limited to, allyl, isoprenyl, 2-butenyl, and 2-hexenyl. An alkenyl group may be optionally substituted with one or more substituents such as halo, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aroyl, heteroaroyl, alkoxycarbonyl, alkylcarbonyloxy, nitro, cyano, amino, acyl, sulfonyl, sulfinyl, sulfanyl, sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, carbamoyl, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroarylalkoxy, or hydroxyl.
  • As used herein, an “alkynyl” group refers to an aliphatic carbon group that contains 2-8 (e.g., 2-6 or 2-4) carbon atoms and at least one triple bond. Like an alkyl group, an alkynyl group can be straight or branched. An alkynyl group may be optionally substituted with one or more substituents such as halo, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, aroyl, heteroaroyl, alkoxycarbonyl, alkylcarbonyloxy, nitro, cyano, amino, acyl, sulfonyl, sulfinyl, sulfanyl, sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, carbamoyl, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroarylalkoxy, or hydroxyl.
  • As used herein, an “amino” group refers to —NRXRY wherein each of RX and RY is independently hydrogen, alkyl, cycloalkyl, sulfonyl, (cycloalkyl)alkyl, aryl, aralkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, heteroaryl, or heteroaralkyl each of which are defined herein and are optionally substituted. When the term “amino” is not the terminal group (e.g., alkylcarbonylamino), it is represented by —NRX—. RX has the same meaning as defined above.
  • As used herein, an “aryl” group used alone or as part of a larger moiety as in “aralkyl”, “aralkoxy”, or “aryloxyalkyl” refers to monocyclic (e.g., phenyl); bicyclic (e.g., indenyl, naphthalenyl, tetrahydronaphthyl, tetrahydroindenyl); tricyclic (e.g., fluorenyl, tetrahydrofluorenyl, anthracenyl, or tetrahydroanthracenyl); or a benzofused group having 3 rings. For example, a benzofused group includes phenyl fused with two or more C4-8 carbocyclic moieties. An aryl is optionally substituted with one or more substituents including aliphatic (e.g., alkyl, alkenyl, or alkynyl); cycloalkyl; (cycloalkyl)alkyl; heterocycloalkyl; (heterocycloalkyl)alkyl; aryl; heteroaryl; alkoxy; cycloalkyloxy; heterocycloalkyloxy; aryloxy; heteroaryloxy; aralkyloxy; heteroaralkyloxy; aroyl; heteroaroyl; amino; aminoalkyl; nitro; —C(O)OH; carbonyl (e.g., alkoxycarbonyl, alkylcarbonyl, aminocarbonyl, (alkylamino)alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl; or sulfonylcarbonyl); aralkylcarbonyloxy; sulfonyl (e.g., alkylsulfonyl or aminosulfonyl); sulfinyl (e.g., allylsulfinyl); sulfanyl alkylsulfanyl); cyano; halo; hydroxyl; acyl; mercapto; sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, or carbamoyl. Alternatively, an aryl may be unsubstituted.
  • Examples of substituted aryls include haloaryl, alkoxycarbonylaryl, alkylaminoalkylaminocarbonylaryl, p,m-dihaloaryl, p-amino-p-alkoxycarbonylaryl, m-amino-m-cyanoaryl, aminoaryl, alkylcarbonylaminoaryl, cyanoalkylaryl, alkoxyaryl, aminosulfonylaryl, alkylsulfonylaryl, aminoaryl, p-halo-m-aminoaryl, cyanoaryl, hydroxyalkylaryl, alkoxyalkylaryl, hydroxyaryl, carboxyalkylaryl, dialkylaminoalkylaryl, m-heterocycloaliphatic-o-alkylaryl, heteroarylaminocarbonylaryl, nitroalkylaryl, alkylsulfonylaminoalkylaryl, heterocycloaliphaticcarbonylaryl, alkylsulfonylalkylaryl, cyanoalkylaryl, heterocycloaliphaticcarbonylaryl, alkylcarbonylaminoaryl, hydroxyalkylaryl, alkylcarbonylaryl, aminocarbonylaryl, alkylsulfonylaminoaryl, dialkylaminoaryl, alkylaryl, and trihaloalkylaryl.
  • As used herein, an “araliphatic” group refers to an aliphatic group (e.g., a C1-4 alkyl group, a C1-4 alkenyl group, or a C1-4 alkynyl group) that is substituted with an aryl group. Both “aliphatic” and “aryl” have been defined above.
  • As used herein, an “aralkyl” group refers to an alkyl group (e.g., a C1-4 alkyl group) that is substituted with an aryl group. Both “alkyl” and “aryl” are defined herein. An example of an aralkyl group is benzyl.
  • As used herein, a “bicyclic ring system” includes 7-12 (e.g., 9, 10, or 11) membered structures that form two rings, wherein the two rings have at least one atom in common (e.g., 2 atoms in common). Bicyclic ring structures include bicycloaliphatics (e.g., bicycloalkyl or bicycloalkenyl), bicycloheteroaliphatics (e.g., bicycloheteroalkyl or bicycloheteroalkenyl), bicyclic aryls, and bicyclic heteroaryls.
  • The term “cycloaliphatic” means a saturated or partially unsaturated monocyclic, bicyclic, or tricyclic hydrocarbon ring that has a single point of attachment to the rest of the molecule. Cycloaliphatic rings are 3-8 membered monocyclic rings (e.g., 3-6 membered rings). Cycloaliphatic rings also include 8-12 membered bicyclic hydrocarbon rings, (e.g., 10 membered bicyclic hydrocarbon rings). A cycloaliphatic group encompasses a “cycloalkyl” group and a “cycloalkenyl” group.
  • As used herein, a “cycloalkyl” group refers to a saturated carbocyclic mono-, bi-, or tri-, or multicyclic (fused or bridged) ring of 3-10 (e.g., 5-10) carbon atoms. Without limitation, examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or the like. Without limitation, examples of bicyclic cycloalkyl groups include octahydro-indenyl, decahydro-naphthyl, bicyclo[3.2.1]octyl, bicyclo[2.2.2]octyl, bicyclo[3.3.1]nonyl, bicyclo[3.3.2.]decyl, bicyclo[2.2.2]octyl, bicyclo[2.2.1]heptanyl, bicyclo[3.1.1]heptanyl, or the like. Without limitation, multicyclic groups include adamantyl, cubyl, norbornyl, or the like. Cycloalkyl rings can be optionally substituted at any chemically viable ring position.
  • A “cycloalkenyl” group, as used herein, refers to a non-aromatic carbocyclic ring of 3-10 (e.g., 4-8) carbon atoms having one or more double bonds. Examples of cycloalkenyl groups include cyclopentenyl, 1,4-cyclohexa-di-enyl, cycloheptenyl, cyclooctenyl, hexahydro-indenyl, octahydro-naphthyl, cyclohexenyl, cyclopentenyl, bicyclo[2.2.2]octenyl, and bicyclo[3.3.1]nonenyl. Cycloalkenyl ring structures can be optionally substituted at any chemically viable position on the ring or rings.
  • A cycloalkyl or cycloalkenyl group can be optionally substituted with one or more substituents such as aliphatic (e.g., alkyl, alkenyl, or alkynyl), cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl, (heterocycloalkyl)alkyl, aryl, heteroaryl, alkoxy, cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, aroyl, heteroaroyl, amino, nitro, carboxy, alkoxycarbonyl, alkylcarbonyloxy, aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, (cycloalkyl)alkylcarbonylamino, arylcarbonylamino, aralkylcarbonylamino, (heterocycloalkyl)carbonylamino, (heterocycloalkyl)alkylcarbonylamino, heteroarylcarbonylamino, heteroaralkylcarbonylamino, cyano, halo, hydroxyl, acyl, mercapto, sulfonyl (e.g., alkylsulfonyl or arylsulfonyl), sulfinyl (e.g., alkylsulfinyl), sulfanyl (e.g., alkylsulfanyl), sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, carbamoyl, or the like.
  • Without limitation, examples of substituted cycloaliphatics include alkylcycloalkyl (e.g., propylcyclohexyl), alkylbicyclo[3.1.1]heptyl, alkylcycloalkenyl, or the like.
  • As used herein, the term “heterocycloaliphatic” and “heterocyclic” encompasses a heterocycloalkyl group and a heterocycloalkenyl group.
  • As used herein, a “heterocycloalkyl” group refers to a 3-10 membered mono or bicyclic (fused or bridged) (e.g., 5 to 10 membered mono or bicyclic) saturated ring structure, in which one or more of the ring atoms is a heteroatom (e.g., N, O, S, or combinations thereof). Examples of a heterocycloalkyl group include optionally substituted piperidinyl, piperazinyl, tetrahydropyranyl, tetrahydrofuranyl, 1,4-dioxolanyl, 1,4-dithianyl; 1,3-dioxolanyl, oxazolidyl, isoxazolidyl, morpholinyl, thiomorpholinyl, octahydro-benzofuranyl, octahydro-chromenyl, octahydro-thiochromenyl, octahydro-indolyl, octahydro-pyrindinyl, decahydro-quinolinyl, octahydro-benzo[b]thiophenyl, 2-oxa-bicyclo[2.2.2]octyl, 1-aza-bicyclo[2.2.2]octyl, 3-aza-bicyclo[3.2.1]octanyl, 2,6-dioxa-tricyclo[3.3.1.03,7]nonyl, tropane. A monocyclic heterocycloalkyl group may be fused with a phenyl moiety such as tetrahydroisoquinoline. Heterocycloalkyl ring structures can be optionally substituted at any chemically viable position on the ring or rings.
  • A “heterocycloalkenyl” group, as used herein, refers to a mono- or bicyclic (e.g., 5- to 10-membered mono- or bicyclic) non-aromatic ring structure having one or more double bonds, and wherein one or more of the ring atoms is a heteroatom (e.g., N, O, or S). Examples of heterocycloalkenyls include 2-pyrrolyl, 3-pyrrolyl, 2-imidazolyl, or 2-pyrazolyl. Monocyclic heterocycloaliphatics are numbered according to standard chemical nomenclature. For instance:
  • Figure US20130345208A1-20131226-C00003
  • Heterocycloalkenyl ring structures can be optionally substituted at any chemically viable position on the ring or rings.
  • A heterocycloalkyl or heterocycloalkenyl group can be optionally substituted with one or more substituents such as alkyl (including carboxyalkyl, hydroxyalkyl, and haloalkyl such as trifluoromethyl), alkenyl, alkynyl, cycloalkyl, (cycloalkyl)alkyl, heterocycloalkyl (such as a benzimidazolidinyl), (heterocycloalkyl)alkyl, aryl, heteroaryl, alkoxy (two alkoxy groups on the same atom or adjacent atoms may form a ring together with the atom(s) to which they are bound), cycloalkyloxy, heterocycloalkyloxy, aryloxy, heteroaryloxy, aralkyloxy, heteroaralkyloxy, aroyl, heteroaroyl, amino, nitro, carboxy, alkoxycarbonyl, alkylcarbonyloxy, aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, (cycloalkyl)alkylcarbonylamino, arylcarbonylamino, aralkylcarbonylamino, (heterocycloalkyl)carbonylamino, (heterocycloalkyl)alkylcarbonylamino, heteroarylcarbonylamino, heteroaralkylcarbonylamino, cyano, halo, hydroxyl, acyl, mercapto, sulfonyl (such as alkylsulfonyl or arylsulfonyl), sulfinyl (such as alkylsulfinyl), sulfanyl (such as alkylsulfanyl), sulfoxy, urea, thiourea, sulfamoyl, sulfamide, oxo, or carbamoyl.
  • Without limitation, examples of substituted heterocycloaliphatics include alkoxycarbonylheterocycloalkyl (e.g., ethoxycarbonyltropane), alkoxycarbonylheterocycloalkyl (e.g., ethoxycarbonylpiperidyl), or the like.
  • A “heteroaryl” group, as used herein, refers to a monocyclic, bicyclic, or tricyclic ring structure having 4 to 15 ring atoms wherein one or more of the ring atoms is a heteroatom (e.g., N, O, S, or combinations thereof) and wherein one or more rings of the bicyclic or tricyclic ring structure is aromatic. A heteroaryl group includes a benzofused ring system having 2 to 3 rings. For example, a benzofused group includes benzo fused with one or two C4-8 heterocyclic moieties (e.g., indolizyl, indolyl, isoindolyl, 3H-indolyl, indolinyl, benzo[b]furyl, benzo[b]thiophenyl, quinolinyl, or isoquinolinyl). Some examples of heteroaryl are azetidinyl, pyridinyl, 1H-indazolyl, furyl, pyrrolyl, thienyl, thiazolyl, oxazolyl, imidazolyl, tetrazolyl, benzofuryl, isoquinolinyl, benzthiazolyl, xanthene, thioxanthene, phenothiazine, dihydroindole, benzo[1,3]dioxole, benzo[b]furyl, benzo[b]thiophenyl, indazolyl, benzimidazolyl, benzthiazolyl, puryl, cinnolyl, quinolyl, quinazolyl, cinnolyl, phthalazyl, quinazolyl, quinoxalyl, isoquinolyl, 4H-quinolizyl, benzo-1,2,5-thiadiazolyl, or 1,8-naphthyridyl.
  • Without limitation, monocyclic heteroaryls include furyl, thiophenyl, 2H-pyrrolyl, pyrrolyl, oxazolyl, thazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, 1,3,4-thiadiazolyl, 2H-pyranyl, 4-H-pyranyl, pyridinyl, pyridazinyl, pyrimidyl, pyrazolyl, pyrazyl, or 1,3,5-triazyl. Monocyclic heteroaryls are numbered according to standard chemical nomenclature. For instance:
  • Figure US20130345208A1-20131226-C00004
  • Without limitation, bicyclic heteroaryls include indolizyl, indolyl, isoindolyl, 3H-indolyl, indolinyl, benzo[b]furyl, benzo[b]thiophenyl, quinolinyl, isoquinolinyl, indolizyl, isoindolyl, indazolyl, benzimidazyl, benzthiazolyl, purinyl, 4H-quinolizyl, quinolyl, isoquinolyl, cinnolyl, phthalazyl, quinazolyl, quinoxalyl, 1,8-naphthyridyl, or pteridyl. Bicyclic heteroaryls are numbered according to standard chemical nomenclature. For instance:
  • Figure US20130345208A1-20131226-C00005
  • A heteroaryl is optionally substituted with one or more substituents such as aliphatic including alkyls (e.g., alkoxyalkyl, carboxyalkyl, hydroxyallyl, oxoalkyl, aralkyl, (alkylsulfonylamino)alkyl, (sulfonylamino)alkyl, cyanoalkyl, aminoallyl, oxoalkyl, alkoxycarbonylalkyl, (cycloalkyl)alkyl heterocycloalkyl, (heterocycloalkyl)alkyl aralkyl, and haloalkyl such as trifluoromethyl), alkenyl, alkynyl; cycloaliphatic including cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl); heterocycloaliphatic including heterocycloalkyl (e.g., thiomorpholinyl, piperazinyl, 1,3,5-trithianyl, morpholinyl, pyrrolyl, 1,3-dioxolanyl, pyrazolidyl, or piperidinyl); aryl, heteroaryl (e.g., quinolyl, indolyl, 3H-indolyl, isoindolyl, benzo[b]-4H-pyranyl, cinnolyl, quinoxylyl, benzimidazyl, benzo-1,2,5-thiadiazolyl, benzo-1,2,5-oxadiazolyl, or benzthiophenyl); alkoxy; cycloalkyloxy; heterocycloalkyloxy; aryloxy; heteroaryloxy; aralkyloxy; heteroaralkyloxy; aroyl; heteroaroyl; amino (e.g., carbonylamino, alkylcarbonylamino, alkylsulfonylamino, arylcarbonylamino, cycloalkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, (heterocycloalkyl)carbonylamino, (cycloalkyl)alkylcarbonylamino, sulfanylamino, and (heterocycloalkyl)alkylcarbonylamino); nitro; carboxy; carbonyl (e.g., alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, arylaminocarbonyl, thiazoleaminocarbonyl, thiomorpholinecarbonyl, aminoalkylaminocarbonyl); alkylcarbonyloxy; cyano; halo; hydroxyl; acyl; mercapto; sulfonyl (e.g., aminosulfonyl, allylsulfonyl, morpholinesulfonyl, or arylsulfonyl); sulfinyl (e.g., alkylsulfinyl); sulfanyl (e.g., alkylsulfanyl); sulfoxy; urea; thiourea; sulfamoyl; sulfamide; oxo; or carbamoyl.
  • A “heteroaraliphatic” group, as used herein, refers to an aliphatic group (e.g., C1-4 alkyl group, C1-4 alkenyl group, or C1-4 alkynyl group) that is substituted with a heteroaryl group. Both “aliphatic” and “heteroaryl” have been defined above.
  • A “heteroaralkyl” group, as used herein, refers to an alkyl group (e.g., a C1-4 alkyl group) that is substituted with a heteroaryl group. Both “alkyl” and “heteroaryl” have been defined above.
  • As used herein, “cyclic moiety” includes cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, aryl, or heteroaryl, each of which has been defined previously.
  • As used herein, “cyclic group” includes mono-, bi-, and tri-cyclic structures including cycloaliphatic, heterocycloaliphatic, aryl, or heteroaryl, each of which has been previously defined.
  • As used herein, an “acyl” group refers to a formyl group or alkyl-C(═O)— (also referred to as “alkylcarbonyl”) where “alkyl” has been defined previously. Acetyl and pivaloyl are examples of acyl groups.
  • As used herein, a “carbonyl” group, when used alone or as part of another structure refers to the structure —C(O)—.
  • As used herein, a “carbamoyl” group refers to a group having the structure —O—CO—NRXRY or —NRX—CO—O—RZ wherein RX and RY have been defined above and RZ can be alkyl, aryl, aralkyl, heterocycloalkyl, heteroaryl, or heteroaralkyl.
  • As used herein, a “carboxy” and a “sulfo” group refer to —C(O)OH or —C(O)ORX and —SO3H or —SO3RX, respectively.
  • As used herein, an “alkoxy” group refers to an alkyl-O— group where “alkyl” has been defined previously. Moreover an alkoxy group includes structures comprising two alkoxy groups on the same atom or adjacent atoms that form a ring together with the atom(s) to which they are bound.
  • As used herein, a “sulfoxy” group refers to —O—SO—RX or —SO—O—RX, where RX has been defined above.
  • As used herein, a “mercapto” group refers to —SH.
  • As used herein, a “sulfonyl” group refers to —S(O)2—.
  • As used herein a “sulfinyl” group refers to —S(O)—.
  • As used herein a “sulfanyl” group refers to —S—.
  • As used herein, a “halogen” or “halo” group refers to fluorine, chlorine, bromine or iodine.
  • As used herein, a “haloaliphatic” group refers to an aliphatic group substituted with 1-3 halogen. For instance, the term haloalkyl includes the group —CF3.
  • As used herein, a “sulfamoyl” group refers to the structure —S(O)2—NRXRY or —NRX—S(O)2—RZ wherein RX, RY, and RZ have been defined above.
  • As used herein, a “sulfamide” group refers to the structure —NRX—S(O)2—NRYRZ wherein RX, RY, and RZ have been defined above.
  • As used herein, a “carbonylamino” group used alone or in connection with another group refers to an amido group such as RX—C(O)—NRX—. For instance an alkylcarbonylamino includes alkyl-C(O)—NRX—, wherein RX has been defined above.
  • As used herein, a “aminocarbonyl” group used alone or in connection with another group refers to an amido group such as N(RX)2—C(O)—.
  • As used herein, an “alkoxycarbonyl” used alone or in connection with another group refers to a carbonyl group such as alkyl-O—C(O)—.
  • As used herein, an “alkoxyalkyl” refers to an alkyl group such as alkyl-O-alkyl-, wherein alkyl has been defined above.
  • As used herein, an “aminocarbonyl” refers to an amido group such as —NRX—C(O)—, wherein RX has been defined above.
  • As used herein, an “aminosulfonyl” refers to the structure —N(RX)2—S(O)2—, wherein RX has been defined above.
  • As used herein, an “oxo” refers to ═O.
  • As used herein, an “aminoalkyl” refers to the structure N(RX)2-alkyl-.
  • As used herein, a “cyanoalkyl” refers to the structure (CN)-alkyl-.
  • As used herein, an “alkylsulfonyl’ group refers to the structure alkyl-S(O)2—.
  • As used herein, a “sulfonylamino” group refers to the structure RX—S(O)2—N(RX)2—, wherein RX has been defined above.
  • As used herein, a “guanidinyl” group refers to the structure NH2C(NH)NH—.
  • As used herein, an “aliphatic chain” refers to a branched or straight aliphatic group. A straight aliphatic chain has the structure —[CH2]p—, where p is 1-6. A branched aliphatic chain is a straight aliphatic chain that is substituted with one or more aliphatic groups. A branched aliphatic chain has the structure —[CHW]p— where W is hydrogen or an aliphatic group; however, W shall be an aliphatic group in at least one instance.
  • As used herein, a “urea” group refers to the structure —NRX—CO—NRYRZ and a “thiourea” group refers to the structure —NRX—CS—NRYRZ. RX, RY, and RZ have been defined above.
  • In general, the term “substituted,” whether preceded by the term “optionally” or not, refers to the replacement of hydrogen radicals in a given structure with the radical of a specified substituent. Specific substituents are described above in the definitions and below in the description of compounds and examples thereof. Unless otherwise indicated, an optionally substituted group may have a substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position. A ring substituent, such as a heterocycloalkyl, may be bound to another ring, such as a cycloalkyl, to form a spiro-bicyclic ring system, e.g., both rings share one common atom. As one of ordinary skill in the art will recognize, combinations of substituents envisioned by this invention are those combinations that result in the formation of stable or chemically feasible compounds.
  • The phrase “stable or chemically feasible,” as used herein, refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and preferably their recovery, purification, and use for one or more of the purposes disclosed herein. In some embodiments, a stable compound or chemically feasible compound is one that is not substantially altered when kept at a temperature of 40° C. or less, in the absence of moisture or other chemically reactive conditions, for at least a week.
  • As used herein, an effective amount is defined as the amount required to confer a therapeutic effect on the treated patient, and is typically determined based on age, surface area, weight, and condition of the patient. The interrelationship of dosages for animals and humans (based on milligrams per meter squared of body surface) is described by Freireich et al., Cancer Chemother. Rep., 50: 219 (1966). Body surface area may be approximately determined from height and weight of the patient. See, e.g., Scientific Tables, Geigy Pharmaceuticals, Ardsley, N.Y., 537 (1970). As used herein, “patient” refers to a mammal, including a human.
  • As used herein, “patient” refers to a mammal, including a human.
  • Unless otherwise stated, structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, all tautomeric forms of the compounds of the invention are within the scope of the invention. Additionally, unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 13C- or 14C-enriched carbon are within the scope of this invention. Such compounds are useful, for example, as analytical tools or probes in biological assays.
    • II. Compounds A. Generic Compounds
  • The present invention provides a method of modulating a sodium ion channel comprising the step of contacting said ion channel with a compound of formula I:
  • Figure US20130345208A1-20131226-C00006
  • or a pharmaceutically acceptable salt thereof.
  • Each X is defined by —ZAR6, wherein each ZA is independently a bond or an optionally substituted branched or straight C1-6 aliphatic chain wherein up to two carbon units of ZA are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONRA—, —CONRANRA—, —CO2—, —OCO—, —NRACO2—, —O—, —NRACONRA—, —OCONRA—, —NRANRA, NRANRACO—, —NRACO—, —S—, —SO—, —SO2—, —NRA—, —SO2NRA—, —NRASO2—, or —NRASO2NRA—.
  • Each R4 is independently RA, halo, —OH, —NH2, —NO2, —CN, —CF3, or —OCF3.
  • Each RA is independently hydrogen, an optionally substituted C1-8 aliphatic group; a 3-8 membered optionally substituted fully saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; an 8-12 membered optionally substituted fully saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two occurrences of RA are taken together with the atom(s) to which they are attached to form an optionally substituted 3-12 membered fully saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • Each n is 1-4.
  • Each R1 and R2 is defined by —ZBR7, wherein each ZB is independently a bond or an optionally substituted straight or branched C1-6 aliphatic chain wherein up to two carbon units of ZB are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONRB—, —CONRBNRB—, —CO2—, —OCO—, —NRBCO2—, —O—, —NRBCONRB—, —OCONRB—, —NRBNRB, —NRBNRBCO—, —NRBCO—, —S—, —SO—, —SO2—, —NRB—, —SO2NRB—, —NRBSO2—, or —NRBSO2NRB—.
  • Each R7 is independently RB, halo, —OH, —NHC(NH)NH2, —NH2, —NO2, —CN, —CF3, or —OCF3.
  • Each RB is independently hydrogen, an optionally substituted C14 aliphatic group, an optionally substituted 3-8 membered fully saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; an optionally substituted 8-12 membered fully saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two occurrences of RB are taken together with the atom(s) to which they are attached to form an optionally substituted 3-12 membered fully saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • Each R3 and R4 is defined by —ZCR8, wherein each ZC is independently a bond or an optionally substituted straight or branched C1-6 aliphatic chain wherein up to two carbon units of ZC are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONRC—, —CONRCNRC—, —CO2—, —OCO—, —NRCCO2—, —O—, —NRCCONRC—, —OCONRC—, —NRCNRC, —NRCNRCCO—, —NRCCO—, —S—, —SO—, —SO2—, —NRC—, —SO2NRC—, —NRCSO2—, or —NRCSO2NRC—.
  • Each R8 is independently RC, halo, —OH, —NH2, —NO2, —CN, —CF3, or —OCF3.
  • Each RC is independently hydrogen, or an optionally substituted C1-3 aliphatic group, an optionally substituted 3-8 membered fully saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; an optionally substituted 8-12 membered fully saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two occurrences of RC are taken together with the atom(s) to which they are attached to form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • Each Y is hydrogen or unsubstituted C1-3 alkyl.
    • B. Specific Embodiments
  • 1. Substituents R1 and R2
  • Each R1 and R2 are defined by —ZBR7, wherein each ZB is independently a bond, or an optionally substituted straight or branched C1 aliphatic chain wherein up to two carbon units of ZB are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONRB—, —CONRBNRB—, —CO2—, —OCO—, —NRBCO2—, —O—, —NRBCONRB—, —OCONRB—, —NRBNRB, —NRBNRBCO—, —NRBCO—, —S—, —SO—, —SO2—, —NRB—, —SO2NRB—, —NRBSO2—, or —NRBSO2NRB—.
  • Each R7 is independently RB, halo, —OH, —NHC(NH)NH2, —NH2, —NO2, —CN, —CF3, or —OCF3.
  • Each RB is independently hydrogen, an optionally substituted C1-8 aliphatic group, an optionally substituted 3-8 membered fully saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; an optionally substituted 8-12 membered fully saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or two occurrences of RB are taken together with the atom(s) to which they are attached to form an optionally substituted 3-12 membered fully saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, each of which is optionally substituted with 1 to 3 substituents.
  • In several embodiments, R1 and R2 are independently hydrogen; or C1-8 aliphatic, araliphatic, heteroaralkyl, alkoxyalkyl, heterocycloaliphatic, guanidinylalkyl, aryloxyalkyl, C1-6 cycloaliphatic; or R1 and R2 together with the nitrogen atom to which they are attached form an optionally substituted 5-8 membered fully saturated, partially unsaturated, or fully unsaturated heterocyclic ring.
  • In several other embodiments, one of R1 and R2 is an optionally substituted araliphatic or arylcycloaliphatic. Several examples of R1 or R2 include —C1-3 aliphatic-aryl that is optionally substituted. In another set of examples, R1 or R2 is optionally substituted arylcycloalkyl (e.g., -cyclopropyl-aryl, -cyclobutyl-aryl, -cyclopentyl-aryl, or the like). In still other examples, R1 or R2 is optionally substituted monocyclic or bicyclic aralkyl. Several more examples of R1 or R2 include optionally substituted —C1-3 aliphatic-phenyl (e.g., phenylmethyl, phenylethyl, phenylpropyl). In other examples, R1 or R2 is optionally substituted bicyclic —C1-3 aliphatic-aryl (e.g., —C1-3 aliphatic-naphthyl or —C1-3 aliphatic-indenyl). In other examples, R1 or R2 is a naphthylmethyl, naphthylethyl, naphthylpropyl, indenylmethyl, indenylethyl, or indenylpropyl, each of which is optionally substituted. In other examples, R1 or R2 is an unsubstituted naphthylmethyl, naphthylethyl, naphthylpropyl, indenylmethyl, indenylethyl, or indenylpropyl. In several embodiments, R1 or R2 is a substituted aralkyl or arylcycloalkyl. For example, R1 or R2 is an aralkyl that is substituted at any chemically feasible position along the aliphatic chain, or on the aryl group. In several embodiments, R1 or R2 is substituted with 1-3 of halo, hydroxy, cyano, nitro, aliphatic, haloaliphatic, alkylamino, cycloaliphatic, heterocycloaliphatic, (heterocycloaliphatic)alkyl, aminocarbonyl, aryl, heteroaryl, or combinations thereof, each of which is optionally substituted. In one embodiment, R1 or R2 is an unsubstituted aralkyl. In one example, R1 or R2 is an unsubstituted phenylmethyl, unsubstituted phenylethyl, or an unsubstituted phenylpropyl.
  • In several other embodiments, R1 or R2 is a C1-8 aliphatic that is optionally substituted with 1-3 substituents. In several embodiments, R1 or R2 are optionally substituted straight (e.g., ethyl, propyl, sec-butyl, or the like) or branched (e.g., isopropyl, isobutyl, sec-propyl, sec-butyl, or the like) aliphatic. For example, R1 or R2 is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, or octyl, each substituted with 1-3 substituents (e.g., 1-2 substituents). In other examples, R1 or R2 is an isopropyl that is optionally substituted with 1-2 substituents, or R1 or R2 is an unsubstituted isopropyl. In more examples, R1 or R2 is a sec-propyl that is substituted with 1-2 substituents. In several embodiments, R1 or R2 is substituted with 1-3 halo, cyano, hydroxy, or optionally substituted aryl, aryloxy, alkylamino, heteroaryl, cycloaliphatic, heterocycloaliphatic, or combinations thereof. In another embodiment, R1 or R2 is substituted with alkoxyalkyl. In other embodiments, R1 or R2 is unsubstituted methyl or sec-propyl.
  • In other embodiments, R1 or R2 is an optionally substituted monocyclic or bicyclic cycloaliphatic. For example, R1 or R2 is an optionally substituted monocyclic C3-4 cycloaliphatic. In other examples, R1 or R2 is fully saturated or partially unsaturated. In other examples, R1 or R2 is a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl, each of which is optionally substituted with 1-2 substituents. For, example, In some embodiments, R1 or R2 is unsubstituted cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In other embodiments, R1 or R2 is substituted cyclopropyl. For example, R1 or R2 is substituted with 1-3 of halo, hydroxy, aliphatic, aryl, heteroaryl, or combinations thereof. In other embodiments, R1 or R2 is an optionally substituted bicyclic cycloaliphatic. In other examples, R1 or R2 is an optionally substituted bridged bicyclic cycloaliphatic. In other embodiments, R1 or R2 is optionally substituted bicyclo[2.1.1]hexyl, bicyclo[3.1.1]heptyl, or bicyclo[2.2.1]heptyl. In more examples R1 or R2 is unsubstituted bicyclo[2.1.1]hexyl, or bicyclo[2.2.1]heptyl substituted with 1-3 methyl groups. In another example, R1 or R2 is 2,6,6-trimethylbicyclo[3.1.1]heptyl.
  • In some embodiments, R1 or R2 is an optionally substituted aryl. For example, R1 or R2 is an optionally substituted 6-10 membered monocyclic or bicyclic aryl. In other examples, R1 or R2 is an optionally substituted phenyl, indenyl, dihydroindenyl or naphthyl. In other embodiments, R1 or R2 is substituted with 1-2 halo, hydroxy, cyano, or optionally substituted aliphatic, alkoxy, aryl, or heteroaryl; or combinations thereof. In other embodiments, R1 or R2 is unsubstituted phenyl, indenyl, dihydroindenyl or naphthyl.
  • In some embodiments, R1 or R2 is an optionally substituted monocyclic or bicyclic heterocycloaliphatic including 1-3 heteroatoms selected from N, O, and S. In one group of examples, R1 or R2 is fully saturated or partially unsaturated. In one group of examples, R1 or R2 is an optionally substituted fully saturated monocyclic heterocycloaliphatic. In another group of examples, R1 or R2 is morpholinyl, pyrroldinyl, thiomorpholinyl, tetrahydro-2H-pyranyl, or tetrahydrothiophenyl, each of which is optionally substituted. For example, R1 or R2 is morpholinyl, pyrroldinyl, thiomorpholinyl, tetrahydro-2H-pyranyl, or tetrahydrothiophenyl, each of which is optionally substituted with 1-3 substituents selected from halo, hydroxyl, aliphatic, or aryl. In another group of examples, R1 or R2 is unsubstituted morpholinyl, thiomorpholinyl, tetrahydro-2H-pyranyl, or tetrahydrothiophenyl. In another group of examples, R1 or R2 is an unsubstituted tropane.
  • In some embodiments, R1 or R2 is an optionally substituted heteroaraliphatic. In some embodiments, R1 or R2 includes a straight or branched aliphatic chain. For example, R1 or R2 includes a straight C1-4 aliphatic chain. In another example, R1 or R2 is optionally substituted —C1-3 aliphatic-heteroaryl. As noted above, R1 or R2 can be substituted at any chemically feasible position on the aliphatic chain or on the heteroaryl group. In other embodiments, R1 or R2 includes a 6-10 membered monocyclic or bicyclic heteroaryl group attached to the core structure with a C1-3 aliphatic chain. For example, R1 or R2 is an optionally substituted 2,3-dihydrobenzofurylalkyl, indolinylalkyl, 2,3-dihydrobenzo[b][1,4]dioxinylalkyl, benzo[d][1,3]dioxolylalkyl, pyridinylalkyl, isoindolinylalkyl, or quinolinylalkyl. In other examples, R1 or R2 is an unsubstituted heteroaralkyl.
  • In some embodiments, R1 or R2 is an optionally substituted heteroaryl. For example, R1 or R2 is 2,3-dihydrobenzo[b][1,4]dioxinyl, or benzo[d][1,3]dioxolyl, each of which is optionally substituted. In several examples, R1 or R2 is unsubstituted 2,3-dihydrobenzo[b][1,4]dioxinyl, or benzo[d][1,3]dioxolyl.
  • In several other embodiments, R1, R2, and the nitrogen atom to which they are attached form an optionally substituted 4-12 membered monocyclic or bicyclic fully saturated or partially unsaturated ring having 1-3 heteroatoms. In several examples, R1 and R2 form a morpholinyl, piperadinyl, piperazinyl, pyrrolyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolidinyl, imidazolidinyl, pyrazolyl, pyrazolidinyl, thiomorpholinyl, or 3,4-dihydro-benzo[b][1,4]oxazine, each of which is optionally substituted with 1-3 substituents independently selected from halo, alkylcarbonyl, C1-4 alkyl, ethyl, alkoxy, and heterocycloalkyl. In another embodiment, R1, R2, and the nitrogen atom to which they are attached form a partially saturated heterocyclic ring that is optionally substituted with 1-2 substituents. For example, R1, R2, and the nitrogen atom to which they are attached form a substituted 1,2,3,6-tetrahydropyridinyl. In other examples, R1, R2, and the nitrogen atom to which they are attached form a piperidinyl, or tetrahydropyridinyl substituted with 1-2 substituents selected from alkyl, alkylcarbonyl, alkoxy, haloaryl, alkoxyaryl, or aryl. In other examples, R1, R2, and the nitrogen atom to which they are attached form an unsubstituted fully saturated or partially unsaturated heterocycloaliphatic.
  • In some embodiments, R1 and R2 together with the nitrogen atom to which they are attached form an optionally substituted 5-10 membered monocyclic or bicyclic ring that is partially unsaturated, or fully unsaturated, and has 1-3 heteroatoms selected from N, O, and S. In several embodiments, R1 and R2 together with the nitrogen atom to which they are attached form an optionally substituted monocyclic or bicyclic heteroaryl. In several examples, the heteroaryl formed from R1, R2, and the nitrogen atom to which they are attached is substituted with 1-3 of halo, cyano, hydroxyl, alkoxy, aliphatic, aryl, or cycloaliphatic. For example, R1, R2, and the nitrogen atom to which they are attached are optionally substituted indolinyl, 1,2,3,4-tetrahydroquinolinyl, or 3,4-dihydro-2H-benzo[b][1,4]oxazinyl. In other examples, the heteroaryl formed from R1, R2, and the nitrogen atom to which they are attached is substituted with 1-2 aliphatic groups. In other examples, the heteroaryl formed from R1, R2, and the nitrogen atom to which they are attached is substituted with 1-2 methyl groups.
  • In some embodiments, R1 or R2 is hydrogen.
  • In some embodiments, R1 or R2 is an optionally substituted guanidinylalkyl having 1-2 substituents. In other embodiments, R1 or R2 is an unsubstituted guanidinylalkyl.
  • In several embodiments, R1 and R2 are each independently selected from: hydrogen, methyl, ethyl,
  • Figure US20130345208A1-20131226-C00007
    Figure US20130345208A1-20131226-C00008
    Figure US20130345208A1-20131226-C00009
  • In several embodiments, R1, R2 and the nitrogen atom to which they are attached form a heterocycloaliphatic or a heterocycloaliphatic fused with phenyl selected from:
  • Figure US20130345208A1-20131226-C00010
  • 2. Substituents R3 and R4
  • Each R3 and R4 are defined by —ZCR8, wherein each ZC is independently a bond or an optionally substituted straight or branched C1-6 aliphatic chain wherein up to two carbon units of ZC are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONRC—, —CONRCNRC—, —CO2—, —OCO—, —NRCCO2—, —O—, —NRCCONRC—, —OCONRC—, —NRCNRC, —NRCNRCCO—, —NRCCO—, —S—, —SO—, —SO2—, —NRC—, —SO2NRC—, —NRCSO2—, or —NRCSO2NRC—.
  • Each Rg is independently RC, halo, —OH, —NH2, —NO2, —CN, —CF3, or —OCF3.
  • Each RC is independently hydrogen, an optionally substituted C1-8 aliphatic group; an optionally substituted 3-8 membered fully saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; an optionally substituted 8-12 membered fully saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two occurrences of RC are taken together with the atom(s) to which they are attached to form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, each of which is optionally substituted with 1 to 3 substituents.
  • In several embodiments, R3, R4 and the nitrogen atom to which they are attached form an optionally substituted 4-8 membered saturated or partially unsaturated monocyclic or bicyclic heterocycloaliphatic. In several embodiments, the heterocycloaliphatic formed from the R3, R4 and the nitrogen atom to which they are attached is substituted with 1-3 substituents.
  • In several embodiments, R3, R4 and the nitrogen atom to which they are attached form an optionally substituted monocyclic heterocycloaliphatic with 1-3 heteroatoms selected from N, O, and S. In another example R3, R4 and the nitrogen atom to which they are attached form a fully saturated optionally substituted heterocycloaliphatic (e.g., heterocycloalkyl). In yet another example, R3, R4, and the nitrogen atom to which they are attached form an optionally substituted morpholinyl, thiomorpholinyl, piperadinyl, piperazinyl, pyrrolidinyl, tetrahydrofuranyl, or imidazolinyl. In several embodiments the fully saturated heterocycloaliphatic formed by R3, R4, and the nitrogen atom to which they are attached is substituted with 1-3 substituents selected from halo, cyano, hydroxy, or optionally substituted C1-5 aliphatic, heterocycloaliphatic, alkoxy, alkoxycarbonyl, alkylaminocarbonyl, or aralkyl. In several embodiments, the heterocycloaliphatic formed from R3, R4, and the nitrogen atom to which they are attached is a piperadinyl that is substituted with aliphatic, cycloaliphatic, alkoxy, alkoxycarbonyl, heterocycloaliphatic, cycloaliphatic, heteroaralkyl or aralkyl; or it is an unsubstituted piperadinyl. For example, the piperadinyl formed from R3, R4 and the nitrogen atom to which they are attached is substituted with methyl, pyrrolidinyl, cyclopentyl, phenylmethyl, or pryridinylmethyl. In some embodiments, R3, R4, and the nitrogen atom to which they are attached form unsubstituted morpholinyl, thiomorpholinyl, piperadinyl, piperazinyl, pyrrolidinyl, or tetrahydrofuranyl. In some embodiments, R3, R4, and the nitrogen atom to which they are attached form an alkyl substituted piperazinyl or morpholinyl. For example, R3, R4, and the nitrogen atom to which they are attached form a piperazinyl or morpholinyl that is optionally substituted with 1-2 alkyl groups. In other examples, R3, R4, and the nitrogen atom to which they are attached form a piperazinyl or a morpholinyl, each of which is substituted with 1-2 alkyl groups.
  • In several embodiments, R3, R4, and the nitrogen atom to which they are attached form an optionally substituted fully saturated or partially unsaturated bicyclic heterocycloaliphatic. For example, the bicyclic heterocycloaliphatic formed from R3, R4, and the nitrogen atom to which they are attached has 1-3 heteroatoms selected from N, O, and S. In other embodiments, the heterocycloaliphatic formed by R3, R4, and the nitrogen atom to which they are attached is substituted with 1-3 substituents. In other embodiments, R3, R4, and the nitrogen atom to which they are attached form an optionally substituted decahydroquinaolinyl, tropane, or octahydroindolyl. In several embodiments, R3, R4, and the nitrogen atom to which they are attached form an unsubstituted decahydroquinaolinyl. In several other embodiments, R3, R4, and the nitrogen atom to which they are attached form a decahydroquinolinyl that is optionally substituted with 1-2 methyl groups.
  • In several embodiments, R3, R4, and the nitrogen atom to which they are attached form an optionally substituted 6-10 membered heteroaryl. For example, the heteroaryl formed by R3, R4, and the nitrogen atom to which they are attached is substituted with 1-3 substituents. The optionally substituted heteroaryl formed by R3, R4, and the nitrogen atom to which they are attached is a monocyclic or bicyclic ring system. In several embodiments, R3, R4, and the nitrogen atom to which they are attached form optionally substituted 1,2,3,4-tetrahydroquinolinyl, or octahydroisoindolyl. In another embodiment, R3, R4, and the nitrogen atom to which they are attached form unsubstituted 1,2,3,4-tetrahydroquinolinyl, or octahydroisoindolyl.
  • In several embodiments, one of R3 or R4 is an optionally substituted 6-10 membered monocyclic or bicyclic aryl. In another example, R3 or R4 is substituted with 1-3 substituents. In some embodiments, R3 or R4 is an optionally substituted monocyclic aryl. For example R3 or R4 is a monocyclic aryl substituted with 1-3 of halo, cyano, hydroxy, methyl, alkoxy, alkoxycarbonyl, C1-6 aliphatic, aminocarbonyl, or combinations thereof. In other examples, R3 or R4 is a phenyl. In several embodiments, R3 or R4 is an optionally substituted bicyclic aryl. In several embodiments, R3 or R4 is an optionally substituted naphthyl or indenyl. In several embodiments, R3 or R4 is substituted with 1-3 substituents. For example, R3 or R4 is substituted with 1-3 substituents selected from halo, cyano, hydroxy, alkoxy, alkoxycarbonyl, alkylaminocarbonyl, C1-4 aliphatic, aryl or heteroaryl. In other examples, R3 or R4 is an unsubstituted naphthyl or indenyl.
  • In several embodiments R3 or R4 is an optionally substituted straight or branched C1-8 aliphatic. For example, R3 or R4 is optionally substituted straight (e.g., methyl, ethyl, propyl, butyl, or the like) or branched (e.g., isopropyl, isobutyl, sec-propyl, sec-butyl or the like) aliphatic. For example, R3 or R4 is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, or octyl, each substituted with 1-3 substituents (e.g., 1-2 substituents). In other examples, R3 or R4 is an isopropyl or sec-propyl that is optionally substituted with 1-3 substituents (e.g., 1-2 substituents), or R3 or R4 is an unsubstituted sec-propyl or isopropyl. In several embodiments, R3 or R4 is unsubstituted methyl, ethyl, propyl, butyl, pentyl, or hexyl. In other embodiments, R3 or R4 is a —C(O)OH substituted aliphatic (e.g., alkyl-C(O)OH). For example, R3 or R4 is a methyl, ethyl, or propyl, each of which is substituted with —C(O)OH. In several embodiments, R3 or R4 is substituted with 1-2 substituents including halo, cyano, hydroxy, or optionally substituted cycloaliphatic, heterocycloaliphatic, aryl, alkoxy, haloalkylaryl, bicycloaliphatic, aryloxy, haloaryl, alkylamino, heteroaryl, cycloaliphatic, heterocycloaliphaticpropyl, isopropyl, or combinations thereof. In other embodiment, R3 or R4 is methyl, ethyl, or propyl that is substituted with a monocyclic optionally substituted aryl. For example, R3 or R4 is methyl, ethyl, or propyl that is substituted with alkoxyphenyl, cycloaliphaticphenyl, haloalkylphenyl, cyanophenyl, halophenyl, or hydroxyphenyl. In other embodiments, R3 or R4 is methyl, ethyl, or propyl that is substituted with a bicyclic aryl. For example R3 or R4 is methyl, ethyl, or propyl that is substituted with unsubstituted naphthyl or indenyl. In other embodiments, R3 or R4 is substituted with two substituents independently selected from halo, cyano, hydroxyl, aliphatic, aryl, heteroaryl, cycloaliphatic, heterocycloaliphatic, or alkoxy. In some embodiments, R3 or R4 is methyl substituted with aliphatic and aryl. In several embodiments, R3 or R4 includes an optionally substituted partially unsaturated aliphatic (e.g., alkenyl or alkynyl). In several examples, R3 or R4 includes optionally substituted ethenyl, propenyl, or butenyl. In other embodiments, R3 or R4 includes unsubstituted propenyl.
  • In several embodiments, R3 or R4 is an optionally substituted heteroaryl. For example R3 or R4 is an optionally substituted 6-10 membered monocyclic or bicyclic heteroaryl. In some examples, R3 or R4 is a monocyclic heteroaryl optionally substituted with 1-3 substituents. In other examples, R3 or R4 is a substituted pyridinyl, pyrimidinyl, pyridazinyl, or pyrazinyl. In other examples R3 or R4 is an unsubstituted pyridinyl, pyrimidinyl, pyridazinyl, or pyrazinyl. In several embodiments, R3 or R4 is an optionally substituted bicyclic heteroaryl. For example, R3 or R4 is a bicyclic heteroaryl substituted with 1-3 substituents. In other examples, R3 or R4 is an optionally substituted isoindolinyl. In some embodiments, R3 or R4 is unsubstituted isoindolinyl.
  • In several embodiments, R3 or R4 is an optionally substituted monocyclic or bicyclic cycloaliphatic. In some embodiments, R3 or R4 is a monocyclic cycloaliphatic optionally substituted with 1-3 substituents including hydroxy, alkoxy, alkylamino, alkyl carbonyl, aliphatic, halo, or combinations thereof. In other embodiments, R3 or R4 is optionally substituted cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl. For example, R3 or R4 is unsubstituted cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl. In other embodiments, R3 or R4 is optionally substituted bicycloaliphatic. In several examples, R3 or R4 is bicycloaliphatic or bridged bicycloaliphatic optionally substituted with 1-3 substituents selected from hydroxy, alkoxy, alkylamino, alkyl carbonyl, aliphatic, and halo. In other examples, R3 or R4 is optionally substituted bicyclo[2.1.1]hexyl, bicyclo[3.1.1]heptyl, or bicyclo[2.2.1]heptyl. In other examples R3 or R4 is unsubstituted bicyclo[2.1.1]hexyl, or bicyclo[2.2.1]heptyl.
  • In several embodiments, R3 or R4 is hydrogen.
  • In several embodiments, each R3, R4, is independently selected from: hydrogen, methyl, ethyl,
  • Figure US20130345208A1-20131226-C00011
    Figure US20130345208A1-20131226-C00012
  • In several embodiments, R3, R4, and the nitrogen atom to which they are attached is one selected from:
  • Figure US20130345208A1-20131226-C00013
  • 3. Substituent X
  • Each X is defined by —ZAR6, wherein ZA is independently a bond or an optionally substituted branched or straight C1-6 aliphatic chain wherein up to two carbon units of ZA are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONRA—, —CONRANRA—, —CO2—, —OCO—, —NRACO2—, —O—, —NRACONRA—, —OCONRA—, —NRANRA, —NRANRACO—, —NRACO—, —S—, —SO—, —SO2—, —NRA—, —SO2NRA—, —NRASO2—, or —NRASO2NRA—.
  • Each R6 is independently RA, halo, —OH, —NH2, —NO2, —CN, —CF3, or —OCF3.
  • Each RA is independently hydrogen, an optionally substituted C1-3 aliphatic group; a 3-8-membered optionally substituted fully saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; an 8-12 membered optionally substituted fully saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two occurrences of RA are taken together with the atom(s) to which they are attached to form an optionally substituted 3-12 membered fully saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • In several embodiments, X is a C1-6 aliphatic that is optionally substituted and branched or straight. For example, X is an optionally substituted branched or straight C1-6 aliphatic that is fully saturated or partially unsaturated. In other examples, X is fully saturated (e.g., alkyl). In some embodiments, X is methyl, ethyl, propyl, butyl, pentyl, or hexyl, each of which is optionally substituted with 1-3 substituents. In other embodiments, X is an optionally substituted branched aliphatic. For example, X is an isopropyl, isobutyl, isopentane, sec-butyl, or sec-propyl, each of which is optionally substituted with 1-2 substituents. In several examples, X is an unsubstituted C1-6 aliphatic. For example, X is unsubstituted methyl, ethyl, propyl, butyl, pentyl, or hexyl. In other embodiments, X is substituted with 1-3 substituents independently selected from alkylcarbonyl, alkoxy, —C(O)OH, aryl, heteroaryl, cycloaliphatic, heterocycloaliphatic, and alkylamino. In several embodiments, X is optionally substituted C1-6 aliphatic that is partially unsaturated. For example, X is an optionally substituted C1-6 aliphatic that has at least 1 C—C double bond, or at least 1 C—C triple bond. In other examples, X is optionally substituted ethenyl, propenyl, but-1-enyl, or but-2-enyl. In some embodiments, X is substituted with 1-3 substituents independently selected from alkylcarbonyl, alkoxy, —C(O)OH, aryl, heteroaryl, cycloaliphatic, heterocycloaliphatic, and alkylamino. In other embodiments, X is ethenyl substituted with —C(O)OH (e.g., acrylic acid).
  • In several embodiments, X is an optionally substituted C1-6 alkoxy. The alkyl group of the alkoxy can be optionally substituted with 1-3 substituents. For example, X is methoxy, ethoxy, propoxy, butoxy, pentoxy, or hexoxy, each of which is optionally substituted. In other examples, X is prop-2-oxy, but-2-oxy, pent-2-oxy, or pent-3-oxy, each of which is optionally substituted. In several embodiments, X is unsubstituted prop-2-oxy, but-2-oxy, pent-2-oxy, or pent-3-oxy. In other examples, X is substituted with a C1-3 aliphatic group. For example, X is ethoxy, propoxy, butoxy, pentoxy, or hexoxy, each of which is substituted with methyl or ethyl.
  • In several embodiments, X is an optionally substituted ring system that that is fully saturated, partially unsaturated, or fully unsaturated and attaches to the core phenyl with an oxy (—O—) group. In several examples, X is selected from optionally substituted aryloxy, heteroaryloxy, cycloaliphaticoxy, or heterocycloaliphaticoxy. In several embodiments, X is an unsubstituted aryloxy, heteroaryloxy, cycloaliphaticoxy, or heterocycloaliphaticoxy. For example, X is an unsubstituted phenoxy. In other embodiments, X is a phenoxy that is substituted with 1-3 substituents selected from halo, —CF3, alkoxy, alkylcarbonyl, and cyano.
  • In several embodiments, X is an optionally substituted amino. For example X is substituted with 1-3 substituents selected from aliphatic, alkoxy, alkylsulfonyl, alkylcarbonyl, aryl, heteroaryl, cycloaliphatic, and heterocycloaliphatic. In several examples, X is alkylcarbonylamino.
  • In several embodiments, X is a halo (e.g., F, Cl, Br, or I).
  • In several embodiments, each X is independently selected from: halo,
  • Figure US20130345208A1-20131226-C00014
  • 4. Substituents Y and n
  • Each Y is hydrogen, or optionally substituted methyl.
  • Each n is 1-4.
  • In several embodiments, Y is methyl.
  • In several embodiments, n is 1 or 2.
  • 5. Exemplary Compound Families
  • Another aspect of the present invention includes compounds of formula Ia:
  • Figure US20130345208A1-20131226-C00015
  • or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, X and n are defined above.
  • In several embodiments of formula Ia, when R1 is alkyl, R2 is not 3,5-bis-trifluoromethyl-phenyl-alkyl; when R1 and R2 together form pyrrolidinyl, morpholinyl, or piperidinyl, each optionally substituted with —CH3 or —CH2CH3, then X is not m-methyl, o-halo, p-aryl, or p-cyano; when R1 or R2 are aliphatic or alkoxyalkyl, then X is not m-methyl, o-halo, p-aryl, or p-cyano; and when R1 is phenylmethyl optionally substituted with 1-2 —CH3 groups or cycloaliphatic, and R2 is one selected from substituted methyl, ethyl, and isopropyl, then
      • (1) R3 together with R4 form pyrrolidinyl, morpholinyl, piperidinyl optionally substituted with aliphatic, aminocarbonyl, or alkylcarbonyl, or one of R3 or R4 is phenylmethyl, methylfuranyl, or methoxypropyl, and
      • (2) X is not m-methyl, p-aryl, o-halo or p-cyano.
  • In other embodiments of formula Ia, R3 or R4 is heterocycloaliphatic, bicycloaryl, bicycloheteroaliphatic, bicycloheteroaryl, heterocycloalkenyl, cycloaliphatic, alkenyl, 5-membered heterocycloaliphatic, heteroaralkyl, or bicycloaralkyl, each of which is optionally substituted; or one of R3 and R4 is hydrogen, R3 or R4 is alkyl substituted with cycloaliphatic, heteroaryl, heterocycloaliphatic, cyano, alkoxycarbonyl, —C(O)OH, guanidinylalkyl, bicycloaryl, halo, or alkoxy, or R3 together with R4 form a ring system selected from thiomorpholinyl, bicycloheteroaryl, bicyclic heterocycloaliphatic, 5-membered heterocycloaliphatic, and 6-membered heterocycloalkenyl, provided that when R1 and R2 together form pyrrolidinyl, morpholinyl, piperidinyl, each optionally substituted with —CH3 or —CH2CH3, then X is not one selected from m-methyl, o-halo, p-aryl, and p-cyano; when R1 and R2 are aliphatic or alkoxyalkyl, then X is not one selected from m-methyl, o-halo, p-aryl, and p-cyano; and
      • (1) when R1 is phenylmethyl optionally substituted with 1-2 —CH3 groups or cycloaliphatic, and R2 is one selected from unsubstituted methyl, ethyl, and isopropyl, then R3 together with R4 must form pyrrolidinyl, morpholinyl, piperidinyl optionally substituted with aliphatic, aminocarbonyl, or alkylcarbonyl; or one of R3 and R4 is phenylmethyl, methylfuranyl, or methoxypropyl, and
      • (2) X is not o-halo or p-cyano.
  • Another aspect of the present invention includes compounds of formula II:
  • Figure US20130345208A1-20131226-C00016
  • or a pharmaceutically acceptable salt thereof, wherein R1, R2, X, n, and Y are defined above.
  • Each V is one selected from —CH—, —CH2—, —N—, —O—, and —S—.
  • Each m is 1 or 2.
  • Each R9 and R10 are defined by —ZDR14, wherein each ZD is independently a bond or an optionally substituted straight or branched C1-6 aliphatic chain wherein up to two carbon units of ZD are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONRD—, —CONRDNRD—, —CO2—, —OCO—, —NRDCO2—, —O—, —NRDCONRD—, —OCONRD—, —NRDNRD, —NRDNRDCO—, —NRDCO—, —S—, —SO—, —SO2—, —NRD—, —SO2NRD—, —NRDSO2—, or —NRDSO2NRD—.
  • Each R14 is independently RD, halo, —OH, —NH2, —NO2, —CN, —CF3, or —OCF3.
  • Each RD is independently hydrogen, or an optionally substituted C1-8 aliphatic group, an optionally substituted 3-8 membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an optionally substituted 8-12 membered saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two occurrences of RD are taken together with the atom(s) to which they are attached form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, each of which is optionally substituted with 1 to 3 substituents.
  • In several embodiments of formula U, when R1 or R2 is 3,5-bis-trifluoromethylphenylmethyl, ring A together with R9 and R10 is not piperazinyl, optionally substituted piperidinyl, morpholinyl, or imidazolyl; when R1 and R2 together form pyrrolidinyl, morpholinyl, piperidinyl, each optionally substituted with —CH3 or —CH2CH3, then X is not m-methyl, o-halo, p-aryl, and p-cyano; when R1 and R2 are aliphatic or alkoxyalkyl, then X is not from m-methyl, o-halo, p-aryl, and p-cyano; and when R1 is phenylmethyl optionally substituted with 1-2 —CH3 groups or cycloaliphatic, and R2 is one selected from unsubstituted methyl, ethyl, and isopropyl, then
      • (1) ring B must form pyrrolidinyl, morpholinyl, piperidinyl optionally substituted with aliphatic, or aminocarbonyl, or alkylcarbonyl, and
      • (2) X is not o-halo, p-aryl, m-alkyl, or p-cyano.
  • Each R9 and R10 is hydrogen, halo, hydroxy, cyano, or C1-6 aliphatic, alkoxy, alkoxycarbonyl, alkoxycarbonylamino, aryl, heteroaryl, aralkyl, heteroaralkyl, cycloaliphatic, or heterocycloaliphatic, each of which is optionally substituted with 1-3 substituents; or R9 and R10 together with the atom(s) to which they are attached form a 5-6 membered ring that is optionally substituted with 1-3 substituents.
  • In several embodiments, R9 or R10 is an optionally substituted C1-6 aliphatic. For example, R9 or R10 is an optionally substituted straight or branched C1-6 aliphatic. For example, R9 or R10 is optionally substituted straight (e.g., methyl, ethyl, propyl, butyl, or the like) or branched (e.g., isopropyl, isobutyl, sec-propyl, sec-butyl or the like) aliphatic. For example, R9 or R10 is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, or octyl, each substituted with 1-3 substituents. In other examples, R9 or R10 is an isopropyl or sec-propyl that is optionally substituted with 1-2 substituents, or R9 or R10 is an unsubstituted sec-propyl or isopropyl. In several embodiments, R9 or R10 is unsubstituted methyl, ethyl, propyl, butyl, pentyl, or hexyl. In other embodiments, R9 or R10 is a —C(O)OH substituted aliphatic (e.g., hydroxycarbonylalkyl). For example, R9 or R10 is a methyl, ethyl, or propyl, each of which is substituted with —C(O)OH. In several embodiments, R9 or R10 is substituted with halo, cyano, hydroxy, or optionally substituted cycloaliphatic, heterocycloaliphatic, aryl, alkoxy, haloalkylaryl, bicycloaliphatic, aryloxy, haloaryl, alkylamino, heteroaryl, cycloaliphatic, or heterocycloaliphatic. In other embodiment, R9 or R10 is methyl, ethyl, or propyl that is substituted with a monocyclic optionally substituted aryl. For example, R9 or R10 is methyl, ethyl, or propyl that is substituted with alkoxyphenyl, cycloaliphaticphenyl, haloalkylphenyl, cyanophenyl, halophenyl, or hydroxyphenyl. In other embodiments, R9 or R10 is methyl, ethyl, or propyl that is substituted with a bicyclic aryl. For example R9 or R10 is methyl, ethyl, or propyl that is substituted with unsubstituted naphthyl or indenyl. In other embodiments, R9 or R10 is di-substituted with two substituents independently selected from halo, cyano, hydroxyl, aliphatic, aryl, heteroaryl, cycloaliphatic, heterocycloaliphatic, or alkoxy. In some embodiments, R9 or R10 is methyl substituted with aliphatic and aryl. In several embodiments, R9 or R10 includes an optionally substituted partially unsaturated aliphatic (e.g., alkenyl or alkynyl). In several examples, R9 or R10 includes optionally substituted ethenyl, propenyl, or butenyl. In other embodiments, R9 or R10 includes unsubstituted methyl or propenyl.
  • In several embodiments, R9, R10, and the atom(s) to which they are attached form a 5-6 membered ring that is optionally substituted with 1-3 substituents. For example, R9 and R10 are attached to different carbon atoms and together with the carbon atoms form an optionally substituted 5-6 membered ring that is fused to ring A of formula II. In some embodiments, R9, R10, and the carbon atoms to which they are attached form an optionally substituted fully saturated, partially unsaturated, or fully unsaturated ring that is optionally substituted. In some embodiments, R9, R10, and the carbon atoms to which they are attached form a fully saturated 5-6 membered ring that is optionally substituted. For example, R9, R10, and the carbon atoms to which they are attached form a 5-6 membered cycloalkyl or heterocycloalkyl that is optionally substituted. In some embodiments, R9, R10, and the carbon atoms to which they are attached form an optionally substituted cyclohexyl or cyclopentyl ring that is fused to ring A. For example, R9, R10, and the carbon atoms to which they are attached form an unsubstituted cyclohexyl that is fused to ring A to create an unsubstituted decahydroquinolinyl or octahydroindolyl. In another embodiment, R9, R10, and the carbon atoms to which they are attached form an unsubstituted cyclopentyl that is fused to ring A to create an unsubstituted octahydrocyclopenta[b]pyridinyl or octahydrocyclopenta[b]pyrrolyl. In other embodiments, R9, R10, and the carbon atoms to which they are attached form a cycloalkyl ring that is fused to ring A and substituted with halo, aliphatic, alkoxy, cycloaliphatic, heterocycloaliphatic, aryl or heteroaryl. In some embodiments, R9, R10, and the carbon atoms to which they are attached form an optionally substituted aryl ring that is fused to ring A. For example, R9, R10, and the carbon atoms to which they are attached form an optionally substituted phenyl that is fused to ring A to form a substituted or unsubstituted 1,2,3,4-tetrahydroquinolinyl or indolinyl.
  • In several embodiments, R9 or R10 is an optionally substituted alkoxy. For example, the aliphatic chain of the alkoxy can be straight or branched and substituted at any chemically feasible position. In some embodiments, R9 or R10 is an optionally substituted methoxy, ethoxy, propoxy, butoxy, pentoxy, or hexoxy. In other embodiments, R9 or R10 is unsubstituted.
  • In several embodiments, R9 or R10 is an optionally substituted alkoxy carbonyl. For example, the aliphatic chain of the alkoxy can be straight or branched and substituted at any chemically feasible position. In some embodiments, R9 or R10 is an optionally substituted methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, pentoxycarbonyl, or hexoxycarbonyl.
  • In several embodiments, R9 or R10 is an optionally substituted monocyclic or bicyclic cycloaliphatic. In some embodiments, R9 or R10 is a monocyclic cycloaliphatic optionally substituted with 1-3 substituents selected from hydroxy, alkoxy, alkylamino, alkyl carbonyl, aliphatic, and halo. In other embodiments, R9 or R10 is optionally substituted cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl. For example, R9 or R10 is unsubstituted cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl. In other embodiments, R9 or R10 is optionally substituted bicycloaliphatic. In several examples, R9 or R10 is bicycloaliphatic optionally substituted with 1-3 substituents selected from hydroxy, alkoxy, alkylamino, alkyl carbonyl, aliphatic, and halo. In other examples, R9 or R10 is optionally substituted bicyclo[1.1.1]pentane, bicyclo[2.1.1]hexane, or bicyclo[2.2.1]heptane. In other examples, R9 or R10 is unsubstituted bicyclo[2.1.1]hexyl, or bicyclo[2.2.1]heptyl.
  • In several embodiments, R9 or R10 is an optionally substituted monocyclic or bicyclic heterocycloaliphatic including 1-3 heteroatoms selected from N, O, and S. In one group of examples, R9 or R10 is fully saturated or partially unsaturated. In one group of examples, R9 or R10 is an optionally substituted fully saturated monocyclic heterocycloaliphatic. In another group of examples, R9 or R10 is morpholinyl, pyrroldinyl, thiomorpholinyl, tetrahydro-2H-pyranyl, or tetrahydrothiophenyl, each optionally substituted with 1-3 substituents. In another group of examples, R9 or R10 is unsubstituted morpholinyl, pyrrolidinyl, thiomorpholinyl, tetrahydro-2H-pyranyl, or tetrahydrothiophenyl. In another group of examples, R9 or R10 is an unsubstituted tropane.
  • In several examples of compounds of formula II, when R9 and R10 are hydrogen, neither R1 nor R2 are H, —CH3, or —CH3C6H5.
  • Another aspect of the present invention includes compounds of formula III:
  • Figure US20130345208A1-20131226-C00017
  • or a pharmaceutically acceptable salt thereof, wherein R3, R4, X, Y, and n are defined above; and
  • Each U is one selected from —CH—, —CH2—, —N—, —O—, and —S—.
  • Each p is 1 or 2.
  • Each R12 and R13 are defined by —ZER15, wherein each ZE is independently a bond or an optionally substituted straight or branched C1-6 aliphatic chain wherein up to two carbon units of ZC are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONRE—, —CONRENRE—CO2—, —OCO—, —NRECO2—, —O—, —NRECONRE—, —OCONRE—, —NRENRE, —NRENRECO—, —NRECO—, —S—, —SO—, —SO2—, —NRE—, —SO2NRE—, —NRESO2—, or —NRESO2NRE—.
  • Each R15 is independently RE, halo, —OH, —NH2, —NO2, —CN, —CF3, or —OCF3.
  • Each RE is independently hydrogen, an optionally substituted C1-8 aliphatic group, an optionally substituted 3-8 membered fully saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; an optionally substituted 8-12 membered fully saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two occurrences of RE are taken together with the atom(s) to which they are attached to form an optionally substituted 3-12 membered fully saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, each of which is optionally substituted with 1 to 3 substituents.
  • In some embodiments of formula III, when ring B is pyrrolidinyl, morpholinyl, piperidinyl, and R12 or R13 is —CH3 or —CH2CH3, then X is not m-methyl, o-halo, p-aryl, or p-cyano.
  • Each R12 and R13 is hydrogen, halo, hydroxy, cyano, or C1-4 aliphatic, alkoxy, alkoxycarbonyl, alkoxycarbonylamino, aryl, heteroaryl, aralkyl, heteroaralkyl, cycloaliphatic, or heterocycloaliphatic, each of which is optionally substituted with 1-3 substituents; or R12 and R13 together with the atom(s) to which they are attached form a 5-6 membered ring that is optionally substituted with 1-3 substituents.
  • In several embodiments, R12, R13, and the atom(s) to which they are attached form a 5-6 membered ring that is optionally substituted with 1-3 substituents. For example, R12 and R13 are attached to different carbon atoms and together with the carbon atoms form an optionally substituted 5-6 membered ring that is fused to ring B of formula III. In some embodiments, R12, R13, and the carbon atoms to which they are attached form an optionally substituted fully saturated, partially unsaturated, or fully unsaturated ring that is optionally substituted. In some embodiments, R12, R13, and the carbon atoms to which they are attached form a fully saturated 5-6 membered ring that is optionally substituted. For example, R12, R13, and the carbon atoms to which they are attached form a 5-6 membered cycloalkyl or heterocycloalkyl that is optionally substituted. In some embodiments, R12, R13, and the carbon atoms to which they are attached form an optionally substituted cyclohexyl or cyclopentyl ring that is fused to ring B. For example, R12, R13, and the carbon atoms to which they are attached form an unsubstituted cyclohexyl that is fused to ring B to create an unsubstituted decahydroquinolinyl or octahydroindolyl. In another embodiment, R12, R13, and the carbon atoms to which they are attached form an unsubstituted cyclopentyl that is fused to ring B to create an unsubstituted octahydrocyclopenta[b]pyridinyl or octahydrocyclopenta[b]pyrrolyl. In other embodiments, R12, R13, and the carbon atoms to which they are attached form a cycloalkyl ring that is fused to ring B and is substituted with halo, aliphatic, alkoxy, cycloaliphatic, heterocycloaliphatic, aryl or heteroaryl. In some embodiments, R12, R13, and the carbon atoms to which they are attached form an optionally substituted aryl ring that is fused to ring B. For example, R12, R13, and the carbon atoms to which they are attached form an optionally substituted phenyl that is fused to ring B to form a substituted or unsubstituted 1,2,3,4-tetrahydroquinolinyl or indolinyl. In other examples, R12, R13, and the carbon atoms to which they are attached form a mono- or di-substituted phenyl. In some embodiments, R12, R13, and the carbon atoms to which they are attached form a phenyl that is substituted with alkoxy (e.g., methoxy), aliphatic, alkylcarbonyl, or alkoxycarbonyl. In several examples, R12, R13, and the carbon atoms to which they are attached form a phenyl substituted with 1-2 methoxy groups that is fused to ring B.
  • In several embodiments, R12 or R13 is optionally substituted aryl. For example, R12 or R13 is aryl substituted with 1-2 substituents. In other examples, R12 or R13 is aryl substituted with aliphatic, halo, hydroxy, cyano, aryl, alkoxy, alkylcarbonyl, or alkoxycarbonyl. In several examples, R12 or R13 is unsubstituted.
  • In several examples, R12 or R13 is an optionally substituted alkoxy. For example, R12 or R13 is optionally substituted C1-6-alkoxy. In several examples, R12 or R13 is optionally substituted methoxy, ethoxy, propoxy, butoxy, pentoxy, or hexoxy. In several other examples, R12 or R13 is substituted with aliphatic, aryl, heteroaryl, cycloaliphatic, or heterocycloaliphatic. In several embodiments, R12 or R13 is unsubstituted methoxy, ethoxy, propoxy, butoxy, pentoxy, or hexoxy.
  • In several embodiments, R12 or R13 is optionally substituted alkylcarbonyl. For example, R12 or R13 is optionally substituted C1-6-alkyl-carbonyl. Other examples include methylcarbonyl, ethylcarbonyl, propylcarbonyl, butylcarbonyl, pentylcarbonyl, or hexylcarbonyl, each of which is optionally substituted with 1-2 substituents. In several embodiments, R12 or R13 is substituted with aliphatic, amino, hydroxyl, aryl, or heteroaryl. In several embodiments, R12 or R13 is unsubstituted methylcarbonyl, ethylcarbonyl, propylcarbonyl, butylcarbonyl, pentylcarbonyl, or hexylcarbonyl.
  • In several embodiments, R12 or R13 is an optionally substituted C1-6 aliphatic. For example, R12 or R13 is an optionally substituted straight or branched C1-6 aliphatic. For example, R12 or R13 is optionally substituted straight (e.g., methyl, ethyl, propyl, butyl, or the like) or branched (e.g., isopropyl, isobutyl, sec-propyl, sec-butyl or the like) aliphatic. For example, R12 or R13 is methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, or octyl, each substituted with 1-3 substituents. In other examples, R12 or R13 is an isopropyl or sec-propyl that is optionally substituted with 1-2 substituents, or R12 or R13 is an unsubstituted sec-propyl or isopropyl. In several embodiments, R12 or R13 is unsubstituted methyl, ethyl, propyl, butyl, pentyl, or hexyl. In other embodiments, R12 or R13 is a —C(O)OH substituted aliphatic (e.g., alkyl-C(O)OH). For example, R12 or R13 is a methyl, ethyl, or propyl, each of which is substituted with —C(O)OH. In several embodiments, R12 or R13 is substituted with halo, cyano, hydroxy, or optionally substituted cycloaliphatic, heterocycloaliphatic, aryl, alkoxy, haloalkylaryl, bicycloaliphatic, aryloxy, haloaryl, alkylamino, heteroaryl, cycloaliphatic, or heterocycloaliphatic. In other embodiment, R12 or R13 is methyl, ethyl, or propyl that is substituted with a monocyclic optionally substituted aryl. For example, R12 or R13 is methyl, ethyl, or propyl that is substituted with alkoxyphenyl, cycloaliphaticphenyl, haloalkylphenyl, cyanophenyl, halophenyl, or hydroxyphenyl. In other embodiments, R12 or R13 is methyl, ethyl, or propyl that is substituted with a bicyclic aryl. For example R12 or R13 is methyl, ethyl, or propyl that is substituted with unsubstituted naphthyl or indenyl. In other embodiments, R12 or R13 is di-substituted with two substituents independently selected from halo, cyano, hydroxyl, aliphatic, aryl, heteroaryl, cycloaliphatic, heterocycloaliphatic, or alkoxy. In some embodiments, R12 or R13 is methyl substituted with aliphatic and aryl. In several embodiments, R12 or R13 includes an optionally substituted partially unsaturated aliphatic (e.g., alkenyl or alkynyl). In several examples, R12 or R13 includes optionally substituted ethenyl, propenyl, or butenyl. In other embodiments, R12 or R13 includes unsubstituted methyl or propenyl.
  • In several examples of compounds of formulae Ia, II, or III:
  • When R1 is alkyl, R2 is not 3,5-bis-trifluoromethyl-phenyl-alkyl.
  • When R1 and R2 together form pyrrolidinyl, morpholinyl, or piperidinyl, each optionally substituted with —CH3 or —CH2CH3, then X is not m-methyl, o-halo, p-aryl, or p-cyano.
  • When each R1 or R2 is aliphatic or alkoxyalkyl, then X is not m-methyl, o-halo, p-aryl, and p-cyano.
  • When R1 is phenylmethyl optionally substituted with 1-2 —CH3 groups or cycloaliphatic, and R2 is unsubstituted methyl, ethyl, or isopropyl, then R3 together with R4 must form pyrrolidinyl, morpholinyl, piperidinyl optionally substituted with aliphatic, aminocarbonyl, or alkylcarbonyl, or each R3 or R4 is phenylmethyl, methylfuranyl, or methoxypropyl, and X is not m-methyl, p-aryl, o-halo or p-cyano.
  • 6. Examples of Compounds
  • Exemplary compounds of the present invention include, but are not limited to, those illustrated in Table 1 below.
  • TABLE 1
    Examples of compounds of the present invention
    Figure US20130345208A1-20131226-C00018
         		1
    Figure US20130345208A1-20131226-C00019
         		2
    Figure US20130345208A1-20131226-C00020
         		3
    Figure US20130345208A1-20131226-C00021
         		4
    Figure US20130345208A1-20131226-C00022
         		5
    Figure US20130345208A1-20131226-C00023
         		6
    Figure US20130345208A1-20131226-C00024
         		7
    Figure US20130345208A1-20131226-C00025
         		8
    Figure US20130345208A1-20131226-C00026
         		9
    Figure US20130345208A1-20131226-C00027
         		10
    Figure US20130345208A1-20131226-C00028
         		11
    Figure US20130345208A1-20131226-C00029
         		12
    Figure US20130345208A1-20131226-C00030
         		13
    Figure US20130345208A1-20131226-C00031
         		14
    Figure US20130345208A1-20131226-C00032
         		15
    Figure US20130345208A1-20131226-C00033
         		16
    Figure US20130345208A1-20131226-C00034
         		17
    Figure US20130345208A1-20131226-C00035
         		18
    Figure US20130345208A1-20131226-C00036
         		19
    Figure US20130345208A1-20131226-C00037
         		20
    Figure US20130345208A1-20131226-C00038
         		21
    Figure US20130345208A1-20131226-C00039
         		22
    Figure US20130345208A1-20131226-C00040
         		23
    Figure US20130345208A1-20131226-C00041
         		24
    Figure US20130345208A1-20131226-C00042
         		25
    Figure US20130345208A1-20131226-C00043
         		26
    Figure US20130345208A1-20131226-C00044
         		27
    Figure US20130345208A1-20131226-C00045
         		28
    Figure US20130345208A1-20131226-C00046
         		29
    Figure US20130345208A1-20131226-C00047
         		30
    Figure US20130345208A1-20131226-C00048
         		31
    Figure US20130345208A1-20131226-C00049
         		32
    Figure US20130345208A1-20131226-C00050
         		33
    Figure US20130345208A1-20131226-C00051
         		34
    Figure US20130345208A1-20131226-C00052
         		35
    Figure US20130345208A1-20131226-C00053
         		36
    Figure US20130345208A1-20131226-C00054
         		37
    Figure US20130345208A1-20131226-C00055
         		38
    Figure US20130345208A1-20131226-C00056
         		39
    Figure US20130345208A1-20131226-C00057
         		40
    Figure US20130345208A1-20131226-C00058
         		41
    Figure US20130345208A1-20131226-C00059
         		42
    Figure US20130345208A1-20131226-C00060
         		43
    Figure US20130345208A1-20131226-C00061
         		44
    Figure US20130345208A1-20131226-C00062
         		45
    Figure US20130345208A1-20131226-C00063
         		46
    Figure US20130345208A1-20131226-C00064
         		47
    Figure US20130345208A1-20131226-C00065
         		48
    Figure US20130345208A1-20131226-C00066
         		49
    Figure US20130345208A1-20131226-C00067
         		50
    Figure US20130345208A1-20131226-C00068
         		51
    Figure US20130345208A1-20131226-C00069
         		52
    Figure US20130345208A1-20131226-C00070
         		53
    Figure US20130345208A1-20131226-C00071
         		54
    Figure US20130345208A1-20131226-C00072
         		55
    Figure US20130345208A1-20131226-C00073
         		56
    Figure US20130345208A1-20131226-C00074
         		57
    Figure US20130345208A1-20131226-C00075
         		58
    Figure US20130345208A1-20131226-C00076
         		59
    Figure US20130345208A1-20131226-C00077
         		60
    Figure US20130345208A1-20131226-C00078
         		61
    Figure US20130345208A1-20131226-C00079
         		62
    Figure US20130345208A1-20131226-C00080
         		63
    Figure US20130345208A1-20131226-C00081
         		64
    Figure US20130345208A1-20131226-C00082
         		65
    Figure US20130345208A1-20131226-C00083
         		66
    Figure US20130345208A1-20131226-C00084
         		67
    Figure US20130345208A1-20131226-C00085
         		68
    Figure US20130345208A1-20131226-C00086
         		69
    Figure US20130345208A1-20131226-C00087
         		70
    Figure US20130345208A1-20131226-C00088
         		71
    Figure US20130345208A1-20131226-C00089
         		72
    Figure US20130345208A1-20131226-C00090
         		73
    Figure US20130345208A1-20131226-C00091
         		74
    Figure US20130345208A1-20131226-C00092
         		75
    Figure US20130345208A1-20131226-C00093
         		76
    Figure US20130345208A1-20131226-C00094
         		77
    Figure US20130345208A1-20131226-C00095
         		78
    Figure US20130345208A1-20131226-C00096
         		79
    Figure US20130345208A1-20131226-C00097
         		80
    Figure US20130345208A1-20131226-C00098
         		81
    Figure US20130345208A1-20131226-C00099
         		82
    Figure US20130345208A1-20131226-C00100
         		83
    Figure US20130345208A1-20131226-C00101
         		84
    Figure US20130345208A1-20131226-C00102
         		85
    Figure US20130345208A1-20131226-C00103
         		86
    Figure US20130345208A1-20131226-C00104
         		87
    Figure US20130345208A1-20131226-C00105
         		88
    Figure US20130345208A1-20131226-C00106
         		89
    Figure US20130345208A1-20131226-C00107
         		90
    Figure US20130345208A1-20131226-C00108
         		91
    Figure US20130345208A1-20131226-C00109
         		92
    Figure US20130345208A1-20131226-C00110
         		93
    Figure US20130345208A1-20131226-C00111
         		94
    Figure US20130345208A1-20131226-C00112
         		95
    Figure US20130345208A1-20131226-C00113
         		96
    Figure US20130345208A1-20131226-C00114
         		97
    Figure US20130345208A1-20131226-C00115
         		98
    Figure US20130345208A1-20131226-C00116
         		99
    Figure US20130345208A1-20131226-C00117
         		100
    Figure US20130345208A1-20131226-C00118
         		101
    Figure US20130345208A1-20131226-C00119
         		102
    Figure US20130345208A1-20131226-C00120
         		103
    Figure US20130345208A1-20131226-C00121
         		104
    Figure US20130345208A1-20131226-C00122
         		105
    Figure US20130345208A1-20131226-C00123
         		106
    Figure US20130345208A1-20131226-C00124
         		107
    Figure US20130345208A1-20131226-C00125
         		108
    Figure US20130345208A1-20131226-C00126
         		109
    Figure US20130345208A1-20131226-C00127
         		110
    Figure US20130345208A1-20131226-C00128
         		111
    Figure US20130345208A1-20131226-C00129
         		112
    Figure US20130345208A1-20131226-C00130
         		113
    Figure US20130345208A1-20131226-C00131
         		114
    Figure US20130345208A1-20131226-C00132
         		115
    Figure US20130345208A1-20131226-C00133
         		116
    Figure US20130345208A1-20131226-C00134
         		117
    Figure US20130345208A1-20131226-C00135
         		118
    Figure US20130345208A1-20131226-C00136
         		119
    Figure US20130345208A1-20131226-C00137
         		120
    Figure US20130345208A1-20131226-C00138
         		121
    Figure US20130345208A1-20131226-C00139
         		122
    Figure US20130345208A1-20131226-C00140
         		123
    Figure US20130345208A1-20131226-C00141
         		124
    Figure US20130345208A1-20131226-C00142
         		125
    Figure US20130345208A1-20131226-C00143
         		126
    Figure US20130345208A1-20131226-C00144
         		127
    Figure US20130345208A1-20131226-C00145
         		128
    Figure US20130345208A1-20131226-C00146
         		129
    Figure US20130345208A1-20131226-C00147
         		130
    Figure US20130345208A1-20131226-C00148
         		131
    Figure US20130345208A1-20131226-C00149
         		132
    Figure US20130345208A1-20131226-C00150
         		133
    Figure US20130345208A1-20131226-C00151
         		134
    Figure US20130345208A1-20131226-C00152
         		135
    Figure US20130345208A1-20131226-C00153
         		136
    Figure US20130345208A1-20131226-C00154
         		137
    Figure US20130345208A1-20131226-C00155
         		138
    Figure US20130345208A1-20131226-C00156
         		139
    Figure US20130345208A1-20131226-C00157
         		140
    Figure US20130345208A1-20131226-C00158
         		141
    Figure US20130345208A1-20131226-C00159
         		142
    Figure US20130345208A1-20131226-C00160
         		143
    Figure US20130345208A1-20131226-C00161
         		144
    Figure US20130345208A1-20131226-C00162
         		145
    Figure US20130345208A1-20131226-C00163
         		146
    Figure US20130345208A1-20131226-C00164
         		147
    Figure US20130345208A1-20131226-C00165
         		148
    Figure US20130345208A1-20131226-C00166
         		149
    Figure US20130345208A1-20131226-C00167
         		150
    Figure US20130345208A1-20131226-C00168
         		151
    Figure US20130345208A1-20131226-C00169
         		152
    Figure US20130345208A1-20131226-C00170
         		153
    Figure US20130345208A1-20131226-C00171
         		154
    Figure US20130345208A1-20131226-C00172
         		155
    Figure US20130345208A1-20131226-C00173
         		156
    Figure US20130345208A1-20131226-C00174
         		157
    Figure US20130345208A1-20131226-C00175
         		158
    Figure US20130345208A1-20131226-C00176
         		159
    Figure US20130345208A1-20131226-C00177
         		160
    Figure US20130345208A1-20131226-C00178
         		161
    Figure US20130345208A1-20131226-C00179
         		162
    Figure US20130345208A1-20131226-C00180
         		163
    Figure US20130345208A1-20131226-C00181
         		164
    Figure US20130345208A1-20131226-C00182
         		165
    Figure US20130345208A1-20131226-C00183
         		166
    Figure US20130345208A1-20131226-C00184
         		167
    Figure US20130345208A1-20131226-C00185
         		168
    Figure US20130345208A1-20131226-C00186
         		169
    Figure US20130345208A1-20131226-C00187
         		170
    Figure US20130345208A1-20131226-C00188
         		171
    Figure US20130345208A1-20131226-C00189
         		172
    Figure US20130345208A1-20131226-C00190
         		173
    Figure US20130345208A1-20131226-C00191
         		174
    Figure US20130345208A1-20131226-C00192
         		175
    Figure US20130345208A1-20131226-C00193
         		176
    Figure US20130345208A1-20131226-C00194
         		177
    Figure US20130345208A1-20131226-C00195
         		178
    Figure US20130345208A1-20131226-C00196
         		179
    Figure US20130345208A1-20131226-C00197
         		180
    Figure US20130345208A1-20131226-C00198
         		181
    Figure US20130345208A1-20131226-C00199
         		182
    Figure US20130345208A1-20131226-C00200
         		183
    Figure US20130345208A1-20131226-C00201
         		184
    Figure US20130345208A1-20131226-C00202
         		185
    Figure US20130345208A1-20131226-C00203
         		186
    Figure US20130345208A1-20131226-C00204
         		187
    Figure US20130345208A1-20131226-C00205
         		188
    Figure US20130345208A1-20131226-C00206
         		189
    Figure US20130345208A1-20131226-C00207
         		190
    Figure US20130345208A1-20131226-C00208
         		191
    Figure US20130345208A1-20131226-C00209
         		192
    Figure US20130345208A1-20131226-C00210
         		193
    Figure US20130345208A1-20131226-C00211
         		194
    Figure US20130345208A1-20131226-C00212
         		195
    Figure US20130345208A1-20131226-C00213
         		196
    Figure US20130345208A1-20131226-C00214
         		197
    Figure US20130345208A1-20131226-C00215
         		198
    Figure US20130345208A1-20131226-C00216
         		199
    Figure US20130345208A1-20131226-C00217
         		200
    Figure US20130345208A1-20131226-C00218
         		201
    Figure US20130345208A1-20131226-C00219
         		202
    Figure US20130345208A1-20131226-C00220
         		203
    Figure US20130345208A1-20131226-C00221
         		204
    Figure US20130345208A1-20131226-C00222
         		205
    Figure US20130345208A1-20131226-C00223
         		206
    Figure US20130345208A1-20131226-C00224
         		207
    Figure US20130345208A1-20131226-C00225
         		208
    Figure US20130345208A1-20131226-C00226
         		209
    Figure US20130345208A1-20131226-C00227
         		210
    Figure US20130345208A1-20131226-C00228
         		211
    Figure US20130345208A1-20131226-C00229
         		212
    Figure US20130345208A1-20131226-C00230
         		213
    Figure US20130345208A1-20131226-C00231
         		214
    Figure US20130345208A1-20131226-C00232
         		215
    Figure US20130345208A1-20131226-C00233
         		216
    Figure US20130345208A1-20131226-C00234
         		217
    Figure US20130345208A1-20131226-C00235
         		218
    Figure US20130345208A1-20131226-C00236
         		219
    Figure US20130345208A1-20131226-C00237
         		220
    Figure US20130345208A1-20131226-C00238
         		221
    Figure US20130345208A1-20131226-C00239
         		222
    Figure US20130345208A1-20131226-C00240
         		223
    Figure US20130345208A1-20131226-C00241
         		224
    Figure US20130345208A1-20131226-C00242
         		225
    Figure US20130345208A1-20131226-C00243
         		226
    Figure US20130345208A1-20131226-C00244
         		227
    Figure US20130345208A1-20131226-C00245
         		228
    Figure US20130345208A1-20131226-C00246
         		229
    Figure US20130345208A1-20131226-C00247
         		230
    Figure US20130345208A1-20131226-C00248
         		231
    Figure US20130345208A1-20131226-C00249
         		232
    Figure US20130345208A1-20131226-C00250
         		233
    Figure US20130345208A1-20131226-C00251
         		234
    Figure US20130345208A1-20131226-C00252
         		235
    Figure US20130345208A1-20131226-C00253
         		236
    Figure US20130345208A1-20131226-C00254
         		237
    Figure US20130345208A1-20131226-C00255
         		238
    Figure US20130345208A1-20131226-C00256
         		239
    Figure US20130345208A1-20131226-C00257
         		240
    Figure US20130345208A1-20131226-C00258
         		241
    Figure US20130345208A1-20131226-C00259
         		242
    Figure US20130345208A1-20131226-C00260
         		243
    Figure US20130345208A1-20131226-C00261
         		244
    Figure US20130345208A1-20131226-C00262
         		245
    Figure US20130345208A1-20131226-C00263
         		246
    Figure US20130345208A1-20131226-C00264
         		247
    Figure US20130345208A1-20131226-C00265
         		248
    Figure US20130345208A1-20131226-C00266
         		249
    Figure US20130345208A1-20131226-C00267
         		250
    Figure US20130345208A1-20131226-C00268
         		251
    Figure US20130345208A1-20131226-C00269
         		252
    Figure US20130345208A1-20131226-C00270
         		253
    Figure US20130345208A1-20131226-C00271
         		254
    Figure US20130345208A1-20131226-C00272
         		255
    Figure US20130345208A1-20131226-C00273
         		256
    Figure US20130345208A1-20131226-C00274
         		257
    Figure US20130345208A1-20131226-C00275
         		258
    Figure US20130345208A1-20131226-C00276
         		259
    Figure US20130345208A1-20131226-C00277
         		260
    Figure US20130345208A1-20131226-C00278
         		261
    Figure US20130345208A1-20131226-C00279
         		262
    Figure US20130345208A1-20131226-C00280
         		263
    Figure US20130345208A1-20131226-C00281
         		264
    Figure US20130345208A1-20131226-C00282
         		265
    Figure US20130345208A1-20131226-C00283
         		266
    Figure US20130345208A1-20131226-C00284
         		267
    Figure US20130345208A1-20131226-C00285
         		268
    Figure US20130345208A1-20131226-C00286
         		269
    Figure US20130345208A1-20131226-C00287
         		270
    Figure US20130345208A1-20131226-C00288
         		271
    Figure US20130345208A1-20131226-C00289
         		272
    Figure US20130345208A1-20131226-C00290
         		273
    Figure US20130345208A1-20131226-C00291
         		274
    Figure US20130345208A1-20131226-C00292
         		275
    Figure US20130345208A1-20131226-C00293
         		276
    Figure US20130345208A1-20131226-C00294
         		277
    Figure US20130345208A1-20131226-C00295
         		278
    Figure US20130345208A1-20131226-C00296
         		279
    Figure US20130345208A1-20131226-C00297
         		280
    Figure US20130345208A1-20131226-C00298
         		281
    Figure US20130345208A1-20131226-C00299
         		282
    Figure US20130345208A1-20131226-C00300
         		283
    Figure US20130345208A1-20131226-C00301
         		284
    Figure US20130345208A1-20131226-C00302
         		285
    Figure US20130345208A1-20131226-C00303
         		286
    Figure US20130345208A1-20131226-C00304
         		287
    Figure US20130345208A1-20131226-C00305
         		288
    Figure US20130345208A1-20131226-C00306
         		289
    Figure US20130345208A1-20131226-C00307
         		290
    Figure US20130345208A1-20131226-C00308
         		291
    Figure US20130345208A1-20131226-C00309
         		292
    Figure US20130345208A1-20131226-C00310
         		293
    Figure US20130345208A1-20131226-C00311
         		294
    Figure US20130345208A1-20131226-C00312
         		295
    Figure US20130345208A1-20131226-C00313
         		296
    Figure US20130345208A1-20131226-C00314
         		297
    Figure US20130345208A1-20131226-C00315
         		298
    Figure US20130345208A1-20131226-C00316
         		299
    Figure US20130345208A1-20131226-C00317
         		300
    Figure US20130345208A1-20131226-C00318
         		301
    Figure US20130345208A1-20131226-C00319
         		302
    Figure US20130345208A1-20131226-C00320
         		303
    Figure US20130345208A1-20131226-C00321
         		304
    Figure US20130345208A1-20131226-C00322
         		305
    Figure US20130345208A1-20131226-C00323
         		306
    Figure US20130345208A1-20131226-C00324
         		307
    Figure US20130345208A1-20131226-C00325
         		308
    Figure US20130345208A1-20131226-C00326
         		309
    Figure US20130345208A1-20131226-C00327
         		310
    Figure US20130345208A1-20131226-C00328
         		311
    Figure US20130345208A1-20131226-C00329
         		312
    Figure US20130345208A1-20131226-C00330
         		313
    Figure US20130345208A1-20131226-C00331
         		314
    Figure US20130345208A1-20131226-C00332
         		315
    Figure US20130345208A1-20131226-C00333
         		316
    Figure US20130345208A1-20131226-C00334
         		317
    Figure US20130345208A1-20131226-C00335
         		318
    Figure US20130345208A1-20131226-C00336
         		319
    Figure US20130345208A1-20131226-C00337
         		320
    Figure US20130345208A1-20131226-C00338
         		321
    Figure US20130345208A1-20131226-C00339
         		322
    Figure US20130345208A1-20131226-C00340
         		323
    Figure US20130345208A1-20131226-C00341
         		324
    Figure US20130345208A1-20131226-C00342
         		325
    Figure US20130345208A1-20131226-C00343
         		326
    Figure US20130345208A1-20131226-C00344
         		327
    Figure US20130345208A1-20131226-C00345
         		328
    Figure US20130345208A1-20131226-C00346
         		329
    Figure US20130345208A1-20131226-C00347
         		330
    Figure US20130345208A1-20131226-C00348
         		331
    Figure US20130345208A1-20131226-C00349
         		332
    Figure US20130345208A1-20131226-C00350
         		333
    Figure US20130345208A1-20131226-C00351
         		334
    Figure US20130345208A1-20131226-C00352
         		335
    Figure US20130345208A1-20131226-C00353
         		336
    Figure US20130345208A1-20131226-C00354
         		337
    Figure US20130345208A1-20131226-C00355
         		338
    Figure US20130345208A1-20131226-C00356
         		339
    Figure US20130345208A1-20131226-C00357
         		340
    Figure US20130345208A1-20131226-C00358
         		341
    Figure US20130345208A1-20131226-C00359
         		342
    Figure US20130345208A1-20131226-C00360
         		343
    Figure US20130345208A1-20131226-C00361
         		344
    Figure US20130345208A1-20131226-C00362
         		345
    Figure US20130345208A1-20131226-C00363
         		346
    Figure US20130345208A1-20131226-C00364
         		347
    Figure US20130345208A1-20131226-C00365
         		348
    Figure US20130345208A1-20131226-C00366
         		349
    Figure US20130345208A1-20131226-C00367
         		350
    Figure US20130345208A1-20131226-C00368
         		351
    • III. Synthetic Scheme
  • Compounds of the invention can be synthesized by any conventional reactions known in the art. One method of syntheses is illustrated in Scheme 1 without limitation.
  • Figure US20130345208A1-20131226-C00369
    Figure US20130345208A1-20131226-C00370
  • Referring to Scheme 1, R5 is a C1-5 alkyl. Reaction of the keto-ester b with a formamide dialkylacetal such as, for example, dimethylformamide dimethylacetal, provides the aminomethylene compound c. Reaction of d with 2-methylisothiourea sulfate in the presence of sodium acetate provides the thiopyrimidine e. Oxidation off with a suitable oxidizing reagent provides the sulfoxo-pyrimidine f. Suitable oxidizing reagents include, for example, m-chloroperbenzoic acid. Reaction off with the amine R3R4NH provides the 2-aminopyrimidine g. Hydrolysis of g with, for example, an alkaline earth hydroxide such as potassium hydroxide or sodium hydroxide, provides the acid g. Conversion of g to the amide a, compounds of the invention, can be achieved by converting the acid g first to an active acid derivative such as, for example, an acid chloride followed by reaction of the active derivative with the amine R1R2NH. Alternatively, the amide formation may be achieved by reaction of g with the amine R1R2NH in the presence of a suitable coupling reagent such as, for example, EDC or HATU. Acid addition salts such as, for example, a hydrochloride, may be prepared by reaction of the basic compound 1 with an acid in a solvent from which the salt will precipitate such as, for example, diethylether.
  • A variation of Scheme 1 is illustrated in Scheme 2 without limitation.
  • Figure US20130345208A1-20131226-C00371
  • In reference to Scheme 2, the esterpyrimidine (Scheme 1) is converted to the corresponding amidepyrimidine h following procedures as described above for preparing the amides a. Oxidation of h and displacement of the sulfonyl group with HNR3R4 as previously described in scheme 1 provides the compounds of the invention a.
  • An alternative method for preparation of the compounds is illustrated in Scheme 3 without limitation.
  • Figure US20130345208A1-20131226-C00372
  • Referring to Scheme 3, condensation of an aryl aldehyde with an acetoacetate ester and urea in the presence of a catalyst such as, for example, cuprous chloride and a Lewis acid such as, for example, borontrifluoride ethereate provides the dihydropyrimidinone j. Oxidation of h with, for example, 60% nitric acid gives the pyrimidinone k. Condensation of with an amine HNR3R4 in the presence of a condensation reagent such as, for example, PyBrop (Bromo-tris-pyrrolidino phosphoniumhexafluorophosphate) provides the aminopyridine f. Conversion off to the compounds of the invention can be achieved as described above in Scheme 1.
  • The amine intermediates HNR1R2 are commercially available, known in the art, or may be prepared by known reductive amination methods or condensation of the amine with an aryl halide using known methodology and as illustrated in the Examples herein.
  • An alternative method for preparation of the compounds is illustrated in Scheme 4 without limitation.
  • Figure US20130345208A1-20131226-C00373
  • Referring to Scheme 4, the pyrimidinedione a′ is converted to the dichloropyrimidine b′ by reaction with phosphorous oxychloride in the presence of dimethylformamide. Coupling of b′ with an arylboronic acid in the presence of a palladium catalyst such as, for example, Pd2(dba)3 and a trialkylphosphine such as, for example, tri-t-butyl phosphine provides the aryl substituted pyrimidine c′. Displacement of the chloro group in c′ with the amine HNR3R4 provides the aminopyrimidine d′. Hydrolysis of the ester in d′ with, for example, sodium hydroxide in ethanol provides the corresponding acid which is converted to the compounds of the invention a using known amide forming conditions.
    • IV. Formulations, Administrations, and Uses
  • A. Pharmaceutically Acceptable Compositions
  • As discussed above, the present invention provides compounds that are inhibitors of voltage-gated sodium ion channels and/or calcium channels, and thus the present compounds are useful for the treatment of diseases, disorders, and conditions including, but not limited to acute, chronic, neuropathic, or inflammatory pain, arthritis, migraine, cluster headaches, trigeminal neuralgia, herpetic neuralgia, general neuralgias, epilepsy or epilepsy conditions, neurodegenerative disorders, psychiatric disorders such as anxiety and depression, myotonia, arrhythmia, movement disorders, neuroendocrine disorders, ataxia, multiple sclerosis, irritable bowel syndrome, and incontinence. Accordingly, in another aspect of the present invention, pharmaceutically acceptable compositions are provided, wherein these compositions comprise any of the compounds as described herein, and optionally comprise a pharmaceutically acceptable carrier, adjuvant or vehicle. In certain embodiments, these compositions optionally further comprise one or more additional therapeutic agents.
  • It will also be appreciated that certain of the compounds of present invention can exist in free form for treatment, or where appropriate, as a pharmaceutically acceptable derivative thereof. According to the present invention, a pharmaceutically acceptable derivative includes, but is not limited to, pharmaceutically acceptable salts, esters, salts of such esters, or any other adduct or derivative which upon administration to a patient in need is capable of providing, directly or indirectly, a compound as otherwise described herein, or a metabolite or residue thereof.
  • As used herein, the term “pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. A “pharmaceutically acceptable salt” means any non-toxic salt or salt of an ester of a compound of this invention that, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or an inhibitorily active metabolite or residue thereof. As used herein, the term “inhibitorily active metabolite or residue thereof” means that a metabolite or residue thereof is also an inhibitor of a voltage-gated sodium ion channel or calcium channel.
  • Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge, et al. describes pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference. Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N+(C1-4alkyl)4 salts. This invention also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersible products may be obtained by such quaternization. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.
  • As described above, the pharmaceutically acceptable compositions of the present invention additionally comprise a pharmaceutically acceptable carrier, adjuvant, or vehicle, which, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired. Remington's Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980) discloses various carriers used in formulating pharmaceutically acceptable compositions and known techniques for the preparation thereof. Except insofar as any conventional carrier medium is incompatible with the compounds of the invention, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutically acceptable composition, its use is contemplated to be within the scope of this invention. Some examples of materials which can serve as pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, or potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, wool fat, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil; sesame oil; olive oil; corn oil and soybean oil; glycols; such a propylene glycol or polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water, isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator.
  • B. Uses of Compounds and Pharmaceutically Acceptable Compositions
  • In yet another aspect, a method for the treatment or lessening the severity of acute, chronic, neuropathic, or inflammatory pain, arthritis, migraine, cluster headaches, trigeminal neuralgia, herpetic neuralgia, general neuralgias, epilepsy or epilepsy conditions, neurodegenerative disorders, psychiatric disorders such as anxiety and depression, myotonia, arrhythmia, movement disorders, neuroendocrine disorders, ataxia, multiple sclerosis, irritable bowel syndrome, incontinence, visceral pain, osteoarthritis pain, postherpetic neuralgia, diabetic neuropathy, radicular pain, sciatica, back pain, head or neck pain, severe or intractable pain, nociceptive pain, breakthrough pain, postsurgical pain, or cancer pain is provided comprising administering an effective amount of a compound, or a pharmaceutically acceptable composition comprising a compound to a subject in need thereof. In certain embodiments, a method for the treatment or lessening the severity of acute, chronic, neuropathic, or inflammatory pain is provided comprising administering an effective amount of a compound or a pharmaceutically acceptable composition to a subject in need thereof. In certain other embodiments, a method for the treatment or lessening the severity of radicular pain, sciatica, back pain, head pain, or neck pain is provided comprising administering an effective amount of a compound or a pharmaceutically acceptable composition to a subject in need thereof. In still other embodiments, a method for the treatment or lessening the severity of severe or intractable pain, acute pain, postsurgical pain, back pain, tinnitis or cancer pain is provided comprising administering an effective amount of a compound or a pharmaceutically acceptable composition to a subject in need thereof.
  • In certain embodiments of the present invention an “effective amount” of the compound or pharmaceutically acceptable composition is that amount effective for treating or lessening the severity of one or more of acute, chronic, neuropathic, or inflammatory pain, arthritis, migraine, cluster headaches, trigeminal neuralgia, herpetic neuralgia, general neuralgias, epilepsy or epilepsy conditions, neurodegenerative disorders, psychiatric disorders such as anxiety and depression, myotonia, arrhythmia, movement disorders, neuroendocrine disorders, ataxia, multiple sclerosis, irritable bowel syndrome, incontinence, visceral pain, osteoarthritis pain, postherpetic neuralgia, diabetic neuropathy, radicular pain, sciatica, back pain, head or neck pain, severe or intractable pain, nociceptive pain, breakthrough pain, postsurgical pain, tinnitis or cancer pain.
  • The compounds and compositions, according to the method of the present invention, may be administered using any amount and any route of administration effective for treating or lessening the severity of one or more of acute, chronic, neuropathic, or inflammatory pain, arthritis, migraine, cluster headaches, trigeminal neuralgia, herpetic neuralgia, general neuralgias, epilepsy or epilepsy conditions, neurodegenerative disorders, psychiatric disorders such as anxiety and depression, myotonia, arrhythmia, movement disorders, neuroendocrine disorders, ataxia, multiple sclerosis, irritable bowel syndrome, incontinence, visceral pain, osteoarthritis pain, postherpetic neuralgia, diabetic neuropathy, radicular pain, sciatica, back pain, head or neck pain, severe or intractable pain, nociceptive pain, breakthrough pain, postsurgical pain, tinnitis or cancer pain. The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular agent, its mode of administration, and the like. The compounds of the invention are preferably formulated in dosage unit form for ease of administration and uniformity of dosage. The expression “dosage unit form”, as used herein refers to a physically discrete unit of agent appropriate for the patient to be treated. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific effective dose level for any particular patient or organism will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed, and like factors well known in the medical arts. The term “patient”, as used herein, means an animal, preferably a mammal, and most preferably a human.
  • The pharmaceutically acceptable compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), bucally, as an oral or nasal spray, or the like, depending on the severity of the infection being treated. In certain embodiments, the compounds of the invention may be administered orally or parenterally at dosage levels of about 0.01 mg/kg to about 50 mg/kg and preferably from about 1 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.
  • Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.
  • The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
  • In order to prolong the effect of a compound of the present invention, it is often desirable to slow the absorption of the compound from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the compound then depends upon its rate of dissolution that, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered compound form is accomplished by dissolving or suspending the compound in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the compound in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of compound to polymer and the nature of the particular polymer employed, the rate of compound release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.
  • Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.
  • Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • The active compounds can also be in microencapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.
  • Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulation, eardrops, and eye drops are also contemplated as being within the scope of this invention. Additionally, the present invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms are prepared by dissolving or dispensing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
  • As described generally above, the compounds of the invention are useful as inhibitors of voltage-gated sodium ion channels or calcium channels, preferably N-type calcium channels. In one embodiment, the compounds and compositions of the invention are inhibitors of one or more of NaV1.1, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8, NaV1.9, or CaV2.2, and thus, without wishing to be bound by any particular theory, the compounds and compositions are particularly useful for treating or lessening the severity of a disease, condition, or disorder where activation or hyperactivity of one or more of NaV1.1, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8, NaV1.9, or CaV2.2 is implicated in the disease, condition, or disorder. When activation or hyperactivity of NaV1.1, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8, NaV1.9, or CaV2.2, is implicated in a particular disease, condition, or disorder, the disease, condition, or disorder may also be referred to as a “NaV1.1, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8 or NaV1.9-mediated disease, condition or disorder” or a “CaV2.2-mediated condition or disorder”. Accordingly, in another aspect, the present invention provides a method for treating or lessening the severity of a disease, condition, or disorder where activation or hyperactivity of one or more of NaV1.1, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8, NaV1.9, or CaV2.2 is implicated in the disease state.
  • The activity of a compound utilized in this invention as an inhibitor of NaV1.1, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8, NaV1.9, or CaV2.2 may be assayed according to methods described generally in the Examples herein, or according to methods available to one of ordinary skill in the art.
  • In certain exemplary embodiments, compounds of the invention are useful as inhibitors of NaV1.3. In other embodiments, compounds of the invention are useful as inhibitors of NaV1.3 and CaV2.2. In still other embodiments, compounds of the invention are useful as inhibitors of CaV2.2.
  • It will also be appreciated that the compounds and pharmaceutically acceptable compositions of the present invention can be employed in combination therapies, that is, the compounds and pharmaceutically acceptable compositions can be administered concurrently with, prior to, or subsequent to, one or more other desired therapeutics or medical procedures. The particular combination of therapies (therapeutics or procedures) to employ in a combination regimen will take into account compatibility of the desired therapeutics and/or procedures and the desired therapeutic effect to be achieved. It will also be appreciated that the therapies employed may achieve a desired effect for the same disorder (for example, an inventive compound may be administered concurrently with another agent used to treat the same disorder), or they may achieve different effects (e.g., control of any adverse effects). As used herein, additional therapeutic agents that are normally administered to treat or prevent a particular disease, or condition, are known as “appropriate for the disease, or condition, being treated”. For example, exemplary additional therapeutic agents include, but are not limited to: nonopioid analgesics (indoles such as Etodolac, Indomethacin, Sulindac, Tolmetin; naphthylalkanones such as Nabumetone; oxicams such as Piroxicam; para-aminophenol derivatives, such as Acetaminophen; propionic acids such as Fenoprofen, Flurbiprofen, Ibuprofen, Ketoprofen, Naproxen, Naproxen sodium, Oxaprozin; salicylates such as Asprin, Choline magnesium trisalicylate, Diflunisal; fenamates such as meclofenamic acid, Mefenamic acid; and pyrazoles such as Phenylbutazone); or opioid (narcotic) agonists (such as Codeine, Fentanyl, Hydromorphone, Levorphanol, Meperidine, Methadone, Morphine, Oxycodone, Oxymorphone, Propoxyphene, Buprenorphine, Butorphanol, Dezocine, Nalbuphine, and Pentazocine). Additionally, nondrug analgesic approaches may be utilized in conjunction with administration of one or more compounds of the invention. For example, anesthesiologic (intraspinal infusion, neural blocade), neurosurgical (neurolysis of CNS pathways), neurostimulatory (transcutaneous electrical nerve stimulation, dorsal column stimulation), physiatric (physical therapy, orthotic devices, diathermy), or psychologic (cognitive methods-hypnosis, biofeedback, or behavioral methods) approaches may also be utilized. Additional appropriate therapeutic agents or approaches are described generally in The Merck Manual, Seventeenth Edition, Ed. Mark H. Beers and Robert Berkow, Merck Research Laboratories, 1999, and the Food and Drug Administration website, www.fda.gov, the entire contents of which are hereby incorporated by reference.
  • The amount of additional therapeutic agent present in the compositions of this invention will be no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent. Preferably the amount of additional therapeutic agent in the presently disclosed compositions will range from about 50% to 100% of the amount normally present in a composition comprising that agent as the only therapeutically active agent.
  • The compounds of this invention or pharmaceutically acceptable compositions thereof may also be incorporated into compositions for coating an implantable medical device, such as prostheses, artificial valves, vascular grafts, stents and catheters. Accordingly, the present invention, in another aspect, includes a composition for coating an implantable device comprising a compound of the present invention as described generally above, and in classes and subclasses herein, and a carrier suitable for coating said implantable device. In still another aspect, the present invention includes an implantable device coated with a composition comprising a compound of the present invention as described generally above, and in classes and subclasses herein, and a carrier suitable for coating said implantable device. Suitable coatings and the general preparation of coated implantable devices are described in U.S. Pat. Nos. 6,099,562; 5,886,026; and 5,304,121. The coatings are typically biocompatible polymeric materials such as a hydrogel polymer, polymethyldisiloxane, polycaprolactone, polyethylene glycol, polylactic acid, ethylene vinyl acetate, and mixtures thereof. The coatings may optionally be further covered by a suitable topcoat of fluorosilicone, polysaccarides, polyethylene glycol, phospholipids or combinations thereof to impart controlled release characteristics in the composition.
  • Another aspect of the invention relates to inhibiting one or more of NaV1.1, NaV1.2, NaV1.3,NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8, NaV1.9, or CaV2.2 activity in a biological sample or a patient, which method comprises administering to the patient, or contacting said biological sample with a compound of formula I or a composition comprising said compound. The term “biological sample”, as used herein, includes, without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof, and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.
  • Inhibition of one or more of NaV1.1, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8, NaV1.9, or CaV2.2 activity in a biological sample is useful for a variety of purposes that are known to one of skill in the art. Examples of such purposes include, but are not limited to, the study of sodium ion channels in biological and pathological phenomena; and the comparative evaluation of new sodium ion channel inhibitors.
    • V. Preparations and Examples Preparation 1: N-Benzylcyclobutylamine
  • Figure US20130345208A1-20131226-C00374
  • A sodium cyanoborohydride (0.88 g, 14 mmol) was added slowly to a stirred solution of benzaldehyde (0.71 g, 7.00 mmol) in methanol (9 mL) and glacial acetic acid (1 mL) at room temperature and the mixture was heated at 60° C. for 3 hr and cooled to room temperature. The solvent was evaporated under reduced pressure, and the crude material was dissolved in water and basified with a 2N NaOH solution (10 mL). The aqueous layer was extracted with EtOAc (3×50 mL), dried and concentrated. The residue was purified by Biotage SP1 on packed silica gel column (10%-80% EtOAc/Hexanes gradient) to give N-benzylcyclobutylamine (0.65 g, 58%). Mass Spec. FIA MS 312 (M+1), 1H NMR (DMSO-d6, 500 MHz) δ 7.26-7.31 (m, 4H), 7.17-7.21 (d, 1H), 3.58 (s, 2H), 3.13 (m, 1H), 2.11 (brs, 1H), 2.04 (m, 2H), 1.50-1.69 (m, 4H).
    • Preparation 2: N-Isopropyl-3-methoxybenzenamine
  • Figure US20130345208A1-20131226-C00375
  • To a microwave tube charged with a stirring bar was added sodium cyanoborohydride (0.10 g, 1.6 mmol) and m-anisidine (0.075 mL, 0.8 mmol) in methanol (1 mL). To this solution was the added acetone (0.5 mL) and glacial acetic acid (0.5 mL). Once the gas evolution had subsided, the tube was crimped and subjected to microwave irradiation at 130° C. for 15 minutes. The solution was diluted with CH2Cl2, washed once with 1N NaOH, and the organic layer was dried (Na2SO4), filtered and concentrated to a yellow liquid. This was purified via silica gel chromatography with an ethyl acetate/hexanes gradient (Rf=0.60 in 4:1 Hex/EtOAc) to give N-isopropyl-3-methoxybenzenamine as a colorless oil. FIA MS 166 (M+1).
    • Preparation 3: N-Cyclopropyl-3-methoxybenzenamine
  • Figure US20130345208A1-20131226-C00376
  • To a high-pressure tube was added 3-bromoanisole (0.250 mL, 2 mmol), cyclopropylamine (0.225 mL, 3.2 mmol), sodium t-butoxide (0.29 g, 3.0 mmol), (+/−) BINAP (0.04 g, 0.06 mmol), and Pd2(dba)3 (0.010 g, 0.01 mmol). This mixture was suspended in 4 mL anhydrous toluene. The tube was flushed with dry nitrogen gas, then capped and wrapped in aluminum foil. The reaction mixture was stirred and heated to 80° C. overnight, then allowed to cool, and the reaction vessel was opened. The mixture was diluted with diethyl ether, filtered through Celite, and the filtrate was concentrated to a yellow oil. LC/MS analysis showed one peak with the correct mass, and due to the limited stability of the material, it was carried through without further purification. FIA MS 164 (M+1).
    • Example 1 4-(2-Fluoro-phenyl)-2-morpholin-4-yl-pyrimidine-5-carboxylic acid benzyl-isopropyl-amide (Compound No. 326)
  • Figure US20130345208A1-20131226-C00377
    Figure US20130345208A1-20131226-C00378
  • Synthesis of 4-(2-Fluoro-phenyl)-2-morpholin-4-yl-pyrimidine-5-carboxylic acid benzyl-isopropyl-amide (Compound No. 326): i. DMF-DMA, toluene; ii. 2-methylisothiourea sulfate, NaOAc, DMF, 80-90° C., 60% over 2 steps; iii. m-CPBA, CH2Cl2, −78 to 0° C.; iv. morpholine, THF, reflux; v. 10 N aq. NaOH, MeOH, reflux, 74% over 3 steps; vi. 1) (COCl)2, CH2Cl2; 2) Bn(i-Pr)NH, toluene, 92%; vii. HCl, Et2O.
    • Step i. 3-Dimethylamino-2-(2-fluoro-benzoyl)-acrylic acid ethyl ester
  • A mixture of ethyl 3-(2-fluorophenyl)-3-oxopropanoate (14.29 g, 68.0 mmol) and DMF-DMA (12.15 g, 0.102 mol, 1.5 eq.) in toluene (50 mL) was refluxed for 2 hours and concentrated to give 3-dimethylamino-2-(2-fluoro-benzoyl)-acrylic acid ethyl ester as a red oil in quantitative yield.
    • Step ii: 4-(2-Fluoro-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid ethyl ester
  • 3-Dimethylamino-2-(2-fluoro-benzoyl)-acrylic acid ethyl ester was dissolved in DMF (100 mL). To the solution was added isothiourea sulfate (18.92 g, 68.0 mmol) and NaOAc (23.24 g, 0.28 mol). The reaction mixture was heated at 80-90° C. overnight. Water was added to the cooled solution. The product was extracted with EtOAc (3×100 mL). The combined organic layers were washed with a saturated aqueous NaHCO3 solution and water, dried over Na2SO4, and concentrated. The crude product was purified by column chromatography (1 L silica, EtOAc) to give 4-(2-fluoro-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid ethyl ester as a yellow oil (11.86 g, 40.6 mmol, 60% over 2 steps).
    • Step iii: 4-(2-Fluoro-phenyl)-2-methanesulfinyl-pyrimidine-5-carboxylic acid ethyl ester
  • A Na2SO4-dried solution of m-CPBA (10.64 g, ca. 45 mmol) in CH2Cl2 (100 mL) was added drop wise to a cold (−65° C.) solution of 4-(2-fluoro-phenyl)-2-methylsulfanyl-pyrimidine-5-carboxylic acid ethyl ester in CH2Cl2 (200 mL) keeping the temperature below −65° C. The yellow suspension was allowed to warm to 0° C. over 1 hour. After 3 hours at 0° C., a saturated aqueous NaHCO3 solution (100 mL) was added to quench the reaction. The organic layer was separated, washed with saturated aqueous NaCl solution, dried over Na2SO4, and concentrated. The product was taken up in CH2Cl2 and washed again with a saturated aqueous NaHCO3 solution to remove traces of m-C(P)BA giving 4-(2-fluoro-phenyl)-2-methanesulfinyl-pyrimidine-5-carboxylic acid ethyl ester (12.86 g, >100%).
    • Step iv: 4-(2-Fluoro-phenyl)-2-morpholin-4-yl-pyrimidine-5-carboxylic acid ethyl ester
  • Morpholine (7.0 mL, 6.9 g, 80 mmol) was added to a solution of 4-(2-fluoro-phenyl)-2-methanesulfinyl-pyrimidine-5-carboxylic acid ethyl ester in THF (80 mL). The resulting mixture was heated at reflux for 3 hours. Concentration of the solution afforded the product as a yellow oil. Traces of morpholine were removed at oil pump vacuum in a Kugelrohr apparatus to yield 4-(2-fluoro-phenyl)-2-morpholin-4-yl-pyrimidine-5-carboxylic acid ethyl ester (16.00 g, >100%).
    • Step v: 4-(2-Fluoro-phenyl)-2-morpholin-4-yl-pyrimidine-5-carboxylic acid
  • 4-(2-Fluoro-phenyl)-2-morpholin-4-yl-pyrimidine-5-carboxylic acid ethyl ester was dissolved in a mixture of methanol (150 mL) and a 33% aqueous NaOH solution (150 mL). The mixture was heated at reflux for 3 hours, and allowed to cool to room temperature overnight. The solution was concentrated to ca. half the volume under reduced pressure. The resulting suspension was adjusted to pH 7 with a 1-5N aqueous HCl solution. The formed precipitate was filtered off, washed with water (3×), and air-dried at 45° C. overnight to give 4-(2-fluoro-phenyl)-2-morpholin-4-yl-pyrimidine-5-carboxylic acid as a tan solid (9.051 g, 29.8 mmol, 74% over 3 steps).
    • Step vi: 4-(2-Fluoro-phenyl)-2-morpholin-4-yl-pyrimidine-5-carboxylic acid benzyl-isopropyl-amide
  • To an ice-cooled solution of 4-(2-fluoro-phenyl)-2-morpholin-4-yl-pyrimidine-5-carboxylic acid (4.321 g, 14.25 mmol) in CH2Cl2 (100 mL) and DMF (2 drops) was added oxalyl chloride (1.5 mL, 2.21 g, 17.5 mmol) dropwise. Most solids dissolved at first, later a precipitate formed. The suspension was stirred for 1 hour at 0° C., and then allowed to warm to room temperature (all solids dissolved). The solution was concentrated to a dark oil, which crystallized upon standing. The crude acid chloride was taken up in toluene (50 mL, distilled, dried over Na2SO4) and cooled in ice. N-Isopropylbenzylamine (9.5 mL, 8.5 g, 56.8 mmol) was added. The resulting suspension was stirred at room temperature for 90 minutes, washed with water and a saturated aqueous NaCl solution, dried over Na2SO4, and concentrated. The crude product was purified by column chromatography (400 mL silica, EtOAc/heptanes 1:1). All fractions containing the product were combined and concentrated. Some of the excess amine eluted with the product. A solution of the mixture in CH2Cl2 (50 mL) was washed with a 10% aqueous citric acid solution (2×25 mL), water (25.mL), and saturated aqueous NaCl solution (25 mL), dried over Na2SO4, and concentrated to give pure 4-(2-fluoro-phenyl)-2-morpholin-4-yl-pyrimidine-5-carboxylic acid benzyl-isopropyl-amide as a yellowish foam (5.685 g, 13.08 mmol, 92%).
    • Step vii: 4-(2-Fluoro-phenyl)-2-morpholin-4-yl-pyrimidine-5-carboxylic acid benzyl-isopropyl-amide HCl salt
  • To a solution of 4-(2-fluoro-phenyl)-2-morpholin-4-yl-pyrimidine-5-carboxylic acid benzyl-isopropyl-amide in Et2O (20 mL) was added 1N HCl in Et2O (15 mL, 15 mmol). The resulting slurry was stirred vigorously for 1 hour. The solids were filtered off, washed with Et2O (2×20 mL), and dried in vacuo (0.01 mbar) overnight to yield 4-(2-fluoro-phenyl)-2-morpholin-4-yl-pyrimidine-5-carboxylic acid benzyl-isopropyl-amide HCl salt (5.70 g, 12.10 mmol, 93%).
    • Example 2 N-benzyl-N-cyclobutyl-4-(2-fluorophenyl)-2-morpholinopyrimidine-5-carboxamide (Compound No. 86)
  • Figure US20130345208A1-20131226-C00379
  • A solution of 2M oxalyl chloride in CH2Cl2 (0.062 mL, 0.125 mmol) was added to a stirred solution of 4-(2-fluorophenyl)-2-morpholinopyrimidine-5-carboxylic acid (Example 1; 0.03 g, 0.1 mmol) in CH2Cl2(2 mL) and DMF (0.030 mL) at room temperature, and stirring continued for 15 min. A solution of N-benzylcyclobutanamine (0.016 g, 0.1 mmol) in CH2Cl2 (1 mL) and diisopropylethylamine (0.044 mL, 0.25 mmol) were added and stirred for 3 h. The solvent was removed under reduced pressure, and the residue was purified by Biotage SP1 on packed silica gel column (10%-80% EtOAc/Hexanes gradient) to give N-benzyl-N-cyclobutyl-442-fluorophenyl)-2-morpholinopyrimidine-5-carboxamide (0.032 g, 72%). Mass Spec. FIA MS 447 (M+1), NMR (DMSO-d6, 500 MHz) δ 8.43 (brs, 1H), 7.52-7.55 (m, 2H), 6.99-7.31 (m, 7H), 4.62 (brm, 2H), 3.78 (brm, 4H0, 3.68 (brm, 4H), 2.15 (brm, 2H), 1.85 (brm, 2H), 1.17 (brm, 2H).
    • Example 3
  • Following the procedures of Examples 1 and 2 making non-critical variations and using amines HNR1R2 prepared by the procedure of preparation 1 the following compounds were prepared.
  • TABLE 2
    Exemplary compounds using amines prepared
    by the procedure of preparation 1.
    Compound No.
    5
    12
    38
    65
    111
    129
    133
    144
    149
    155
    156
    157
    188
    208
    215
    228
    242
    268
    292
    328
    339
    342
    • Example 4
  • Following the procedures of Examples 1 and 2 making non-critical variations and using amines HNR1R2 prepared by the procedure of preparation 2 the following compounds were prepared.
  • TABLE 3
    Exemplary compounds using amines prepared by
    the procedure of preparation 2.
    Compound No.
    4
    8
    14
    19
    20
    29
    41
    47
    53
    62
    63
    74
    91
    94
    95
    101
    102
    116
    119
    127
    128
    131
    135
    142
    152
    153
    159
    161
    162
    170
    172
    177
    190
    196
    200
    210
    212
    213
    219
    222
    224
    230
    244
    247
    249
    252
    256
    258
    263
    265
    267
    294
    297
    300
    320
    322
    325
    327
    • Example 5
  • Following the procedures of Examples 1 and 2 making non-critical variations commonly known in the art and using amines HNR1R2 prepared by the procedure of preparation 3, Compound No. 31 was prepared.
    • Example 6
  • Additional compounds prepared following the above general procedures include those in Table 4.
  • TABLE 4
    Exemplary compounds prepared using general
    procedures of Examples 1-5.
    Compound No.
    6
    7
    11
    13
    23
    25
    34
    36
    45
    46
    57
    59
    64
    75
    76
    80
    85
    85
    103
    107
    112
    115
    117
    120
    122
    137
    158
    174
    187
    192
    194
    195
    203
    207
    260
    266
    275
    277
    287
    295
    296
    304
    306
    310
    314
    316
    326
    331
    340
    346
    • Example 7 4-(2-fluorophenyl)-N-isopropyl-N-(3-methoxybenzyl)-2-(piperidin-1-yl)pyrimidine-5-carboxamide (Compound No. 20)
  • Figure US20130345208A1-20131226-C00380
  • Synthesis of 4-(2-fluorophenyl)-N-isopropyl-N-(3-methoxybenzyl)-2-(piperidin-1-yl)pyrimidine-5-carboxamide (Compound No. 20). i. NaOH, water, MeOH, reflux, 1 h. ii. a. (COCl)2, DMF, CH2Cl2, b. N-(3-methoxybenzyl)propan-2-amine, DIPEA MCPBA, CH2Cl2 iv piperidine, THF, heat
    • Steps i and ii: N-(3-Methoxybenzyl)-4-(2-fluorophenyl)-N-isopropyl-2(methylthio)pyrimidine-5-carboxamide
  • A mixture of ethyl 4-(2-fluorophenyl)-2-(methylthio)pyrimidine-5-carboxylate (3.3 g, 10.96 mmol), solid NaOH (3.2 g) in ethanol (30 mL) and water (6 mL) was refluxed for 1 h. and cooled to room temperature. The solvent was removed under reduced pressure, and the residue was acidified with 6N HCl. The product was extracted with EtOAC (3×50 mL), and the organic extracts were dried and concentrated to give crude acids (1.6 g). A solution of 2 M oxalyl chloride in CH2Cl2 (3.00 mL, 6 mmol) was added to a stirred solution of the crude acids (1.6 g) in CH2Cl2 (25 mL) and DMF (1 mL) at room temperature, and stirring continued for 15 min. A solution of N-(3-methoxybenzyl)propan-2-amine, (1.07 g, 6.00 mmol) in CH2Cl2 (2 mL) and diisopropylethylamine (2 mL, 12 mmol) was added and stirred for 1 hr. The solvent was removed under reduced pressure and the residue was purified by Biotage SP1 on packed silica gel column (10%-80% EtOAc/Hexanes gradient) to give N-(3-methoxybenzyl)-4-(2-fluorophenyl)-N-isopropyl-2(methylthio)pyrimidine-5-carboxamide (0.6 g, 13%). Mass Spec. FIA MS 426 (M+1).
    • Step iii: N-(3-Methoxybenzyl)-4-(2-fluorophenyl)-N-isopropyl-2-(methylsulphonyl)pyrimidine-5-carboxamide
  • 70% of MCPBA (0.688 g, 2.80 mmol) was added to a stirred solution of N-(3-methoxybenzyl)-4-(2-fluorophenyl)-N-isopropyl-2(methylthio)pyrimidine-5-carboxamide (0.60 g, 1.41 mmol) in CH2Cl2 (10 mL), and the mixture was stirred at room temperature for 2 h. The solution was washed with saturated NaHCO3, dried and concentrated. The solvent was removed under reduced pressure, and the residue was purified by Biotage SP1 on packed silica gel column (5%-40% MeOH/CH2Cl2 gradient) to give N-(3-methoxybenzyl)-4-(2-fluorophenyl)-N-isopropyl-2-(methylsulfonyl)pyrimidine-5-carboxamide (0.32 g, 49%). Mass Spec. FIA MS 463 (M+1).
    • Step iv: N-(3-Methoxybenzyl)-4-(2-fluorophenyl)-N-isopropyl-2-(piperidin-1-yl)pyrimidine-5-carboxamide (Compound No. 20)
  • Piperidine (0.0054 g, 0.064 mmol) was added to a stirred solution of N-(3-methoxybenzyl)-4-(2-fluorophenyl)-N-isopropyl-2-(methylsulfonyl)pyrimidine-5-carboxamide (0.015 g, 0.032 mmol) in THF (1 mL) and the mixture was heated at 80° C. for 1 h. The solvent was removed under reduced pressure, and the product was purified by preparative HPLC (5-80% CH3CN/0.05% TFA gradient over 15 min) to give N-(3-methoxybenzyl)-4-(2-fluorophenyl)-N-isopropyl-2-(piperidin-1-yl)pyrimidine-5-carboxamide Compound No. 20 (0.012 g, 81%).
    • Example 8
  • Following the procedures of Example 7, and making non-critical variations, the following compounds in Table 5 were prepared.
  • TABLE 5
    Exemplary compounds prepared by procedures of Example 7.
    Compound No.
    2
    3
    9
    17
    21
    24
    35
    44
    50
    67
    69
    84
    89
    92
    113
    114
    134
    139
    151
    164
    165
    189
    204
    218
    226
    229
    235
    238
    246
    250
    255
    270
    274
    279
    284
    288
    308
    311
    312
    313
    321
    323
    332
    335
    336
    351
    • Example 9 N-benzyl-4-(2-fluorophenyl)-N-isopropyl-6-methyl-2-morpholinopyrimidine-5-carboxamide (Compound No. 338)
  • Figure US20130345208A1-20131226-C00381
  • Synthesis of N-benzyl-4-(2-fluorophenyl)-N-isopropyl-6-methyl-2-morpholinopyrimidine-5-carboxamide Compound No. 338: i. CuCl, BF3OEt2, THF, reflux, 18 h ii 60% HNO3, rt, 30 min iii PyBrop, morpholine, Et3N, THF, RT, 2 h iv NaOH, water, EtOH v. a. (COCl2, DMF, CH2Cl2 b. DIPEA, N-benzylpropan-2-amine, RT 16 h
    • Step i: Ethyl 4-(2-fluorophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxopyrimidine-5-carboxylate
  • A mixture of 2-fluorobenzaldehyde (5 g, 40.28 mmol), urea (3.8 g, 61 mmol), ethylacetoaceate (5.24 g, 40.28 mmol), CuCl (0.4 g, 4 mmol), BF3OEt2 (7 mL, 53 mmol), and glacial acetic acid (0.24 g, 4 mmol) in THF (80 mL) was refluxed for 18 h and then cooled to room temperature. The mixture was quenched with saturated NaHCO3 (50 mL), and EtOAc (100 mL) was added. The layers were separated and the organic layer with a white suspension was evaporated to give a white solid. The solid was suspended in toluene (100 mL) and stirred for 2 days at room temperature. The solid was filtered, washed with ether, and dried to give ethyl 4-(2-fluorophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxopyrimidine-5-carboxylate (9.9 g, 88%). Mass Spec. FIA MS 279 (M+1).
    • Step ii: Ethyl 4-(2-fluorophenyl)-1,2-dihydro-6-methyl-2-oxopyrimidine-5-carboxylate
  • Ethyl 4-(2-fluorophenyl)-1,2,3,4-tetrahydro-6-methyl-2-oxopyrimidine-5-carboxylate (2.00 g, 7.2 mmol) was added in small portions to a stirred solution of a 60% nitric acid solution (12 mL) at 0° C. over 5 min. The resulting solution was warmed to room temperature (30 min) and then poured into ice and basified slowly with 6N NaOH. The product was extracted with CHCl3 (3×50 mL), dried, and concentrated. The residue was purified by Biotage SP1 on packed silica gel column (7%-20% MeOH/CH2Cl2 gradient) to give ethyl 4-(2-fluorophenyl)-1,2-dihydro-6-methyl-2-oxopyrimidine-5-carboxylate as a green foam (1.5 g, 76%). Mass Spec. LCMS 277 (M+1).
    • Step iii: 4-(2-Fluorophenyl)-6-methyl-2-morpholin-4-yl-pyrimidine-5-carboxylic acid ethyl ester
  • Morpholine (0.5 mL) was added to a stirred solution of ethyl 4-(2-fluorophenyl)-1,2-dihydro-6-methyl-2-oxopyrimidine-5-carboxylate (0.75 g, 2.72 mmol), PyBroP (1.4 g, 3 mmol), and triethylamine (1 mL) in 1,4-dioxane (20 mL) at room temperature. The solution was stirred at room temperature for 3 h and diluted with EtOAc. The solution was washed with saturated NH4Cl and saturated aqueous NaCl solution, and dried. The solvent was removed under reduced pressure, and the residue was purified by Biotage SP1 on packed silica gel column (5%-80% EtOAC/hexanes gradient) to give 4-(2-fluorophenyl)-6-methyl-2-morpholin-4-yl-pyrimidine-5-carboxylic acid ethyl ester as an oil (0.937 g, 64%). Mass Spec. LCMS 346 (M+1).
    • Step iv: 4-(2-Fluorophenyl)-6-methyl-2-morpholin-4-yl-pyrimidine-5-carboxylic acid
  • A mixture of 4-(2-fluorophenyl)-6-methyl-2-morpholin-4-yl-pyrimidine-5-carboxylic acid ethyl ester (0.6 g, 10.96 mmol), and solid NaOH (2 g, 50 mmol) in ethanol (5 mL) and water (1 mL) was refluxed for 1 h, then cooled to room temperature. The solvent was removed under reduced pressure, and the residue was acidified with a 6N HCl solution. Then, the product was extracted with EtOAC (3×25 mL) and the organic extracts were dried and concentrated to give 4-(2-fluorophenyl)-6-methyl-2-morpholin-4-yl-pyrimidine-5-carboxylic acid (0.43 g, 78%) as white solid. Mass Spec. LCMS 318 (M+1).
    • Step v: 4-(2-Fluorophenyl)-6-methyl-2-morpholin-4-yl-pyrimidine-5-carboxylic acid benzyl-isopropyl-amide (Compound No. 338)
  • A solution of 2 M oxalyl chloride in CH2Cl2 (0.070 mL, 0.14 mmol) was added to a stirred solution of 4-(2-fluorophenyl)-6-methyl-2-morpholin-4-yl-pyrimidine-5-carboxylic acid (0.03 g, 0.09 mmol) in CH2Cl2 (2 mL) and DMF (0.030 mL) at room temperature, and stirring continued for 15 min. A solution of N-benzylisopropylamine (0.013 g, 0.1 mmol) in CH2Cl2(1 mL) and diisopropylethylamine (0.044 mL, 0.25 mmol) were added and stirred for 24 hr. The solvent was removed under reduced pressure, and the residue was purified by Biotage SP1 on packed silica gel column (10%-80% EtOAc/Hexanes gradient) to give 4-(2-fluorophenyl)-6-methyl-2-morpholin-4-yl-pyrimidine-5-carboxylic acid benzyl-isopropyl-amide (0.016 g, 40%). Mass Spec. LCMS 449(M+1).
  • Following the procedures of Example 9, and making non-critical variations, the following compounds were prepared.
  • TABLE 6
    Exemplary compounds prepared by the procedures of Example 9.
    Compound No.
    49
    83
    173
    186
    245
    251
    253
    259
    • Example 10 N-benzyl-4-(2-chlorophenyl)-N-Isopropyl-2-morpholinopyrimidine-5-carboxamide (Compound No. 194)
  • Figure US20130345208A1-20131226-C00382
  • Synthesis of N-benzyl-4-(2-chlorophenyl)-N-isopropyl-2-morpholinopyrimidine-5-carboxamide: i. POCl3, DMA ii. Pd2(dba)3, P(t-Bu)3, K3PO4, THF, 160° C., mW iii. Morpholine, 100° C. iv. A. NaOH, EtOH, 80° C., B. amine, BtSO2Me, NEt3, Dioxane, 160° C., mW
    • Step i. Ethyl 2,4-dichloropyrimidine-5-carboxylate
  • Under an N2 atmosphere, a mixture of 5-carbethoxyuracil (1.0 g, 5.4 mmol) and POCl3 (10 mL) was heated at reflux for 30 minutes. The solution was concentrated under reduced pressure to remove the excess of POCl3, and the residue was poured into ice (20 g). CH2Cl2 (100 mL) was added, and the mixture was basified to pH 9 using saturated aqueous NaHCO3 solution. The organic portion was dried over MgSO4 and concentrated to obtain ethyl 2,4-dichloropyrimidine-5-carboxylate as a yellow oil (900 mg, 75%).
    • Step ii. Ethyl 2-chloro-4-(2-chlorophenyl)pyrimidine-5-carboxylate
  • In a microwave tube was added 1 eq. of ethyl 2,4-dichloropyrimidine-5-carboxylate (200 mg, 0.91 mmol), 0.5 eq. of 3-chlorophenyl boronic acid (67 mg), 0.1 eq. of Pd2(dba)3 (83 mg), 3 eq. of K3PO4 in 4 mL of Dioxane. To this solution was added 1 eq. of tri-(t-butyl)phosphine. The reaction was heated in the microwave to 160° C./300 W/for 1200 sec. The crude product was purified by prep HPLC. ES+=296.8.
    • Step iii. Ethyl 4-(2-cyanophenyl)-2-morpholinopyrimidine-5-carboxylate
  • A flask containing ethyl 2-chloro-4-(2-chlorophenyl)pyrimidine-5-carboxylate (50 mg) in 1 mL morpholine was heated to 100° C. for 12 h. The crude mixture was purified by prep HPLC. The ester was then hydrolyzed with NaOH in ethanol at reflux for 5 hrs. ES+=319.9, ES−=318.0.
    • Step iv. N-Benzyl-4-(2-chlorophenyl)-N-isopropyl-2-morpholinopyrimidine-5-carboxamide
  • In a microwave tube was added 1 eq. of 4-(2-chlorophenyl)-2-morpholino pyrimidine-5-carboxylic acid (80 mg), 1.1 eq. of isopropyl benzylamine (43 mL), 2.5 eq. of triethylamine (80 mL) and 1.2 eq. of BtSO2Me in 4 mL of dioxane. The reaction mixture was heated to 160° C./300 W for 1200 sec. The crude product was purified by prep HPLC. ES+=451.0. NMR confirmed the structure.
    • Example 11
  • Following the procedures of Example 11, and making non-critical variations known in the art, the following compounds were prepared.
  • TABLE 7
    Exemplary compounds prepared by the procedures of Example 11.
    Compound No.
    16
    17
    46
    89
    121
    123
    139
    168
  • A person skilled in the chemical arts can use the examples and schemes along with known synthetic methodologies to synthesize compounds of the present invention, including the compounds in Table 8 below.
  • TABLE 8
    Physical data for exemplary compounds.
    Compound LC/MS LC/RT
    No. M + 1 min NMR
    1 449.4 4 DMSO-d6: 8.49 (s, 1H), 7.59 (m, 1H), 7.52 (m, 1H),
    7.35-7.42 (m, 2H), 7.11 (brm, 3H), 6.77 (brs, 2H), 3.78 (brm, 7H),
    1.63 (brm, 2H), 1.53 (brm, 4H), 0.83 (brm, 6H)
    2 505 4.1 DMSO-d6: 8.55 (s, 1H), 7.44 (m, 2H), 7.27 (d, 2H), 7.15 (m, 2H),
    7.00 (d, 2H), 4.46 (brs, 2H), 4.12 (m, 4H), 2.64 (m, 4H),
    1.95 (brm, 1H), 0.49 (brm, 4H).
    3 491.5 4.5 DMSO-d6: 8.42 (s, 1H), 7.49 (br s, 2H), 7.41 (m, 1H), 7.28 (m,
    1H), 7.22 (m, 1H), 7.12 (m, 1H), 6.74 (s, 1H), 6.38 (br s, 1H),
    4.68 (br s, 1H), 3.67 (br s, 4H), 1.59 (br s, 2H), 1.43 (br s, 4H),
    1.16 (s, 9H), 0.92 (br s, 6H).
    4 490.3 4 DMSO-d6: 8.44 (s, 1H), 7.52 (m, 2H), 7.27 (m, 2H), 7.08 (m, 1H),
    6.74 (m, 2H), 6.50 (m, 1H), 3.43-4.40 (m, 8H), 1.64 (m, 2H),
    1.13 (m, 1H), 0.88 (m, 9H), 0.44 (m, 2H), 0.30 (m, 2H),
    5 451 3.09 DMSO-d6: 8.51 (s, 1H), 7.49 (m, 2H), 7.30 (m, 2H), 6.94 (m, 1H),
    6.34-6.62 (m, 3H), 4.30 (brs, 2H), 3.63-4.10 (m, 9H),
    0.82 (brm, 6H).
    6 534.3 3.7 DMSO-d6: 8.47 (s, 1H), 7.52 (m, 2H), 7.26 (m, 2H), 7.07 (m, 1H),
    6.74 (m, 2H), 6.49 (m, 1H), 4.57 (m, 2H), 4.30 (m, 2H), 4.08 (q, 2H),
    3.95 (m, 1H), 3.71 (s, 3H), 3.13 (m, 2H), 2.63 (m, 1H), 1.92 (m, 2H),
    1.55 (2H), 1.18 (t, 3H), 0.92 (m, 6H)
    7 489.5 3.8 DMSO-d6: 8.49 (s, 1H), 7.49 (m, 2H), 7.30 (m, 2H),
    6.50-6.80 (brm, 3H), 4.49 (t, 2H), 4.35 (brs, 2H), 3.78 (t, 4H),
    3.09 (t, 2H), 1.95 (brm, 1H), 1.63 (m, 2H), 1.53 (m, 4H), 0.49 (4H)
    8 491.4 4.1 DMSO-d6: 8.41 (s, 1H), 7.53 (d, 1H, J = 8 Hz), 7.49 (t, 1H, J = 8 Hz),
    7.43 (t, 1H, J = 8 Hz), 7.34 (d, 1H, J = 8 Hz), 7.14 (t, 1H, J = 8 Hz),
    6.81 (d, 1H, J = 8 Hz), 6.32 (d, 1H, J = 7 Hz), 6.17 (s,
    1H), 4.53 (br s, 1H), 3.69 (m, 4H), 3.63 (s, 3H), 1.62 (m, 4H),
    1.46 (m, 4H), 1.39 (m, 4H), 1.22 (m, 2H).
    9 465.2 3.4 DMSO-d6: 7.15-7.50 (m, 4H), 6.97 (t, 2H), 6.86 (m, 2H),
    4.85 (d, 1H), 3.99 (d, 1H), 3.72 (m, 4H), 3.65 (m, 4H), 2.30 (s, 3H),
    2.29 (s, 3H), 1.85 (m, 1H), 0.20-0.50 (m, 4H),
    10 460.2 3.5 DMSO-d6: 7.15-7.47 (m, 4H), 7.01 (m, 2H), 6.78 (s, 1H),
    6.54 (d, 1H) 4.79 (d, 1H), 4.02 (d, 1H), 3.73 (m, 4H), 3.65 (m, 4H),
    2.30 (s, 3H), 2.22 (s, 3H), 1.90 (m, 1H), 0.20-0.46 (m, 4H),
    11 392.2 3
    12 503.5 4.2 DMSO-d6: 8.25 (s, 1H), 7.54 (m, 1H), 7.36 (m, 1H), 7.30 (m,
    2H), 6.72 (d, 2H, J = 8 Hz), 6.61 (d, 2H, J = 6 Hz), 4.76 (m, 1H),
    4.10 (m, 1H), 4.00 (m, 1H), 3.70 (s, 3H), 3.21 (m, 2H), 1.85 (m,
    1H), 1.75 (m, 2H), 1.55-1.65 (m, 3H), 1.15-1.40 (m, 6H),
    0.92 (s, 6H).
    13 449.1 3.93 CD3OD: 7.45 (m, 2H), 7.13-7.25 (m, 5H), 6.90 (d, 1H), 4.75 (d, 1H),
    4.25 (d, 1H), 3.85 (m, 4H), 3.73 (m, 4H), 2.41 (s, 3H), 3.0 (m, 1H),
    1.05 (d, 3H), 0.61 (d, 3H)
    14 508.5 2.4 DMSO-d6: 8.83 (d, 2H), 8.56 (s, 1H), 8.04 (d, 2H), 7.79 (d, 1H),
    7.69 (brs, 1H), 7.25-7.50 (m, 6H), 4.61 (brs, 2H), 3.80 (m, 4H),
    2.20 (brm, 1H), 1.64 (brm, 2H), 1.54 (brm, 4H), 0.54 (brm, 6H)
    15 471.5 3.47
    16 453.1 3.6
    17 487.1 3
    18 447 0.92 CD3OD: 8.73 (d, 2H), 8.71 (brs, 1H), 7.79 (m, 2H) 7.58 (m, 1H),
    7.52 (m, 1H), 7.28 (m, 1H), 7.19 (m, 1H), 5.10 (brs, 2H),
    4.85 (m, 2H), 3.40-3.65 (brm, 4H), 3.15 (brm, 2H), 2.98 (s, 3H),
    2.41 (brm, 1H), 0.67 (m, 2H), 0.61 (m, 2H)
    19 371 2.91 DMSO-d6: 1.33-1.46 (m, 6H), 1.70 (m, 2H), 3.66 (m, 4H),
    3.77 (m, 4H), 4.03 (m, 1H) 7.17 (m, 1H), 7.26 (t, 1H), 7.46 (m, 1H),
    7.53 (m, 1H), 7.90 (d, 1H), 8.50 (s, 1H)
    20 462.2 3.8 DMSO-d6: 8.48 (s, 1H), 7.52 (m, 2H), 7.30 (m, 2H), 7.07 (m, 1H),
    6.74 (m, 2H), 6.48 (m, 1H), 4.27 (m, 2H), 3.90 (m, 1H), 3.79 (m, 2H),
    3.71 (s, 3H)), 1.50-165 (m, 6H), 0.91 (m, 6H).
    21 465.5 3.3 CD3OD: 7.53 (m, 2H), 7.41 (m, 1H), 7.23 (m, 3H), 7.03 (m,
    1H), 6.79 (m, 1H), 4.83 (m, 1H), 3.75 (m, 4H), 3.67 (s, 3H),
    3.65 (m, 4H), 2.49 (s, 3H), 0.98 (d, 6H, J = 7 Hz).
    22 511.2 4 DMSO-d6: 8.53 (s, 1H), 7.50 (m, 2H), 7.07-7.30 (m, 8H),
    6.74 (m, 2H), 3.91-4.15 (m, 5H), 2.91 (m, 2H), 0.91 (m, 6H)
    23 434.5 2.2 CD3OD: 8.44 (s, 1H), 7.58 (q, 1H, J = 8 Hz, 12 Hz), 7.37 (t, 1H,
    J = 7 Hz), 7.27 (t, 1H, J = 7 Hz), 7.21 (q, 2H, J = 11 Hz, 20 Hz),
    7.15 (t, 2H, J = 8 Hz), 6.59 (d, 2H, J = 8 Hz), 4.87 (m, 1H),
    3.52 (br s, 4H), 3.09 (br s, 4H), 2.92 (s, 3H), 1.05 (d, 6H, J = 7 Hz).
    24 491 3.9 DMSO-d6: 8.51 (s, 1H), 7.53 (m, 1H), 7.55 (m, 1H)<
    7.17-7.29 (m, 3H), 6.89 (m, 2H), 4.07 (m, 2H), 3.60-3.96 (9H),
    1.25 (s, 9H), 0.90 (brm, 6H)
    25 435.4 3.3 CD3OD: 7.55 (q, 1H, J = 7 Hz, 14 Hz), 7.18-7.46 (m, 6H),
    7.13 (t, 2H, J = 7 Hz), 4.87 (m, 1H), 3.70 (m, 4H), 3.64 (m, 4H),
    2.49 (s, 3H), 0.96 (d, 6H, J = 6 Hz).
    26 447 3.68 DMSO-d6: 1.67 (brm, 2H), 1.70-2.10 (brm, 6H), 3.68 (brm, 4H),
    3.78 (brm, 4H), 4.27 (m, 1H), 4.62 (brs, 2H), 6.99 (brm, 2H),
    7.17-7.31 (m, 5H), 7.54 (m, 2H), 8.41 (s, 1H)
    27 477.4 4 DMSO-d6: 8.39 (s, 1H), 7.52 (d, 1H, J = 7 Hz), 7.50 (t, 1H, J = 7 Hz),
    7.42 (t, 1H, J = 11 Hz), 7.31 (d, 1H, J = 8 Hz), 7.19 (t, 1H,
    J = 8 Hz), 6.84 (d, 1H, J = 8 Hz), 6.34 (d, 1H, J = 8 Hz), 6.20 (s,
    1H), 4.57 (m, 1H), 3.70 (t, 4H, J = 5 Hz), 3.68 (s, 3H), 1.92 (m,
    2H), 1.66 (m, 2H), 1.59 (m, 2H), 1.48 (m, 5H), 1.39 (m, 1H).
    28 463 1.82 CD3OD: 8.41 (s, 1H), 7.65 (t, 1H), 7.56 (m, 1H), 7.34 (m., 4H),
    7.25 (t, 1H), 7.15 (d, 2H), 4.44 (s, 2H), 3.88 (m, 4H), 3.73 (m, 4H),
    3.65 (m, 2H), 3.07 (m, 2H), 2.83 (s, 6H)
    29 459.1 3.7 CD3OD: 8.38 (s, 1H), 7.51 (m, 2H), 7.18-7.30 (m, 5H),
    7.04 (m, 2H),, 4.15 (s, 2H), 3.97 (m, 1H), 3.79 (m, 1H),
    2.29 (m, 2H), 1.80 (m, 1H), 1.15-1.60 (8H), 1.01 (brm, 6H).
    30 490.2 3.6 DMSO-d6: 8.44 (s, 1H), 7.50 (m, 2H), 6.90-7.15 (m, 4H),
    6.60 (d, 1H), 4.53 (m, 4H), 4.22 (m, 4H), 3.15 (m, 2H), 2.65 (m, 4H),
    1.80 (, 1H), 0.48 (m, 4H)
    31 505.2 4 DMSO-d6: 7.23-7.55 (m, 4H), 7.13 (d, 2H), 6.76 (d, 2H),
    4.56 (d, 1H), 4.16 (d, 1H), 3.63-3.73 (m, 8H), 2.34 (s, 3H),
    1.25 (9H, m), 0.98 (d, 3H), 0.53 (d, 3H)
    32 503.5 4.3 CD3OD: 7.17-7.52 (m, 6H), 6.86 (d, 1H), 6.81 (d, 1H), 4.68 (d, 1H),
    4.23 (d, 1H), 3.81-3.87 (m, 5H), 2.39 (s, 1H)1.71 (m, 2H),
    1.60 (m, 4H), 1.29 (d, 9H), 1.03 (d, 3H), 0.63 (d, 3H)
    33 419.1 3.1 DMSO-d6: 8.58 (s, 1H), 8.45 (d, 1H), 7.57 (m, 1H), 7.49 (m, 1H),
    7.09-7.30 (m, 6H), 5.30 (m, 1H), 3.77 (m, 4H), 3.66 (m, 4H),
    2.86 (m, 1H), 2.78 (m, 1H), 2.35 (M, 1H), 1.76 (m, 1H)
    34 503.5 4.2 DMSO-d6: 8.3 (s, 1H), 7.55 (m, 1H), 7.05, (m, 1H), 6.77 (d,
    1H, J = 8 Hz), (m, 3H), 6.18 (m, 1H), 6.13 (br s, 1H), 4.76 (m,
    1H), 4.08 (m, 3H), 3.63 (s, 3H), 3.20 (br d, 2H), 1.69 (m, 1H),
    1.5-1.63 (m, 4H), 1.24-1.45 (M, 6H), 0.96 (br s, 6H).
    35 491.5 3.5 DMSO-d6: 8.63 (s, 1H), 7.54 (m, 1H), 7.31 (m, 1H), 7.26 (m,
    2H), 7.15 (m, 1H), 6.82 (d, 1H, J = 7 Hz), 6.34 (d, 1H, J = 8 Hz),
    6.25 (s, 1H), 4.56 (br s, 1H), 3.86 (m, 4H), 3.79 (m, 2H),
    3.62 (s, 3H), 3.32 (t, 2H, J = 11 Hz), 1.67 (m, 2H), 1.58 (m, 2H),
    1.46 (m, 4H), 1.29 (m, 2H).
    36 477.4 3.8 DMSO-d6: 8.49 (s, 1H), 7.49 (d, 1H), 7.44 (m, 1H), 7.31 (m, 2H),
    6.84 (m, 2H), 6.76 (m, 2H), 4.35 (brs, 2H), 3.78 (m, 4H),
    3.72 (s, 3H), 1.95 (m, 1H), 1.63 (m, 2H), 1.53 (m, 4H), 0.49 (m, 4H)
    37 476.2 2.2 DMSO-d6 8.78 (s, 1H), 8.72 (d, 1H), 7.31-7.49 (m, 8H), 7.19 (t, 1H),
    7.02 (t, 1H), 5.33 (m, 1H), 3.79 (t, 4H), 3.65 (t, 4H), 3.52 (m, 2H),
    3.21 (m, 1H), 3.13 (m, 1H), 2.02 (m, 1H), 1.88 (m, 1H)
    38 553.2 4.2 DMSO-d6: 8.44 (s, 1H), 7.51 (m, 2H), 7.07-7.30 (m, 8H),,
    6.73 (m, 2H), 6.48 (m, 1H), 4.07-4.70 (m, 7H), 3.71 (s, 3H),
    2.87 (m, 2H), 1.64-1.82 (m, 3H), 1.16 (m, 2H), 0.91 (m, 6H)
    39 464 2.3 DMSO-d6 8.64 (s, 1H), 7.48 (m, 2H), 7.23 (m, 2H), 7.09 (m, 4H),
    6.99 (m, 2H), 4.67 (d, 2H), 4.50 (brm, 2H), 3.50 (m, 2H),
    3.31 (m, 2H), 3.10 (m, 2H), 2.84 (s, 3H), 2.00 (m, 1H),
    0.48 (brm, 4H).
    40 483 3.87 CD3OD: 8.45 (s, 1H), 8.17 (brs, 1H), 7.90 (m, 1H), 7.82 (m, 1H),
    7.52 (m, 2H), 7.37 (m, m, 3H), 7.10 (brs, 1H), 6.80 (m, 2H),
    5.09 (brs, 2H), 3.85 (m, 4H), 3.73 (m, 4H), 1.80 (brs, 1H),
    0.60 (brm, 4H)
    41 475.5 4.3 DMSO-d6: 8.34 (s, 1H), 7.45 (m, 1H), 7.25 (d, 3H, J = 5 Hz),
    7.18 (d, 1H, J = 6 Hz), 7.06 (br s, 1H), 6.71 (s, 1H), 6.37 (br s,
    1H), 4.75 (br s, 1H), 3.66 (br s, 4H), 1.59 (br s, 2H), 1.43 (br s,
    4H), 1.12 (s, 9H), 0.98 (br s, 6H).
    42 475.5 3.9 DMSO-d6: 8.34 (s, 1H), 7.54 (m, 1H), 7.34 (m, 1H), 7.27 (m,
    2H), 7.12 (t, 1H, J = 8 Hz), 6.79 (d, 1H, J = 6 Hz), 6.34 (d, 1H, J = 7 Hz),
    6.24 (s, 1H), 4.61 (m, 1H), 3.69 (m, 6H), 3.64 (s, 3H),
    1.17, (br s, 2H), 1.59 (m, 2H), 1.44 (d, 6H, J = 18 Hz), 1.29 (m,
    2H).
    43 465.4 3.8 DMSO-d6: 8.33 (s, 1H), 7.55 (m, 1H), 7.49 (t, 1H, J = 7 Hz),
    7.43 (t, 1H, J = 7 Hz), 7.35 (d, 1H, J = 7 Hz), 6.76 (m, 2H),
    6.62 (d, 2H, J = 8 Hz), 4.72 (m, 1H), 3.71 (s, 3H), 3.66 (br s, 4H),
    1.59 (br s, 2H), 1.45 (br s, 4H), 0.86 (d, 6H, J = 6 Hz).
    44 477.2 3.4 DMSO-d6: 8.48 (s, 1H), 7.57 (m, 2H), 7.34 (m, 2H), 7.15 (m, 1H),
    6.91 (m, 3H), 4.45 (brs, 2H), 3.78 (m, 4H), 3.75 (s, 1H),
    3.67 (m, 4H), 3.60 (brm, 2H), 3.00 (brm, 2H), 1.30-1.80 (m, 4H)
    45 434.2 2.8 CD3OD: 8.43 (s, 1H), 7.53 (m, 2H), 7.03-7.30 (m, 7H),
    7.05 (m, 2H), 4.50 (m, 2H), 4.15 (d, 2H), 3.97 (m, 1H), 3.70 (m, 3H),
    2.05 (m, 2H), 1.01 (brm, 6H).
    46 495.1 3.5 NMR 1H (DMSO-d6): 8.4 (s, 1H), 8.3 (s, 1H), 7.7 (m, 2H),
    7.4 (m, 2H), 7.0-7.3 (m, 10H), 3.8 (s, 4H), 3.7 (s, 4H), 3.1 (m, 2H),
    2.5 (m, 2H), 1.7 (m, 2H).
    47 491 3.9 DMSO-d6: 8.51 (s, 1H), 7.10-7.60 (m, 7H), 6.95 (d, 2H),
    3.95-4.25 (6H), 3.35 (m, 1H), 2.65 (m, 4H), 0.90-1.60 (m, 10H)
    48 467 3.6 DMSO-d6: 8.56 (s, 1H), 7.47 (t, 2H), 7.19 (m, 2H),
    7.06-7.12 (d, 4H), 4.48 (brs, 2H), 4.12 (m, 4H), 2.63 (m, 4H),
    2.02 (brm, 1H), 0.49 (brm, 4H).
    49 492.3 3.6 DMSO-d6: 6.75-7.50 (m, 9H), 4.47 (d, 1H), 4.33 (d, 1H),
    3.63-3.69 (m, 8H), 3.45 (m, 1H), 3.02 (s, 3H), 2.37 (s, 3H), 1.05 (m, 2H),
    0.50 (t, 3H)
    50 502.5 3.1 DMSO-d6: 8.46 (s, 1H), 7.53 (brm, 2H), 7.28 (brm, 2H)_,
    6.84 (brm, 2H), 6.38 (brm, 2H), 4.14 (brm, 9H), 3.18 (brm, 4H),
    1.93 (brm, 4H), 1.64 (brm, 2H), 1.53 (m, 4H), 0.88 (brm, 6H)
    51 484.2 3.4
    52 433.1 3.5 CDCl3: 8.27 (brs, 1H), 7.29 (q, 1H), 7.11 (brs, 1H), 7.01 (t, 1H),
    6.92 (m, 3H), 6.82 (d, 2H), 6.64 (brs, 1H), 4.71 (brm, 2H),
    3.70-3.90 (m, 8H), 2.33 (m, 1H), 2.11 (m, 1H), 1.27 (m, 1H), 1.07 (d, 3H)
    53 475 3.4 CD3OD: 88.45 (s, 1H), 7.46 (m, 1H), 7.39 (m, 1H), 7.10 (m, 1H),
    7.00 (m, 2H), 6.89 (m, 1H), 6.60 (d, 1H), 4.53 (m, 4H), 3.87 (t, 4H)<
    3.74 (t, 4H), 3.15 (t, 2H), 1.84 (brm, 1H), 0.47-0.55 (brm, 4H)
    54 498.5 4 DMSO-d6: 8.42 (s, 1H), 7.66 (m, 1H), 7.60 (m, 1H), 7.35 (m,
    1H), 7.29 (m, 2H), 7.23 (m, 1H), 6.93 (m, 1H), 6.83 (br s, 1H),
    4.74 (br s, 1H), 4.24 (m, 2H), 1.85 (m, 1H), 1.54-1.69 (m, 5H),
    1.45 (m, 1H), 1.33 (m, 4H), 1.24 (m, 3H), 0.95 (dd, 6H, J = 6 Hz,
    20 Hz).
    55 479.4 3.9 DMSO-d6: 8.47 (m, 1H), 7.35-7.56 (m, 4H), 7.00 (m, 1′H),
    6.64-6.75 (m, 2H), 6.25 (m, 1H), 3.77 (m, 7H), 3.69 (s, 3H), 1.63 (m, 2H),
    1.64 (m, 2H), 1.53 (m, 4H), 0.84 (brm, 6H)
    56 463 3.3 DMSO-d6: 8.58 (s, 1H), 7.46 (m, 2H), 7.17 (m, 3H),
    6.79 (dd, 1H), 6.75 (m, 1H), 6.63 (t, 1H), 4.48 (brs, 2H), 3.78 (m, 4H),
    3.72 (s, 3H), 3.67 (m, 4H), 2.15 (brm, 1H), 0.50 (m, 4H)
    57 502.2 3.3 DMSO-d6: 8.44 (s, 1H), 7.55 (t, 1H), 7.45 (m, 1H), 7.37 (t, 2H),
    7.21-7.29 (m, 5H), 3.78 (t, 4H), 3.67 (t, 4H), 3.00-3.35 (brm, 8H),
    2.19 (m, 2H), 0.73 (t, 3H)
    58 463.4 3.8 DMSO-d6: 8.48 (s, 1H), 7.95 (d, 1H, J = 8 Hz), 7.67 (m, 1H),
    7.49 (m, 1H), 7.36 (m, 2H), 7.17 (m, 1H), 6.58 (m, 1H),
    6.28 (m, 1H), 3.66 (s, 3H), 3.57 (br s, 4H), 2.74 (m, 1H), 1.60 (m,
    2H), 1.49 (m, 4H), 0.85 (m, 1H), 0.65 (m, 1H), 0.51 (m, 1H),
    0.36 (m, 1H).
    59 507.1 4.2 DMSO-d6: 8.50 (s, 1H), 7.53 (m, 1H), 7.45 (m, 1H),
    7.18-7.26 (m, 3H), 6.90 (m, 2H), 4.10 (m, 6H), 3.85 (m, 1H), 2.63 (m, 4H),
    1.25 (s, 9H), 0.91 (brm, 6H)
    60 510 2.1 CD3OD: 8.67 (d, 2H), 8.52 (s, 1H), 8.36 (d, 2H), 7.90 (m, 2H),
    7.57 (t, 1H), 7.46 (m, 2H), 7.25 (m, 1H), 7.10 (m, 1H), 6.80 (m, 1H),
    4.73 (m, 1H), 3.88 (m, 4H), 3.74 (m, 4H), 2.02 (m, 1H), 0.62 (m, 4H)
    61 535.2 3.7 DMSO-d6: 8.41 (s, 1H), 7.06-8.21 (m, 11 H), 6.73 (m, 2H),
    6.40 (m, 1H), 5.01 (m, 2H), 4.35 (m, 2H), 3.95 (m, 1H), 3.70 (s, 3H),
    0.91 (m, 6H)
    62 467.4 3.6 DMF-d7: 8.42 (s, 1H), 7.55 (m, 1H), 7.35 (br s, 1H), 7.28 (m,
    2H), 7.10 (m, 1H), 6.79 (d, 1H, J = 9 Hz), 6.29 (br s, 1H),
    6.19 (br s, 1H), 4.78 (br s, 1H), 4.00 (br s, 4H), 3.64 (s, 3H), 2.54 (br
    s, 4H), 0.96 (br s, 6H).
    63 454.2 3.6
    64 475 3.88 DMSO-d6: 0.9-1.65 (brm, 10H), 1.51 (brm, 4H), 3.28 (m, 1H),
    3.68 (brm, 4H), 3.77 (brm, 4H), 4.03 (brm, 1H), 6.93 (brd, 2H),
    7.15 (brm, 3H), 7.29 (m, 2H), 7.45 (m, 1H), 7.55 (m, 1H), 8.52 (s, 1H)
    65 515.5 4.4 DMSO-d6: 8.28 (s, 1H), 7.52 (m, 1H), 7.36, (m, 1H), 7.26 (m,
    2H), 7.17 (t, 1H, J = 8 Hz), 6.77 (d, 1H, J = 8 Hz), 6.80 (d, 1H, J = 8 Hz),
    6.32 (d, 1H, J = 7 Hz), 6.26 (s, 1H), 4.66 (m, 1H),
    4.08 (m, 3H), 3.66 (s, 3H), 3.23 (m, 2H), 1.86 (m, 2H), 1.72 (m, 1H),
    1.69 (m, 4H), 1.43 (m, 4H), 1.34 (m, 6H).
    66 435.5 3.2 DMSO-d6: 9.44 (s, 1H), 8.28 (s, 1H), 7.54 (m, 1H), 7.37 (m,
    1H), 7.26 (m, 2H), 6.98 (t, 1H, J = 7 Hz), 6.61 (d, 1H, J = 8 Hz),
    6.16 (m, 2H), 4.70 (br s, 1H), 3.69 (br s, 4H), 1.58 (m, 2H),
    1.47 (m, 4H), 0.95 (d, 6H, J = 6 Hz).
    67 479.4 3.1 DMSO-d6: 8.39 (s, 1H), 7.54 (m, 1H), 7.37 (m, 1H), 7.27 (m,
    2H), 6.65 (d, 1H, J = 8 Hz), 6.25 (d, 1H, J = 8 Hz), 6.02 (s, 1H),
    4.73 (m, 1H), 4.19 (s, 4H), 3.66 (br s, 4H), 3.61 (br s, 4H),
    0.92 (d, 6H, J = 6 Hz).
    68 545.6 4.1 DMSO-d6: 8.30 (s, 1H), 7.55 (m, 1H), 7.30 (m, 1H), 7.26 (m,
    2H), 7.15 (m, 1H), 7.10 (m, 1H), 6.80 (d, 1H, J = 8 Hz), 6.23 (s,
    1H), 4.70 (br s, 1H), 4.13 (m, 2H), 3.80 (m, 2H), 3.65 (s, 3H),
    3.30 (m, 2H), 1.85 (m, 1H), 1.69 (m, 2H), 1.50-1.63 (m, 4H),
    1.22-1.44 (m, 11H).
    69 462.2 3.6
    70 463.4 3.6 DMSO-d6: 8.34 (s, 1H), 7.54 (m, 1H), 7.36 (br s, 1H), 7.28 (m,
    2H), 6.71 (d, 1H, J = 6 Hz), 6.18 (m, 2H), 6.00 (s, 2H), 4.73 (m,
    1H), 3.69 (br s, 4H), 1.60 (br s, 2H), 1.47 (br s, 4H), 0.93 (d,
    6H, J = 6 Hz).
    71 463.1 3.4 DMSO-d6: 8.46 (2 × s, 1H), 7.01-7.67 (m, 8H), 5.74 &6.02 (2 × s,
    1H), 4.16 (brs, 1H), 3.86-3.90 (m, 7H), 3.75 (m, 4H), 3.44 (m, 1H),
    2.44 (m, 1H),
    72 436.2 2.6
    73 484 2.94
    74 465 3.48 CDCl3: 8.37&8.18 (2 × s, 1H), 7.00-7.60 (m, 4H),
    6.51-6.72 (m, 3H), 4.36 (brs, 2H), 3.66-4.02 (m, 9H), 3.69 (s, 3H),
    0.88 (brm, 6H)
    75 446 3.17 CD3OD: 8.37 (s, 1H), 7.00-7.70 (m, 9H),,
    4.46 (brs, 2H), 3.86 (m, 4H), 3.73 (m, 4H), 3.58 (m, 2H), 2.56 (t, 2H).
    76 471.4 3.5 DMSO-d6: 8.35 (s, 1H), 7.87 (d, 1H, J = 8 Hz), 7.81 (d, 1H, J = 8 Hz),
    7.76 (d, 1H, J = 8 Hz), 7.61 (m, 1H), 7.55 (t, 1H, J = 8 Hz),
    7.49 (t, 1H, J = 8 Hz), 7.35 (m, 3H), 7.23 (t, 1H, J = 8 Hz),
    6.24 (d, 1H, J = 7 Hz), 4.82 (m, 1H), 3.49 (s, 4H), 3.34 (s, 4H),
    1.13 (d, 3H, J = 6 Hz), 0.77 (d, 3H, J = 6 Hz).
    77 473.5 3.6 DMSO-d6: 8.48 (m, 1H), 7.45 (m, 2H), 7.30 (m, 2H), 6.89 (s, 1H),
    6.79 (m, 1H), 6.61 (d, 1H), 4.51 (t, 2H), 4.40 (brs, 2H), 3.80 (t, 2H),
    3.12 (t, 2H), 1.95 (brm, 1H), 1.63 (m, 2H), 1.54 (m, 4H),
    0.47 (brm, 4H)
    78 480.2 4 CD3OD: 8.48 (s, 1H), 7.53 (m, 2H), 7.00-7.45 (m, 1H),
    4.96 (brs, 4H), 4.10 (s, 2H), 3.97 (m, 1H), 2.94 (m, 2H), 1.02 (brm, 6H)
    79 343 2.4 DMSO-d6: 0.34 (m, 2H), 0.59 (m, 2H), 2.61 (m, 1H), 3.65 (m, 4H),
    3.78 (m, 4H), 7.19 (m, 1H), 7.29 (t, 1H), 7.48 (m, 1H), 7.53 (m, 1H),
    8.11 (d, 1H), 8.49 (s, 1H)
    80 463 3.8 DMSO-d6: 8.40 (s, 1H), 7.55 (m, 2H), 7.15-7.31 (m, 5H),
    7.00 (m, 2H), 4.63 (brS, 2H), 4.27 (m, 1H), 4.13 (m, 4H),
    2.66 (m, 4H), 1.33-2.15 (brm, 6H)
    81 495 4.06 CD3OD: 8.50 (s, 1H), 7.50 (m, 2H), 7.05-7.25 (m, 9H),
    4.10-4.25 (m, 8H), 4.60 (m, 1H), 3.17 (s, 3H), 2.60-2.67 (m, 4H),
    1.30-1.60 (m, 2H), 0.64 (m, 3H)
    82 435.4 3.9 DMSO-d6: 8.37 (s, 1H), 7.53 (m, 2H), 7.43 (t, 1H, J = 7 Hz),
    7.33 (d, 1H, J = 7 Hz), 7.24 (s, 3H), 6.70 (br s, 2H), 4.65 (br s,
    1H), 3.67 (br s, 4H), 1.58 (br s, 2H), 1.45 (br s, 4H), 0.88 (d,
    6H, J = 6 Hz).
    83 450.2 3.6 CD3OD: 8.41 (s, 1H), 7.57 (m, 2H), 7.22 (m, 5H), 7.05 (m, 2H),
    4.09 (m, 2H), 3.55-4.15 (m, 7H), 3.57 (s, 3H), 1.20 (t, 2H),
    1.01 (brm, 6H).
    84 435.4 3.2 DMSO-d6: 8.60 (br s, 1H), 7.45 (m, 2H), 7.18 (m, 2H), 6.94 (m,
    2H), 6.69 (m, 2H), 4.61 (br s, 1H), 4.05 (m, 2H), 3.67-3.92 (br
    m, 8H), 1.00 (br s, 3H).
    85 517 3.8 DMSO-d6: 8.60 (s, 1H), 7.62 (d, 2H), 7.46 (m, 2H), 7.30 (d, 2H),
    7.20 (m, 2H), 4.59 (brs, 2H), 4.12 (m, 4H), 2.64 (m, 4H),
    2.15 (brm, 1H), 0.51 (brm, 4H).
    86 491.5 3.6 DMSO-d6: 8.40 (s, 1H), 7.55 (m, 1H), 7.37 (br s, 1H), 7.30 (d,
    2H, J = 6 Hz), 7.11 (m, 1H), 6.79 (d, 1H, J = 7 Hz), 6.32 (m, 1H),
    6.21 (br s, 1H), 4.37 (m, 1H), 3.65 (s, 3H), 3.58 (br d, 8H, J = 16 Hz),
    1.67 (m, 4H), 1.49 (d, 1H, J = 11 Hz), 1.24 (m, 2H),
    0.97 (m, 2H), 0.86 (m, 1H).
    87 464.5 2.2 CD3OD: 8.47 (s, 1H), 7.55 (m, 1H), 7.39 (m, 1H), 7.27 (m,
    1H), 7.21 (m, 1H), 7.05 (m, 1H), 6.77 (m, 1H), 6.22 (m, 1H),
    6.10 (m, 1H), 4.85 (m, 1H), 3.66 (s, 3H), 3.50 (br s, 4H),
    3.09 (br s, 4H), 2.92 (s, 3H), 1.06 (d, 6H, J = 7 Hz).
    88 421 3.52 CD3OD: 8.34 (s, 1H), 7.54 (m, 1H), 7.10-7.40 (m, 6H),
    6.60 (m, 2H), 4.90 (brm, 1H), 3.74 (m, 4H), 3.67 (m, 4H),
    1.06 (brm, 4H)
    89 477.2 3.1
    90 431.5 3.7 CD3OD:: 8.43 (s, 1H), 7.49 (m, 1H), 7.39 (m, 1H),
    7.00-7.30 (m, 7H), 4.59 (m, 2H), 3.88 (m, 4H), 1.91 (m, 1H), 1.72 (m, 2H),
    1.63 (m, 4H), 0.52 (m, 4H)
    91 445.2 3.3 DMSO-d6: 8.50 (s, 1H), 7.20-7.70 (m, 9H), 5.90&6.15 (2 × s, 1H),
    4.07 (brs, 1H), 3.68-3.80 (m, 11H), 2.35 (m, 2H)
    92 487.5 4.4 CD3OD: 8.38 (s, 1H), 7.05-7.70 (brm, 9H), 4.4 (m, 4H),
    3.97 (m, 1H), 3.40 (m, 2H), 1.35-1.95 (m, 12H), 1.02 (m, 6H)
    93 419.4 3.7 DMSO-d6: 8.91 (s, 1H), 8.39 (d, 1H, J = 2 Hz), 7.71 (m, 1H),
    7.55 (m, 2H), 7.42 (m, 1H), 7.33 (m, 3H), 7.21 (br s, 1H),
    4.06 (m, 1H), 3.89 (m, 2H), 3.67 (m, 2H), 1.59 (m, 4H), 1.45 (m,
    2H), 0.94 (br s, 6H).
    94 477.5 3.7 DMSO-d6: 8.44 (s, 1H), 7.51 (m, 2H), 7.26 (m, 2H), 6.69 (m, 1H),
    6.61 (s, 1H), 6.50 (m, 1H), 5.96 (s, 2H), 4.59 (m, 2H),
    3.79-4.00 (m, 7H), 1.63 (m, 2H), 1.54 (m, 4H), 0.90 (m, 6H)
    95 527.5 4.2 CD3OD: 8.39 (s, 1H), 7.46 (m2H), 6.85-7.25 (m, 4H), 6.60 (d, 1H),
    4.53 (t, 2H), 4.47 (m, 4H), 3.40 (m, 2H), 3.15 (t, 2H), 1.97 (m, 1H),
    1.30-1.85 (m12H), 0.50 (m, 4H)
    96 445.2 3.4 CD3OD: 8.48 (s, 1H), 7.51 (m, 2H), 6.99-7.35 (m, 7H), 4.50 (m, 1H),
    4.06 (s, 2H), 3.60-3.95 (m, 6H), 2.85 (t, 2H), 1.25 (t, 3H),
    1.02 (brm, 6H)
    97 419.1 3.1 DMSO-d6: 8.54 (s, 1H), 8.39 (d, 1H), 7.55 (m, 1H) 7.50 (m, 1H),
    7.06-7.30 (m, 7H), 3.78 (t, 4H), 3.66 (m, 4H), 2.80 (m, 1H),
    1.88 (m, 1H), 1.13 (m, 2H),
    98 451 3.7 DMSO-d6: 8.52 (s, 1H), 6.95-7.65 (m, 9H), 4.00-4.25 (m, 6H),
    3.90 (m, 1H), 2.5 (m, 4H), 0.91 (brS, 6H)
    99 484 2.64 CD3OD: 9.11 (s, 1H), 8.87 (m, 2H), 8.56 (s, 1H), 8.25 (m, 2H),
    8.16 (m, 1H), 7.98 (m, 1H), 7.47 (m, 1H), 7.20 (m, 1H), 6.98 (m, 1H),
    6.65 (m, 1H), 4.90 (brs, 2H), 3.88 (t, 4H), 3.74 (t, 4H),
    2.22 (brm, 1H), 0.72 (m, 2H), 0.64 (m, 2H)
    100 433 3.41 DMSO-d6: 0.48 (brs, 4H), 2.08 (brs, 1H), 3.67 (m, 1H), 3.77 (m,
    4H), 4.51 (brs, 2H), 7.06 (d, 2H), 7.21-7.26 (m, 5H), 7.48 (m, 2H),
    8.58 (s, 1H)
    101 460.5 3.7 DMSO-d6: 8.50 (s, 1H), 7.70 (d, 1H, J = 8 Hz), 7.54 (d, 2H, J = 4 Hz),
    7.45 (m, 2H), 7.29 (d, 1H, J = 8 Hz), 7.04 (d, 1H, J = 8 Hz),
    6.79 (br s, 1H), 4.63 (br s, 1H), 3.70 (br s, 4H), 1.59 (m,
    2H), 1.46 (m, 4H), 0.90 (d, 6H, J = 6 Hz).
    102 454.2 2.17
    103 481.2 3.6 CD3OD: 8.45 (s, 1H), 7.50 (m, 2H), 7.25 (m, 3H), 7.09 (m, 1H),
    6.73 (m, 2H), 6.50 (m, 1H), 3.50-4.10 (m, 9H), 3.75 (s, 3H),
    3.25 (brm, 3H), 1.23 (brm, 3H), 0.91 (brm, 6H)
    104 463.5 3.7 DMF-d7: 7.57 (m, 1H), 7.35 (m, 1H), 7.26 (m, 2H), 7.05 (t, 1H,
    J = 8 Hz), 6.79 (m, 1H), 6.00 (br s, 1H), 5.75 (br s, 1H), 4.75 (m,
    1H), 3.83 (br s, 2H), 3.62 (s, 3H), 3.61 (br s, 2H), 2.40 (s, 3H),
    1.56 (m, 2H), 1.42 (m, 4H), 0.87 (dd, 6H, J = 7 Hz, 12 Hz).
    105 473.5 4.3 CDCl3: 8.27 (s, 1H), 7.46 (m, 2H), 7.17 (m, 5H), 6.65 (br s,
    2H), 4.92 (m, 1H), 4.28 (br d, 1H, J = 8 Hz), 4.20 (br d, 1H, J = 8 Hz),
    3.31 (m, 2H), 1.98 (s, 1H), 1.87 (m, 1H), 1.74 (m, 2H),
    1.56 (m, 2H), 1.49 (m, 1H), 1.28 (m, 4H), 1.36 (m, 4H), 1.04 (br
    s, 6H).
    106 480.2 2.6
    107 419 3.3 DMSO-d6: 8.50 (s, 1H), 6.95-7.60 (m, 8H), 4.57 (brs, 1H),
    4.42 (brs, 1H), 3.80 (m, 4H), 3.68 (m, 5H), 3.42 (brm, 1H),
    2.50-2.71 (brm, 2H)
    108 449.4 3.7 DMSO-d6: 8.28 (s, 1H), 7.55 (m, 1H), 7.37 (m, 1H), 7.30 (m,
    2H), 6.74 (d, 2H, J = 8 Hz), 6.63 (d, 2H, J = 8 Hz), 4.76 (m, 1H),
    3.70 (s, 3H), 3.67 (br s, 4H), 1.59 (m, 2H), 1.46 (m, 4H),
    0.91 (d, 6H, J = 6 Hz).
    109 449 3.6 DMSO-d6: 8.56 (s, 1H), 7.48 (t, 2H), 7.21-7.26 (m, 5H),
    7.06 (d, 2H), 4.50 (brS, 2H), 4.12 (m, 4H), 2.64 (m, 4H),
    2.00 (m, 1H), 0.48 (m, 4H)
    110 451 3.3 DMSO-d6: 8.61 (s, 1H), 7.47 (m, 2H), 7.29 (m, 1H), 7.20 (m, 2H),
    7.06 (m, 1H), 6.91 (t, 2H), 4.51 (brs, 2H), 3.78 (m, 4H), 3.67 (m, 4H),
    2.15 (brm, 1H), 0.51 (m, 4H)
    111 464.5 2.5 DMSO-d6: 8.40 (s, 1H), 7.54 (m, 1H), 7.38 (m, 1H), 7.26 (m,
    2H), 6.98 (m, 1H), 6.55 (d, 1H, J = 7 Hz), 6.04 (s, 2H), 4.73 (br
    s, 1H), 3.64 (br s, 4H), 3.60 (br s, 4H), 2.78 (s, 6H), 0.97 (d, 6H,
    J = 6 Hz).
    112 469.5 3.9 DMSO-d6: 8.27 (s, 1H), 7.86 (d, 1H, J = 8 Hz), 7.80 (d, 1H, J = 8 Hz),
    7.74 (d, 1H, J = 8 Hz), 7.62 (m, 1H), 7.54 (t, 1H, J = 7 Hz),
    7.48 (t, 1H, J = 7 Hz), 7.33 (m, 3H), 7.21 (t, 1H, J = 7 Hz),
    6.24 (d, 1H, J = 8 Hz), 4.80 (m, 1H), 3.46 (br s, 4H), 1.50 (m, 2H),
    1.32 (br s, 4H), 1.13 (d, 3H, J = 6 Hz), 0.77 (d, 3H, J = 6 Hz).
    113 479 3.63 CD3OD: 0.64 (t, 3H), 1.55 (m, 2H), 3.15 (s, 3H), 3.07-3.80 (m, 7H),
    3.87 (m, 4H), 4.20 (m, 2H), 7.06-7.53 (m, 9H), 8.48 (s, 1H)
    114 562.5 2.9 CD3OD: 8.86 (d, 2H), 8.44 (s, 1H), 8.37 (d, 2H), 7.89 (m, 2H),
    7.57 (t, 1H), 7.55 (m, 2H), 7.30 (m, 1H), 7.15 (m, 1H), 6.80 (m, 1H),
    4.70 (m, 2H),, 4.40 (m, 4H), 3.40 (m, 2H), 3.15 (t, 2H), 1.95 (m, 1H),
    1.30-1.85 (m12H), 0.63 (m, 2H), 0.56 (m, 2H)
    115 505.5 4.2 DMSO-d6: 8.41 (s, 1H), 7.52 (m, 2H), 7.44 (t, 1H, J = 7 Hz),
    7.34 (d, 1H, J = 7 Hz), 7.13 (m, 1H), 6.81 (d, 1H, J = 7 Hz),
    6.31 (d, 1H, J = 7 Hz), 6.15 (s, 1H), 4.38 (br s, 1H), 3.67 (s, 3H),
    3.34 (br s, 4H), 1.55-1.63 (m, 5H), 1.45 (br s, 5H), 1.22 (m, 3H),
    0.84-0.93 (m, 3H).
    116 461.4 3.8 DMSO-d6: 8.31 (s, 1H), 7.52 (m, 1H), 7.39 (t, 1H, J = 7 Hz),
    7.27 (m, 2H), 7.17, (t, 1H, J = 6 Hz), 6.82 (d, 1H, J = 8 Hz),
    6.36 (d, 1H, J = 8 Hz), 6.28 (s, 1H), 4.66 (m, 1H), 3.71 (t, 4H, J = 6 Hz),
    3.67 (s, 3H), 1.98 (m, 2H), 1.68 (m, 2H), 1.59 (m, 2H),
    1.49 (m, 6H).
    117 433.5 3.8 DMSO-d6: 8.46 (s, 1H), 7.55 (m, 1H), 7.54 (m, 1H),
    7.15-7.30 (m, 5H), 6.95 (m, 2H), 3.70-4.10 (m, 7H), 1.64 (brm, 2H),
    1.54 (brm, 6H), 0.9 (brm, 6H)
    118 487 3.91 CD3OD: 8.37 (s, 1H), 7.47-7.53 (m, 3H), 7.18-7.27 (m, 6H),
    7.04 (m, 2H), 6.96 (m, 2H), 4.12 (s, 2H), 3.95 (m, 1H), 3.68 (m, 2H),
    2.92 (m, 2H), 1.02 (m, 6H).
    119 505.5 4.5 CD3OD:: 8.48 (s, 1H), 7.57 (d, 1H), 7.50 (t, 1H), 7.49 (m, 1H),
    7.39 (m, 1H), 7.00-7.30 (m, 7H), 7.35 (m, 2H), 7.11 (m, 2H),
    6.72 (m, 2H), 3.95 (m, 1H), 3.78 (m, 6H), 1.91 (m, 1H),
    1.63 (m, 2H), 1.53 (m, 4H), 1.24 (s, 9H), 0.83 (m, 4H)
    120 531.5 4.2 CD3OD: 8.36 (s, 1H), 7.49 (m, 2H), 7.24 (m, 1H), 7.15 (m, 1H),
    6.56-6.70 (m, 3H), 5.90 (s, 2H), 4.4 (m, 4H), 3.95 (m, 1H),
    3.40 (m, 2H), 1.35-1.95 (m, 12H), 1.02 (m, 6H)
    121 497.1 3.4 NMR 1H (DMSO-d6): 8.6 (s, 1H), 8.4 (s, 1H), 7.7 (m, 2H),
    7.4 (m, 2H), 7.2 (m, 3H), 7.0 (m, 2H), 6.9 (m, 5H), 4.0 (t, 2H),
    3.8 (m, 4H), 3.7 (m, 4H), 3.5 (m, 2H).
    122 489.5 4.3 DMSO-d6: 8.45 (m, 1H), 7.60 (m, 1H), 7.54 (m, 1H), 7.54 (m, 1H),
    7.17-7.30 (m, 4H), 6.90 (m, 2H), 3.70-4.10 (m, 7H), 1.63 (brm, 2H),
    1.54 (brm, 6H), 0.91 (brm, 6H)
    123 509 4.08 NMR 1H (CDCl3): “Show rotameres” 8.3 (s, 1H), 7.8 (d, 2H),
    6.9-7.4 (m, 12H), 4.7 (m, 2H), 4.4 (m, 1H), 3.7-4.0 (m, 8H),
    1.0-1.1 (2 × s, 4H), 0.6 (s, 2H).
    124 501 3.5 DMSO-d6: 8.62 (s, 1H), 7.62 (m, 2H), 7.46 (brm, 2H), 7.30 (d, 2H),
    7.20 (m, 2H), 4.59 (brs, 2H), 3.78 (m, 4H),, 3.67 (m, 4H),
    2.06 (brm, 1H), 0.52 (brm, 4H)
    125 444.5 3.6 DMSO-d6: 8.45 (s, 1H), 7.67 (d, 1H, J = 7 Hz), 7.58 (m, 1H),
    7.38 (m, 1H), 7.29 (m, 3H), 7.01 (m, 1H), 6.82 (br s, 1H),
    4.70 (br s, 1H), 3.70 (br s, 4H), 1.60 (m, 2H), 1.46 (m, 4H), 0.95 (d,
    6H, J = 6 Hz).
    126 514 2.5 DMSO-d6 8.69 (s, 1H), 7.62 (d, 2H), 7.48 (m, 2H), 7.29 (d, 2H),
    7.23 (m, 2H), 4.77 (d, 2H), 4.60 (brm, 2H), 3.53 (m, 2H),
    3.32 (m, 2H), 3.30 (m, 2H), 2.84 (s, 3H), 2.10 (m, 1H),
    0.51 (brm, 4H).
    127 489.5 4 DMSO-d6: 8.34 (s, 1H), 7.54 (m, 1H), 7.36 (br s, 1H), 7.28 (m,
    2H), 7.10 (m, 1H), 6.79 (d, 1H, J = 8 Hz), 6.31 (m, 1H), 6.20 (s,
    1H), 4.31 (br s, 1H), 3.68 (br s, 4H), 3.65 (s, 3H), 1.66 (m, 2H),
    1.59 (m, 2H), 1.46 (m, 6H), 1.24 (m, 2H), 0.97 (m, 2H),
    0.85 (m, 2H).
    128 451 3.3 DMSO-d6: 8.57 (s, 1H), 7.47 (m, 2H), DMSO-d6: 7.21 (m, 2H),
    7.11 (m, 4H), 4.48 (brs, 2H), 3.77 (m, 4H),, 3.67 (m, 4H),
    2.05 (brm, 1H), 0.49 (brm, 4H)
    129 446 2.2 DMSO-d6 0.5 (brm, 4H), 0.85 (brm, 1H), 2.95 (s, 3H),
    3.15-3.65 (brm, 6H), 4.60 (brm, 2H), 5.02 (brs, 2H), 6.95-7.45 (m, 9H),
    8.56 (s, 1H)
    130 467 3.8 CD3OD: 8.51 (s, 1H), 7.58 (m, 2H), 7.06-7.40 (m, 9H),
    7.06 (m, 2H), 4.96 (brs, 4H), 4.15 (s, 2H), 4.00 (m, 1H),
    1.03 (brm, 6H)
    131 481 3.94 CD3OD: 8.45 &8.00 (2 × s, 1H), 7.11-7.65 (m, 5H), 6.52-6.80 (m,
    3H), 3.95-4.25 (m, 7H), 3.75 (s, 3H), 2.65 (m, 4H), 1.02 (brm, 6H).
    132 457 3.22
    133 449 3.94 CDCl3: 8.26 (s, 1H), 7.41 (m, 2H), 7.17 (t, 1H, J = 8 Hz),
    7.07 (m, 2H), 6.70 (d, 1H, J = 7 Hz), 6.29 (br s, 1H), 6.14 (br s, 1H),
    5.90 (br m, 1H), 3.73 (br S, 4H), 3.66 (s, 3H), 1.62 (br s, 2H),
    0.85 (d, 6H, J = 7 Hz).
    134 497.1 3.8 DMSO-d6: 8.56 (s, 1H), 7.20-7.60 (8H), 7.08 (m, 1H),
    6.73 (m, 2H), 6.50 (m, 1H), 4.92 (brm, 2H), 4.87 (brm, 2H),
    4.11 (brs, 2H), 3.92m, 1H), (s, 3H), 0.92 (brm, 6H)
    135 505.1 3.7 CD3OD: 8.45 (s, 1H), 8.15 (d, 1H), 7.87 (d, 1H), 7.79 (d, 1H),
    7.49 (m, 5H), 7.43 (t, 1H), 7.18 (m, 5H), 7.03 (m, 2H), 5.12 (s, 2H),
    4.10 (s, 2H), 3.97 (m, 1H), 1.02 (brm, 6H).
    136 459.5 4 DMSO-d6: 8.43 (s, 1H), 7.57 (m, 1H), 7.47 (m, 1H), 7.30 (t, 2H),
    7.17 (m, 2H), 6.93 (m, 2H), 3.70-4.10 (m, 7H), 1.35-1.64 (brm, 14H)
    137 556.5 3.7 CD3OD: 8.37 (s, 1H), 6.70-7.60 (m, 9H), 4.40 (m, 4H),
    4.00 (m, 1H), 3.59 (m, 4H), 3.37 (m, 2H), 2.20 (m, 4H),
    3.40 (m, 2H), 1.20-2.10 (m, 12H), 1.05 (m, 6H)
    138 434 1.93 CD3OD: 8.75 (m, 2H), 8.55 (s, 1H), 8.39 (m, 1H), 8.00 (m, 1H),
    7.54 (m, 1H), 7.46 (m, 1H), 7.19 (m, 1H), 7.03 (m, 1H),
    4.77 (brS, 2H), 3.89 (t, 4H), 3.75 (t, 4H), 2.21 (brm, 1H),
    0.68 (m, 2H), 0.59 (m, 2H)
    139 453.1 3.6
    140 464.5 3.7 DMSO-d6: 8.49 (s, 1H), 8.07 (d, 1H, J = 8 Hz), 7.56 (m, 1H),
    7.50 (t, 1H, J = 8 Hz), 7.27 (m, 5H), 4.76 (m, 1H), 3.69 (br s,
    4H), 1.59 (m, 2H), 1.45 (br s, 4H), 0.97 (d, 6H, J = 6 Hz).
    141 483.5 4.4
    142 463 3.2 DMSO-d6: 8.54 (s, 1H), 7.48 (t, 2H), 7.20 (brm, 2H), 7.69 (d, 2H),
    4.40 (brs, 2H), 3.78 (m, 4H), 3.73 (s, 3H), 3.67 (m, 4H),
    1.90 (brm, 1H), 0.47 (brm, 4H)
    143 475.2 3.7 DMSO-d6: 7.60 (m, 1H), 7.27-7.40 (m, 3H), 7.08 (m, 3H),
    6.43 (d, 2H), 4.74 (d, 1H), 4.10 (d, 1H), 3.94 (m, 1H), 3.72 (m, 4H),
    3.66 (m, 4H), 2.32 (s, 3H), 1.00-1.60 (m, 8H)
    144 479 2.94 CD3OD: 8.45 (s, 1H), 7.65& 6.90 (2 × t, 1H), 7.49 (m, 1H),
    7.26 (m, 1H), 7.10 (m, 1H), 6.61 (d, 1H), 6.72&6.45 (2 × s, 1H),
    4.58 (brs, 1H), 4.28 (brs, 1H), 3.90 (m, 4H), 3.74-3.78 (m, 11H),
    3.449brS, 1H), 2.67 (t, 1H), 2.45 (brs, 1H)
    145 447.1 3.89 CD3OD: 7.35-7.50 (m, 2H), 7.01-7.25 (m, 5H), 6.94 (d, 1H),
    5.00 (d, 1H), 4.05 (d, 1H), 3.84 (m, 4H), 3.72 (m, 4H), 2.36 (s, 3H),
    1.90 (m, 1H), 0.45 (m, 3H), 0.30 (m, 1H)
    146 493.4 3.9 DMSO-d6: 8.47 (s, 1H), 7.34-7.55 (m, 4H), 6.62 (m, 1H),
    6.46 (m, 1H), 6.29 (s, 1H), 5.95 (s, 2H), 3.77 (m, 7H), 1.63 (m, 2H),
    1.53 (m, 4H), 0.83 (m, 6H)
    147 488 2.5 DMSO-d6 7.53 (s, 1H), 6.45-6.60 (m, 2H), 6.16-6.30 (m, 5H),
    6.03 (m, 2H), 3.75-4.10 (m, 4H), 3.14 (m, 1H), 2.10-2.65 (m, 6H),
    1.95 (s, 3H), 0.35-0.70 (m, 10 H)
    148 474 2.4 DMSO-d6 8.53 (s, 1H), 7.54-7.58 (m, 2H), 7.18-7.30 (m, 5H),
    6.98-7.04 (m, 2H), 4.90-5.10 (m, 2H), 4.05-4.40 (m, 3H),
    3.05-3.70 (m, 6H), 2.95 (s, 3H), 1.30-1.70 (m, 8H)
    149 429.4 3.8
    150 419.4 3.2 CD3OD: 8.65 (br s, 1H), 6.82-7.60 (br m, 8H), 4.81 (m, 1H),
    3.92 (t, 4H), 3.77 (t, 4H), 2.61 (br s, 1H), 2.34 (br s, 1H),
    1.17 (br s, 3H).
    151 531.5 4 DMSO-d6: 8.30 (s, 1H), 7.53 (m, 1H), 7.35 (m, 1H), 7.27 (m,
    2H), 6.63 (m, 1H), 6.21 (m, 1H), 6.00 (br s, 1H), 4.72 (m, 1H),
    4.18 (s, 4H), 3.25 (m, 2H), 2.07 (s, 1H), 1.85 (m, 1H), 1.67 (m,
    2H), 1.60 (m, 3H), 1.56 (m, 1H), 1.45 (m, 3H), 1.24 (m, 3H),
    0.92 (br s, 6H).
    152 462.5 3 DMSO-d6: 8.35 (s, 1H), 7.49 (m, 1H), 7.36 (s, 1H), 7.27 (m,
    2H), 6.98 (m, 1H), 6.55 (d, 1H, J = 7 Hz), 6.03 (s, 2H), 4.71 (m,
    1H), 3.84 (m, 2H), 3.67 (m, 2H), 2.77 (s, 6H), 1.58 (m, 2H),
    1.46 (m, 2H), 0.97 (br s, 6H).
    153 422.2 2.6
    154 529.5 4.5 DMSO-d6: 8.31 (s, 1H), 7.55 (m, 1H), 7.34 (m, 1H), 7.28 (m,
    1H), 7.10 (m, 1H), 6.78 (m, 1H), 6.22 (br d, 2H), 4.61 (br s, 1H),
    4.14 (br s, 4H), 3.64 (s, 3H), 3.25 (br d, 2H), 1.69 (m, 1H),
    1.4-1.8 (m, 6H), 1.3-1.35 (br m, 6H), 1.24 (br s, 8H).
    155 445.4 4
    156 445.1 3.9 DMSO-d6: 8.43 (s, 1H), 7.50 (m, 2H), 7.15-7.26 (m, 5H),
    7.06 (m, 2H), 5.88 (m, 2H), 5.14 (m, 4H), 4.08-4.40 (m, 5H),
    3.98 (m, 1H), 1.03 (m, 6H)
    157 477 3.9 DMSO-d6: 8.48 (s, 1H), 7.56 (m, 2H), 7.17-7.33 (m, 5H),
    6.94 (m, 2H), 4.11 (brS, 7H), 2.65 (m, 4H), 1.30-1.5 (brm, 8H)
    158 447.5 3.6
    159 461 3.78 DMSO-d6: 1.35 (brm, 4H), 1.51 (brm, 4H), 3.67 (brm, 4H),
    3.76 (brm, 4H), 4.03 (brm, 1H), 6.91 (brm, 2H),
    7.16 (brm, 3H), 7.31 (m, 2H), 7.48 (m, 1H), 7.57 (m, 1H), 8.49 (s, 1H)
    160 451.4 3.2 CD3OD: 8.36 (s, 1H), 7.53 (m 1H), 7.36 (m, 1H), 7.25 (m, 1H),
    7.19 (m, 1H), 7.07 (m, 1H), 6.78 (m, 1H), 6.24 (m, 1H),
    6.10 (m, 1H), 4.81 (m, 1H), 3.76 (m, 4H), 3.68 (m, 7H), 1.07 (br m,
    6H).
    161 489 3.9 DMSO-d6: 8.56 (s, 1H), 7.45 (m, 2H), DMSO-d6: 7.27 (d, 2H),
    7.10 (brm, 2H), 7.00 (d, 2H), 4.46 (brs, 2H),
    3.77 (m, 4H), 3.67 (m, 4H), 1.95 (brm, 1H), 0.48 (brm, 4H)
    162 516.3 4.4 DMSO-d6: 8.42 (s, 1H), 7.52 (m, 2H), 7.25 (m, 2H), 7.08 (m, 1H),
    6.74 (m, 2H), 6.50 (m, 1H), 4.26-4.90 (m, 6H), 4.19 (m, 1H),
    3.71 (s, 3H), 1.20-1.90 (m, 12H), 0.90 (m, 6H)
    163 447.1 3.5 DMSO-d6: 8.55 (s, 1H), 7.48 (m, 2H), 7.15 (m, 3H),
    7.04 (d, 1H), 6.95 (m, 1H), 6.84 (d, 1H), 4.45 (brs, 2H), 3.78 (m, 4H),
    3.67 (m, 4H), 2.26 (s, 3H), 2.15 (brm, 1H), 0.48 (m, 4H)
    164 479 3.6 CD3OD: 8.45 (s, 1H), 7.40 (m, 2H), 6.95-7.15 (m, 4H),
    6.81 (d, 2H), 4.53 (brs, 2H), 4.21 (m, 4H), 2.65 (m, 4H),
    1.85 (brm, 1H), 0.51 (brm, 4H).
    165 477.5 3.8 DMSO-d6: 8.41 (s, 1H), 7.55 (m, 1H), 7.26 (m, 3H), 7.18 (m,
    1H), 7.07 (m, 1H), 6.71 (s, 1H), 6.39 (br s, 1H), 4.76 (br s, 1H),
    3.62 (br s, 4H), 3.58 (br s, 4H), 1.12 (s, 9H), 0.97 (d, 6H, J = 5 Hz).
    166 532.2 2.5 DMSO-d6: 8.51 (s, 1H), 7.65 (m, 2H), 7.29 (m, 2H), 7.07 (m, 1H),
    6.74 (m, 2H), 6.47 (m, 1H), 4.78 (m, 2H), 4.09 (m, 1H), 3.87 (s, 3H),
    3.56 (brm, 5H), 3.12 (m, 2H), 2.98 (m, 2H), 1.53-2.25 (m, 8H),
    0.91 (m, 6H)
    167 448 2.3 DMSO-d6: 8.61 (s, 1H), 7.45-7.60 (m, 2H), 7.15-7.45 (m, 5H),
    6.94 (m, 2H), 4.74-7.80 (m, 4H), 3.85 (m, 1H), 3.50 (m, 2H),
    3.30 (m, 2H), 3.10 (m, 2H), 2.85 (s, 3H), 0.90 (brS, 6H)
    168 474.1 2.8
    169 477.5 3.5 DMSO-d6: 8.40 (s, 1H), 7.54 (m, 1H), 7.39 (m, 1H), 7.28 (m,
    2H), 7.13 (t, 1H, J = 8 Hz), 6.80 (d, 1H, J = 7 Hz), 6.35 (d, 1H, J = 7 Hz),
    6.25 (s, 1H), 4.61 (m, 1H), 3.73 (br s, 4H), 3.65 (s, 3H),
    3.60 (d, 4H, J = 4 Hz), 1.72 (br s, 2H), 1.43 (br s, 4H), 1.29 (br s,
    2H).
    170 475 3.98 NMR 1H (CDCl3): “show rotameres” 8.8 (s, 1H), 8.3 (d, 2H),
    7.2-7.4 (m, 5H), 6.7-7.0 (m, 2H), 4.4-4.8 (m, 2H), 3.7-4.0 (M,
    8H), 3.2 (m, 2H), 1.0-1.5 (m, 12H).
    171 477.5 3.5 DMSO-d6: 8.32 (s, 1H), 7.54 (m, 1H), 7.35 (m, 1H), 7.27 (m,
    2H), 6.64 (d, 1H, J = 8 Hz), 6.23 (m, 1H), 6.02 (s, 1H), 4.73 (m,
    1H), 4.19 (s, 4H), 3.69 (br s, 4H), 1.60 (br s, 2H), 1.47 (br s,
    4H), 0.92 (d, 6H, J = 6 Hz).
    172 431.4 3.3 DMSO-d6: 8.41 (s, 1H), 7.52 (m, 2H), 7.29 (m, 2H), 3.76 (m,
    4H), 3.67 (m, 5H), 2.81 (br s, 1H), 2.72 (br s, 1H), 1.48 (br s,
    1H), 1.24 (s, 6H), 1.13 (m, 2H), 0.86 (m, 1H).
    173 536.2 3.7 CD3OD: 8.38 (s, 1H), 7.75 (m, 1H), 7.10-7.65 (10H), 7.15 (m, 1H),
    3.85 (brs, 2H), 3.55 (m, 3H), 2.98 (m, 2H), 0.89 (brm, 6H)
    174 357 2.77 DMSO-d6: 1.60 (m, 2H), 1.83 (m, 2H), 2.10 (m, 2H),
    3.66 (m, 4H), 3.78 (m, 4H), 7.17 (m, 1H), 7.27 (t, 1H), 7.46 (m, 1H),
    7.53 (m, 1H), 8.23 (d, 1H), 8.53 (s, 1H)
    175 465.4 3.8 DMSO-d6: 8.42 (s, 1H), 7.50 (m, 2H), 7.42 (t, 1H, J = 7 Hz),
    7.34 (d, 1H, J = 7 Hz), 7.13 (t, 1H, J = 8 Hz), 6.80 (d, 1H, J = 7 Hz),
    6.30 (d, 1H, J = 7 Hz), 6.14 (s, 1H), 4.66 (br s, 1H),
    3.68 (br s, 4H), 3.66 (s, 3H), 1.59 (m, 2H), 1.46 (br s, 4H), 0.88 (d,
    6H, J = 6 Hz).
    176 501 2.6 DMSO-d6: 8.63 (s, 1H), 7.45 (m, 2H), 7.26 (d, 2H), 7.17 (m, 2H),
    6.99 (d, 2H), 4.77 (d, 2H), 4.48 (brs, 2H), 3.51 (m, 2H), 4.48 (m, 2H),
    3.51 (m, 2H), 3.31 (m, 2H), 3.15 (m, 2H), 2.84 (s, 3H), 2.00 (m, 1H),
    1.28 (s, 9H), 0.48 (m, 4H).
    177 475.5 3.72
    178 466.4 3.2 DMSO-d6: 8.55 (s, 1H), 8.08 (d, 1H, J = 8 Hz) 7.58 (m, 1H),
    7.51 (m, 1H), 7.28 (m, 5H), 4.76 (br s, 1H), 3.67 (br s, 4H),
    3.59 (d, 4H, J = 4 Hz), 0.98 (d, 6H, J = 4 Hz).
    179 433.4 3.7 DMSO-d6: 7.57 (m, 1H), 7.37 (m, 2H), 7.29 (m, 2H), 7.19 (m,
    1H), 7.14 (t, 2H, J = 8 Hz), 6.35 (br s, 1H), 4.78 (m, 1H),
    3.79 (br s, 2H), 3.62 (br s, 2H), 2.41 (s, 3H), 1.56 (m, 2H), 1.42 (m,
    4H), 0.85 (dd, 6H, J = 7 Hz, 16 Hz).
    180 459 2.4 DMSO-d6 8.49 (s, 1H), 7.57 (m, 2H), 7.32 (t, 2H), 7.21 (m, 3H),
    6.98 (m, 2H), 4.77 (m, 2H), 4.65 (m, 1H), 4.20 (m, 2H), 3.51 (m, 2H),
    3.33 (m, 2H), 3.11 (m, 2H), 2.85 (s, 3H), 2.05 (m, 2H),
    1.25-1.50 (4H)
    181 459.4 3.5
    182 465.4 3.1 DMSO-d6: 8.40 (s, 1H), 7.54 (m, 1H), 7.39 (m, 1H), 7.29 (m,
    2H), 6.71 (d, 1H, J = 7 Hz), 6.18 (m, 2H), 6.01 (s, 2H), 4.73 (m,
    1H), 3.66 (br s, 4H), 3.61 (br s, 4H), 0.93 (d, 6H, J = 6 Hz).
    183 449.4 3.1 DMSO-d6: 8.48 (s, 1H), 7.55 (m, 1H), 7.42 (t, 1H, J = 7 Hz),
    7.29 (m, 2H), 7.13 (t, 1H, J = 8 Hz), 6.76 (dd, 1H, J = 2 Hz,
    8 Hz), 6.40 (d, 1H, J = 8 Hz), 6.37 (s, 1H), 3.72 (t, 4H, J = 5 Hz),
    3.67 (s, 3H), 3.64 (t, 4H, J = 5 Hz), 2.85 (m, 1H), 0.67 (m, 2H),
    0.39 (m, 2H).
    184 515.5 4.2 DMSO-d6: 8.45 (s, 1H), 7.60 (m, 2H), 7.20 (m, 2H), 6.99 (d, 2H),
    6.81 (d, 2H), 4.30 (m, 4H), 3.73 (s, 3H), 3.40 (m, 2H), 2.06 (m, 1H),
    1.25-1.90 (m, 12H), 0.46 (brm, 4H)
    185 451.5 3.2 DMSO-d6: 8.35 (s, 1H), 7.55 (m, 1H), 7.39 (m, 1H), 7.29 (m,
    2H), 6.75 (d, 2H, J = 8 Hz), 6.63 (d, 2H, J = 8 Hz), 4.76 (m, 1H),
    3.70 (s, 3H), 3.64 (br s, 4H), 3.60 (br s, 4H), 0.92 (d, 6H, J = 6 Hz).
    186 479.2 3.4 DMSO-d6: 7.04-7.60 (m, 6H), 6.72 (m, 2H), 6.31 (d, 2H),
    4.52 (d, 1H), 4.22 (d, 1H), 3.62-3.82 (m, 11H), 2.34 (s, 3H),
    0.95 (d, 3H), 0.51 (d, 3H)
    187 405 3.21 CDCl3: 8.43 (s, 1H), 7.61 (t, 1H), 7.28 (m, 1H), 7.12-7.21 (m, 4H),
    7.05 (d, 1H), 6.96 (m, 1H), 4.79 (s, 2H), 4.55 (s, 2H), 3.85 (t, 4H),
    3.72 (t, 4H),
    188 499.1 3.6 DMSO-d6: 8.36 (s, 1H), 7.05-7.60 (m, 10H), 6.72 (2H),
    5.17 (m, 1H), 4.36 (m, 2H), 3.89 (m, 1H), 3.69 (s, 3H), 1.45 (m, 3H),
    0.79 (m, 6H)
    189 501.5 4.2
    190 463.4 3.4 DMSO-d6: 8.37 (s, 1H), 7.54 (m, 1H), 7.41 (t, 1H, J = 7 Hz),
    7.29 (m, 2H), 7.18, (t, 1H, J = 6 Hz), 6.82 (d, 1H, J = 8 Hz),
    6.36 (d, 1H, J = 8 Hz), 6.28 (s, 1H), 4.66 (m, 1H), 3.67 (m, 7H),
    3.61 (m, 4H), 1.98 (m, 2H), 1.69 (m, 2H), 1.52 (m, 1H), 1.42 (m,
    1H).
    191 465.1 3.4 DMSO-d6: 8.46 (brs, 1H), 7.55 (brm, 2H), 7.30 (brm, 3H),
    7.12 (brm, 3H), 4.35 (m, 1H), 3.65-3.80 (m, 12H),
    1.50-1.80 (brm, 4H)
    192 487.5 3.6 CD3OD: 7.36 (m, 2H), 7.06 (m, 2H), 6.82 (s, 1H), 6.73 (d, 1H),
    6.53 (d, 1H), 4.95 (d, 1H), 4.52 (t, 2H), 3.94 (d, 1H), 3.84 (m, 4H),
    3.12 (m, 2H), 2.35 (s, 3H), 1.87 (m, 1H), 1.70 (m, 2H), 1.61 (m, 4H),
    0.51 (3H), 0.20 (m, 1H)
    193 476 2.2 DMSO-d6 8.62 (s, 1H), 7.47 (m, 2H), 7.22 (m, 2H), 6.98 (d, 2H),
    6.80 (d, 2H), 4.76 (d, 2H), 4.45 (brm, 2H), 3.74 (d, 3H), 3.51 (m, 2H),
    3.30 (m, 2H), 2.84 (s, 3H), 1.95 (m, 1H), 0.47 (brm, 4H).
    194 451.1 3.5
    195 501 3.6 DMSO-d6: 8.65 (brs, 1H), 7.61 (d, 1H), 7.50 (m, 4H), 7.38 (d, 1H),
    7.05-7.15 (m, 2H), 4.60 (brs, 2H), 3.78 (m, 4H), 3.67 (m, 4H),
    2.20 (brm, 1H), 0.53 (m, 4H)
    196 385 3.11 DMSO-d6: 1.06-1.23 (m, 5H), 1.51 (m, 1H), 1.61-1.69 (m, 4H),
    1.70 (m, 2H), 3.54 (m, 1H), 3.66 (m, 4H), 3.77 (m, 4H), 7.17 (m,
    1H), 7.25 (t, 1H), 7.46 (m, 1H), 7.53 (m, 1H), 7.85 (d, 1H),
    8.50 (s, 1H)
    197 493.5 2.9 DMSO-d6: 8.69 (s, 1H), 7.56 (m, 1H), 7.39 (m, 1H), 7.29 (m,
    2H), 7.16 (m, 1H), 6.83 (d, 1H, J = 7 Hz), 6.35 (d, 1H, J = 7 Hz),
    6.27 (s, 1H), 4.55 (br s, 1H), 3.82 (m, 2H), 3.66 (s, 3H), 3.45 (br
    s, 8H), 3.33 (m, 2H), 1.59 (m, 2H), 1.28 (m, 2H).
    198 518.5 3.2 DMSO-d6: 8.45 (d, 2H), 7.34-7.55 (m, 4H), 6.67 (m, 2H),
    6.63 (m, 2H), 3.77-3.98 (m, 11H), 3.17 (t, 4H), 1.93 (t, 4H),
    2.20 (brm, 1H), 1.63 (brm, 2H), 1.53 (brm, 4H), 0.82 (brm, 6H)
    199 421.2 3.2 DMSO-d6: 8.33 (s, 1H), 7.03-7.53 (m, 9H), 3.77 (m, 4H),
    3.67 (m, 4H), 3.49 (m, 1H), 2.73 (s, 3H), 2.66 (m, 2H)
    200 489.2 3.3 DMSO-d6: 7.10-7.60 (m, 3H), 6.51-6.66 (m, 3H), 4.83 (d, 1H),
    4.48 (t, 2H), 3.89 (d, 1H), 3.64-3.73 (m, 8H), 2.29 (s, 3H),
    1.84 (m, 1H), 0.20-0.50 (m, 4H)
    201 437.4 3.6 CD3OD: 8.33 (s, 1H), 7.54 (q, 1H, J = 6 Hz, 13 Hz), 7.35 (br s,
    1H), 7.09-7.30 (m, 5H), 6.60 (br s, 2H), 4.86 (m, 1H), 4.09 (br
    s, 4H), 2.56 (br s, 4H), 1.06 (d, 6H, J = 6 Hz).
    202 446.4 3.1 DMSO-d6: 8.51 (s, 1H), 7.69 (d, 1H, J = 7 Hz), 7.63 (m, 1H),
    7.40 (m, 1H), 7.32 (t, 3H, J = 9 Hz), 7.05 (m, 1H), 6.8 (br s, 1H),
    4.75 (br s, 1H), 3.67 (d, 4H, J = 5 Hz), 3.61 (d, 4H, J = 5 Hz),
    0.96 (d, 6H, J = 6 Hz).
    203 507.5 3.6 DMSO-d6: 8.41 (s, 1H), 7.51 (m, 1H), 7.43 (m, 2H), 7.17 (m,
    1H), 6.83 (d, 1H, J = 7 Hz), 6.62 (d, 1H, J = 2 Hz), 6.33 (d, 1H, J = 7 Hz),
    6.19 (s, 1H), 4.54 (br s, 1H), 3.82 (m, 2H), 3.75 (m,
    4H), 3.68 (s, 3H), 3.26 (m, 2H), 1.65 (m, 1H), 1.54-1.59 (m,
    4H), 1.45 (m, 4H), 1.22 (m, 3H).
    204 526.1 2.37 DMSO-d6: 8.87 (d, 2H), 8.51 (s, 1H), 8.34 (m, 2H), 7.89 (m, 2H),
    7.58 (t, 1H), 7.56 (m, 2H), 7.48 (m, 1H), 7.05 (m, 1H), 7.85 (m, 1H),
    4.73 (brs, 2H), 4.22 (m, 4H), 2.65 (brm, 4H), 2.05 (m, 1H),
    0.63 (m, 2H), 0.56 (m, 2H)
    205 434 2 DMSO-d6: 8.75 (brs, 1H), 8.62 (d, 2H), 7.52 (m, 2H), 7.41 (m, 2H),
    7.26 (m, 2H), 4.64 (brs, 2H), 3.78 (m, 4H), 3.67 (m, 4H),
    2.45 (brm, 1H), 0.57 (m, 4H)
    206 421 3.65 CDCl3: 8.41 (s, 1H), 7.59 (t, 1H), 7.29 (m, 1H), 7.12-7.21 (m, 4H),
    7.05 (d, 1H), 6.96 (m, 1H), 4.79 (s, 2H), 4.55 (s, 2H), 4.17 (t, 4H),
    2.63 (t, 4H),
    207 475.4 3.72
    • VI. Assays for Detecting and Measuring Inhibition Properties of Compounds
  • A. Optical Methods for Assaying CaV Inhibition Properties of Compounds:
  • Compounds of the embodiments are useful as antagonists of voltage-gated calcium ion channels. Antagonist properties of test compounds were assessed as follows. Cells expressing the CaV of interest were placed into microtiter plates. After an incubation period, the cells were stained with fluorescent dyes sensitive to the transmembrane potential. The test compounds were added to the microtiter plate. The cells were stimulated with electrical means to evoke a CaV dependent membrane potential change from unblocked channels, which was detected and measured with trans-membrane potential-sensitive dyes. Antagonists were detected as a decreased membrane potential response to the stimulus. The optical membrane potential assay utilized voltage-sensitive FRET sensors described by Gonzalez and Tsien (See, Gonzalez, J. E. and R. Y. Tsien (1995) “Voltage sensing by fluorescence resonance energy transfer in single cells” Biophys J 69(4): 1272-80, and Gonzalez, J. E. and R. Y. Tsien (1997) “Improved indicators of cell membrane potential that use fluorescence resonance energy transfer” Chem Biol 4(4): 269-77) in combination with instrumentation for measuring fluorescence changes such as the Voltage/Ion Probe Reader (VIPR®) (See, Gonzalez, J. E., K. Oades, et al. (1999) “Cell-based assays and instrumentation for screening ion-channel targets” Drug Discov Today 4(9): 431-439).
  • VIPR® Optical Membrane Potential Assay Method with Electrical Stimulation
  • The following is an example of how CaV2.2 inhibition activity is measured using the optical membrane potential method. Other subtypes are performed in an analogous mode in a cell line expressing the CaV of interest.
  • HEK293 cells stably expressing CaV2.2 are plated into 96-well microtiter plates. After an appropriate incubation period, the cells are stained with the voltage sensitive dyes CC2-DMPE/DiSBAC2(3) as follows.
    • Reagents:
  • 100 mg/mL Pluronic F-127 (Sigma #P2443), in dry DMSO
    • 10 mM DiSBAC6(3) (Aurora #00-100-010) in dry DMSO 10 mM CC2-DMPE (Aurora #00-100-008) in dry DMSO 200 mM Acid Yellow 17 (Aurora #VABSC) in H20 370 mM Barium Chloride (Sigma Cat# B6394) in H20 Bath X 160 mM NaCl (Sigma Cat# S-9888) 4.5 mM KCl (Sigma Cat# P-5405) 1 mM MgCl2 (Fluke Cat#63064) 10 mM HEPES (Sigma Cat# H-4034)
  • pH 7.4 using NaOH
    • Loading Protocol:
  • 2×CC2-DMPE=20 μM CC2-DMPE:
  • 10 mM CC2-DMPE is vortexed with an equivalent volume of 10% Pluronic, followed by vortexing in required amount of HBSS containing 10 mM HEPES. Each cell plate will require 5 mL of 2×CC2-DMPE. 50 μL of 2×CC2-DMPE is added to wells containing washed cells, resulting in a 10 μM final staining concentration. The cells are stained for 30 minutes in the dark at RT.
  • 2×CC2DMPE & DISBAC6(3)=8 μM CC2DMPE & 2.5 μM DISBAC6(3):
  • Vortex together both dyes with an equivalent volume of 10% Pluronic (in DMSO). Vortex in required amount of Bath X with beta-cyclodextrin. Each 96 well cell plate will require 5 ml of 2×CC2DMPE. Wash plate with ELx405 with Bath X, leaving a residual volume of 50 μL/well. Add 50 AL of 2XCC2DMPE & DISBAC6(3) to each well. Stain for 30 minutes in the dark at RT.
  • 1.5×AY17=750 μM AY17 with 15 mM BaCl2:
  • Add Acid Yellow 17 to vessel containing Bath X. Mix well. Allow solution to sit for 10 minutes. Slowly mix in 370 mM BaCl2. This solution can be used to solvate compound plates. Note that compound plates are made at 1.5× drug concentration and not the usual 2×. Wash CC2 stained plate, again, leaving residual volume of 50 μL. Add 100 uL/well of the AY17 solution. Stain for 15 minutes in the dark at RT. Run plate on the optical reader.
  • The electrical stimulation instrument and methods of use are described in ION Channel Assay Methods PCT/US01/21652, herein incorporated by reference. The instrument comprises a microtiter plate handler, an optical system for exciting the coumarin dye while simultaneously recording the coumarin and oxonol emissions, a waveform generator, a current- or voltage-controlled amplifier, and a device for inserting electrodes in well. Under integrated computer control, this instrument passes user-programmed electrical stimulus protocols to cells within the wells of the microtiter plate.
    • Assay Protocol
  • Insert or use electrodes into each well to be assayed.
  • Use the current-controlled amplifier to deliver stimulation wave pulses for 3-5 s. Two seconds of pre-stimulus recording are performed to obtain the un-stimulated intensities. Five seconds of post-stimulation recording are performed to examine the relaxation to the resting state.
    • Data Analysis
  • Data are analyzed and reported as normalized ratios of background-subtracted emission intensities measured in the 460 nm and 580 nm channels. Background intensities are then subtracted from each assay channel. Background intensities are obtained by measuring the emission intensities during the same time periods from identically treated assay wells in which there are no cells. The response as a function of time is then reported as the ratios obtained using the following formula:
  • R ( t ) = ( intensity 460 nm - background 460 nm ) ( intensity 580 nm - background 580 nm )
  • The data is further reduced by calculating the initial (Ri) and final (Rf) ratios. These are the average ratio values during part or all of the pre-stimulation period, and during sample points during the stimulation period. The response to the stimulus R=Rf/Ri is then calculated.
  • Control responses are obtained by performing assays in the presence of a compound with the desired properties (positive control), such as mibefradil, and in the absence of pharmacological agents (negative control). Responses to the negative (N) and positive (P) controls are calculated as above. The compound antagonist activity A is defined as:
  • A = R - P N - P * 100.
  • where R is the ratio response of the test compound.
    • Electrophoresiology Assays for CaV Activity and Inhibition of Test Compounds
  • Patch clamp electrophysiology was used to assess the efficacy of calcium channel blockers expressed in HEK293 cells. HEK293 cells expressing CaV2.2 have been visually identified and probed with fine tip glass electrodes connected to an amplifier (Axon Instruments). The “voltage clamp” mode has been used to assess the compound's IC50 holding the cells at −100 mV. The results of these experiments have contributed to the definition of the efficacy profile of the compounds.
    • Voltage-Clamp Assay in HEK293 Cells Expressing CaV2.2
  • CaV2.2 calcium currents were recorded from HEK293 cells using the whole-cell variation of the patch clamp technique. Recordings were made at room temperature (˜22° C.) with thick walled borosilicate glass electrodes (WPI; resistance 3-4 MΩ using an Axopatch 200B amplifier (Axon Instruments). After establishing the whole-cell configuration, approximately 15 minutes were allowed for the pipette solution to equilibrate within the cell before beginning recording. Currents were lowpass filtered between 2-5 kHz and digitally sampled at 10 kHz. Series resistance was compensated 60-70% and was monitored continuously throughout the experiment. The liquid junction potential (−7 mV) between the intracellular pipette solution and the external recording solution was not accounted for in the data analysis. Test solutions were applied to the cells with a gravity driven fast perfusion system (SF-77; Warner Instruments).
  • Dose-response relationships were determined in voltage clamp mode by repeatedly depolarizing the cell from the experiment specific holding potential to a test potential of +20 mV for 50 ms at frequencies of 0.1, 1, 5, 10, 15, and 20 Hz. Blocking effects were allowed to plateau before proceeding to the next test concentration.
    • Solutions
  • Intracellular solution (in mM): Cs—F (130), NaCl (10), MgCl2 (1), EGTA (1.5), CaCl2 (0.1), HEPES (10), glucose (2), pH=7.42, 290 mOsm.
  • Extracellular solution (in mM): NaCl (138), BaCl2 (10), KCl (5.33), KH2PO4 (0.44), MgCl2 (0.5), MgSO4 (0.41), NaHCO3 (4), Na2HPO4 (0.3), glucose (5.6), HEPES (10).
  • (A) Following these procedures, representative compounds of the embodiments were found to possess desired N-type calcium channel modulation activity and selectivity.
  • B. Assays for Detecting and Measuring NaV Inhibition Properties of Compounds
    • Optical Methods for Assaying NaV Inhibition Properties of Compounds:
  • Compounds of the invention are useful as antagonists of voltage-gated sodium ion channels. Antagonist properties of test compounds were assessed as follows. Cells expressing the NaV of interest were placed into microtiter plates. After an incubation period, the cells were stained with fluorescent dyes sensitive to the transmembrane potential. The test compounds were added to the microtiter plate. The cells were stimulated with either chemical or electrical means to evoke a NaV dependent membrane potential change from unblocked channels, which was detected and measured with trans-membrane potential-sensitive dyes. Antagonists were detected as a decreased membrane potential response to the stimulus. The optical membrane potential assay utilized voltage-sensitive FRET sensors described by Gonzalez and Tsien (See, Gonzalez, J. E. and R. Y. Tsien (1995) “Voltage sensing by fluorescence resonance energy transfer in single cells” Biophys J 69(4): 1272-80, and Gonzalez, J. E. and R. Y. Tsien (1997) “Improved indicators of cell membrane potential that use fluorescence resonance energy transfer” Chem Biol 4(4): 269-77) in combination with instrumentation for measuring fluorescence changes such as the Voltage/Ion Probe Reader (VIPR®) (See, Gonzalez, J. E., K. Oades, et al. (1999) “Cell-based assays and instrumentation for screening ion-channel targets” Drug Discov Today 4(9): 431-439).
  • VIPR® Optical Membrane Potential Assay Method with Chemical Stimulation
    • Cell Handling and Dye Loading
  • 24 hours before the assay on VIPR, CHO cells endogenously expressing a NaV 1.2 type voltage-gated NaV are seeded in 96-well poly-lysine coated plates at 60,000 cells per well. Other subtypes are performed in an analogous mode in a cell line expressing the NaV of interest.
    • 1) On the day of the assay, medium is aspirated and cells are washed twice with 225 μL of Bath Solution #2 (BS#2).
    • 2) A 15 μM CC2-DMPE solution is prepared by mixing 5 mM coumarin stock solution with 10% Pluronic 127 1:1 and then dissolving the mix in the appropriate volume of BS#2.
    • 3) After bath solution is removed from the 96-well plates, the cells are loaded with 80 μL of the CC2-DMPE solution. Plates are incubated in the dark for 30 minutes at room temperature.
    • 4) While the cells are being stained with coumarin, a 15 μL oxonol solution in BS#2 is prepared. In addition to DiSBAC2(3), this solution should contain 0.75 mM ABSC1 and 30 μL veratridine (prepared from 10 mM EtOH stock, Sigma #V-5754).
    • 5) After 30 minutes, CC2-DMPE is removed and the cells are washed twice with 225 μL of BS#2. As before, the residual volume should be 40 μL.
    • 6) Upon removing the bath, the cells are loaded with 80 μL of the DiSBAC2(3) solution, after which test compound, dissolved in DMSO, is added to achieve the desired test concentration to each well from the drug addition plate and mixed thoroughly. The volume in the well should be roughly 121 μL. The cells are then incubated for 20-30 minutes.
    • 7) Once the incubation is complete, the cells are ready to be assayed on VIPR® with a sodium addback protocol. 120 μL of Bath solution #1 is added to stimulate the NaV dependent depolarization. 200 μL tetracaine was used as an antagonist positive control for block of the NaV channel.
    Analysis of VIPR Data:
  • Data are analyzed and reported as normalized ratios of background-subtracted emission intensities measured in the 460 nm and 580 nm channels. Background intensities are then subtracted from each assay channel. Background intensities are obtained by measuring the emission intensities during the same time periods from identically treated assay wells in which there are no cells. The response as a function of time is then reported as the ratios obtained using the following formula:
  • R ( t ) = ( intensity 460 nm - background 460 nm ) ( intensity 580 nm - background 580 nm )
  • The data is further reduced by calculating the initial (Ri) and final (Rf) ratios. These are the average ratio values during part or all of the pre-stimulation period, and during sample points during the stimulation period. The response to the stimulus Rr=Rf/Ri is then calculated. For the Na+ addback analysis time windows, baseline is 2-7 sec and final response is sampled at 15-24 sec.
  • Control responses are obtained by performing assays in the presence of a compound with the desired properties (positive control), such as tetracaine, and in the absence of pharmacological agents (negative control). Responses to the negative (N) and positive (P) controls are calculated as above. The compound antagonist activity A is defined as:
  • A = R - P N - P * 100.
  • where R is the ratio response of the test compound
  • Solutions [mM]:
    • Bath Solution #1: NaCl 160, KCl 4.5, CaCl2 2, MgCl2 1, HEPES 10, pH 7.4 with NaOH
    • Bath Solution #2 TMA-Cl 160, CaCl2 0.1, MgCl2 1, HEPES 10, pH 7.4 with KOH (final K concentration ˜5 mM)
    • CC2-DMPE: prepared as a 5 mM stock solution in DMSO and stored at −20° C.
    • DiSBAC2(3): prepared as a 12 mM stock in DMSO and stored at −20° C.
    • ABSC1: prepared as a 200 mM stock in distilled H2O and stored at room temperature
    Cell Culture
  • CHO cells are grown in DMEM (Dulbecco's Modified Eagle Medium; GibcoBRL #10569-010) supplemented with 10% FBS (Fetal Bovine Serum, qualified; GibcoBRL #16140-071) and 1% Pen-Strep (Penicillin-Streptomycin; GibcoBRL #15140-122). Cells are grown in vented cap flasks, in 90% humidity and 10% CO2, to 100% confluence. They are usually split by trypsinization 1:10 or 1:20, depending on scheduling needs, and grown for 2-3 days before the next split.
  • VIPR® Optical Membrane Potential Assay Method with Electrical Stimulation
  • The following is an example of how NaV1.3 inhibition activity is measured using the optical membrane potential method#2. Other subtypes are performed in an analogous mode in a cell line expressing the NaV of interest.
  • HEK293 cells stably expressing NaV 1.3 are plated into 96-well microtiter plates. After an appropriate incubation period, the cells are stained with the voltage sensitive dyes CC2-DMPE/DiSBAC2(3) as follows.
    • Reagents:
      • 100 mg/mL Pluronic F-127 (Sigma #P2443), in dry DMSO
      • 10 mM DiSBAC2(3) (Aurora #00-100-010) in dry DMSO
      • 10 mM CC2-DMPE (Aurora #00-100-008) in dry DMSO
      • 200 mM ABSC1 in H20
      • Hank's Balanced Salt Solution (Hyclone #SH30268.02) supplemented with 10 mM HEPES (Gibco #15630-080)
    Loading Protocol:
  • 2×CC2-DMPE=20 μM CC2-DMPE:
  • 10 mM CC2-DMPE is vortexed with an equivalent volume of 10% pluronic, followed by vortexing in required amount of HBSS containing 10 mM HEPES. Each cell plate will require 5 mL of 2×CC2-DMPE. 50 μL of 2×CC2-DMPE is added to wells containing washed cells, resulting in a 10 μM final staining concentration. The cells are stained for 30 minutes in the dark at RT.
  • 2×DISBAC2(3) with ABSC1=6 μM DISBAC2(3) and 1 mM ABSC1:
  • The required amount of 10 mM DISBAC2(3) is added to a 50 ml conical tube and mixed with 1 μL 10% pluronic for each mL of solution to be made and vortexed together. Then HBSS/HEPES is added to make up 2× solution. Finally, the ABSC1 is added.
  • The 2×DiSBAC2(3) solution can be used to solvate compound plates. Note that compound plates are made at 2× drug concentration. Wash stained plate again, leaving residual volume of 50 μL. Add 50 μL/well of the 2×DiSBAC2(3) w/ABSC1. Stain for 30 minutes in the dark at RT.
  • The electrical stimulation instrument and methods of use are described in ION Channel Assay Methods PCT/US01/21652, herein incorporated by reference. The instrument comprises a microtiter plate handler, an optical system for exciting the coumarin dye while simultaneously recording the coumarin and oxonol emissions, a waveform generator, a current- or voltage-controlled amplifier, and a device for inserting electrodes in well. Under integrated computer control, this instrument passes user-programmed electrical stimulus protocols to cells within the wells of the microtiter plate.
    • Reagents
  • Assay buffer #1
    140 mM NaCl, 4.5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, 10 mM glucose, pH 7.40, 330 mOsm
    Pluronic stock (1000×): 100 mg/mL pluronic 127 in dry DMSO
    Oxonol stock (3333×): 10 mM DiSBAC2(3) in dry DMSO
    Coumarin stock (1000×): 10 mM CC2-DMPE in dry DMSO
    ABSC1 stock (400×): 200 mM ABSC1 in water
    • Assay Protocol
      • 1. Insert or use electrodes into each well to be assayed.
      • 2. Use the current-controlled amplifier to deliver stimulation wave pulses for 3 s. Two seconds of pre-stimulus recording are performed to obtain the un-stimulated intensities. Five seconds of post-stimulation recording are performed to examine the relaxation to the resting state.
    Data Analysis
  • Data are analyzed and reported as normalized ratios of background-subtracted emission intensities measured in the 460 nm and 580 nm channels. Background intensities are then subtracted from each assay channel. Background intensities are obtained by measuring the emission intensities during the same time periods from identically treated assay wells in which there are no cells. The response as a function of time is then reported as the ratios obtained using the following formula:
  • R ( t ) = ( intensity 460 nm - background 460 nm ) ( intensity 580 nm - background 580 nm )
  • The data is further reduced by calculating the initial (Ri) and final (Rf) ratios. These are the average ratio values during part or all of the pre-stimulation period, and during sample points during the stimulation period. The response to the stimulus Rr=Rf/Ri is then calculated.
  • Control responses are obtained by performing assays in the presence of a compound with the desired properties (positive control), such as tetracaine, and in the absence of pharmacological agents (negative control). Responses to the negative (N) and positive (P) controls are calculated as above. The compound antagonist activity A is defined as:
  • A = R - P N - P * 100.
  • where R is the ratio response of the test compound.
    • Electrophysiology Assays for NaV Activity and Inhibition of Test Compounds
  • Patch clamp electrophysiology was used to assess the efficacy and selectivity of sodium channel blockers in dorsal root ganglion neurons. Rat neurons were isolated from the dorsal root ganglions and maintained in culture for 2 to 10 days in the presence of NGF (50 ng/ml) (culture media consisted of NeurobasalA supplemented with B27, glutamine and antibiotics). Small diameter neurons (nociceptors, 8-12 μm in diameter) have been visually identified and probed with fine tip glass electrodes connected to an amplifier (Axon Instruments). The “voltage clamp” mode has been used to assess the compound's IC50 holding the cells at −60 mV. In addition, the “current clamp” mode has been employed to test the efficacy of the compounds in blocking action potential generation in response to current injections. The results of these experiments have contributed to the definition of the efficacy profile of the compounds.
    • Voltage-Clamp Assay in DRG Neurons
  • TTX-resistant sodium currents were recorded from DRG somata using the whole-cell variation of the patch clamp technique. Recordings were made at room temperature (˜22° C.) with thick walled borosilicate glass electrodes (WPI; resistance 3-4 MΩ) using an Axopatch 200B amplifier (Axon Instruments). After establishing the whole-cell configuration, approximately 15 minutes were allowed for the pipette solution to equilibrate within the cell before beginning recording. Currents were lowpass filtered between 2-5 kHz and digitally sampled at 10 kHz. Series resistance was compensated 60-70% and was monitored continuously throughout the experiment. The liquid junction potential (−7 mV) between the intracellular pipette solution and the external recording solution was not accounted for in the data analysis. Test solutions were applied to the cells with a gravity driven fast perfusion system (SF-77; Warner Instruments).
  • Dose-response relationships were determined in voltage clamp mode by repeatedly depolarizing the cell from the experiment specific holding potential to a test potential of +10 mV once every 60 seconds. Blocking effects were allowed to plateau before proceeding to the next test concentration.
    • Solutions
  • Intracellular solution (in mM): Cs—F (130), NaCl (10), MgCl2 (1), EGTA (1.5), CaCl2 (0.1), HEPES (10), glucose (2), pH=7.42, 290 mOsm.
  • Extracellular solution (in mM): NaCl (138), CaCl2 (1.26), KCl (5.33), KH2PO4 (0.44), MgCl2 (0.5), MgSO4 (0.41), NaHCO3(4), Na2HPO4 (0.3), glucose (5.6), HEPES (10), CdCl2 (0.4 NiCl2 (0.1), TTX (0.25×10−3).
    • Current-Clamp Assay for NaV Channel Inhibition Activity of Compounds
  • Cells were current-clamped in whole-cell configuration with a Multiclamp 700A amplifier (Axon Inst). Borosilicate pipettes (4-5 MOhm) were filled with (in mM):150 K-gluconate, 10 NaCl, 0.1 EGTA, 10 HEPES, 2 MgCl2, (buffered to pH 7.34 with KOH). Cells were bathed in (in mM): 140 NaCl, 3 KCl, 1 MgCl, 1 CaCl, and 10 HEPES). Pipette potential was zeroed before seal formation; liquid junction potentials were not corrected during acquisition. Recordings were made at room temperature.
  • Examples of activities of the ion channel modulators of formulae (I and Ia) on modulating CaV 2.2, NaV 1.3, and NaV 1.8 receptors are shown below in Table 9. The compound activity for the CaV 2.2, NaV 1.3, and NaV 1.8 receptors is illustrated with “+++” if activity was measured to be less than 2.0 μM, “++” if activity was measured to be 2.0 μM to 10.0 μM, “+” if activity was measured to be greater than 10.0 μM, and “−” if no data was available.
  • TABLE 9
    Activities of the ion channel modulators of formulae (I, Ia)
    Compound No. CaV 2.2 NaV 1.3 NaV 1.8
    1 +++ ++ ++
    2 ++ + +
    3 + ++ +
    4 +++ ++ ++
    5 ++ + +
    6 − − −
    7 ++ ++ +
    8 ++ ++ +
    9 ++ ++ +
    10 ++ ++ +
    11 + + +
    12 +++ + +
    13 ++ + +
    14 ++ + +
    15 + + +
    16 + + +
    17 + + +
    18 + + +
    19 + + +
    20 +++ ++ ++
    21 + + +
    22 +++ ++ +
    23 + + +
    24 +++ ++ ++
    25 + + +
    26 ++ ++ +
    27 ++ ++ +
    28 + + +
    29 +++ ++ ++
    30 ++ ++ +
    31 ++ ++ +
    32 ++ ++ +
    33 + + +
    34 ++ ++ +
    35 + + +
    36 ++ ++ +
    37 + + +
    38 − − −
    39 + + +
    40 + ++ +
    41 + ++ +
    42 ++ ++ +
    43 ++ ++ +
    44 + ++ ++
    45 + + +
    46 + + +
    47 ++ ++ +
    48 ++ ++ +
    49 + ++ +
    50 ++ + +
    51 ++ ++ +
    52 ++ ++ +
    53 ++ ++ +
    54 ++ ++ +
    55 ++ ++ ++
    56 ++ + +
    57 + + +
    58 + + +
    59 +++ ++ ++
    60 ++ + +
    61 − − −
    62 ++ ++ +
    63 + + +
    64 ++ ++ +
    65 ++ + +
    66 ++ + +
    67 + + +
    68 ++ + +
    69 ++ + +
    70 +++ ++ +
    71 + + +
    72 + + +
    73 + + +
    74 ++ ++ +
    75 + + +
    76 + + +
    77 ++ ++ +
    78 +++ ++ ++
    79 + + +
    80 ++ ++ +
    81 ++ ++ +
    82 ++ + +
    83 +++ ++ ++
    84 + + +
    85 + ++ ++
    86 ++ + +
    87 + + +
    88 ++ + +
    89 + + +
    90 ++ ++ ++
    91 + + +
    92 +++ + +
    93 ++ ++ +
    94 +++ +++ ++
    95 ++ + +
    96 +++ ++ +
    97 + + +
    98 +++ ++ ++
    99 + + +
    100 ++ ++ +
    101 ++ ++ +
    102 + + +
    103 +++ +++ +
    104 + ++ +
    105 ++ ++ +
    106 + + +
    107 + + +
    108 +++ ++ +
    109 ++ ++ +
    110 ++ + +
    111 + + +
    112 + ++ +
    113 + ++ +
    114 +++ + +
    115 ++ + +
    116 ++ ++ +
    117 +++ ++ ++
    118 +++ ++ +
    119 ++ + +
    120 +++ ++ +
    121 ++ ++ +
    122 ++ + +
    123 ++ + +
    124 ++ ++ +
    125 ++ + +
    126 ++ + +
    127 ++ ++ +
    128 ++ ++ +
    129 + + +
    130 ++ ++ +
    131 +++ ++ ++
    132 + + +
    133 ++ ++ +
    134 +++ ++ +
    135 ++ + +
    136 ++ ++ +
    137 +++ + +
    138 + + +
    139 ++ ++ ++
    140 ++ ++ +
    141 ++ + +
    142 +++ +++ +++
    143 ++ ++ ++
    144 + + +
    145 ++ ++ +
    146 ++ ++ ++
    147 ++ + +
    148 ++ + +
    149 + + +
    150 + + +
    151 ++ ++ +
    152 ++ ++ +
    153 + + +
    154 ++ + +
    155 ++ + +
    156 +++ ++ ++
    157 ++ ++ +
    158 + + +
    159 ++ ++ ++
    160 + + +
    161 ++ ++ ++
    162 +++ +++ +
    163 ++ + +
    164 ++ ++ ++
    165 + ++ +
    166 − − −
    167 + + +
    168 + + +
    169 + ++ +
    170 + + +
    171 ++ ++ +
    172 + + +
    173 +++ ++ +
    174 + + +
    175 ++ ++ +
    176 ++ + +
    177 + + +
    178 + + +
    179 + + +
    180 ++ ++ +
    181 + + +
    182 ++ + +
    183 + + +
    184 ++ + +
    185 ++ + +
    186 ++ ++ +
    187 + + +
    188 +++ +++ ++
    189 ++ + +
    190 + ++ +
    191 + + +
    192 + + +
    193 + + +
    194 +++ ++ ++
    195 ++ + +
    196 + + +
    197 + + +
    198 ++ + +
    199 + + +
    200 ++ ++ +
    201 ++ ++ +
    202 + + +
    203 + + +
    204 ++ ++ +
    205 + + +
    206 + + +
    207 + + +
    208 + + −
    209 + + −
    210 + + −
    211 + + −
    212 + − −
    213 + − −
    214 + − −
    215 + − −
    216 + + −
    217 + + −
    218 + + −
    219 ++ + −
    220 ++ + −
    221 + − −
    222 + + −
    223 + + −
    224 + + −
    225 ++ + −
    226 + + −
    227 + + −
    228 + + −
    229 + + −
    230 + + −
    231 + + −
    232 ++ + −
    233 + + −
    234 + − −
    235 + + −
    236 + + −
    237 ++ + −
    238 + + −
    239 ++ + −
    240 + + −
    241 + + −
    242 + + −
    243 + + −
    244 + + −
    245 + + −
    246 ++ + −
    247 + + −
    248 + + −
    249 + − −
    250 + − −
    251 ++ + −
    252 + + −
    253 + + −
    254 + − −
    255 + + −
    256 + + −
    257 + + −
    258 + + −
    259 + + −
    260 + + −
    261 + + −
    262 + + −
    263 ++ + −
    264 + + −
    265 + + −
    266 + + −
    267 + + −
    268 + + −
    269 + + −
    270 + + −
    271 + + −
    272 + + −
    273 + + −
    274 + + −
    275 + − −
    276 + + −
    277 ++ + −
    278 ++ − −
    279 + + −
    280 + + −
    281 + + −
    282 ++ + −
    283 + − −
    284 + + −
    285 + + −
    286 + + −
    287 + − −
    288 + + −
    289 + + −
    290 + + −
    291 + + −
    292 + + −
    293 + + −
    294 + + −
    295 ++ + −
    296 + + −
    297 + + −
    298 + + −
    299 + + −
    300 + + −
    301 + + −
    302 + + −
    303 + + −
    304 + + −
    305 + + −
    306 + + −
    307 + + −
    308 + + −
    309 + + −
    310 + + −
    311 + − −
    312 ++ − −
    313 + + −
    314 + + −
    315 + − −
    316 + + −
    317 + + −
    318 + − −
    319 + + −
    320 + + −
    321 + + −
    322 + + −
    323 + + −
    324 + + −
    325 + + −
    326 ++ + −
    327 + + −
    328 + − −
    329 ++ + −
    330 + + −
    331 + + −
    332 + + −
    333 + + −
    334 ++ + −
    335 ++ − −
    336 + + −
    337 + + −
    338 + + −
    339 + + −
    340 + + −
    341 + + −
    342 + + −
    343 + + −
    344 + + −
    345 + + −
    346 + + −
    347 + + −
    348 + + −
    349 + + −
    350 + + −
    351 + + −
    • VIII. Other Embodiments
  • It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

Claims (67)

What is claimed is:
1. A method of modulating a sodium ion channel comprising the step of contacting said sodium ion channel with a compound of formula I:
Figure US20130345208A1-20131226-C00383
or a pharmaceutically acceptable salt thereof; wherein:
Each X is defined by —ZAR6, wherein each ZA is independently a bond or an optionally substituted branched or straight C1-6 aliphatic chain wherein up to two carbon units of ZA are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONRA—, —CONRANRA—, —CO2—, —OCO—, —NRACO2—, —O—, —NRACONRA—, —OCONRA—, —NRANRA, —NRANRACO—, —NRACO—, —S—, —SO—, —SO2—, —NRA—, —SO2NRA—, —NRASO2—, or —NRASO2NRA—;
Each R6 is independently RA, halo, —OH, —NH2, —NO2, —CN, —CF3, or —OCF3;
Each RA is independently hydrogen, an optionally substituted C1-8 aliphatic group; a 3-8 membered optionally substituted fully saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; an 8-12 membered optionally substituted fully saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or two occurrences of RA are taken together with the atom(s) to which they are attached to form an optionally substituted 3-12 membered fully saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
Each n is 1-4;
Each R1 and R2 is defined by —ZBR7, wherein each ZB is independently a bond or an optionally substituted straight or branched C1-6 aliphatic chain wherein up to two carbon units of ZB are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONRB—, —CONRBNRB—, CO2—, —OCO—, —NRBCO2—, —O—, —NRBCONRB—, —OCONRB—, —NRBNRB, —NRBNRBCO—, —NRBCO—, —S—, —SO—, —SO2—, —NRB—, —SO2NRB—, —NRBSO2—, or —NRBSO2NRB—;
Each R7 is independently RB, halo, —OH, —NHC(NH)NH2, —NH2, —NO2, —CN, —CF3, or —OCF3;
Each RB is independently hydrogen, an optionally substituted C1-8 aliphatic group, an optionally substituted 3-8 membered fully saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; an optionally substituted 8-12 membered fully saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two occurrences of RB are taken together with the atom(s) to which they are attached to form an optionally substituted 3-12 membered fully saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
Each R3 and R4 is defined by —ZCR8, wherein each —ZC is independently a bond or an optionally substituted straight or branched C1-6 aliphatic chain wherein up to two carbon units of ZC are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONRC—, —CONRCNRC—, —CO2—, —OCO—, —NRCCO2—, —O—, —NRCCONRC—, —OCONRC—, —NRCNRC, —NRCNRCCO—, —NRCCO—, —S—, —SO—, —SO2—, —NRC—, —SO2NRC—, —NRCSO2—, or —NRCSO2NRC—;
Each R8 is independently RC, halo, —OH, —NH2, —NO2, —CN, —CF3, or —OCF3;
Each RC is independently hydrogen, or an optionally substituted C1-8 aliphatic group, an optionally substituted 3-8 membered fully saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; an optionally substituted 8-12 membered fully saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two occurrences of RC are taken together with the atom(s) to which they are attached to form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, each of which is optionally substituted with 1 to 3 substituents; and
Each Y is hydrogen or unsubstituted C1-3 alkyl.
2. The method of claim 1, wherein R1 is an optionally substituted araliphatic, an optionally substituted heteroaraliphatic, an optionally substituted C1-8 aliphatic, an optionally substituted cycloaliphatic, an optionally substituted heterocycloaliphatic, an optionally substituted aryl, or an optionally substituted heteroaryl.
3. The method of claim 2, wherein R1 is an optionally substituted —C1-3 aliphatic-aryl.
4. The method of claim 3, wherein R1 is a phenylmethyl, phenylethyl, or phenylpropyl, in which the aliphatic and phenyl portion are each optionally substituted with 1-3 substituents independently selected from halo, hydroxy, cyano, nitro, aliphatic, haloaliphatic, alkylamino, cycloaliphatic, heterocycloaliphatic, (heterocycloaliphatic)alkyl, aminocarbonyl, aryl, and heteroaryl.
5. The method of claim 2, wherein R1 is an optionally substituted aliphatic.
6. The method of claim 5, wherein R1 is isopropyl.
7. The method of claim 2, wherein R1 is an optionally substituted cycloaliphatic or an optionally substituted heterocycloaliphatic.
8. The method of claim 2, wherein R1 is an optionally substituted aryl or an optionally substituted heteroaryl.
9. The method of claim 2, wherein R2 is hydrogen, an optionally substituted aliphatic, or an optionally substituted cycloaliphatic.
10. The method of claim 9, wherein R1 is an optionally substituted aryl, optionally substituted heteroaryl, optionally substituted araliphatic, or optionally substituted heteroaraliphatic.
11. The method of claim 1, wherein R1, R2, and the nitrogen atom to which they are attached form an optionally substituted 4-12 membered fully saturated or partially unsaturated monocyclic or bicyclic ring including 1-3 heteroatoms.
12. The method of claim 11, wherein R1, R2, and the nitrogen atom to which they are attached form a morpholinyl, piperadinyl, piperazinyl, pyrrolyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolidinyl, imidazolidinyl, pyrazolyl, pyrazolidinyl, thiomorpholinyl, or 3,4-dihydro-benzo[b][1,4]oxazine, each of which is optionally substituted with 1-3 substituents selected from alkylcarbonyl, halo, cyano, hydroxy, an optionally substituted C1-5 aliphatic, cycloaliphatic, heterocycloaliphatic, alkoxy, alkoxycarbonyl, alkylaminocarbonyl, aralkyl and heteroaralkyl.
13. The method of claim 1, wherein, R3, R4 and the nitrogen atom to which they are attached form a 4-8 membered saturated or partially unsaturated monocyclic or bicyclic heterocycloaliphatic, or an optionally substituted 8-12 membered bicyclic heteroaryl, each of which includes 1-3 heteroatoms selected from N, O, and S.
14. The method of claim 13, wherein R3, R4 and the nitrogen atom to which they are attached form a morpholinyl, thiomorpholinyl, piperadinyl, piperazinyl, pyrrolidinyl, tetrahydrofuranyl, imidazolinyl, a fully saturated or partially unsaturated bicyclic heterocycloaliphatic having 1-3 heteroatoms selected from N, O, and S, each of which is optionally substituted with 1-3 of alkylcarbonyl, halo, cyano, hydroxy, an optionally substituted C1-5 aliphatic, cycloaliphatic, heterocycloaliphatic, alkoxy, alkoxycarbonyl, alkylaminocarbonyl, aralkyl and heteroaralkyl.
15. The method of claim 1, wherein R3 is an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted cycloaliphatic, an optionally substituted heterocycloalipahtic, or an optionally substituted C1-8 aliphatic.
16. The method of claim 16, wherein R3 is an optionally substituted aryl.
17. The method of claim 16, wherein R3 is an optionally substituted aliphatic.
18. The method of claim 16, wherein R3 is an optionally substituted heteroaryl.
19. The method of claim 1, wherein X is o-halo.
20. A method of modulating a calcium or sodium ion channel comprising the step of contacting said calcium or sodium ion channel with a compound of formula Ia:
Figure US20130345208A1-20131226-C00384
or a pharmaceutically acceptable salts thereof, wherein:
Each X is defined by —ZAR6, wherein each ZA is independently a bond or an optionally substituted branched or straight C1-6 aliphatic chain wherein up to two carbon units of ZA are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONRA—, —CONRANRA—, —CO2—, —OCO—, —NRACO2—, —O—, —NRACONRA—, —OCONRA—, —NRANRA, —NRANRACO—, —NRACO—, —S—, —SO—, —SO2—, —NRA—, —SO2NRA—, NRASO2—, or —NRASO2NRA—;
Each R6 is independently RA, halo, —OH, —NH2, —NO2, —CN, —CF3, or —OCF3;
Each RA is independently hydrogen, an optionally substituted C1-8 aliphatic group; a 3-8 membered optionally substituted fully saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; an 8-12 membered optionally substituted fully saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two occurrences of RA are taken together with the atom(s) to which they are attached to form an optionally substituted 3-12 membered fully saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
Each n is 1-4;
Each R1 and R2 is defined by —ZBR7, wherein each ZB is independently a bond or an optionally substituted straight or branched C1-6 aliphatic chain wherein up to two carbon units of ZB are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONRB—, —CONRBNRB—, —CO2—, —OCO—, —NRBCO2—, —O—, —NRBCONRB—, —OCONRB—, —NRBNRB, —NRBNRBCO—, —NRBCO—, —S—, —SO—, —SO2—, —NRB—, —SO2NRB—, —NRBSO2—, or —NRBSO2NRB—;
Each R7 is independently RB, halo, —OH, —NHC(NH)NH2, —NH2, —NO2, —CN, —CF3, or —OCF3;
Each RB is an optionally substituted C1-8 aliphatic group, an optionally substituted 3-8 membered fully saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; an optionally substituted 8-12 membered fully saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two occurrences of RB are taken together with the atoms) to which they are attached to form an optionally substituted 3-12 membered fully saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
Each R3 and R4 is defined by —ZCR8, wherein each ZC is independently bond or an optionally substituted straight or branched C1-6 aliphatic chain wherein up to two carbon units of ZC are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONRC—, —CONRCNRC—, —CO2—, —OCO—, —NRCCO2—, —O—, —NRCCONRC—, —OCONRC—, —NRCNRC, —NRCNRCCO—, —NRCCO—, —S—, —SO—, —SO2—, —NRC—, —SO2NRC—, —NRCSO2—, or —NRCSO2NRC—;
Each R8 is independently RC, halo, —OH, —NH2, —NO2, —CN, —CF3, or —OCF3; and
Each RC is independently hydrogen, or an optionally substituted C1-8 aliphatic group, an optionally substituted 3-8 membered fully saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; an optionally substituted 8-12 membered fully saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two occurrences of RC are taken together with the atom(s) to which they are attached to form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocycle or bicyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, each of which is optionally substituted with 1 to 3 substituents.
21. The method of claim 20, wherein R1 is an optionally substituted araliphatic, an optionally substituted heteroaraliphatic, an optionally substituted C1-8 aliphatic, an optionally substituted cycloaliphatic, an optionally substituted heterocycloaliphatic, an optionally substituted aryl, or an optionally substituted heteroaryl.
22. The method of claim 21, wherein R1 is an optionally substituted —C1-3 aliphatic-aryl.
23. The method of claim 21, wherein R1 is an optionally substituted aliphatic.
24. The method of claim 23, wherein R1 is isopropyl.
25. The method of claim 21, wherein R1 is an optionally substituted cycloaliphatic or an optionally substituted heterocycloaliphatic.
26. The method of claim 21, wherein R1 is an optionally substituted aryl or an optionally substituted heteroaryl.
27. The method of claim 21, wherein R2 is hydrogen, an optionally substituted aliphatic, or an optionally substituted cycloaliphatic.
28. The method of claim 27, wherein R1 is an optionally substituted aryl, optionally substituted heteroaryl, optionally substituted araliphatic, or optionally substituted heteroaraliphatic.
29. The method of claim 20, wherein R1, R2, and the nitrogen atom to which they are attached form an optionally substituted 4-12 membered fully saturated or partially unsaturated monocyclic or bicyclic ring including 1-3 heteroatoms.
30. The method of claim 20, wherein, R3, R4 and the nitrogen atom to which they are attached form a 4-8 membered saturated or partially unsaturated monocyclic or bicyclic heterocycloaliphatic, or an optionally substituted 8-12 membered bicyclic heteroaryl, each of which includes 1-3 heteroatoms selected from N, O, and S.
31. The method of claim 20, wherein R3 is an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted cycloaliphatic, an optionally substituted heterocycloalipahtic, or an optionally substituted C1-8 aliphatic.
32. A method of modulating a sodium or calcium ion channel comprising the step of contacting said sodium ion channel with a compound selected from compound numbers 1-351 in Table 1.
33. A compound of formula Ia:
Figure US20130345208A1-20131226-C00385
or a pharmaceutically acceptable salt thereof, wherein:
Each X is defined by —ZAR6, wherein each ZA is independently a bond or an optionally substituted branched or straight C1-6 aliphatic chain wherein up to two carbon units of ZA are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONRA—, —CONRANRA—, —CO2—, —OCO—, —NRACO2—, —O—, —NRACONRA—, —OCONRA—, —NRANRA, —NRANRACO—, —NRACO—, —S—, —SO—, —SO2—, NRA—, —SO2NRA—, —NRASO2—, or —NRASO2NRA—;
Each R6 is independently RA, halo, —OH, —NH2, —NO2, —CN, —CF3, or —OCF3;
Each RA is independently hydrogen, an optionally substituted C1-8 aliphatic group; a 3-8 membered optionally substituted fully saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; an 8-12 membered optionally substituted fully saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two occurrences of RA are taken together with the atom(s) to which they are attached to form an optionally substituted 3-12 membered fully saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
Each n is 1-4;
Each R1 and R2 is defined by —ZBR7, wherein each ZB is independently a bond or an optionally substituted straight or branched C1-6 aliphatic chain wherein up to two carbon units of ZB are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONRB—, —CONRBNRB—, —CO2—, —OCO—, —NRBCO2—, —O—, —NRBCONRB—, —OCONRB—, —NRBNRB, —NRBNRBCO—, —NRBCO—, —S—, —SO—, —SO2—, —NRB—, —SO2NRB—, —NRBSO2—, or —NRBSO2NRB—, or —NRBSO2NRB;
Each R7 is independently RB, halo, —OH, —NHC(NH)NH2, —NH2, —NO2, —CN, —CF1, or —OCF3;
Each RB is an optionally substituted C1-8 aliphatic group, an optionally substituted 3-8 membered fully saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; an optionally substituted 8-12 membered fully saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two occurrences of RB are taken together with the atom(s) to which they are attached to form an optionally substituted 3-12 membered fully saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
Each R3 and R4 is defined by —ZCR8, wherein each ZC is independently a bond or an optionally substituted straight or branched C1-6 aliphatic chain wherein up to two carbon units of ZC are optionally and independently replaced by —CO—, —CS—, —COCO—, —CONRC—, —CONRCNRC—, —CO2—, —OCO—, —NRCCO2—, —O—, —NRCCONRC—, —OCONRC—, —NRCNRC, —NRCNRCCO—, —NRCCO—, —S—, —SO—, —SO2—, —NRC—, —SO2NRC—, —NRCSO2—, or —NRCSO2NRC—;
Each R8 is independently RC, halo, —OH, —NH2, —NO2, —CN, —CF3, or —OCF3; and
Each RC is independently hydrogen, or an optionally substituted C1-8 aliphatic group, an optionally substituted 3-8 membered fully saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; an optionally substituted 8-12 membered fully saturated, partially unsaturated, or fully unsaturated bicyclic ring system having 0.5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two occurrences of RC are taken together with the atom(s) to which they are attached to form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, each of which is optionally substituted with 1 to 3 substituents,
Provided that:
when R1 is alkyl, R2 is not 3,5-bis-trifluoromethyl-phenyl-alkyl;
when R1 and R2 together form pyrrolidinyl, morpholinyl, or piperidinyl, each optionally substituted with —CH3 or —CH2CH3, then X is not m-methyl, o-halo, p-aryl, or p-cyano;
when R1 or R2 are aliphatic or alkoxyalkyl, then X is not m-methyl, o-halo, p-aryl, or p-cyano; and
when R1 is phenylmethyl optionally substituted with 1-2 —CH3 groups or cycloaliphatic, and R2 is unsubstituted methyl, ethyl, or isopropyl, then
(1) R3 together with R4 form pyrrolidinyl, morpholinyl, piperidinyl optionally substituted with aliphatic, aminocarbonyl, or alkylcarbonyl, or one of R3 or R4 is phenylmethyl, methylfuranyl, or methoxypropyl; and
(2) X is not m-methyl, p-aryl, o-halo or p-cyano.
34. The compound of claim 33, wherein R1 is an optionally substituted araliphatic, an optionally substituted heteroaraliphatic, an optionally substituted C1-8 aliphatic, an optionally substituted cycloaliphatic, an optionally substituted heterocycloaliphatic, an optionally substituted aryl, or an optionally substituted heteroaryl.
35. The compound of claim 34, wherein R1 is an optionally substituted —C1-3 aliphatic-aryl.
36. The compound of claim 35, wherein R1 is a phenylmethyl, phenylethyl, or phenylpropyl, in which the aliphatic and phenyl portion are each optionally substituted with 1-3 substituents independently selected from halo, hydroxy, cyano, nitro, aliphatic, haloaliphatic, alkylamino, cycloaliphatic, heterocycloaliphatic, (heterocycloaliphatic)alkyl, aminocarbonyl, aryl, and heteroaryl.
37. The compound of claim 35, wherein R1 is a naphthylmethyl, naphthylethyl, naphthylpropyl, indenylmethyl, indenylethyl, or indenylpropyl, in which the aliphatic and the bicyclic aryl group are each optionally substituted with 1-3 of halo, hydroxy, cyano, nitro, aliphatic, haloaliphatic, alkylamino, cycloaliphatic, heterocycloaliphatic, (heterocycloaliphatic)alkyl, aminocarbonyl, aryl, heteroaryl, or combinations thereof.
38. The compound of claim 35, wherein the aryl portion is an optionally substituted 2,3-dihydrobenzo[b][1,4]dioxinyl or an optionally substituted benzo[d][1,3]dioxolyl.
39. The compound of claim 34, wherein R1 is an optionally substituted 2,3-dihydrobenzofurylalkyl, an optionally substituted indolinylalkyl, an optionally substituted 2,3-dihydrobenzo[b][1,4]dioxinylalkyl, an optionally substituted benzo[d][1,3]dioxolylalkyl, an optionally substituted pyridinylalkyl, an optionally substituted isoindolinylalkyl, or an optionally substituted quinolinylalkyl.
40. The compound of claim 34, wherein R1 is methyl, ethyl, propyl, butyl, or isopropyl, each of which is optionally substituted with 1-2 substituents independently selected from halo, cyano, hydroxy, or optionally substituted aryl, aryloxy, alkylamino, heteroaryl, cycloaliphatic, or heterocycloaliphatic.
41. The compound of claim 40, wherein R1 is isopropyl.
42. The compound of claim 34, wherein R1 is an optionally substituted cycloaliphatic or an optionally substituted heterocycloaliphatic.
43. The compound of claim 42, wherein R1 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[2.1.1]hexyl, bicyclo[3.1.1]heptyl, or bicyclo[2.2.1]heptyl, each of which is optionally substituted with 1-2 halo, hydroxy, aryl, heteroaryl, or combinations thereof.
44. The compound of claim 34, wherein R1 is an optionally substituted aryl or an optionally substituted heteroaryl.
45. The compound of claim 34, wherein R1 is phenyl, indenyl, dihydroindenyl, naphthyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, or benzo[d][1,3]dioxolyl, each of which is optionally substituted with 1-2 halo, hydroxy, cyano, or optionally substituted aliphatic, alkoxy, aryl, heteroaryl; or combinations thereof.
46. The compound of claim 34, wherein R2 is hydrogen, an optionally substituted aliphatic, or an optionally substituted cycloaliphatic.
47. The compound of claim 46, wherein R1 is an optionally substituted aryl, optionally substituted heteroaryl, optionally substituted araliphatic, or optionally substituted heteroaraliphatic.
48. The compound of claim 33, wherein R1 and R2 are each independently selected from hydrogen, methyl, ethyl,
Figure US20130345208A1-20131226-C00386
Figure US20130345208A1-20131226-C00387
Figure US20130345208A1-20131226-C00388
49. The compound of claim 33, wherein R1, R2, and the nitrogen atom to which they are attached form an optionally substituted 4-12 membered fully saturated or partially unsaturated monocycle or bicyclic ring including 1-3 heteroatoms.
50. The compound of claim 49, wherein R1, R2, and the nitrogen atom to which they are attached form a morpholinyl, piperadinyl, piperazinyl, pyrrolyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolidinyl, imidazolidinyl, pyrazolyl, pyrazolidinyl, thiomorpholinyl, or 3,4-dihydro-benzo[b][1,4]oxazine, each of which is optionally substituted with 1-3 substituents selected from, alkylcarbonyl, halo, cyano, hydroxy, an optionally substituted C1-5 aliphatic, cycloaliphatic, heterocycloaliphatic, alkoxy, alkoxycarbonyl, alkylaminocarbonyl, aralkyl and heteroaralkyl.
51. The compound of claim 33, wherein R1, R2 the nitrogen atom to which they are attached form a heterocycloaliphatic or a heterocycloaliphatic fused with phenyl selected from:
Figure US20130345208A1-20131226-C00389
Figure US20130345208A1-20131226-C00390
52. The compound of claim 33, wherein, R3, R4 and the nitrogen atom to which they are attached form a 4-8 membered saturated or partially unsaturated monocyclic or bicyclic heterocycloaliphatic, or an optionally substituted 8-12 membered bicycle heteroaryl, each of which includes 1-3 heteroatoms selected from N, O, and S.
53. The compound of claim 52, wherein R3, R4 and the nitrogen atom to which they are attached form a morpholinyl, thiomorpholinyl, piperadinyl, piperizinyl, pyrrolidinyl, tetrahydrofuranyl, imidazolinyl, a fully saturated or partially unsaturated bicycle heterocycloaliphatic having 1-3 heteroatoms selected from N, O, and S, each of which is optionally substituted with 1-3 of alkylcarbonyl, halo, cyano, hydroxy, an optionally substituted C1-5 aliphatic, cycloaliphatic, heterocycloaliphatic, alkoxy, alkoxycarbonyl, alkylaminocarbonyl, aralkyl and heteroaralkyl.
54. The compound of claim 33, wherein R3 is an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted cycloaliphatic, an optionally substituted heterocycloalipahtic, or an optionally substituted C1-8 aliphatic.
55. The compound of claim 54, wherein R3 is phenyl, naphthyl or indenyl each optionally substituted with 1-3 of halo, cyano, hydroxy, alkoxy, alkoxycarbonyl, an optionally substituted C1-6 aliphatic, aminocarbonyl, alkylaminocarbonyl, aryl, and heteroaryl.
56. The compound of claim 54, wherein R3 is alkyl optionally substituted with 1-2 of halo, cyano, —C(O)OH, hydroxy, cycloaliphatic, heterocycloaliphatic, optionally substituted aryl, alkoxy, haloalkylaryl, bicycloaliphatic, aryloxy, haloaryl, alkylamino, heteroaryl, cycloaliphatic, and heterocycloaliphaticpropyl.
57. The compound of claim 54, wherein R3 is an optionally substituted alkenyl.
58. The compound of claim 54, wherein R3 is an optionally substituted pyridinyl, pyrimidinyl, pyridazinyl, pyridinyl, isoindolinyl.
59. The compound of claim 54, wherein R3 is an optionally substituted cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, bicyclo[2.1.1]hexyl, bicyclo[3.1.1]heptyl, or bicyclo[22.1]heptyl.
60. The compound of claim 33, wherein X is o-halo.
61. The compound of claim 33, wherein R3 and R4 are each independently selected from hydrogen, methyl, ethyl,
Figure US20130345208A1-20131226-C00391
Figure US20130345208A1-20131226-C00392
62. The compound of claim 33, wherein R3, R4 the nitrogen atom to which they are attached form a heterocycloaliphatic or a heterocycloaliphatic fused with phenyl selected from:
Figure US20130345208A1-20131226-C00393
63. The compound of claim 33, wherein R1, R2, R3 and R4 are each independently selected from hydrogen, methyl, ethyl,
Figure US20130345208A1-20131226-C00394
Figure US20130345208A1-20131226-C00395
Figure US20130345208A1-20131226-C00396
Figure US20130345208A1-20131226-C00397
Figure US20130345208A1-20131226-C00398
64. The compound of claim 33, wherein R1, R2 and the nitrogen atom to which they are attached, or R3, R4 and the nitrogen atom to which they are attached, form a heterocycloaliphatic or a heterocycloaliphatic fused with phenyl selected from:
Figure US20130345208A1-20131226-C00399
65. The compound of claim 33, wherein
Each R3 or R4 is heterocycloaliphatic, bicycloaryl, bicycloheteroaliphatic, bicycloheteroaryl, heterocycloalkenyl, cycloaliphatic, alkenyl, 5-membered heterocycloaliphatic, heteroaralkyl, or bicycloaralkyl, each of which is optionally substituted;
One of R3 and R4 is hydrogen;
R3 or R4 is alkyl substituted with cycloaliphatic, heteroaryl, heterocycloaliphatic, cyano, alkoxycarbonyl, carboxy, guanidinylalkyl, bicycloaryl, halo, or alkoxy; or
R3 together with R4 form a ring system selected from thiomorpholinyl, bicycloheteroaryl, bicyclic heterocycloaliphatic, 5-membered heterocycloaliphatic, and 6-membered heterocycloalkenyl;
Provided that:
when R1 and R2 together form pyrrolidinyl, morpholinyl, piperidinyl, each optionally substituted with —CH3 or —CH2CH3, then X is not one selected from m-methyl, o-halo, p-aryl, and p-cyano;
when R1 and R2 are aliphatic or alkoxyalkyl, then X is not one selected from m-methyl, o-halo, p-aryl, and p-cyano; and
when R1 is phenylmethyl optionally substituted with 1-2 —CH3 groups or cycloaliphatic, and R2 is one selected from unsubstituted methyl, ethyl, and isopropyl, then R3 together with R4 form pyrrolidinyl, morpholinyl, piperidinyl optionally substituted with aliphatic, or aminocarbonyl, or alkylcarbonyl, or R3 or R4 is phenylmethyl, methylfuranyl, or methoxypropyl, and X is not o-halo or p-cyano.
66. A compound selected from compound numbers 1-207 from Table 2.
67. A pharmaceutical composition, comprising a compound as in any of claims 32-66 and a pharmaceutically acceptable carrier.
US13/974,986 2004-11-03 2013-08-23 Ion channel modulators and methods of use Abandoned US20130345208A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/974,986 US20130345208A1 (en) 2004-11-03 2013-08-23 Ion channel modulators and methods of use

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US62471604P 2004-11-03 2004-11-03
US62471804P 2004-11-03 2004-11-03
US62480004P 2004-11-03 2004-11-03
US11/266,142 US7767680B2 (en) 2004-11-03 2005-11-03 Ion channel modulators and methods of use
US12/724,077 US8236815B2 (en) 2004-11-03 2010-03-15 Ion channel modulators and methods of uses
US13/538,667 US8546414B2 (en) 2004-11-03 2012-06-29 Ion channel modulators and methods of use
US13/974,986 US20130345208A1 (en) 2004-11-03 2013-08-23 Ion channel modulators and methods of use

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US13/538,667 Division US8546414B2 (en) 2004-11-03 2012-06-29 Ion channel modulators and methods of use

Publications (1)

Publication Number Publication Date
US20130345208A1 true US20130345208A1 (en) 2013-12-26

Family

ID=36319810

Family Applications (4)

Application Number Title Priority Date Filing Date
US11/266,142 Active 2026-08-09 US7767680B2 (en) 2004-11-03 2005-11-03 Ion channel modulators and methods of use
US12/724,077 Active 2026-01-30 US8236815B2 (en) 2004-11-03 2010-03-15 Ion channel modulators and methods of uses
US13/538,667 Active US8546414B2 (en) 2004-11-03 2012-06-29 Ion channel modulators and methods of use
US13/974,986 Abandoned US20130345208A1 (en) 2004-11-03 2013-08-23 Ion channel modulators and methods of use

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US11/266,142 Active 2026-08-09 US7767680B2 (en) 2004-11-03 2005-11-03 Ion channel modulators and methods of use
US12/724,077 Active 2026-01-30 US8236815B2 (en) 2004-11-03 2010-03-15 Ion channel modulators and methods of uses
US13/538,667 Active US8546414B2 (en) 2004-11-03 2012-06-29 Ion channel modulators and methods of use

Country Status (4)

Country Link
US (4) US7767680B2 (en)
EP (1) EP1809290A2 (en)
JP (1) JP2008519034A (en)
WO (1) WO2006050476A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110035995A (en) * 2016-12-16 2019-07-19 范德比尔特大学 MAChR M4Positive allosteric modulators

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200533357A (en) 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
HUP0400405A3 (en) * 2004-02-10 2009-03-30 Sanofi Synthelabo Pyrimidine derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
TW200836719A (en) 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
EA201001669A1 (en) * 2008-04-22 2011-06-30 Астразенека Аб SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281
WO2010113834A1 (en) 2009-03-30 2010-10-07 アステラス製薬株式会社 Pyrimidine compound
CA2789711C (en) 2010-02-17 2014-08-05 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
AR081331A1 (en) * 2010-04-23 2012-08-08 Cytokinetics Inc AMINO- PYRIMIDINES COMPOSITIONS OF THE SAME AND METHODS FOR THE USE OF THE SAME
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (en) * 2010-04-23 2012-10-10 Cytokinetics Inc AMINO-PYRIDAZINIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME TO TREAT CARDIAC AND SKELETIC MUSCULAR DISORDERS
US8580805B2 (en) * 2010-08-31 2013-11-12 Hubert Maehr Pyrimidine carboxamide derivatives
CN103930437A (en) 2011-03-16 2014-07-16 安姆根有限公司 Potent and selective inhibitors of Nav1.3 and Nav1.7
CA2846463C (en) * 2011-09-02 2017-10-24 Purdue Pharma L.P. Pyrimidines as sodium channel blockers
UY35397A (en) 2013-03-12 2014-10-31 Amgen Inc POWERFUL AND SELECTIVE INHIBITORS OF NaV1.7
US9636418B2 (en) 2013-03-12 2017-05-02 Amgen Inc. Potent and selective inhibitors of NAV1.7
CA2939501C (en) * 2014-02-12 2020-07-07 Purdue Pharma L.P. Isoquinoline derivatives and use thereof
CN107686456B (en) * 2017-07-25 2018-10-23 杭州师范大学 A kind of quinolione key intermediate ethyl ester aminate and its preparation method and application
KR102006547B1 (en) * 2017-11-16 2019-08-01 서울대학교산학협력단 Benzamide derivatives compounds, preparation method thereof, and pharmaceutical composition for use in preventing or treating inflammatory disease as an active ingredient
US20220119363A1 (en) * 2018-11-02 2022-04-21 Merck Sharp & Dohme Corp. 2-amino-n-phenyl-nicotinamides as nav1.8 inhibitors
US20210387966A1 (en) * 2018-11-02 2021-12-16 Merck Sharp & Dohme Corp. 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
JP2022538588A (en) * 2019-06-27 2022-09-05 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 2,3-dihydroquinazoline compounds as NaV1.8 inhibitors
CN117597339A (en) * 2021-05-07 2024-02-23 默沙东有限责任公司 Aryl 3-oxo-piperazine carboxamides and heteroaryl 3-oxo-piperazine carboxamides as NAV1.8 inhibitors
CN116789644A (en) * 2022-03-17 2023-09-22 中国科学院上海药物研究所 Amide compound and preparation method and application thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US128277A (en) * 1872-06-25 Improvement in car-brakes
US4151A (en) * 1845-08-16 Am photu litho cd n y
IL91418A (en) * 1988-09-01 1997-11-20 Rhone Poulenc Agrochimie (hetero) cyclic amide derivatives, process for their preparation and fungicidal compositions containing them
US5530000A (en) * 1993-12-22 1996-06-25 Ortho Pharmaceutical Corporation Substituted pyrimidinylaminothiazole derivatives useful as platelet aggreggation inhibitors
US5795905A (en) * 1995-06-06 1998-08-18 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US6274588B1 (en) 1999-05-31 2001-08-14 Hoffmann-La Roche Inc. 4-phenyl-pyrimidine derivatives
JP4623354B2 (en) 2000-09-14 2011-02-02 味の素株式会社 Novel pyrimidine derivatives and novel pyridine derivatives
BR0116411A (en) 2000-12-21 2003-11-11 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
EP1361879A1 (en) 2001-02-20 2003-11-19 Bristol-Myers Squibb Company 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators
CA2438868A1 (en) 2001-02-20 2002-09-19 Valentin K. Gribkoff Modulators of kcnq potassium channels and use thereof in treating migraine and mechanistically related diseases
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
AR039208A1 (en) 2002-04-03 2005-02-09 Syngenta Participations Ag PHENYL AND PIRIDYL ALKIN COMPOUNDS, HERBICIDE COMPOSITION CONTAINING THEM, PROCEDURE FOR PREPARATION OF THOSE AND PROCEDURE TO COMBAT THE GROWTH OF INDENATED PLANTS
JP4497930B2 (en) 2002-04-23 2010-07-07 アベンティス・ファーマスーティカルズ・インコーポレイテツド 3-Substituted amino-1H-indole-2-carboxylic acid and 3-substituted amino-benzo (b) thiophene-2-carboxylic acid derivatives as interleukin-4 gene expression inhibitors
JP4570955B2 (en) 2002-07-09 2010-10-27 バーテクス ファーマスーティカルズ インコーポレイテッド Imidazoles with protein kinase inhibitory activity
AU2003280558A1 (en) 2002-10-11 2004-05-04 Kowa Co., Ltd. Method for treatment of cancer
US7459460B2 (en) 2003-05-28 2008-12-02 Bristol-Myers Squibb Company Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators
HUP0400405A3 (en) * 2004-02-10 2009-03-30 Sanofi Synthelabo Pyrimidine derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110035995A (en) * 2016-12-16 2019-07-19 范德比尔特大学 MAChR M4Positive allosteric modulators

Also Published As

Publication number Publication date
US8236815B2 (en) 2012-08-07
JP2008519034A (en) 2008-06-05
WO2006050476A3 (en) 2006-10-19
US7767680B2 (en) 2010-08-03
US20060160817A1 (en) 2006-07-20
WO2006050476A2 (en) 2006-05-11
US8546414B2 (en) 2013-10-01
EP1809290A2 (en) 2007-07-25
US20100184753A1 (en) 2010-07-22
US20120270318A1 (en) 2012-10-25

Similar Documents

Publication Publication Date Title
US8546414B2 (en) Ion channel modulators and methods of use
US8193194B2 (en) Ion channel modulators and methods of use
US7786137B2 (en) Bicyclic derivatives as modulators of ion channels
US8343763B2 (en) Heterocyclic derivatives as modulators of ion channels
US8883781B2 (en) Thienopyrimidines useful as modulators of ion channels
US7605174B2 (en) Indane derivatives as modulators of ion channels
US8536195B2 (en) Bicyclic derivatives as modulators of ion channels
US7994174B2 (en) Pyridyl sulfonamides as modulators of ion channels
US7858786B2 (en) Pyrimidines and pyrazines useful as modulators of ion channels
US7683066B2 (en) Isoquinolines useful as modulators of ion channels
US7713983B2 (en) Quinazolines useful as modulators of ion channels
US7683065B2 (en) Pyridines useful as modulators of ion channels
US7705002B2 (en) Biaryls useful as modulators of ion channels

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION